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Next generation sequencing generates a large quantity of sequence data which has 
the potential to be highly informative when evaluated using appropriate analytical methods. 
One of the key aims of human genetic disease studies is to use such methods to help identify 
sequence variants having some phenotypic effect. In the past few years, whole exome 
sequencing in particular has been used to identify single variants that cause many monogenic 
diseases. However, monogenic diseases in which genetic heterogeneity plays a role present a 
more difficult problem because different affected individuals in a study may not carry 
disease-causing mutations in the same gene. 
A major focus of my work is to develop and implement algorithms to identify 
disease-causing variants in such diseases. In particular I make use of functional information, 
such as that encoded by interaction networks, to prioritise genes for follow-up analysis. In 
this thesis I present two different analysis tools designed for this purpose. Simulated datasets 
are constructed to demonstrate the utility of these tools and test their performance under 
varying conditions. 
The tools are applied to a whole exome sequencing study for a genetically-
heterogeneous monogenic disease (Adams-Oliver syndrome) with the aim of generating 
novel hypotheses regarding disease aetiology. This work also allows comparison and 
exploration of the challenges facing network-based methods in practice. The tools are also 
applied to a study of families exhibiting atypically strong recurrence of a complex disorder 
(Crohn’s disease), testing the hypothesis that one or a small number of rare highly-penetrant 
variants might be implicated in each family. In this way it is proposed that the application of 
network-based methods to next generation sequencing data can help to describe disease 
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1.1 Background to Genetic Disease 
1.1.1 Genes and Disease 
Many diseases have a genetic component. This means that there will be one or more 
positions in the genome at which variation in a person’s DNA sequence can directly cause 
the disease, or can increase or decrease a person’s likelihood of developing it relative to a 
person without that variation (all else being equal). In addition, genetic differences can affect 
the clinical phenotype and course of a disease (Zlotogora 2003), susceptibility to diseases 
caused by environmentally borne pathogens (Frodsham and Hill 2004) and response to 
treatment (Weinshilboum 2003). For most individual sequence variants that have a 
substantial effect on health, the harmful (disease-causing) allele will be less common in any 
given population than the non-disease allele; this is due to evolutionary pressure, where 
damaging sequence variants are selected against (Blekhman et al. 2008). 
The central dogma of molecular biology describes how genetic information is 
transcribed from DNA into messenger RNA (mRNA), which is subsequently translated into 
a chain of amino acid residues to form the proteins that perform a vast range of cellular and 
inter-cellular functions (Crick 1970). There are several different types of genetic variation 
(den Dunnen and Antonarakis 2000). Of particular relevance to this thesis are DNA 
sequence variants affecting exons, the protein-coding DNA subunits of genes, which can 
alter downstream the ability of proteins to function correctly. If protein function is 
sufficiently impaired by the mutation this can cause or contribute to the clinical phenotypes 
characterising a disease. 
Although there are examples of synonymous mutations playing a role in genetic 
disease (Sauna and Kimchi-Sarfaty 2011), most known disease-linked mutations in coding 
regions are non-synonymous, in that they alter the amino acid sequence and often 
consequently the structure of a protein (Cooper et al. 2010). Single nucleotide variants 
(SNVs) within exons are called missense if they result in an amino acid substitution or 
nonsense if they prematurely stop translation. Splice-site mutations at exon boundaries can 
cause exon-skipping or protein truncation. Small insertions or deletions (indels) that are in-




while frameshift indels result in a protein with a completely altered amino acid sequence 
which is also likely to be truncated or elongated. 
Other types of genetic variation can cause disease, including sequence variants in 
introns or intergenic regions (Cooper et al. 2010) or larger-scale mutations including 
rearrangement or expansion of repeated sequences (Lupski 1998), large deletions or 
translocations (Abeysinghe et al. 2006) and chromosome number abnormalities (Torres et al. 
2008). 
However, recent advances in sequencing technology have made the identification of 
exonic sequence variants (particularly SNVs and small indels in non-repetitive DNA) in tens 
to hundreds of individuals fast and affordable, and therefore viable even for smaller research 
groups. Interpretation of this type of genetic variation is also more straightforward than non-
coding variants. For these reasons, it is currently a key aim in medical genetics to identify 
exonic mutations that result in disease (Brunham and Hayden 2013). Knowledge of such 
variants can improve the understanding of the molecular basis of a disease, potentially 
leading to diagnostic and therapeutic advances. This provides strong motivation for the 
development of analysis methods for SNVs and small indels, which will be the focus of this 
thesis. 
1.1.2 Monogenic Disease 
In this thesis, the term monogenic disease will refer to diseases in which a single 
DNA sequence variant is sufficient to cause the disease. This avoids the ambiguity of the 
term Mendelian disease, since sequence variants involved in other types of genetic disease 
are also subject to Mendelian inheritance. 
Monogenic diseases can result from sporadic (or de novo) mutations (errors in DNA 
replication after fertilisation) or from sequence variants inherited from one or both parents 
(Boycott et al. 2013). 
Autosomal dominant (AD) monogenic diseases are caused by a single mutated copy 
of the disease gene (heterozygous mutation). When this is the result of an inherited sequence 
variant, one parent would be expected to have the disease phenotype. The mutations 
underlying AD disorders can be gain-of-function mutations in which the resulting protein 
gains some new abnormal function, or loss-of-function mutations if the gene is 
haploinsufficient (one copy alone produces insufficient protein product for normal function). 
Examples of AD disorders include Huntington’s disease (gene HTT; Online Mendelian 





Autosomal recessive (AR) monogenic diseases require both copies of the disease 
gene to be mutated. This can result from homozygous mutations, where both copies contain 
the same sequence variant, or from compound heterozygous mutations, where different 
variants affect each copy. Frequently in AR disease cases, each parent will carry one 
mutated copy of the disease gene so that neither are affected by the disease, but one in four 
children will be (with an additional two in four also being unaffected carriers). Mutations 
underlying AR disorders are often loss-of-function for haplosufficient genes. Examples of 
AR disorders include cystic fibrosis (gene CFTR; OMIM #219700) and sickle-cell disease 
(gene HBB; OMIM #603903). 
Mutations on the sex chromosomes can also result in monogenic disease. X-linked 
disorders can be dominant (such as Rett syndrome [OMIM #312750] caused by the gene 
MECP2 and resulting in a severe phenotype in females but fatal in males) or recessive (such 
as Duchenne muscular dystrophy [OMIM #310200], caused by the gene DMD and much 
rarer in females than in males, who have no working second copy of the gene should they 
inherit a mutation). 
There are estimated to be around 7,000 known monogenic diseases with the genetic 
basis of half of these having been determined (Boycott et al. 2013). There are likely to be 
many more monogenic diseases as-yet-uncharacterised due to being very rare or occurring in 
less well-studied populations (Antonarakis and Beckmann 2006). 
1.1.3 Penetrance and Expressivity 
For a monogenic disease, penetrance refers to the proportion of people carrying a 
disease-causing mutation that actually display the disease phenotype. There are examples of 
diseases for which penetrance is 100% (such as the AD disorder achondroplasia [OMIM 
#100800]), but often monogenic diseases can have incomplete penetrance. 
A related concept is expressivity, which refers to the range and severity of 
phenotypic features that can occur in a monogenic disease patient (Lobo 2008). For 
example, the AD disorder neurofibromatosis, type I (OMIM #162200) can result in a range 
of clinical phenotypes, even within families where the same disease allele is causal. 
There are several factors that can cause incomplete penetrance and variable 
expressivity. One is mutation type; for example in retinoblastoma (OMIM #180200) low 
penetrance disease-causing mutations in the gene RB1 lead to partially functional or reduced 
levels of the retinoblastoma protein. However, other reasons can include environmental 
factors, epigenetic modifications and mutations in modifier genes (Zlotogora 2003; Cooper 




Modifier genes are perhaps the first step beyond the simple picture of monogenic 
disease presented so far. If the primary gene for a monogenic disease is the gene which can 
harbour a disease-causing mutation, mutations in modifier genes can also influence the 
disease phenotype by altering expression of the primary gene, or by playing some other 
functional role in the process impaired by a mutant primary gene product (Dipple and 
McCabe 2000; Weatherall 2001). Cystic fibrosis gives an example of how modifier genes 
can affect some of the clinical symptoms in affected individuals (Drumm et al. 2005). 
1.1.4 Oligogenic Disease 
Oligogenic disease refers to disorders in which mutations are required in two or 
more genes to produce a disease phenotype. There are several examples of diseases 
displaying digenic inheritance, requiring mutations in two genes (Schäffer 2013). 
The difference between a digenic disease and a monogenic disease in which a 
modifier gene plays a role is blurry, since a modifier gene affects the presence or severity of 
the monogenic disease phenotype. While the distinction generally lies in the magnitude of 
effect of the primary gene (Samuels 2010), both cases illustrate that the genetic basis of 
disease is not necessarily simple. When multiple genes are involved in a disease it is more 
difficult to observe clear familial inheritance, and more difficult to identify disease-causing 
genes using traditional methods such as linkage and positional cloning. 
Multiple genes can be involved in a disease because the protein encoded by each 
gene is only one element of a complex molecular system carrying out some physiological 
function. For example, one protein may directly interact with another protein, compensate 
for the lack of another protein, be involved in regulating expression of another gene, or play 
a role complementary to proteins in other tissues or systems. This complexity at the 
molecular level is one reason why it is rare to find straightforward genotype-phenotype 
relationships (Weatherall 2001). In fact diseases caused by one or a small number of genes 
lie at one end of a continuum from simple monogenic to complex polygenic disease 
(Antonarakis and Beckmann 2006). 
1.1.5 Complex Disease 
At the other end of the scale are common complex diseases such as diabetes or heart 
disease. A person’s risk of developing a complex disease is linked to a large number of 
genetic and environmental factors, and they have no clear mode of inheritance (the elevated 
risk due to a family history of disease varies between complex disorders). Complex diseases 




mutation has only a small effect on disease risk individually and is therefore not under the 
same selective pressure as a monogenic disease-causing mutation (Blekhman et al. 2008). 
The common disease–common variant hypothesis proposed that the genetic 
mutations underlying complex diseases in an affected population are relatively common 
single nucleotide polymorphisms (SNPs) (Gibson 2011). Since 2005 (Klein et al. 2005), 
genome-wide association studies (GWAS) have used microarrays to genotype up to five 
million common SNPs (Illumina 2014b) in large case and control cohorts, testing for 
association of SNPs with disease state. The SNPs are spaced throughout the genome, making 
GWAS hypothesis-free. GWAS require large sample sizes to have the power to detect 
disease associations (Wellcome Trust Case Control Consortium 2007), and are subject to 
stringent multiple testing corrections (Johnson et al. 2010). 
This approach has resulted in disease-associated loci being identified for many 
complex diseases (Hindorff et al. 2009). However, associated SNPs are unlikely to play a 
direct role in the disease themselves; more likely they are “tagging” variants with true 
disease involvement due to linkage disequilibrium (LD). Thus even replicated GWAS 
associations require much further work to draw conclusions about the molecular basis of a 
disease. 
Despite their success as an analysis tool, GWAS have not fully explained the 
heritability of complex disease and it is therefore an ongoing problem to identify the role 
that rarer sequence variants play (Gibson 2011). 
1.1.6 Genetic Heterogeneity 
A key concept for this thesis is that of genetic heterogeneity, where several different 
sequence variants in the same gene (allelic heterogeneity), or sequence variants in several 
different genes (locus heterogeneity), can cause the same disease phenotype (McClellan and 
King 2010). Since allelic heterogeneity is compatible with a single disease-causing gene, 
this thesis will have a particular focus on locus heterogeneity, and it is primarily this type 
that will be meant when genetic heterogeneity is referred to. 
It is important to distinguish between monogenic diseases with locus heterogeneity, 
which require a mutation in only one of several alternative genes (that is, there are several 
alternative primary disease genes), and oligogenic diseases, which require mutations in more 
than one gene. An example of locus heterogeneity is acne inversa (OMIM #142690), which 
can be caused by single sequence variants in any one of three genes involved in the γ-
secretase complex (Wang et al. 2010a). 
Motivated by recent reports attributing sporadic cases of relatively common 




suggest a relationship between the prevalence of a disorder and its mutational target size 
(Gilissen et al. 2011). This suggests that for more commonly observed genetic diseases 
causal variants might be found in many genes. Identifying and understanding these complex 
molecular mechanisms is a key goal of human genetic disease research, one for which next 
generation sequencing has provided renewed hope. 
1.2 Next Generation Sequencing 
1.2.1 The New Sequencing Technology 
Initial draft sequences of the human genome were published in 2001, eleven years 
after the Human Genome Project commenced in 1990 (Lander et al. 2001; Venter et al. 
2001). A finished sequence was declared complete in 2003 (National Human Genome 
Research Institute 2003). The availability of the complete (euchromatic) genome was a 
landmark development in genetics because it provided a comprehensive foundation for the 
sequencing of further genomes, for the study of functional elements such as genes and 
regulatory elements, and for comparative studies to investigate the genetic basis of disease. 
However, the project cost an estimated $3 billion and took thirteen years to 
complete. Sequencing was completed using automated Sanger sequencing (Sanger et al. 
1977), an enzyme-based sequencing method that could generate up to 115 kbp of sequence 
per day (Mardis 2011). 
Since then, the study of genetics and genetic disease has been transformed by the 
arrival of next generation sequencing (NGS) methods. These are a group of commercialised 
high-throughput DNA (or RNA) sequencing methods that have dramatically improved the 
accessibility of genome-scale sequencing (Mardis 2011). Although the precise details vary 
between different NGS methods, a key innovation is the cyclic sequencing in parallel of 
millions of template DNA fragments, each of which is amplified to form a separate cluster 
on a solid surface. A single set of reagents is used to synthesise simultaneously the 
complementary DNA strands for each cluster, the sequence being determined using image-
based detection when fluorescently-labelled nucleotides are incorporated (Shendure and Ji 
2008; Metzker 2010). 
Competition between providers of NGS methods has made them relatively 
affordable (Illumina are currently marketing a system capable of sequencing “the first $1000 
genome” (Illumina 2014a)) and fast. Recent NGS instruments can sequence in the region of 
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technology has changed the landscape of genetic disease research; studies are no longer 
limited to individual genes but can encompass the whole genome. 
1.2.2 Read Alignment and Variant Calling 
NGS results in relatively short DNA sequence reads of at most a few hundred base 
pairs (Metzker 2010; Liu et al. 2012). It is a considerable algorithmic challenge to map these 
reads to the reference genome of three billion base pairs, maintained by the Genome 
Reference Consortium. This problem is confounded by the fact that NGS reads can have an 
error rate of as much as 2% (Liu et al. 2012), and the fact that each individual’s genome 
carries SNVs, indels and structural variation relative to the reference genome. Early 
alignment methods were based on hash-table algorithms (Flicek and Birney 2009); more 
recently methods such as Burrows-Wheeler Alignment (Li and Durbin 2009) make use of 
the Burrows-Wheeler transform for efficient read alignment (Flicek and Birney 2009; Li and 
Homer 2010). 
Accurate sequencing requires each base pair to be read multiple times by different 
sequencing reads, and a genome-wide sequencing depth of 30× or higher is recommended 
(Koboldt et al. 2010; Ajay et al. 2011). Since reads need to be consistent, local re-alignment 
is performed to re-map reads where others indicate that an indel has occurred. For NGS 
methods which use paired-end reads, the placement of mate pair reads also needs to be 
consistent. Alignment algorithms are also able to take into account the sequencing quality 
scores at each base pair. 
Read alignment is particularly difficult for repetitive regions (typically reads which 
map non-uniquely to the reference genome are discarded) or where there is structural 
variation relative to the reference genome. Performance varies depending on the tool used, 
parameters chosen and sequencing protocol used, but typically at least 10% (and sometimes 
substantially more) of the reads cannot be mapped to the reference genome (Hatem et al. 
2013). 
Variant calling is the process of determining where the sequenced genome differs 
from the (haploid) reference genome. A variant calling algorithm determines for each base 
pair whether a homozygous or heterozygous SNV has occurred, based on the likelihood of 
observing the mapped reads at that position. Mapping and sequencing quality are also taken 
into account (Li et al. 2008). Separate steps are required to identify indels and other 
structural variants. Since longer sequencing reads can be mapped with higher confidence 
they should result in better variant calling than shorter reads (Turner et al. 2009).  
Since alignment and variant calling report the most likely genotype based on the 




Several widely-used software packages provide universal tools for read alignment and 
variant calling, such as SAMtools (Li et al. 2009) and the Genome Analysis Toolkit (GATK) 
(McKenna et al. 2010). It is worth noting that several recent comparative analyses have 
shown that results can be highly dependent on the choice of software used (Liu et al. 2013; 
O'Rawe et al. 2013; Pabinger et al. 2014). 
1.2.3 Whole Exome Sequencing 
Rather than sequence the whole genome, a more cost-effective approach to genetic 
disease studies involves sequencing only the exome, the ~180,000 exons that comprise 
around 1% of the full genome sequence (Ng et al. 2009). Several methods exist for the 
targeted enrichment of genomic regions prior to sequencing. Most suitable for the whole 
exome is hybrid capture, in which a synthetic library of DNA fragments designed to cover 
the full exome sequence are used to hybridise to and capture complementary DNA from the 
input sample (Mamanova et al. 2010; Mertes et al. 2011). 
For this purpose the definition of the exome is important. Most exome-capture kits 
work to a conservative definition based on the confirmed protein-coding sequences 
described in the Consensus Coding Sequence (CCDS) database (Pruitt et al. 2009), but a 
wider range (using definitions from databases such as RefSeq (Pruitt et al. 2014) or Ensembl 
(Flicek et al. 2014)) could include unverified coding sequences and potential pseudogenes 
(Ng et al. 2010c). For each exon, the targeted DNA sequence will usually include the exon 
body as well as short flanking regions at each end which incorporate splice acceptor and 
donor sites. Since some of the DNA fragments will overlap the target region boundaries it is 
also usual to co-capture longer flanking sequences of up to 200 bp (depending on 
sequencing read length) as a by-product; usually these are not utilised in genetic disease 
studies (Guo et al. 2012). 
Whole exome sequencing nevertheless does not capture the whole exome. Exome-
capture kits omit a small proportion of the exome from their target region due to technical 
difficulties in capturing those sequences. This can be up to 10% of CCDS-defined coding 
regions (Parla et al. 2011). In addition, due to sequence similarity with targeted regions a 
substantial fraction of sequenced reads will map to off-target regions; a recent comparison of 
exome sequencing platforms found a range of 9-35% (Clark et al. 2011). Coverage of the 
targeted regions depends on the depth at which sequencing is performed (i.e. the total 
number of reads), but the same study found that for 80M total reads only between 90% and 
97% of targeted base pairs are covered at 10× depth. This is due in large part to GC-bias, 





Despite these limitations, the wide availability of NGS instruments and the relative 
affordability of whole exome sequencing has made it an extremely popular tool for genetic 
research, as will be discussed in detail in section 1.3 below. 
1.2.4 Variant Databases 
One important development that has occurred alongside the changes in sequencing 
technology has been the growth of databases making sequence and variant information 
quickly and easily available to researchers. There are a large number of valuable data 
resources (Fernández-Suárez et al. 2014), a few of which will be briefly mentioned here. 
The 1000 Genomes Project aims to provide a comprehensive map of human 
sequence variation by using low-coverage sequencing to identify almost all variants with 
frequencies above 1% in a range of populations (1000 Genomes Project Consortium 2010). 
The UK10K Project has sequenced 4,000 genomes and 6,000 exomes from carefully 
phenotyped individuals, making the data available for the study of genotype-phenotype 
relationships (UK10K Consortium 2011). The Exome Variant Server (EVS) provides 
information on variants identified in more than 6,500 exomes (albeit with a particular focus 
on individuals with heart, lung and blood disorders) (NHLBI Exome Sequencing Project 
2014). 
The NCBI database of Short Genetic Variation (dbSNP; previously the Single 
Nucleotide Polymorphism Database) provides an archive to record all identified genetic 
variation across a range of species (Sherry et al. 2001). Newly identified variants can be 
submitted by users, and are associated with annotation including population frequency and 
disease relevance where available. More recently NCBI launched a companion database, 
ClinVar, which is more disease-focused and is designed to provide access to phenotype-
related variant annotation (Landrum et al. 2014). Similarly, the Human Gene Mutation 
Database (HGMD) has a direct focus on disease, manually curating from published literature 
mutations that cause (or are associated with) genetic disease (Stenson et al. 2014). 
Many journals now encourage authors to deposit newly identified sequence variants 
in a public database at the time of publication. This will ensure that comprehensive resources 
are available for use in methods development, epidemiological studies and in investigations 




1.3 Genetic Disease in the Post-Genomic Era 
1.3.1 Genetic Disease + NGS = Data 
NGS is a powerful tool with which to study the genetic basis of disease because it 
can give a relatively complete picture of the genetic variation of an individual. However, 
with this clarity of vision comes a new problem: making sense of the deluge of information 
now available. For example, whole exome sequencing of an individual routinely identifies 
more than 20,000 SNVs alone (Bamshad et al. 2011). Thus in the past few years genetics has 
become more than ever a data science, with a great need for methods (including novel 
analysis strategies and new bioinformatics tools) that can pinpoint those variants playing a 
role in the disease under study. 
1.3.2 Monogenic Disease: Intersection Filtering 
A key milestone in this respect came in 2009, when Ng et al. at the University of 
Washington demonstrated a systematic approach to the identification of monogenic disease-
causing sequence variants by whole exome sequencing (Ng et al. 2009). Their proof-of-
principle study focused on Freeman-Sheldon Syndrome (FSS; OMIM #193700), a rare AD 
disorder affecting ≪ 1 in 3,000 people and known to be caused by the gene MYH3 
(Toydemir et al. 2006). However, the analysis strategy is hypothesis-free, using no prior 
knowledge of the disease aetiology. 
The authors sequenced the exomes of four unrelated individuals affected with FSS 
in order to look for genes in which all four carried a sequence variant. Unrelated individuals 
are used in order to minimise the number of identical-by-descent sequence variants, and 
therefore narrow the search space at the outset. The target capture region consisted of 
26.6 Mb of CCDS coding sequence, which excluded 1.3 Mb of the exome that was 
considered poorly-mapped due to sequence similarity with other genomic regions. For each 
of the four individuals, between 95.9% and 96.4% of the target region was sequenced 
sufficiently to allow variant calling. 
There were 2,479 genes in which all four affected individuals carried a non-
synonymous coding SNV, splice-site SNV or coding indel (but not necessarily the same 
variant in all four individuals). In order to reduce the number of genes under consideration, 
several filtering steps were performed to discard variants that are less likely to cause a rare 
monogenic disease. The term intersection filtering has been used to describe this method 




Firstly, all variants catalogued in dbSNP were excluded from the analysis. The 
reasoning for this is that a rare, highly-penetrant variant is expected to cause the disease and 
therefore a variant which causes FSS is unlikely to have been described in dbSNP without 
linking it to the FSS phenotype. Since 93-94% of the identified variants for each affected 
individual were in dbSNP this drastically reduced the number of genes in which all four 
individuals carried a variant to 53. Similar reasoning suggested that the disease-causing 
variant should not be present in any of eight healthy control exomes obtained from the 
HapMap project and sequenced by the authors using the same sequencing protocols as the 
FSS exomes. Further filtering of sequence variants on this basis left just a single gene with a 
sequence variant in all four affected individuals: the correct FSS gene, MYH3. This 
 
Figure 1.1 – Overview of intersection filtering 
An example of intersection filtering applied to four exomes using three filtering steps. (1) Exomes of 
four affected individuals, with sequence variants marked in red. Five genes (green boxes) contain 
variants in all four exomes. Variants listed in dbSNP (indicated in green) are filtered out (2). Excluded 
variants are denoted in grey; note that gene B no longer contains a variant in all four exomes after 
filtering. Subsequent filtering steps against control exomes (3) and using variant prediction tools (4) 





demonstrates the power of intersection filtering to efficiently filter a large number of 
variants and quickly arrive at the disease-causing gene. 
Had it been required, a third filtering step was also available. After excluding 
variants that were not predicted to be damaging by PolyPhen, a rule-based variant classifier 
which considers the amino acid change and its effect on protein structure (Ramensky et al. 
2002), MYH3 still contained a variant in all four affected individuals. Although not needed 
in this case the authors showed that this can still be an effective filtering step by considering 
the number of genes in which any three of the four FSS patients contained a sequence 
variant. After filtering against dbSNP and the eight HapMap individuals there were 22 such 
genes; this fell to three genes after further filtering using PolyPhen predictions. (Considering 
any three of four exomes allows the authors to conclude that “modelling of even a modest 
degree of genetic heterogeneity or data incompleteness is observed to have a significant 
impact on performance”, which will be discussed further in section 1.3.11 below) (Ng et al. 
2009). 
1.3.3 Examples of Intersection Filtering 
Following this pioneering initial paper, exome sequencing with intersection filtering 
quickly became a standard technique for the study of rare monogenic diseases. Since 
previous approaches to monogenic disease genetics relied on linkage studies within 
multiply-affected families, intersection filtering offered a new opportunity to study 
extremely rare disorders using only a small number of cases, which could include sporadic 
cases or familial cases where only one affected individual’s DNA is available (Ku et al. 
2011). 
A number of review papers exhaustively list instances of monogenic disease gene 
identification through exome sequencing, the majority of which use some form of 
intersection filtering (Gilissen et al. 2011; Ku et al. 2011; Rabbani et al. 2012). Several 
examples will be discussed here to demonstrate variations of intersection filtering that have 
been successfully used in practice; these examples show that intersection filtering is an 
iterative investigative process in which logical filtering steps are applied that are consistent 
with prior expectations of the disease’s genetic architecture based on its observed mode of 
inheritance, and with the clinical phenotypes observed. 
Ng et al. followed their proof-of-concept FSS study with two applications to other 
diseases in 2010. Firstly they identified DHODH as the causal gene for Miller syndrome 
(OMIM #263750) by exome sequencing a pair of affected siblings and two unrelated cases 
(Ng et al. 2010b). Their study considered both AD and AR models, the recessive model 




ultimately identifying the causal gene. The filtering steps used were identical to the original 
FSS paper. The siblings were analysed no differently from unrelated individuals, but were 
advantageous because they were assured to have the same disease-causing gene, limiting any 
possible problems due to genetic heterogeneity. 
Secondly the same group identified MLL2 as a causal gene for Kabuki syndrome 
(OMIM #147920) by exome sequencing ten unrelated affected individuals (Ng et al. 2010a). 
Filtering was performed against known variants from dbSNP and the 1000 Genomes Project, 
and against 16 control exomes which included the FSS and Miller syndrome exomes. 
Interestingly the investigators ranked the exomes according to phenotypic severity and 
performed sequential intersection filtering with an additional filter for nonsense SNVs and 
frameshift indels only. Ultimately MLL2 mutations were identified in nine of the ten exomes 
(seven were identified through whole exome sequencing and two via subsequent Sanger 
sequencing). 
Fowler syndrome (OMIM #225790) is another example where mode of inheritance 
was successfully used as a filter (Lalonde et al. 2010). Using only two unrelated affected 
individuals, filtering against dbSNP and 1000 Genomes Project variants resulted in a single 
gene, FLVCR2, harbouring compound heterozygous mutations in both exomes. 
Hoischen et al. found that the gene SETBP1 causes Schinzel-Giedion syndrome 
(OMIM #269150) (Hoischen et al. 2010). By sequencing four unrelated affected exomes and 
filtering non-synonymous and splice site variants against dbSNP, they identified 12 genes 
harbouring variants in all four exomes. Ten of these genes were discarded because all four 
exomes carried the exact same variant, which were presumed to be as-yet-unidentified SNPs 
(that is, relatively common SNVs). Of the two remaining genes one was discarded because 
the investigators observed it had frequently contained variants in other in-house sequencing 
studies. The remaining gene, SETBP1, was found to be mutated in eight of nine additional 
cases. The disease-causing mutations were all located in a highly-conserved 11 bp exonic 
region and were confirmed to be de novo mutations by sequencing parental DNA. 
MLL was identified as a causal gene for Wiedemann-Steiner syndrome (OMIM 
#605130) by intersection filtering on four individuals under an AD model, filtering against 
dbSNP, the 1000 Genomes Project and 600 control exomes (Jones et al. 2012). MLL was the 
only candidate gene remaining when looking for sharing between any three of the four 
exomes; no causal mutation was found in the fourth exome. 
In a study of genitopatellar syndrome (OMIM #606170), the exomes of six unrelated 
affected individuals were sequenced, and intersection filtering identified causal variants in 
the gene KAT6B for five of them (Simpson et al. 2012). Initially an AR mode of inheritance 




variant in more than one exome. Causal variants were subsequently identified using a 
(sporadic) AD model. 
Intersection filtering of five unrelated Floating-Harbor syndrome (OMIM #136140) 
exomes identified causal mutations in the gene SRCAP (Hood et al. 2012). Instead of 
filtering for novel variants only, this study used dbSNP and 1000 Genomes Project data to 
exclude variants with a minor-allele frequency of ≥ 1%, as well as filtering against 270 
control exomes. The causal gene would have been identified using any four of the five 
exomes, and variants were subsequently found in SRCAP in all eight additional affected 
individuals tested. 
In a study of mandibulofacial dysostosis with microcephaly (OMIM # 610536) 
undertaken by the same group, intersection filtering initially identified MUC4 as the only 
gene containing post-filtering variants in all four sequenced exomes (Lines et al. 2012). 
However, this gene was discarded because it is frequently seen as a false positive result in 
exome sequencing studies of monogenic disease. Eight genes harboured variants in three of 
the four exomes, and the causal gene (EFTUD2) was discerned from these because it 
showed a region of reduced read depth in the fourth exome, which was subsequently proven 
to result from a chromosomal deletion spanning the last nine exons of the gene. Variants in 
EFTUD2 were identified in eight out of eight follow-up cases; the range of mutation types 
found was consistent with haploinsufficiency causing this AD/sporadic disorder. 
UVSSA was identified as a causal gene for the ultra-rare UV-sensitive syndrome 
(OMIM #614640) by intersection filtering the exomes of two unrelated affected Japanese 
individuals, neither of whom carried a mutation in ERCC6 or ERCC8, the previously known 
causal genes (Nakazawa et al. 2012). The study assumed an AR disease model and UVSSA 
was the only candidate gene after filtering against dbSNP, 1000 Genomes Project and seven 
control exomes; variants were found in the same gene in a further Japanese case and an 
Israeli subject. 
Polvi et al. identified CTC1 as a causal gene for cerebroretinal microangiopathy 
with calcifications and cysts (OMIM #612199) by intersection filtering the exomes of four 
unrelated affected individuals (Polvi et al. 2012). Of the 15 subjects available to the 
investigators, they chose to sequence two pairs having the most similar clinical phenotypes 
in order to maximise the likelihood of the same gene being causal in each case. Under an AR 
model, filtering to exclude synonymous SNVs and those previously observed in dbSNP 
resulted in four genes having two or more variants in all four exomes. CTC1 was highlighted 
as the most likely causal gene based on its function and the number of variants observed in a 





Clearly then, intersection filtering is rarely as straightforward in practice as the FSS 
test case, and it must be applied carefully in order to make best use of the information 
obtained by exome sequencing and arrive at a sensible conclusion. 
1.3.4 Key Assumptions of the Intersection Filtering Method 
Although it is a powerful analysis method, intersection filtering makes several 
assumptions. Should any of these not hold, the disease-causing variant may not be identified. 
These assumptions include: 
 That the disease-causing variants occur in exons. If the disease under study is 
caused by an intronic or intergenic sequence variant it will not be captured by 
exome sequencing. A survey of HGMD in 2010 found that 11% of recorded 
disease-causing mutations occur in introns, at least some of these being >100 bp 
from the nearest exon and typically having a functional effect by activating a 
cryptic splice site resulting in aberrant splicing (Cooper et al. 2010). 3% occur in 
gene regulatory regions which may lie in untranslated regions at the gene 
boundary or considerably further upstream. The same article describes examples 
of diseases being caused by remote deletions and other genomic rearrangements, 
as well as by mutations in non-protein-coding genes. Nonetheless, exome 
sequencing remains a prudent approach because the majority of monogenic 
diseases-causing mutations identified to date have been found in exons. 
Successful identification of the disease-causing mutation can also depend 
on the definition of the exome used for DNA capture. For example in the Kabuki 
syndrome study (Ng et al. 2010a) the causal gene (MLL2) would not have been 
captured or sequenced using the CCDS definition of the exome, but fortunately 
the more inclusive RefSeq definition was used (Ng et al. 2010c). 
 That the exonic variants are identified by whole exome sequencing. As 
discussed in section 1.2.3 above, exome capture methods are unable to target the 
complete coding region, and the portion that is captured is subject to sequencing 
error. False negative variant calls, which could result in a true disease-causing 
mutation being missed, are a bigger problem than false positive calls, which can 
be identified by Sanger sequencing (Kuhlenbaumer et al. 2011). In the Kabuki 
syndrome study, two of the nine identified causal variants were missed by whole 
exome sequencing and only discovered subsequently by Sanger sequencing; 
fortunately the sample size was large enough that the disease-causing gene could 




 That the filters applied are appropriate. At each stage of filtering the objective is 
to narrow down the list of remaining sequence variants in each exome to those 
most likely to cause a rare monogenic disease. Therefore there is a risk at each 
stage of filtering that the true disease-causing variant in one or more of the 
exomes might be incorrectly filtered out because it does not match closely 
enough the expected characteristics. For example, used blindly in the Miller 
syndrome study, PolyPhen variant effect prediction would have erroneously 
excluded a disease-causing variant in one of the exomes (Ng et al. 2010b). The 
next three points will discuss specific filtering assumptions. 
 That the variant is non-synonymous. Since synonymous mutations typically 
have a smaller effect than non-synonymous mutations it is often effective to filter 
them out, typically reducing the number of variants per exome by more than half 
(Bamshad et al. 2011). However, synonymous mutations can play a role in 
disease. While many known examples contribute to disease susceptibility, there 
are several diseases which can be directly caused by synonymous mutations, 
typically by introducing new splicing events (Sauna and Kimchi-Sarfaty 2011). 
 That the mode of inheritance is as predicted. If a disease appears to have AR 
mode of inheritance then a filtering step can be performed to leave homozygous 
or compound heterozygous variants only, as in the Fowler syndrome study 
(Lalonde et al. 2010). However, given that different variants can impact the 
encoded protein in different ways it is feasible that some sporadic cases could 
result from heterozygous changes. 
 That the variant is rare and highly-penetrant. This important assumption allows 
variants to be excluded by comparing against a population of healthy controls or 
database of known variants. If the disease under study has a severe clinical 
phenotype and is caused by a single mutation, it seems a reasonable assumption 
that the variant would have a severe molecular effect that (almost) always results 
in the disease. For example, the initial FSS study excluded variants which were 
observed in eight HapMap exomes, as well as those described in dbSNP (Ng et 
al. 2009). 
However, as described in section 1.1.3 above, it is possible that the true 
disease-causing variants are not fully penetrant for reasons that include modifier 
genes or environmental, epigenetic and other factors. A recent study investigated 




1000 Genomes Project) of mutations listed in HGMD as causing early-onset 
dysmorphic disorders. Several examples were found, suggesting at least some of 
these variants show incomplete penetrance (Winand et al. 2014). These might 
therefore be observed in a set of healthy controls used for intersection filtering. 
Arguably filtering against databases such as dbSNP will become less 
effective as more and more variants are identified and catalogued using NGS 
methods. The greater the number of whole exomes and whole genomes made 
publicly available, the more likely a rare mutation is to have been seen elsewhere 
and therefore a naive filtering approach that does not account for how those 
sequences were ascertained becomes less advisable. 
An alternative to filtering based on entirely novel variants is to consider 
both novel and very rare variants, keeping for example variants to which the 1000 
Genomes project or EVS ascribes an alternative allele frequency below a fixed 
threshold such as 1% or 0.1%. For example, a 1% threshold was used in the 
Floating-Harbor syndrome study (Hood et al. 2012). The limitations of requiring 
a very low population frequency are similar to requiring novel variants only.  
 That a single gene is responsible for all or most cases of the disease. Finally, a 
fundamental principle of intersection filtering is that by carrying DNA sequence 
variants with characteristics appropriate for involvement in a rare monogenic 
disease, unrelated individuals will independently incriminate a single functional 
unit (i.e. gene). If in fact locus heterogeneity is present, so that a number of 
alternative genes are responsible for the disease in the set of individuals 
sequenced, these may be indistinguishable from background variation because no 
gene causes a majority of cases.
*
 
Although intersection filtering studies are published which cannot 
identify a causal variant for a minority of the cases (e.g. Ng et al. 2010a; Simpson 
et al. 2012), it is difficult to estimate the number of studies which do not make it 
                                                     
*
 Technically intersection filtering can be effective without all or most cases of a disease being caused 
by a single gene: the method just requires that a gene is responsible for a sufficient number of cases to 
stand out against background variation after filtering. For small samples (as in the examples cited in 
section 1.3.3) this will usually mean one gene being responsible for all or most cases unless very 
stringent filtering can be employed. For example, Tatton-Brown et al. were able to show that 
mutations in DNMT3A cause an overgrowth syndrome with intellectual disability (OMIM #615879) 
because two of their ten cases carried a variant after filtering (Tatton-Brown et al. 2014). However, 
this was only possible because their “filtering” step was to identify the de novo sequence variants for 
each case, which requires the sequencing of additional exomes (discussed further in section 1.3.6). 





to publication because they do not find any causal gene. However, it seems likely 
that the proportion of studies that are unsuccessful will grow as the number of 
diseases which are good candidates for intersection filtering (unsolved single-
gene monogenic diseases; these are more likely to have a clear inheritance pattern 
and thus be studied first) falls. 
Note that unlike association studies, which need to carefully match the ethnic 
backgrounds of case and control cohorts, intersection filtering does not require any explicit 
assumptions about the ethnic background of case and control exomes. Since genes have 
similar functions across ethnic populations, a mutation with a severe effect could generally 
be expected to have a similar phenotypic outcome for different ethnic populations. Control 
exomes in this case are used simply to rule out disease-causing variants. Nevertheless there 
are a couple of points to be aware of: different ethnic populations could in theory carry 
different alleles of modifier genes; and, any control exomes that have a different ethnic 
background to the cases may be less effective as filters because the set of SNVs found in the 
two populations will not fully overlap (although Ng et al. showed that the use of HapMap 
control exomes of different ethnic backgrounds could still be effective (Ng et al. 2009; Ng et 
al. 2010a; Ng et al. 2010b)). 
It is important to be aware of these assumptions, and to factor them in to the study 
design and to the interpretation of intersection filtering results. 
1.3.5 Some Genes Frequently Contain Variants 
The reason that intersection filtering is needed at all is that every exome carries 
20,000 or more SNVs (Bamshad et al. 2011), making it very difficult to pick out which one 
may cause a disease. One problem for the intersection filtering approach is that some genes 
are much more likely than others to contain rare non-synonymous SNVs, the majority of 
which are not disease-causing (Petrovski et al. 2013). These include genes such as TTN that 
have particularly long coding sequences, as well as highly polymorphic genes such as those 
encoding olfactory receptor proteins. Such genes cause problems because they tend to 
contain many SNVs per individual, giving a good chance that one or more will remain after 
all filtering steps are completed (e.g. Lines et al. 2012). 
There are also technical reasons why genes might frequently appear as false 
positives in exome sequencing studies, including susceptibility to read misalignment and the 




Although there exist tools to predict whether variants are disease-causing (see 
section 1.3.7), coping with frequently-mutated genes continues to be a challenge for 
intersection filtering studies. 
1.3.6 Monogenic Disease: Alternative Approaches 
Whole exome intersection filtering is not the only approach to finding monogenic 
disease genes using NGS. Several alternative approaches take advantage of basic genetic 
principles to effectively pinpoint causal variants (often by building on pre-genomic 
techniques). 
For X-linked disorders, it can be sufficient to sequence only the X chromosome and 
perform intersection filtering (Johnston et al. 2010). However, given the falling cost of NGS 
it may be more advisable to sequence the whole exome and exclude non-X chromosome 
variants as a provisional filtering step. 
Where exomes are available from multiple affected family members it is possible to 
perform a combination of exome sequencing and linkage analysis. Since the same mutation 
is expected to cause the disorder for related individuals, only the variants shared by affected 
family members need be considered. The more recombination events that separate two 
members of a family (and the more family members sequenced), the shorter the list of 
shared variants will be; unaffected family members can also be sequenced to filter out non-
causal mutations. Wang et al. provide an example where a disease-causing gene for a 
spinocerebellar ataxia (OMIM #613908) was identified by exome sequencing four affected 
individuals from the same family and filtering shared variants (Wang et al. 2010b). In other 
studies, linkage is performed first to identify a candidate region, with exome sequencing of 
related affected individuals used to pinpoint the causal gene within that region (Depienne et 
al. 2012; Rademakers et al. 2012). This approach also shows potential to study diseases with 
more complex genetics: recently, family-based exome sequencing was used to identify a 
risk-gene for familial Alzheimer’s disease (Cruchaga et al. 2014). 
For affected individuals born to a consanguineous union, homozygosity mapping 
can be used to identify long stretches of homozygous DNA sequence in a single patient. 
These autozygous regions are strong candidates to harbour mutations causing AR diseases. 
The mapping is typically done using genotyping arrays, before exome sequencing is used to 
examine the implicated regions in greater detail (e.g. Walsh et al. 2010; Abou Jamra et al. 
2011; Cullinane et al. 2011; Erlich et al. 2011). 
For disorders thought to be caused by de novo mutations (for example, where there 
is no family history of disease), exome sequencing of parent-child trios can be performed. 




(O'Roak et al. 2011). This approach has been used successfully to identify causal mutations 
in multiple genes for relatively common sporadic diseases such as autism spectrum disorders 
(O'Roak et al. 2011; O'Roak et al. 2012) and schizophrenia (Fromer et al. 2014). 
1.3.7 Variant Effect Prediction 
A complementary approach to analysing large numbers of sequence variants is 
variant effect prediction. Tools that estimate the functional impact of a variant can be 
effective either as an intersection filtering step or as a method of prioritising genes for 
further study when multiple viable disease-causing variants remain after initial analysis. The 
aim of such tools is to estimate the likelihood that an observed variant is pathogenic. A range 
of evidence types can be used, such as the degree of evolutionary sequence conservation 
relative to other species or the impact of the variant on the encoded protein in terms of 
sequence (e.g. whether it occurs in a binding site), biochemistry (e.g. charge, 
hydrophobicity) or structure (e.g. where the variant occurs in the folded protein) (Cooper 
and Shendure 2011). 
SIFT is a widely-used tool that scores amino acid-altering variants using sequence 
homology; variants in amino acids that are more highly conserved across a range of species 
are assumed to be more deleterious (Kumar et al. 2009). SIFT provides an example of a tool 
that directly estimates deleteriousness based on biological assumptions, as does MAPP, 
which incorporates biochemical properties (Stone and Sidow 2005). 
Other tools use a machine-learning approach to estimate deleteriousness, basing 
predictions on a range of variant properties and using true positive and true negative datasets 
to derive classification rules. The advantage of this approach is that a wide range of variant 
properties can be considered without establishing in detail the biological relationships 
between them. Conversely, the interpretation of a variant’s score is less clear. 
For example, PolyPhen-2 predicts variant effect using eleven structure- and 
sequence-based features (including PSIC scores (Sunyaev et al. 1999), which use sequence 
data from homologous proteins to assess the likelihood of observing a variant) (Adzhubei et 
al. 2010). MutationTaster uses different classifiers for variants which cause no amino acid 
change (including intronic variants), variants affecting one amino acid and variants with 
more complex effect, and bases predictions on evolutionary conservation as well as 
biochemical and structural properties (Schwarz et al. 2010). 
Several tools quantify evolutionary conservation of nucleotide sequence (rather than 
focusing on properties of the encoded protein), making them suitable for variants in both 
coding and non-coding regions. These include Genomic Evolutionary Rate Profiling 




mammalian genomes than expected (Cooper et al. 2005). PhyloP uses four different 
statistical tests (including GERP) to measure sequence conservation (and faster than neutral 
nucleotide substitution) (Pollard et al. 2010). 
Given that these various approaches to predicting variant effect are based on 
different underlying assumptions, several attempts have been made to combine information 
from different approaches into an integrated pathogenicity score. Thus, for example, 
CAROL combines predictions from SIFT and PolyPhen-2 (Lopes et al. 2012), CoVEC 
integrates scores from four different individual classifiers (Frousios et al. 2013), and Condel 
from five (Gonzalez-Perez and Lopez-Bigas 2011). The KGGSeq analysis platform 
implements a logistic regression which combines scores from SIFT, PolyPhen-2, 
MutationTaster, PhyloP and a likelihood ratio test based on sequence conservation (Li et al. 
2012). These tools show improved performance relative to any of the individual classifiers 
from which they are derived. 
1.3.8 Verifying Causal Variants 
When a monogenic disease-causing variant is identified by exome sequencing it is 
necessary to validate the finding and demonstrate supporting evidence for causality 
(MacArthur et al. 2014). 
Given the relatively high error rate of NGS, the first requirement is to Sanger 
sequence the variant-containing gene in the case exomes, in order to confirm the mutations 
are true positives. 
Variant effect prediction tools (discussed in the previous section) can provide 
supporting evidence that a mutation is expected to have a severe phenotypic effect. Beyond 
this, there are two broad classes of evidence to link the mutation to the specific phenotypic 
effect that is the disease. 
Statistical genetic evidence can be provided by showing statistically significant 
association with the disease in a case-control study. Association could be tested for the 
individual variant by genotyping a large number of cases and controls at that locus, or for the 
containing gene by sequencing and performing a burden test. It is also possible to strongly 
suggest causality in familial cases by identifying segregating variants in the same gene in 
multiple affected families (Rabbani et al. 2012). 
Experimental functional evidence can also apply at the variant or gene level, and can 
include: demonstrating that knocking out the gene or introducing the variant in an animal 
model results in a consistent phenotype; showing that the gene is expressed in disease-
relevant tissues and/or that expression is affected by the variant; or demonstrating that the 




variant occurs in a protein domain likely to impact this interaction (for example, see Jones et 
al. 2012; Nakazawa et al. 2012). 
1.3.9 Complex Disease: Rare Variant Association Testing 
Beyond monogenic disease, exome sequencing is also used to study common 
complex disease, providing an alternative to the common disease–common variant study 
design of GWAS. NGS enables testing of the hypotheses that many small-effect rare 
variants or fewer large-effect rare variants explain the heritability of common diseases 
(Gibson 2011). 
To this end, several region-based association tests have been developed that 
determine whether there is a statistically significant overoccurrence of rare variants within 
defined regions (usually genes) in case exomes relative to controls. Li and Leal compared 
single marker tests (which test single variants separately and then combine test results across 
a region), multiple marker tests (which test all variants in a region simultaneously using a 
multivariate test) and collapsing methods (which seek to avoid large multiple testing 
corrections by simply testing for presence or absence of rare variants in a region) (Li and 
Leal 2008). They developed a combined multivariate and collapsing (CMC) test and showed 
it to be more powerful than any of the individual methods. The CMC test is a “burden” test 
because it assumes all rare variants in a gene affect the phenotype in the same direction and 
to a similar degree (Lee et al. 2012). 
Other tests have looked to improve power by using a weighting scheme that places 
higher emphasis on rarer variants (Madsen and Browning 2009), by using a variable 
frequency threshold to classify rare variants (Price et al. 2010) or by testing the variance 
rather than the mean of rare variant counts to allow for a mixture of risk and protective 
variants in a region (Neale et al. 2011). This last approach is generalised by the sequence 
kernel association test (SKAT), a widely-adopted method that allows covariates to be 
incorporated using multiple regression (Wu et al. 2011). Finally, since burden tests remain 
more powerful than SKAT when variant effects are highly correlated, SKAT-O seeks an 
optimal combination of the two tests (Lee et al. 2012). 
These association tests can only test for the presence or absence of rare variants, and 
not whether those variants play a functional role. Thus their power is affected by the way 
that functional information is incorporated: collapsing tests suffer if non-functional variants 
are included (and potentially, due to sequencing gaps or annotation errors, if functional 
variants are excluded), while methods that can incorporate variant effect prediction (such as 
SKAT) rely on the accuracy of these scores. If a gene is significantly associated with a trait, 




demonstrate the mechanism of causality – although it may be possible to pick out good 
candidate variants based on sequence conservation or functional effect (e.g. Cruchaga et al. 
2014; Holmen et al. 2014). 
1.3.10 Beyond Exome Sequence Data 
In a sense, exome sequencing represents the tip of a data iceberg. Continuing 
improvements in NGS and other high-throughput technologies have led to a broad range of 
data-driven disciplines focusing on a range of physiological systems. One of the great 
challenges facing bioinformaticians in the immediate future is to keep up with the rate of 
data generation, developing novel integrative approaches to handling these data and drawing 
out biological insights (Hawkins et al. 2010). 
It is expected that whole genome sequencing will ultimately become a more cost-
effective approach to study disease than whole exome sequencing, allowing analysis of 
variants outside of protein-coding regions. However, identifying and understanding the 
disease-causing role of such variants will be difficult due to the size of the genome and our 
limited knowledge of non-exonic function; convenient functional units for intersection 
filtering are not well-defined as the genes are for the exome (Boycott et al. 2013). Whole 
genome sequencing of matched tumour and normal tissue pairs can also provide a complete 
picture of the mutations found in cancer cells (Goh et al. 2011), and an understanding of the 
regulatory function of non-coding regions is needed to help distinguish the key driver 
mutations that give cancer cells a selective advantage from the passenger mutations that 
occur as a by-product of uncontrolled cell division (Stratton et al. 2009). 
However, annotation of non-coding regions is improving through efforts such as the 
Encyclopedia of DNA Elements (ENCODE) project, which has systematically searched the 
genome for units of DNA sequence with likely biochemical function, including transcribed 
regions, transcription factor binding sites, regions with distinct chromatin structures and 
enhancer- or promoter-like features, and DNA featuring specific histone modifications 
(ENCODE Project Consortium 2012). Although there are necessary limitations in the scope 
of this work (Eddy 2013), it is a good first step towards a more comprehensive 
understanding of the regulatory role played by non-exonic DNA. 
Beyond sequencing an individual’s DNA, NGS has enabled the acquisition of a 
number of high-throughput data types. This is frequently referred to as “omics” data when it 
encompasses all of a particular class of molecule. For example, RNA-seq has become a 
viable alternative to expression microarrays for the study of gene expression, allowing 
quantification of the whole transcriptome in a given cell type under different conditions 




Likewise, data generation has begun apace in fields such as: epigenomics, which 
studies DNA modifications (for example, bisulfite sequencing can identify genome-wide 
DNA methylation (Krueger et al. 2012)); proteomics, the study of the structure and function 
of the entire set of proteins in an organism (Altelaar et al. 2013); metabolomics, in which 
chemical processes in cells are studied via metabolites (Wishart et al. 2013), and 
metagenomics, which studies environmental DNA (for example characterising the essential 
microbes found in the human gut by their genomes (Qin et al. 2010)). This thesis will have a 
particular interest in the interactome, as will be discussed in detail in section 1.4. 
1.3.11 The Need for New Bioinformatics Methods 
While the growing volume of biological data provides new opportunities to improve 
our understanding of human genetic disease mechanisms, it will be a challenging process to 
integrate such diverse data types and draw meaningful conclusions. 
For monogenic disease in particular, identifying the causal variants from whole 
exome sequencing data will become increasingly challenging as intersection filtering and 
related approaches provide diminishing returns. A variety of complicating factors mean that 
the continued success of existing methods will be limited. These include locus 
heterogeneity, suggesting a more complex underlying biology and increasingly likely as 
more common genetic diseases are studied (Gilissen et al. 2011), the existence of diseases 
with overlapping clinical phenotypes, and phenocopies which may confound analyses 
because they have different disease mechanisms. 
New methods that can integrate emerging omics data into whole exome sequencing 
studies should prove more successful at untangling these complex genotype-phenotype 
relationships. The goal of this thesis will be to develop and examine exome sequence 
analysis methods that counter genetic heterogeneity by using interaction networks to identify 
putative molecular pathways underlying monogenic disease. 
1.4 Interaction Networks 
1.4.1 Network Basics 
Networks provide a structured way to represent information about how genes 
interact with one another. Genes are represented as network nodes, and two nodes are 
connected by an edge when the two genes are related, the type of relationship defining the 
type of network. Edges can be directed and/or weighted, depending on the information they 




In mathematical terms interaction networks are graphs. Graph theory has a long 
history as a well-studied branch of discrete mathematics; this means that many network 
properties are well characterised and that efficient algorithms exist for many standard 
network analysis problems. From a biological point of view, graph theory provides a 
powerful framework which can take pairwise relationships between genes and suggest 
hypotheses about the way those genes function together as part of a system (Mason and 
Verwoerd 2007). Networks can be employed to systematically interpret experimental data 
for a wide range of investigations, including the study of disease processes. 
Graph theory has a wealth of terminology and it is worth defining some basic terms 
here (illustrated in Figure 1.3). A neighbour of node g is any node that is connected to g by 
an edge, and the number of neighbours is denoted the degree of g. A path from node g to 
node h in an unweighted and undirected network is a sequence of nodes g = g1, g2, …, gn = h 
such that successive nodes in the sequence are neighbours. A path’s length is the number of 
edges it traverses, and the minimum distance between node g and node h is the length of the 
shortest path that connects them. Two nodes are in different components of a network if 
there is no path that connects them. Cliques are subnetworks in which every node is 
connected to every other node by an edge. 
 
Figure 1.2 – Network edge types 
1. Unweighted and undirected edges represent binary relationships between genes such as interaction 
of their protein products (A interacts with B but not with E); 2. Directed edges can indicate a 
directional relationship such as regulation; 3. Weighted edges can be used to indicate correlation or 




1.4.2 Protein Interaction Networks 
Protein interaction networks (PINs) connect two genes when there is evidence that 
the proteins they encode interact physically
*
 (Raman 2010). Two high-throughput methods 
have mainly been used to generate evidence of protein-protein interactions (PPIs) (Lehne 
and Schlitt 2009). 
The yeast two-hybrid method involves binding protein A to the transactivation 
domain and protein B to the DNA-binding domain of the yeast transcription factor GAL4. If 
the transactivation domain is located in a promoter region of a gene in yeast it will trigger its 
transcription. Interaction of proteins A and B thus allows the transactivation domain to be 
                                                     
*
 Formally a PIN connects proteins that interact, not genes. However, interactions between specific 
protein isoforms are not readily available in protein-protein interaction databases and in general PINs 
treat all isoforms of a protein as a single node (in which case it is convenient to refer to this node by 
the encoding gene). A recent report of a small isoform-resolved PIN suggests that it will become 
necessary to avoid this conflation in future (Corominas et al. 2014). 
 
Figure 1.3 – Network terminology 
This network consists of three components; no path exists from a node in one component to a node in 
another. The red node has three neighbours and hence degree 3. A clique of five nodes is indicated in 
blue. The yellow nodes and edges indicate a path between nodes A and B of length 4. However the 




recruited to an upstream activating sequence inserted in front of a reporter gene, resulting in 
its expression (Fields and Song 1989). 
The tandem affinity purification and mass spectrometry (TAP-MS) method involves 
tagging the protein of interest with a compound protein fragment that allows two rounds of 
affinity purification. Proteins interacting with the tagged protein are co-purified and 
subsequently retained when the tag is cleaved. After eluting, the proteins making up the 
complex are identified via mass spectrometry (Rigaut et al. 1999). 
Several databases collate interactions derived via these high-throughput methods, 
along with literature-curated interactions identified in smaller-scale experiments and 
interactions deposited directly by researchers. PPIs are studied for a wide range of 
organisms; larger databases that contain human PPIs include the Human Protein Reference 
Database (HPRD; Keshava Prasad et al. 2009), BioGRID (Chatr-Aryamontri et al. 2013), 
IntAct (Orchard et al. 2014) and the Biomolecular Interaction Network Database (BIND; 
Isserlin et al. 2011). 
There also exist meta-databases, such as the Protein Interaction Network Analysis 
(PINA) platform (Cowley et al. 2012), which integrate data from several of these primary 
sources. Although meta-databases can include more data they often lag behind the primary 
databases in incorporating new interactions. It is also a non-trivial task to integrate different 
data sources, for example due to the complex mapping between different gene and protein 
identifiers (Lehne and Schlitt 2009). 
PINs can be derived by downloading the contents of a PPI database and constructing 
an unweighted and undirected network based on pairwise PPIs. 
1.4.3 Other Types of Interaction Network 
Although PINs are perhaps the most studied type of biological network in the 
context of human disease, networks can be constructed using any type of relationship 
between genes. Many other classes of network have been studied. 
Co-expression networks connect two genes when there is statistically significant 
similarity in their expression patterns across gene expression datasets covering multiple cell 
types and conditions (Stuart et al. 2003). Genome-wide expression profiles can be obtained 
using microarrays comprising DNA probes; the mRNA present in a cell is converted to 
complementary DNA (cDNA), labelled with a fluorophore and hybridised to the array, so 
that an optical signal will be emitted at probes corresponding to expressed mRNA (Schena et 
al. 1995). More recently, RNA-seq has provided a sequencing-based approach to mRNA 
quantification (Marioni et al. 2008). One useful resource is COXPRESdb (Co-expression 




experiments for over 19,000 human genes (Obayashi et al. 2013). Co-expression networks 
are undirected but edge weights can express the degree to which each pair of genes is co-
expressed. An unweighted (binary) network can be derived using a threshold for correlation. 
Gene regulatory networks have directed edges that describe regulatory relationships 
between genes. Transcription factor proteins regulate the expression of other genes by 
binding to their promoter regions, either enabling or preventing the recruitment of RNA 
polymerase to begin transcription. Hence a network encoding such relationships can contain 
different node types (transcription factor genes and regulated genes) and directed edges (Lee 
et al. 2002; Shen-Orr et al. 2002; Babu et al. 2004). 
Metabolic networks connect enzymes that catalyse consecutive reactions and 
correspond to implicit underlying networks of chemical reactions with nodes representing 
biological compounds and edges representing reactions (Duarte et al. 2007; Yamada and 
Bork 2009). 
Networks of genetic interactions can also be inferred by knocking out genes in 
model organisms, for example by comparing genome-wide expression levels (Li et al. 2013) 
or phenotypic traits between different gene knockouts (Wang et al. 2013b), or looking for 
deviations from the expected effect of double-knockout models based on the observed effect 
of single gene knockouts (Costanzo et al. 2010). 
Literature or co-citation networks are undirected networks that are constructed 
computationally and do not directly use experimental results. In the simplest case, two genes 
are connected when they are found to have been cited together in publication abstracts 
significantly frequently, suggestive of some functional relationship (Jenssen et al. 2001). 
More sophisticated text-mining approaches exist to identify connections between genes, 
such as the “relatedness” measure developed by Raychaudhuri et al. that assesses the 
similarity of descriptive text in literature abstracts without necessarily requiring co-citation 
(Raychaudhuri et al. 2009). 
However, due to the lack of direct empirical evidence supporting specific 
interactions literature networks are not usually depended on exclusively for the study of 
molecular systems or the interpretation of experimental data; rather, text-mined evidence for 
interaction is used to improve the accuracy of other types of network, for example by 
providing prior knowledge from which Bayesian networks describing co-expression 
(Djebbari and Quackenbush 2008) or gene interaction (Olsen et al. 2014) can be constructed. 
STRING is a database of PPIs which supplements interactions derived from high-throughput 
experiments with interactions predicted by text-mining, as well as those predicted using 




Finally, with the goal of achieving a more comprehensive picture of sub-cellular-
level processes, functional networks have been constructed which integrate diverse 
interaction types. For example, the HumanNet network connects genes using functional 
relationships learned from PPIs, co-expression, genomic context of orthologous genes across 
archaea and bacteria, protein domain co-occurrence, interaction in model organisms and 
literature-mining (Lee et al. 2011). The Multinet network combines interactions from protein 
interaction, genetic, regulatory and metabolic networks together with phosphorylation 
relationships and membership of common signalling pathways (Khurana et al. 2013). 
Interaction networks are typically used to provide a tractable genome-wide 
representation of our knowledge of how genes relate to one another, giving a context for the 
further analysis of many types of experimental results (discussed in subsequent sections). 
When deciding on an interaction network for this purpose it should be noted that there is a 
natural conflict between genomic coverage on the one side, and interpretability of, and 
confidence in, the interactions represented on the other. 
1.4.4 Network Topology Provides Clues to Gene Function 
It is well established that interaction networks are organised non-randomly, so the 
study of a network’s global structure or topology can reveal clues to the underlying biology 
of the genes involved. 
Interaction networks tend to display a scale-free topology, which means the 
proportion of network nodes having degree k tends to have a power-law distribution, such 
that P(k) ≈ Ak-γ for some degree exponent γ (usually between 2 and 3) and constant of 
normalisation A (Albert 2005). In practice this means that interaction networks contain many 
nodes of small degree and fewer nodes of large degree, with a handful of very high-degree 
“hub” nodes (see Figure 1.4). (Hub genes can be alternatively defined as those having a high 
betweenness centrality, where a large proportion of the shortest paths between all pairs of 
nodes pass through the gene, or closeness centrality, where the gene has a low average 
distance to all other nodes.) 
Studies in model organisms have shown that hubs in PINs tend to represent essential 
genes for which knockouts are lethal (Jeong et al. 2001; Hahn and Kern 2005), and to be 
evolutionarily conserved (Fraser et al. 2002; Saeed and Deane 2006; Kim et al. 2007). This 
is generally attributed to the central role played by hub genes in the network’s structure 
(removal of hub genes has more severe consequences to network topology than non-hub 
genes), but an alternative theory is that it is not genes but certain PPIs that are essential, with 
hub genes the most likely to participate in an essential PPI because they participate in the 




“party” or “date” hubs depending on whether they interact with many other genes 
simultaneously (playing a central role in a specific function) or at different times and cellular 
locations (connecting genes involved in different processes) (Han et al. 2004). The relative 
essentiality of party and date hubs has been debated (Han et al. 2004; Kim et al. 2006). 
Another area of study is how networks are organised into distinct functional 
modules. Communities or modules can be loosely defined as groups of network nodes that 
are connected by relatively many edges but have relatively few connections to nodes outside 
of the group (Fortunato 2010) (see Figure 1.5). Many clustering algorithms exist to 
determine communities from global network structure, and applications of such algorithms 
to interaction networks have revealed communities of interacting genes that are shown to 
have related functions, for example by comparison with known protein complexes or Gene 
Ontology terms (Spirin and Mirny 2003; Luo et al. 2007; Lewis et al. 2010; Li et al. 2010). 
Weighted gene co-expression network analysis has emerged as a popular method of 
analysing gene expression data by systematically identifying modules of genes that have 
correlated expression (Langfelder and Horvath 2008). Modules are then considered as basic 
functional units to simplify the analysis of external data, and to generate systems-level 
hypotheses by studying inter-module relationships. 
It has also been demonstrated that network structure on a local, rather than global, 
scale can be informative. Network motifs, small recurring patterns of interaction that occur 
more frequently than expected by chance, have been identified in many types of directed 
networks (Milo et al. 2002). In gene regulatory networks, motifs correspond to specific types 
 
Figure 1.4 – Example degree distribution for a scale-free network 
The Multinet network that combines various interaction types (see section 1.4.3) has an 




of regulatory mechanism (Babu et al. 2004) and almost all regulation can be understood in 
terms of a small number of motifs (Alon 2007). Many algorithms have been developed for 
motif identification but it has been noted that caution should be used in their application 
because not all motifs in a network are necessarily biologically meaningful (Kim et al. 
2011). 
To examine the local- to intermediate-range structure of interaction networks, 
Pržulj et al. developed the concept of graphlets, which characterise all possible induced 
subnetworks of up to five nodes (Pržulj et al. 2004). For each gene a “graphlet degree 
signature” is determined, describing the number of graphlets of each type in which it 
participates. Graphlet degree signatures have been shown to correlate with gene function 
(Milenković and Pržulj 2008) and to highlight biologically important genes (Milenković et 
al. 2011). 
But while it has been shown that network topology can be informative regarding 
gene function, an overreliance on such analyses has been cautioned. For example, Gillis and 
Pavlidis suggest that the presence of multifunctional genes may give a deceptively 
favourable impression of consistent function in local network regions (Gillis and Pavlidis 
2011). Meanwhile Ideker and Krogan highlight that inferences drawn from static networks 
(as described in sections 1.4.2 and 1.4.3) are limited, and that consideration of how 
interaction networks change in response to different biological stimuli is necessary for a 
fuller understanding of how genes function together (Ideker and Krogan 2012). 
 
Figure 1.5 – Communities in a network 
Communities consist of nodes that are more highly connected to each other than to nodes elsewhere in 




1.4.5 Network Properties of Disease Genes 
By considering genes that contain known inherited disease mutations, Feldman et al. 
show that disease-causing genes tend to be of intermediate connectivity in PINs, having 
higher average degree than non-disease genes but generally not representing hubs (Feldman 
et al. 2008). Goh et al. distinguish essential from non-essential disease genes and find no 
tendency for the non-essential disease genes to be network hubs (Goh et al. 2007). These 
findings are consistent with the notion that mutations in hub genes are more likely to be 
lethal during gestation, while mutations in genes of intermediate centrality are more likely to 
be viable, but result in a disease phenotype (Goh et al. 2007; Feldman et al. 2008). In the 
Multinet network, which integrates various types of interaction, genes were categorised into 
tolerant of loss-of-function mutations, neutral, disease-causing and essential, and a 
statistically significant increasing trend was observed in average degree across these 
categories (Khurana et al. 2013). 
It has been shown that disease genes are significantly more likely to interact with 
one another than with non-disease genes (Gandhi et al. 2006). Further, when OMIM diseases 
were classified based on organ system and disease type, most classes exhibited strong 
enrichment for PPIs between within-class causal genes relative to across-class causal genes 
(Gandhi et al. 2006). Likewise, pairs of genes causing the same disorder were found to be 
significantly likely to interact in a PIN (Goh et al. 2007; Feldman et al. 2008). Van Driel et 
al. use a text-mining framework to quantify the phenotypic similarity between different 
diseases, finding that this measure is correlated with the connectedness of causal genes in a 
PIN (van Driel et al. 2006). This supports the idea of moving past arbitrary syndromic 
definitions, considering instead that similar clinical phenotypes might result from mutations 
in a localised region of an interaction network (Oti and Brunner 2007). 
It could be argued that the reported enrichment of interactions between disease-
causing genes results from a knowledge bias, since the functional roles of such genes are 
closely scrutinised once they are identified. However, this argument is countered by the 
finding that genes associated with the same complex disease via GWAS, a hypothesis-free 
approach, also display an enrichment of interactions (Barrenas et al. 2009). Similar evidence 
has been identified by exome sequencing. Two studies found that a statistically significant 
number of de novo truncating or severe missense mutations identified in autism spectrum 
disorder trios occurred in genes forming a highly interconnected subnetwork in a PIN (Neale 
et al. 2012; O'Roak et al. 2012). Recently, candidate causal genes for hereditary spastic 
paraplegias (HSP) found by intersection filtering were also found to be significantly highly 




Barabasi et al. provide a neat conceptualisation of this relationship. They 
differentiate topological modules from functional modules (connected sets of genes with 
related function, discussed above in section 1.4.4) and disease modules (connected sets of 
genes with related disease roles), suggesting that a degree of overlap between these module 
types can be usefully assumed provided the distinction is not forgotten (Barabasi et al. 
2011). A more detailed understanding of the topology of such functional and disease 
modules is needed to explain how diseases can display phenotypic variability, and how 
genes can have roles in different diseases; for example genetic variants which affect 
different binding domains of a protein can “perturb” different edges of a PIN, with distinct 
phenotypic consequences, each different again to a variant which causes a complete loss of 
function, effectively removing a node from the network (Zhong et al. 2009). 
1.4.6 Network Methods for Disease Gene and Pathway Identification 
Given that networks describe functional relationships between genes and that 
disease-causing genes tend to be co-localised in interaction networks, numerous methods 
have been developed that make use of network data to identify or prioritise disease-causing 
genes in high-throughput studies. 
To investigate how well network-based guilt-by-association (GBA) methods can 
predict disease-causing genes, Lee et al. considered six different GBA methods applied to 
the HumanNet confidence-weighted network of multiple interaction types, with performance 
measured using cross-validation analysis on sets of known disease genes (Lee et al. 2011). 
Starting with initial gene scores of 1 for disease genes and 0 for all other network genes, two 
diffusion methods that are mathematically related to Google’s PageRank algorithm (Brin 
and Page 1998) offered the best performance. Other methods considered were based on 
simple neighbour counting, naive Bayes label propagation (in which edge weights, rather 
than the neighbouring genes themselves, are summed), network clustering and an electrical 
circuit algorithm (Lee et al. 2011). 
However, most de novo pathway discovery methods are designed for application to 
complex diseases and cancers (Lehne and Schlitt 2012). Several approaches focus on 
expression microarray data, with the aim of identifying dysregulated subnetworks – 
connected sets of genes in the network that collectively show differential expression 
between two experimental conditions (for example different samples representing different 
disease states). Ideker et al. developed jActiveModules, a tool which uses simulated 
annealing (Kirkpatrick et al. 1983) to identify subnetworks that minimise a combined 
differential expression p-value function (Ideker et al. 2002). The MATISSE tool 




expression dataset being analysed, before clustering to identify relevant network modules 
(Ulitsky and Shamir 2007). 
A related tool from the same group, DEGAS, reformulates the problem, considering 
separately the genes differentially expressed in each of a number of disease-affected 
individuals (Ulitsky et al. 2010). Within a PIN they search for the smallest connected 
subnetwork in which all but l of the individuals have at least k differentially expressed 
genes, for suitable parameters k and l, employing a greedy algorithm which is limited to 
subnetworks of small radius around a root node. The KeyPathwayMiner tool addresses the 
same problem, taking a less sophisticated approach by classifying genes as differentially 
expressed if they exhibit differential expression in all but l samples, and seeking maximal 
subnetworks in which all but k genes are differentially expressed (Alcaraz et al. 2011; 
Alcaraz et al. 2012). Subnetworks are identified using an Ant Colony Optimisation heuristic, 
and results are broadly comparable to DEGAS (but the authors note that the repurposed k 
and l parameters are more intuitively interpretable and it is no longer necessary to specify a 
minimum subnetwork size). 
Several approaches seek to identify subnetwork markers whose dysregulation is 
predictive of cancer type or prognosis; various methods have been proposed based on graph-
search (Chuang et al. 2007; Dao et al. 2010; Chowdhury et al. 2011) and integer linear 
programming algorithms (Dittrich et al. 2008; Backes et al. 2012). 
Besides expression microarray data, the other main application of networks in 
disease gene identification has been to GWAS data. Networks have been employed both to 
highlight potentially relevant genes from the many which can be in LD with genome-wide 
significant SNPs, and to explore the disease role of SNPs that show nominally significant 
disease association but do not quite exceed the stringent genome-wide significance level 
after correction for multiple testing. 
In the former category, Rossin et al.’s DAPPLE tool seeks to identify disease genes 
and suggest underlying molecular processes by identifying connected genes in a PIN that are 
in LD with different disease-associated GWAS SNPs. Connectivity of identified 
subnetworks is assessed by comparison to 50,000 randomly permuted PINs (Rossin et al. 
2011). This approach is conceptually similar to GRAIL (developed by the same group), 
which examines literature-derived relationships instead of PPIs to infer disease-relevant 
interactions between genes in different implicated GWAS loci (Raychaudhuri et al. 2009). 
On the other hand, to overcome the stringent genome-wide significance cut-off 
required for GWAS, Baranzini et al. present an analysis strategy which searches for 
subnetworks of a PIN showing disease association. Gene-wise p-values are obtained by 




jActiveModules tool (described above) is employed using these gene-wise measures of 
association in place of the usual differential expression p-values (Baranzini et al. 2009). 
Region Growing Analysis (RGA) is a related network-search method. It first ranks genes 
according to GWAS SNP association (adjusted for gene size), before examining various 
ranking thresholds to identify network regions enriched for GWAS signal. Significance is 
established using degree-constrained network permutation (Lehne 2011). In the HumanNet 
edge-weighted network, Bayes label propagation (as discussed above) was shown to 
successfully identify disease-linked genes which interact with those identified via GWAS 
(Lee et al. 2011). 
To date, there have been relatively few network methods designed specifically to 
identify disease-causing genes using NGS data. Whole exome sequence data usually 
contains few directly disease-relevant variants and much noise, and initially, at least, sample 
sizes have been relatively small. Therefore it may not be possible or appropriate to directly 
apply network methods designed for microarray or GWAS data, which have different 
statistical properties. The secondary nature of network-based methods means that their 
development will inevitably lag behind direct analysis of NGS data, particularly when it has 
been initially so fruitful. 
However, for diseases with known causal genes, one natural approach is to use 
simple GBA to help prioritise variants identified by whole exome sequencing. Thus tools 
have begun to appear which provide an integrated exome analysis framework which can 
perform variant filtering and highlight those variants found in genes which interact with 
some specified seed list (Li et al. 2012; Sifrim et al. 2012). One successful application of 
GBA to exome data was the HSP study referred to in section 1.4.5 above; after initial exome 
sequence analysis identified a subnetwork of causal genes, examination of the neighbouring 
genes and a second cohort of exomes identified three further candidates (Novarino et al. 
2014). 
An example where an existing tool could be applied is one of the autism spectrum 
disorder studies, where the DAPPLE tool (originally designed to analyse GWAS loci) was 
used to infer a relevant PIN subnetwork from de novo mutations obtained by sequencing 
trios (Neale et al. 2012). The enrichment for interactions between genes harbouring 
mutations in different families lends credibility to the assertion that these genes underlie 
autism. 
A very recently published tool, SPRING (SNV Prioritisation via the Integration of 
Genomic Data) aims to prioritise non-synonymous SNVs found in a single exome for 
disease causality, by integrating several data sources including functional prediction scores 




disease-relevance measure is proximity in a PIN to a set of seed genes; where known 
disease-causing genes do not exist these are generated from genes that cause phenotypically 
similar disorders (Wu et al. 2014). 
Outside of the monogenic disease field, VarWalker is designed to identify consensus 
mutation networks in cancer, with the aim of identifying driver mutations in NGS data. In 
each sample, mutation-harbouring genes are identified from sequence data, before random 
walk with restart in a PIN identifies interacting genes (with those that are frequently found in 
permuted networks being removed). Consensus mutation networks are found by comparing 
across samples (Jia and Zhao 2014). For complex diseases, the first applications of networks 
to rare variant association tests are being reported. Wu and Zhi compare pathway-based 
approaches for sequence-based association tests (Wu and Zhi 2013), which could include 
putative pathways identified in interaction networks; this approach was taken in a recent 
study of type 2 diabetes, where neighbours of known diabetes genes were used to define 
pathways (with negative results) (Lohmueller et al. 2013). 
While network methods have long been used in genetic disease studies, the 
development of NGS-appropriate methods is still in its infancy. Two novel approaches to 
exome sequencing studies of monogenic disease are described in this thesis. 
1.5 Thesis Outline 
This thesis will describe the development, assessment and application of two 
network-based methods to identify monogenic disease genes from exome sequencing data in 
the presence of genetic heterogeneity. To facilitate a clear and logical discussion of the work 
it is necessary to present the four main chapters (4, 5, 7 and 8) as separate “reports”, each 
containing a short introduction, methods, results and discussion. The thesis is structured as 
follows. 
Chapter 2 describes the data resources that are common to subsequent chapters, 
including the construction of interaction networks. Chapter 3 is a short chapter presenting 
results which motivate the subsequent work: interacting sets of genes which cause the same 
monogenic disease. 
Chapters 4 and 5 report the development and performance assessment of the two 
methods. BioGranat-IG, discussed in chapter 4, seeks to identify small connected 
subnetworks of genes which harbour post-filtering variants in all (or most) exomes from of a 
cohort of unrelated affected individuals. Performance testing is undertaken using simulated 




of the limitations of BioGranat-IG by using a variant-ranking approach. Simulated data are 
again used to assess the performance of HetRank and compare it to BioGranat-IG. 
Two supporting methods which are used in both of the subsequent chapters, 
primarily for the interpretation of BioGranat-IG and HetRank results, are described fully in 
chapter 6. 
In chapters 7 and 8 BioGranat-IG and HetRank, plus other simple network-based 
strategies, are applied to real exome sequencing studies. Findings will include putative 
disease-relevant pathways identified by the methods, and will enable a discussion of the 
utility of these tools in practice. Chapter 7 describes a study of Adams-Oliver syndrome, a 
monogenic disease with several known causal genes but demonstrated genetic heterogeneity. 
Chapter 8 analyses exome data from several families affected with Crohn’s disease; while 
Crohn’s disease is a complex disease the strong inheritance in these families suggests a 
prominent role for one or a small number of genes. 




2 Data Resources 
2.1 Interaction Networks 
2.1.1 Network Construction 
The work presented in this thesis makes use of six interaction networks. Key 
properties of these networks are summarised in Table 2.1. Interaction data and networks 
were stored as plain text files; processing was performed using UNIX commands with 
simple Perl scripts and MySQL commands where required for more complex data 
manipulation. 
 HuPPI2. This network is a protein interaction network (PIN) which integrates 
experimentally-verified interactions from six human protein-protein interaction 
(PPI) databases: BioGRID, MINT, BIND, DIP, IntAct and HPRD (Lehne and 
Schlitt 2009; Lehne 2011). Since multiple independent sources of evidence result 
in more reliable PPIs, the network includes only those interactions supported by 
two or more separate publications (Lehne 2011). Binary interactions are 
combined to give an unweighted and undirected network of 3,666 nodes 
(identified by Ensembl gene symbols) connected by 6,187 edges. The interaction 
data underlying the network was obtained in 2008; the network is not regularly 
updated and was obtained directly from Dr Thomas Schlitt on 19
th
 October 2011. 
 PINA. A more recent PIN is PINA, comprising interaction data from the publicly 
available PINA meta-database which integrates manually-curated PPIs from 
BioGRID, MINT, DIP, IntAct, HPRD and MIPS MPact (Cowley et al. 2012). 
Interaction data were downloaded on 20
th
 December 2012 and comprised both 
self-interactions and binary interactions specified using UniProt gene names. 
Removal of the self-interactions gave an unweighted and undirected network of 
14,380 nodes and 104,572 edges.
*
 
                                                     
*
 Note that the work described in chapter 5 is based on a version of this network for which self-
interactions were not removed. The properties of this version of the network are similar (see Table 
2.1) and the expected impact on results is negligible. 




 PINAmin2. This network is a higher-confidence subnetwork of PINA, 
comprising only interactions supported by two or more independent publications. 
This results in reduced coverage of the genome relative to the full PINA network: 
7,363 nodes are connected by 17,826 edges.
*
 
 CPDBconf95. The ConsensusPathDB (CPDB) database combines literature-
curated interactions and large-scale experimental data from 19 PPI databases 
(including all six databases underlying PINA) (Kamburov et al. 2013). 
Interactions are also assigned scores between 0 and 1 which combine three 
topology-based and three annotation-based measures of interaction confidence 
(Kamburov et al. 2012). These scores are most strongly influenced by two of the 
annotation-based measures: number of independent publications reporting an 
interaction, and similarity of Gene Ontology cellular component annotations 
(Kamburov et al. 2013 [Supplementary methods]). 
Interaction data were downloaded on 7
th
 October 2013 (version 27) and 
comprised both self-interactions and binary interactions specified by UniProt IDs. 
These were converted to HUGO Gene Nomenclature Committee (HGNC) official 
gene symbols using a mapping file obtained from BioMart (Kasprzyk 2011). 
Removal of the self-interactions gave a weighted and undirected network, which 
was converted to an unweighted network using a “high-confidence” threshold of 
0.95 (Kamburov et al. 2013 [Supplementary methods]) for the edge weights. The 
final network, CPDBconf95, consists of 6,136 nodes and 30,058 edges. 
 COXPRES30. COXPRESdb is a gene co-expression database (Obayashi et al. 
2013). For a given gene g, the other 19,000+ human genes included in the 
database are ranked according to the similarity between their expression profile 
and gene g’s expression profile across a wide range of microarray samples. The 
mutual rank between gene g1 and gene g2 is the (geometric) average of g1’s rank 
among genes similar to g2 and g2’s rank among genes similar to g1; mutual rank 
was found to be a better measure of relatedness than directly quantifying 
expression profile similarity (Obayashi et al. 2008). 
Mutual ranks for all gene pairs, encoded by Entrez IDs, were downloaded 
on 9
th
 April 2014 (version c4.1), and converted to HGNC official gene symbols 
                                                     
*
 Note that the work described in chapter 5 is based on a version of this network for which self-
interactions were not removed. The properties of this version of the network are similar (see Table 
2.1) and the expected impact on results is negligible. 




using the mapping file provided by COXPRESdb. An unweighted and undirected 
network, COXPRES30, was constructed where edges connect pairs of genes 
having mutual rank <30. This corresponds to medium- and high-similarity co-
expression pairs (Obayashi et al. 2008) and gives a network of 18,454 nodes and 
128,688 edges.  
 Multinet. This is a “unified” network in which edges can represent one of several 
different types of relationship between genes. Interactions comprise PPIs 
(extracted from BioGRID), as well as genetic, regulatory, metabolic, signalling 
and phosphorylation (kinase-substrate) relationships (Khurana et al. 2013). The 
authors suggest that different interaction types are needed to comprehensively 
model how genes and their protein products collaborate to form a functioning 
system, and find a very low level of redundancy between interaction types 
(Khurana et al. 2013). Interaction data, comprising binary interactions specified 
by gene symbols, were downloaded on 13
th
 February 2014; these resulted in an 
unweighted and undirected network of 14,445 nodes and 109,598 edges. 
For all six networks, the majority of nodes are connected in a single large 
component (see Table 2.1). 
Figure 2.1 shows plots of the degree distributions for all six networks. The networks 
show a broadly scale-free topology, meaning that the degree distributions follow a power 
law. However, the distribution for the COXPRES30 network appears to differ from those of 
the other networks due to a poorer fit at lower degrees, suggesting a slightly different 
topology with a relatively higher proportion of medium-degree nodes. The properties of this 
network in Table 2.1 also suggest an atypical topology; notably it has a lower maximum 
degree and higher large component average path length than other networks of comparable 
size. These topological differences most likely reflect the different data types underlying the 
networks: while the other networks mainly comprise physical interactions between proteins, 
COXPRES30 is based on pairwise expression profile similarity (and the mutual rank 
measure prevents nodes from having extremely high degree). 
2.1.2 Hub Removal 
It has been shown that removing network nodes of high degree (hubs) can lead to 
improved identification of functional modules (Liu et al. 2011) and disease-associated 
subnetworks (Lehne 2011) within an interaction network. 
HuPPI2_d25, a subnetwork of HuPPI2 derived by removing nodes with degree 25 
or greater, was obtained directly from Dr Thomas Schlitt on 19
th
 October 2011. 
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HuPPI2 PPI 3,666 6,187 3.38 108 3,027 5.88 
PINA PPI 14,380 104,572 14.54 7,804 14,326 2.91 
(with self-interactions retained) 14,434 105,801 14.66 7,804 14,326 2.91 
PINAmin2 PPI 7,363 17,826 4.84 4,778 7,128 2.84 
(with self-interactions retained) 7,417 18,092 4.88 4,778 7,128 2.84 
CPDBconf95 PPI 6,136 30,058 9.80 850 5,768 4.23 
COXPRES30 Co-expression 18,454 128,688 13.95 282 18,360 5.11 
Multinet Integrated 14,445 109,598 15.17 1,496 14,399 3.39 
 
 
















HuPPI2_d25 PPI 3,433 4,630 2.70 23 2,659 7.53 
PINA_d50 PPI 10,375 29,803 5.75 41 10,141 5.11 
(with self-interactions retained) 10,481 30,950 5.91 43 10,141 5.11 
PINAmin2_d50 PPI 4,565 9,561 4.19 41 4,022 5.86 
(with self-interactions retained) 4,647 9,820 4.23 41 4,022 5.86 
CPDBconf95_d50 PPI 5,548 16,247 5.86 47 5,111 5.48 
COXPRES30_d50 Co-expression 17,001 90,183 10.61 49 16,860 5.60 




For each network, node degrees are plotted against the fraction of nodes in the network of that degree. Regression is performed assuming a power-law trend line. Values 
are plotted against a logarithmic scale on both axes. 
 
 
Figure 2.1 – Degree distributions of interaction networks 
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For each network, node degrees are plotted against the fraction of nodes in the network of that degree. Regression is performed assuming a power-law trend line. Values 
are plotted against a logarithmic scale on both axes. 
 
 
Figure 2.2 – Degree distributions of interaction networks following hub removal 
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For all other networks, hub-free versions with the suffix “_d50” were derived by 
removing nodes with degree 50 or greater.
*
 Hub removal was performed in R using the 
igraph library for network analysis (Csardi and Nepusz 2006). 
Table 2.2 gives the key properties of the networks following hub removal. In all 
cases the hub-free networks have a lower average degree and higher large component 
average path length than the corresponding original networks. Figure 2.2 shows the degree 
distributions for these networks, which are truncated relative to the full degree distributions 
in Figure 2.1. 
2.1.3 Network Agreement 
Given that many of these networks share common underlying data sources (and in 
particular that the PINs are intended to describe the same underlying interactome of PPIs), 
some overlap between the networks is expected. Table 2.3 shows the proportion of nodes 
and edges (that is, genes and interactions) that are shared between the networks. 
Table 2.3a gives the overlap between the full networks before hub removal. As 
expected, all of PINAmin2’s nodes and edges are contained in PINA because it is a 
subnetwork. PINA also includes the majority of nodes from the other high-confidence PINs, 
HuPPI2 and CPDBconf95 (over 97% in each case), and covers 90.6% and 62.2% of their 
edges respectively. The agreement between PINA and Multinet is more limited, with 79.1% 
of Multinet’s nodes and 35.3% of its edges present in PINA (and roughly similar proportions 
of PINA’s nodes and edges present in Multinet). Strikingly, while COXPRES30 covers the 
majority of nodes found in each of the other networks, there is very little correspondence 
between edges. The interactions in COXPRES30, where an edge signifies that genes have 
highly similar expression profiles, largely therefore describe a distinct type of functional 
relationship compared to the mainly physical interactions described by the other networks. 
Table 2.3b gives the overlap between the hub-free networks. Although there are a 
few exceptions, what we largely see is a fall in the degree of sharing of both nodes and edges 
compared to the full networks. This is due to the fact that hub removal affects different 
genes in each network. However, we see broadly the same patterns overall: most of the 
nodes from the smaller high-confidence networks are seen in the bigger networks, but fewer 
of the edges; the two bigger networks of mainly physical interactions have a considerable 
overlap of edges, with 45.7% of Multinet_d50’s present in PINA_d50 and 36.2% of 
                                                     
*
 A higher threshold is used for the networks other than HuPPI2 because they are larger and more 
densely connected. However, the thresholds of 25 and 50 are somewhat arbitrary; a more rigorous 
approach to hub removal is proposed in section 9.2.3 (in the Future Work section of the Concluding 
Discussion). 
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Table 2.3 – Agreement of nodes and edges between networks 
Grey shading denotes same network; red shading denotes <10% overlap; yellow shading denotes 
>50% overlap; green shading denotes >90% overlap. 





HuPPI2 PINA PINAmin2 CPDBconf95 COXPRES30 Multinet 
HuPPI2 100.0% 97.0% 84.4% 74.6% 93.8% 96.0% 
PINA 24.7% 100.0% 51.2% 41.7% 85.4% 79.4% 
PINAmin2 42.0% 100.0% 100.0% 59.9% 92.6% 91.2% 
CPDBconf95 44.5% 97.8% 71.9% 100.0% 93.6% 91.9% 
COXPRES30 18.6% 66.6% 36.9% 31.1% 100.0% 66.7% 





HuPPI2 PINA PINAmin2 CPDBconf95 COXPRES30 Multinet 
HuPPI2 100.0% 90.6% 60.8% 46.2% 3.4% 68.8% 
PINA 5.4% 100.0% 17.1% 17.9% 1.0% 37.0% 
PINAmin2 21.1% 100.0% 100.0% 35.9% 2.2% 56.3% 
CPDBconf95 9.5% 62.2% 21.3% 100.0% 5.1% 38.2% 
COXPRES30 0.2% 0.8% 0.3% 1.2% 100.0% 0.6% 
Multinet 3.9% 35.3% 9.2% 10.5% 0.7% 100.0% 

















HuPPI2_d25 100.0% 81.3% 79.2% 70.4% 86.3% 78.7% 
PINA_d50 26.9% 100.0% 37.2% 45.3% 81.4% 66.7% 
PINAmin2_d50 59.6% 84.5% 100.0% 68.2% 86.2% 78.3% 
CPDBconf95_d50 43.6% 84.6% 56.1% 100.0% 86.0% 73.3% 
COXPRES30_d50 17.4% 49.7% 23.1% 28.1% 100.0% 41.1% 

















HuPPI2_d25 100.0% 43.6% 56.8% 36.5% 3.1% 36.6% 
PINA_d50 6.8% 100.0% 12.5% 20.4% 1.2% 36.2% 
PINAmin2_d50 27.5% 39.0% 100.0% 35.1% 2.6% 35.2% 
CPDBconf95_d50 10.4% 37.5% 20.6% 100.0% 2.7% 23.6% 
COXPRES30_d50 0.2% 0.4% 0.3% 0.5% 100.0% 0.3% 
Multinet_d50 7.2% 45.7% 14.3% 16.3% 1.3% 100.0% 
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PINA_d50’s present in Multinet_d50; and again, COXPRES30_d50 has many nodes in 
common with the other networks but very few edges. 
2.2 BioGranat Software 
BioGranat (“Molecular Biology Graph Visualisation and Analysis Tool”) is a 
software tool for the analysis and visualisation of biological interaction networks (Mendig et 
al. 2009). It is implemented using the Java OSGi framework and is freely available from 
www.biogranat.org. BioGranat was developed by Dr Thomas Schlitt at King’s College 
London (KCL) in collaboration with Prof. Volker Ahlers and Prof. Frauke Sprengel at the 
University of Applied Sciences and Arts in Hannover, Germany. 
BioGranat provides a user interface and basic network analysis functionality, 
allowing customised tools for specific analyses to be developed as BioGranat bundles. 
BioGranat-IG (described in chapter 4 and applied in chapters 7 and 8) and Region Growing 
Analysis (discussed in chapter 6 and used extensively in chapters 7 and 8) are both 
BioGranat bundles. 
2.3 Exome Sequencing and Annotation 
All whole exome sequence data (including disease cases, healthy controls and 
exomes used to generate test data) were obtained as annotated output files from the exome 
sequencing pipeline employed by the KCL rare disease programme, overseen by Dr Michael 
Simpson. 
The majority of whole exome samples were sequenced at the NIHR Biomedical 
Research Centre at Guy's and St Thomas' NHS Foundation Trust and KCL. For these 
exomes, whole-exome capture was performed using the Agilent Sure Select XT Human All 
Exome Kit. Enriched DNA fragments were sequenced using an Illumina HiSeq 2000 
instrument. The exomes of 45 Crohn’s disease cases (analysed in chapter 8) were sequenced 
at the Institute of Clinical Molecular Biology at the University of Kiel, Germany. For these 
exomes, whole-exome capture was performed using the Nextera Rapid Capture Expanded 
Exome kit and enriched DNA fragments were also sequenced using an Illumina HiSeq 2000 
instrument. 
For all sequenced exomes, paired-end reads were aligned to the UCSC Genome 
Browser’s hg19 reference sequence (Karolchik et al. 2014) using Novoalign (v.2.07.17; 
Novocraft Technologies). SNVs and small indels were called using SAMtools (v.0.1.18; Li 
et al. 2009) and annotated with gene and transcript identifiers from RefSeq (Pruitt et al. 
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2014) using ANNOVAR (2013Feb21 version; Wang et al. 2010c). Variants were also 
annotated with reference to 1000 Genomes Project and Exome Variant Server (EVS) data 
(1000 Genomes Project Consortium 2010; NHLBI Exome Sequencing Project 2014) and 





3 Motivation: Interacting Genes Cause the Same 
Monogenic Disease 
3.1 Introduction 
It has previously been established that pairs of genes causing the same disorder are 
significantly likely to be connected in a protein interaction network (PIN). Feldman et al. 
showed that significantly many genes causing the same (mainly monogenic) diseases form 
connected clusters in a network (Feldman et al. 2008). Likewise, Goh et al. found significant 
overlap between the connections in a PIN and the connections in a network formed by 
linking two genes if they are associated with the same monogenic or complex disease (Goh 
et al. 2007). Using a more general notion of phenotype, Van Driel et al. demonstrated that a 
text-based measure of similarity between disease phenotypes is correlated with the 
connectedness of causal genes in a PIN (van Driel et al. 2006). 
The use of interaction networks to address genetic (locus) heterogeneity is central to 
this thesis. To motivate our approach, and to generate working examples on which to base 
simulated test data, we therefore undertook an independent investigation of the extent to 
which genes causing the same monogenic disease interact in PINs. 
For two PINs (PINA and the high-confidence subnetwork PINAmin2) we identified 
disease subnetworks, defined as directly-connected sets of two or more genes that are 
designated in OMIM (Amberger et al. 2009) as being causal for the same monogenic disease 
(disregarding disease sub-types). By comparison against randomly-permuted networks we 
found that significantly many diseases display locus heterogeneity that can be modelled by 
disease subnetworks. 
3.2 Methods 
Analysis was performed separately using the PINA and PINAmin2 networks 
described in section 2.1.1; all data analysis was performed in R using the igraph library for 
network analysis (Csardi and Nepusz 2006). 
Disease-gene mappings were obtained from OMIM’s Morbid Map (downloaded 20th 
March 2013) (Amberger et al. 2009). Unconfirmed mappings and mappings which either 
involve non-disease phenotypes or where the gene is not directly causal (such as genes 
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which contribute to susceptibility to a multifactorial disorder or infection) were excluded, 
leaving 4,956 monogenic disease mappings. 
OMIM disease terms were replaced with generalised disease terms by removing 
disease “type” or “group” names, and any words consisting entirely of numbers. This 
resulted in 3,193 generalised disease terms in total. 541 diseases displayed locus 
heterogeneity by mapping to more than one causal gene. 
In each of the two PINs, OMIM disease subnetworks were found by considering one 
generalised disease term at a time and identifying direct interactions between causal genes. 
To test the null hypothesis that the disease subnetworks found could arise by chance 
due to the number of disease genes mapping into each network, disease subnetworks were 
also identified in 10,000 randomisations of each PIN. To counter the potential bias in 
curated interaction networks towards well-studied disease-causing genes, the degree-
constrained network permutation approach described in (Lehne 2011) was used. Briefly, 
node labels are preferentially swapped with nodes of similar degree. For node g this is 
achieved by listing all other network nodes in increasing order of degree difference relative 
to g (with nodes of equal degree ordered uniformly randomly); a one-tailed normal 
distribution centred at the top of this list is then used to select a node and labels are swapped. 
The default standard deviation of 5.0 nodes was used. 
3.3 Results and Discussion 
172 connected subnetworks were found in the PINA network, and 84 in the 
PINAmin2 network, each of which is causal for a single disease. Table 3.1 summarises these 
findings, and a full list of disease subnetworks is provided in Appendix A. 
Table 3.1 also gives the average number of disease subnetworks found in 10,000 
permutations of each network, the distributions of which are illustrated in Figure 3.1. In each 
case the observed number of disease subnetworks is highly significant (p < 10
-4
), enabling us 
to conclude that these disease subnetworks could not arise by chance. 
The methods used here are similar to those employed by Feldman et al., and these 
results corroborate their findings, although the number of disease subnetworks found 
exceeds the 30 specific to monogenic diseases that they reported in 2008 (Feldman et al. 
2008). As expected our results support the broader assertion that interacting genes are more 
likely to have similar phenotypic consequences (van Driel et al. 2006; Goh et al. 2007). 
Even allowing for the possibility that our degree-constrained permutation approach 
insufficiently overcomes the potential knowledge bias in curated interaction networks, this 
still makes a compelling case that genes causing similar or identical clinical phenotypes





Figure 3.1 – Interactions between genes involved in the same disease occur frequently 
Frequency plots showing the number of disease subnetworks (connected sets of two or more genes 
causing the same disease) identified in 10,000 random permutations of the PINA and PINAmin2 








Table 3.1 – OMIM disease subnetworks 
Observed = number of disease subnetworks of given size induced by a single disease term in the 
original network; Permutation Average = average number of disease subnetworks of given size 
induced by a single disease term across 10,000 randomly permuted networks (mean ± standard 
deviation). 
 
Number of disease subnetworks 
 
PINA network PINAmin2 network 








2 124 12.54 ± 3.35 61 3.46 ± 1.93 
3 27 1.65 ± 1.25 11 0.44 ± 0.73 
4 11 0.40 ± 0.60 7 0.06 ± 0.25 
5+ 10 0.28 ± 0.49 5 0.07 ± 0.26 
Total 172 14.87 ± 3.46 84 4.03 ± 2.13 
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frequently interact and thus it makes sense to use interaction networks as a means to identify 
new sources of genetic heterogeneity, particularly given that high-throughput methods are 
continually improving network coverage (Yu et al. 2011). 
In addition to re-iterating this important observation, the disease subnetworks 
identified here can be used to generate realistic test data with which to assess the 
performance of the methods developed in this thesis. In chapter 5 randomised exome data 
will be “spiked” with disease-causing mutations in genes drawn from disease subnetworks. 
The ability to recover these disease subnetworks will be an important measure of the 
performance of the BioGranat-IG and HetRank methods, and of the extent to which they 
improve upon simple intersection filtering. 
It could be argued that the use of generalised disease terms, which disregard disease 
“type” or “group”, will conflate sub-types of a disease that could display phenotypic 
differences. While in some cases this may be true, many disease sub-types in OMIM 
represent different molecular bases of a given disorder. Moreover, in practice – due to 
limitations of available data – whole exome sequencing studies of rare diseases often seek to 
identify a causal gene using exomes from a group of affected individuals with the same 
clinical diagnosis but some phenotypic variability. Therefore the disease subnetworks 
identified here provide a reasonable basis on which to test analysis methods designed to 





4 Development of BioGranat-IG Analysis Tool 
4.1 Introduction 
As previously discussed, improvements in sequencing technology have led to 
considerable successes in the identification of disease-causing sequence variants for several 
rare monogenic diseases. Typically intersection filtering is used, in which a series of filtering 
steps are applied to whole exome sequence variants from several unrelated affected 
individuals (e.g. Ng et al. 2010a; Simpson et al. 2011). However, depending on the disease, 
one might not observe any genes in the intersection of the filtered lists. One phenomenon 
that can cause this is genetic heterogeneity, where one phenotypic outcome results from any 
one of a number of possible mutations, possibly in different loci (McClellan and King 2010). 
An example would be two genes that are functionally related through their protein products, 
both playing a critical role in some cellular function and such that a mutation in either gene 
leads to the failure of that function. 
One possible way to deal with this problem would be to look for the smallest set of 
genes such that all individuals carry a post-filtering sequence variant in the set. This frames 
the problem as one of minimal set cover (MSC; Cormen 2001) and will not guarantee any 
biological meaning or functional relatedness for the set of genes found. 
Instead, in this chapter, we present BioGranat-IG (“BioGranat Individuals-
Grouping”), a tool that uses the additional structure found in interaction networks to analyse 
sequence data for multiple individuals and suggest possible sources of genetic heterogeneity. 
Interaction networks are ideal for this purpose because they connect genes for which 
a functional relationship is known – or predicted – to exist. Several tools, such as 
GeneMANIA (Warde-Farley et al. 2010) and STRING (Franceschini et al. 2013), exist that 
use interaction networks to suggest additional functionally related genes for a given input 
gene list. Conversely, our tool will use the networks to focus on which of the input genes are 
likely to be causative and provide a relatively short list of candidate genes for follow-up 
study. 
The premise behind BioGranat-IG is that if a disease has an underlying mechanism 
of locus heterogeneity, the genes involved may be functionally related and therefore closely 
connected in an interaction network; if not directly connected, they might be interacting with 
one or more common neighbours. To identify disease gene candidates, given a number of 




usual manner based on novelty or variant frequency, functional consequence etc.), we mark 
each node in our network with the individuals who carry a mutant version of that gene. 
Subsequently, we seek the smallest connected subnetwork marked with all individuals (see 
Figure 4.1). 
Our network thus consists of “marked” nodes, representing genes where a sequence 
variant was observed in some individual, and “empty” nodes, where no variant was observed 
for any individual. As an additional constraint on the subnetwork we seek, we require that 
each marked node is connected to another marked node via at most one empty node. That is, 
the subnetwork is allowed to incorporate “jumps” of one empty node, but not more (see 
Figure 4.2). The rationale underlying this is that interaction networks tend to exhibit the 
small world phenomenon, meaning that the average path length between any two nodes is 
 
Figure 4.1 – BioGranat-IG strategy for gene identification 
For individuals A-D, genes containing variants that have not been removed during the filtering step 
are represented as red, yellow, blue and green tokens respectively. These tokens are mapped to the 
corresponding nodes in a gene network. Not every token can be mapped to the network because gene 
networks typically do not cover the entire genome. The smallest connected subnetwork to cover all 




short, typically four to six edges (Xu et al. 2011). We are therefore interested only in 
localised connections, and allowing too many empty nodes into our subnetwork could 
reduce the chance of it having any biological meaning. This constraint allows a 
computationally efficient implementation, making it possible to run BioGranat-IG on large 
sets of permuted data to establish statistical significance. 
This chapter will present the methods implemented by BioGranat-IG and 
demonstrate the validity of the approach using simulated whole exome sequencing output. 
The performance of the tool under various conditions is analysed, before considering the 
outstanding challenges of the approach. 
To our knowledge, BioGranat-IG is the first tool developed to tackle the problem of 
finding disease-causing genes from whole exome sequence data for monogenic diseases in 
the presence of locus heterogeneity. As discussed at length in chapter 1 (section 1.4.6), 
finding dysregulated subnetworks is an intensively studied problem (Lehne and Schlitt 2012; 
Staiger et al. 2012), but few approaches consider data for individuals separately. Rather, 
most approaches work with summary statistics. Notably, a method by Dao et al. (Dao et al. 
2010), DEGAS (Ulitsky et al. 2010) and KeyPathwayMiner (Alcaraz et al. 2012) use 
differential expression data for individuals to find subnetworks containing genes 
differentially expressed in patients versus controls. While for differential gene-expression 
data one usually expects to find clusters of co-expressed functionally related genes, our 
problem differs because we expect all individuals to carry only a limited number (probably 
less than tens) of disease-causing genes hidden among a large number (hundreds) of variants 
not related to the disease of interest. Therefore, the problem addressed by KeyPathwayMiner 
and DEGAS is similar to the problem we address here in general, but there are important 
differences in the detail that have an impact on the algorithm design. 
 
Figure 4.2 – Allowed jumps in BioGranat-IG 
Subnetworks returned by BioGranat-IG can connect marked nodes via jumps of one empty node (a 





The DAPPLE tool (Rossin et al. 2011) prioritises genes in genomic regions 
associated with a disease using a network-based approach conceptually related to BioGranat-
IG. However, DAPPLE is designed to improve understanding of disease-associated loci, and 
is not readily applicable to the sequencing problem we describe. 
The work presented in this chapter has been published (Dand et al. 2013) and is 
reproduced here by permission of Oxford University Press. Co-author contributions are as 
follows: Prof. Volker Ahlers and Prof. Frauke Sprengel at the University of Applied 
Sciences and Arts in Hannover, Germany, developed BioGranat in collaboration with Dr 
Thomas Schlitt at King’s College London; Dr Schlitt also initiated and obtained funding for 
network method development projects (including my PhD studentship), conceived the 
analysis strategy and oversaw analysis of results. The algorithm design and implementation, 
analysis, and interpretation of results presented in this chapter were performed by Nick 
Dand. 
4.2 Methods 
BioGranat-IG has been developed as a BioGranat bundle (see chapter 2) and is 
available from www.biogranat.org. 
In graph-theoretic terms, the problem we face can be expressed as follows. Let Sn be 
the set of n elements {1, 2, ..., n}. The power set P(Sn) of Sn is the set of all possible subsets 
of Sn, including the empty set. Then, given a graph G with nodes V(G), and for each g in 
V(G) a mapping f(g) into P(Sn), we wish to find the smallest connected subgraph G’ of G 
such that: 
         
        
 
Here, smallest is taken to mean least number of nodes. It is possible that no such subgraph 
exists, in which case we seek the smallest connected subgraph such that: 
      
        
     
where m is the maximum number of elements of Sn that are mapped to by the nodes of a 
single connected component of G. (Note that in this chapter, we refer more loosely to 




The problem is an example of the minimal connected set cover problem (MCSC) 
(Cerdeira and Pinto 2005; Zhang et al. 2009), which is NP-hard because it is a generalisation 
of the MSC problem (Karp 1972). Several authors have published approximation algorithms 
for MCSC in recent years (Ren and Zhao 2011; Elbassioni et al. 2012). However, for 
BioGranat-IG, we have developed a new method because we want to collect not just the size 
of the optimal subnetwork, but all examples of optimal and near-optimal subnetworks, up to 
a user-specified size. BioGranat-IG cannot determine which subnetworks will be of most 
interest to the user, and so must output them all. 
The following sections present the methods used by BioGranat-IG to find near-
optimal small subnetworks containing variants for maximum individuals. 
4.2.1 Network Pre-processing 
BioGranat-IG works by marking lists of genes for multiple individuals onto an 
interaction network. There are >20,000 human genes but the function and expression of 
many genes is only poorly understood. Therefore, currently available networks are all 
incomplete. Nevertheless, they contain thousands of nodes and edges. To speed 
computation, the network is pre-processed (see Figure 4.3). 
 Because jumps of more than one empty node are not allowed, all edges with an 
empty node at both ends are removed. From this point on, any neighbour of an 
empty node must be a marked node. 
 All empty nodes of degree zero or one are removed. 
 Where two empty nodes are connected to the same set of neighbours, one of the 
nodes can be removed from the network (and stored to provide an alternative 
result should the kept node turn out to form part of a minimal subnetwork). 
 Any empty node whose neighbours form a clique (a complete subnetwork) is 
removed from the network. Such a node will never be called on to link two 
marked nodes. 
4.2.2 Triplet and Quadruplet Search 
Before resorting to heuristic methods, which cannot guarantee that all minimal 
subnetworks are returned, BioGranat-IG performs two searches (triplet search and 
quadruplet search), which together comprise an exhaustive search of all subnetworks of up 
to four nodes. If a subnetwork is found that covers all individuals, there is no need to 




The triplet search identifies all candidate subnetworks of up to three nodes, using the 
fact that for three nodes to be connected there must be at least one path of length two 
connecting them. We call the subnetwork induced by such a path a triplet. For each node in 
the network (whether marked or empty) we first check whether this node alone contains all 
individuals, and then identify the neighbouring nodes. All pairs formed from the original 
node plus one marked neighbour, and triplets formed from the original node plus two 
marked neighbours are examined. At this point, if a subnetwork is found containing all 
individuals, there is no need to continue with the quadruplet search. 
 
Figure 4.3 – Network pre-processing 
Panel 1 shows a graph labelled with individuals A-D. First, edges connecting two empty nodes 
(marked in red) are removed, giving the graph in panel 2. Next, nodes of degree zero or one (marked 
in green) are removed, giving the graph in panel 3. Next, alternative connecting empty nodes (marked 
in blue) are removed, giving the graph in panel 4. These alternative nodes are stored because they 
could potentially be needed later to generate alternative optimal subnetworks. Finally, empty nodes 
whose neighbours form a clique (marked in yellow) are removed, giving the final pre-processed graph 




The quadruplet search builds on the triplet search. Using the constraint that only one 
empty node can be jumped at a time, we know that for a subnetwork of four nodes to 
minimally cover all individuals it must contain at least one triplet with two individuals. 
Using this set of triplets as a starting point, quadruplets are thus constructed through the 
addition of any neighbouring nodes that confer additional individuals. 
4.2.3 Minimum Distance Search 
If the triplet and quadruplet searches fail to find a subnetwork covering all 
individuals, BioGranat-IG will perform heuristic searches based on a minimum distance 
approach (described here) and a multi-minimum distance approach (described in the next 
section). 
The minimum distance search uses a greedy approach to build subnetworks starting 
from a single node. The selection function used to determine the most valuable neighbour to 
add to the subnetwork at each step is the sum of the minimum distances (length of shortest 
path) from each neighbour to all individuals not already covered by the subnetwork. 
This approach requires that for every node in the network, the minimum distance to 
each individual is calculated. For node g, the distances {d1(g), ..., dn(g)} represent the 
minimum distance from g to any node that contains individual 1, ..., n, respectively. 
Distances are calculated using a multi-source breadth-first search approach, as described by 
the following pseudocode: 
1: For each individual, i 
2:     For each node g in the component 
3:         If g is marked with i, set di(g) = 0, and add g to the queue 
4:         Else set di(g) = ∞ 
5:     While the queue is not empty 
6:         Take node g from the queue, and for all neighbours g’ of g 
7:             If di(g’) = ∞, set di(g’) = di(g) + 1, and add g’ to the queue 
Because the pre-processed network may consist of several components, infinite 




The search proceeds, only in components that contain sufficiently many individuals, 
by recursively building up subnetworks starting from a single node (see Figure 4.4). The 
basis for recursion is as follows: in a component containing individuals I = {i1, ..., in’}, then 
given a subnetwork G’ of that component containing individuals J = {j1, ..., jm} (m < n’), 
examine all neighbours of nodes in G’. Of these neighbours, find the node g that minimises 
the sum: 
       
      
 
Form a new subnetwork, G’’ by adding g to G’, and repeat until all n’ individuals are 
incorporated. 
 
Figure 4.4 – Minimum distance search 
A network of genes labelled 1-7 has been marked with individuals R (red tokens), B (blue tokens) and 
Y (yellow tokens). Panels I-IV illustrate how a subnetwork is built up (indicated by green shading), 
starting from gene 4. Let dX(n) indicate the minimum distance from node n to any node marked with 
individual X. Panel I: the subnetwork contains node 4 and covers individual R. The neighbouring 
nodes are 3 and 5. Since dB(3) + dY(3) = 2 + 1 = 3 and dB(5) + dY(5) = 1 + 1 = 2, node 5 is added next. 
Panel II: the subnetwork contains nodes 4 and 5 and covers individual R. The neighbouring nodes are 
3, 6 and 7. Since dB(3) + dY(3) = 3, as before, dB(6) + dY(6) = 1 + 0 = 1 and dB(7) + dY(7) = 0 + 1 = 1, 
either node 6 or 7 can be added next. Panel III: The subnetwork is 4-5-7 and covers individuals R and 
B. The neighbouring nodes are 3 and 6. Since dY(3) = 1 and dY(6) = 0, node 6 is added next. Panel IV: 
the subnetwork is 4-5-6-7 and covers all individuals, so the search terminates. Note that in this case 
subnetwork 1-2-3-4 is equally small and covers all individuals, but would not be found by the 




At each step, there may be a tie amongst neighbours for the smallest minimum 
distance sum, and in this case each alternative G’’ is explored in turn. In practice this occurs 
frequently, leading to many calls of the recursive function in what is effectively a depth-first 
search strategy (Cormen 2001). 
The results of this search depend on the starting node chosen, so the approach taken 
is to use all nodes in a component as starting nodes. This is not as costly as it may first 
appear owing to several steps that are taken to ensure the search runs efficiently: 
 To avoid duplication of effort, a list of all subnetworks explored is kept. Suppose 
a search starting at node g1 adds node g2 first. If then the search starting at node g2 
were to add node g1 first, the search will stop because the subnetwork g1-g2 has 
already been explored. 
 The size, s, of the smallest subnetwork found containing all reachable individuals 
is maintained. Subsequently, node g will not be added to subnetwork G’ to form 
G’’ unless g is within distance s – |G’| of one of the individuals needed by G’. 
 Nodes are used as starting nodes in order (from smallest to largest) of their total 
minimum distance to all reachable individuals so that the smallest subnetwork 
size is found as quickly as possible. 
 The number of calls of the recursive function can be limited (e.g. to 1,000) from 
each starting node, preventing excessive worst-case running times due to many 
ties between neighbours. Hitting 1,000 calls would make it highly unlikely that 
our starting node is part of a small subnetwork of interest to us. 
4.2.4 Multi-Minimum Distance Search 
Although the minimum distance search often works well, it does not guarantee 
finding the optimal subnetwork. One reason for this is that no credit is given for the fact that 
a neighbour might extend a subnetwork towards more than one individual. If a node is 
labelled with individuals 1 and 2, then its neighbour g has d1(g) + d2(g) = 2, overstating the 
actual distance. Figure 4.5 gives an example where the minimum distance search would not 
find the optimal subnetwork, regardless of which node is used as a starting node. 
The multi-minimum distance search partially addresses this problem by 
preferentially seeking nodes with multiple individuals during the recursive step. The search 
runs recursively in the same way as the minimum distance search, with the only difference 





Having previously defined the simple minimum distance di(g), we now introduce the 
multi-minimum distance di,k(g) for k = 1, ..., n. This is defined as the length of the shortest 
path from g to any node that is marked with ≥ k individuals, such that one of those 
individuals is individual i. If no such marked node exists (that is, the component under 
consideration does contain individual i, but not in any node with ≥ k individuals), then we 
set di,k(g) = di,k-1(g). This is always well-defined because di,1(g) is equivalent to the simple 
minimum distance di(g). Distances are calculated in the same way as the simple minimum 
distance, for one value of k at a time, starting with k = 1. 
The search proceeds recursively as before, only now given a subnetwork G’ 
containing individuals J = {j1, ..., jm} (m < n’), the next node g is the neighbour that 
minimises the following sum: 
           
      
 
The reasoning behind this approach is that when few individuals have been found, it 
is beneficial to extend the subnetwork towards nodes with multiple individuals. Conversely, 
later in the search, if only one more individual is sought, the nearest node that contains it 
will do. 
 
Figure 4.5 – Example of a network where minimum distance search fails 
In this network the minimum distance search would fail to find the smallest subnetwork containing all 
individuals A–G. Nodes are labelled with the individuals attached to them. The true optimal 
subnetwork comprises the uppermost five nodes, indicated in by thicker lines. However, nodes from 
the bottom row will be incorporated into any subnetwork found by the minimum distance search, 
regardless of which node the search starts from. Note that in this case the multi-minimum distance 




Although this search recognises that nodes with multiple individuals are important, 
it is not always efficient. For example, suppose individual i is one of three individuals still 
needed by a subnetwork. The distance di,3(g) does not necessarily give the distance from 
node g to a node containing those three individuals, but just the distance from g to a node 
containing any three individuals, one of which is individual i. To know the former distance 
would effectively require the distances be recalculated at each recursion. This is 
prohibitively expensive, yet provides no guarantee of finding the optimal subnetwork. 
If there is a small subnetwork in which two or three nodes contain most of the 
individuals (which is feasible biologically), the multi-minimum distance search is likely to 
find it, albeit a simple extension of the minimum-distance search. 
4.2.5 Program Output and User Options 
Sometimes several minimal subnetworks are found that overlap (have nodes in 
common). Suppose subnetwork g1-g2-g3 is the true underlying cause of a disease, and all 
individuals have a mutation in one of these genes. It could be the case, by chance, that some 
of the individuals also have mutations in a connected gene g4, such that g1-g2-g4 also covers 
all individuals. Equally, it could also be true that elsewhere in the network, three different 
connected genes g5-g6-g7 cover all individuals by chance. BioGranat-IG can group 
overlapping subnetworks and return the resulting “regions” of nodes. In this case, two 
regions would be returned, g1-g2-g3-g4 and g5-g6-g7 (along with the frequency of inclusion 
for each node, to quantify its importance in the group; the first group here would have a 
count of 2 for g1 and g2, and 1 for g3 and g4). Thus, we can provide candidate genes for 
experimental follow-up studies to determine the true disease-causing genes. 
In BioGranat-IG, the criteria for “optimal” subnetworks can be relaxed by tolerating 
more nodes, or fewer individuals, up to user-specified limits (specified by size flexibility and 
number flexibility parameters, respectively). This flexibility allows the user a fuller analysis 
of potentially interesting results. In addition, there is a parameter for maximum subnetwork 
size, which will limit the size of any subnetworks found. This is useful in the situation where 
the smallest subnetwork containing all individuals is large: we might be interested in 
whether there exist much smaller subnetworks that contain most (rather than all) of the 
individuals. 
In the typical situation where a small subnetwork is found that covers all 
individuals, BioGranat-IG offers the functionality to test whether this subnetwork is a 
significant finding. This can be done by generating random gene lists having the same 
number of genes in the network as the original gene lists. For each random instance the 




measured by the frequency with which equally small or smaller subnetworks cover all 
individuals in the random simulations. 
It is worth mentioning at this stage that we can still construct examples of networks 
labelled with individuals for which none of the methods described would find the optimal 
subnetwork (for example, see Appendix B). But these counter-examples are much larger and 
more contrived, and it would seem unlikely that such a region would be biologically 
relevant. 
4.2.6 Interaction Networks 
All testing is performed in the HuPPI2 protein interaction network (PIN), as 
described in chapter 2. The user can choose which network to use with BioGranat-IG; as 
with other network-based analysis methods, this choice involves consideration of competing 
factors. There is typically a trade-off between network coverage (number of genes 
represented in the network) and the degree of confidence that can be placed on network 
interactions. The choice of network will also be influenced by whether a particular type of 
genetic mechanism is predicted and by the sequence data available. When sequencing small 
groups of affected individuals, one approach that could be taken is to run BioGranat-IG on 
smaller high-quality networks initially (this minimises the risk of connecting the individuals 
using false positive interactions, as would be more likely in a larger network) and proceed to 
larger networks if no positive results are found. Smaller networks also have the added 
advantage of reduced computation time. 
4.2.7 Performance Testing: Methodology and Metrics 
All tests examine how well BioGranat-IG can recover a specified gene complex in 
1,000 tests using simulated whole exome sequencing output. For each simulation, we 
randomly generate lists of variant-containing genes for a fixed number of individuals. Unless 
otherwise stated, we use 15 individuals per simulation, to represent a typical exome 
sequencing study size. Each simulated individual is generated by randomly picking one gene 
from within the complex of interest and a fixed number of non-causal genes from the rest of 
the HuPPI2 network. Unless otherwise stated, we generate 35 non-causal nodes per 
individual. This number corresponds to the typical number of candidate genes per individual 
generated by exome sequencing (after filtering) (Ng et al. 2009; Simpson et al. 2011) that 
map to HuPPI2. We refer to this process as generating random individuals and spiking in the 
complex of interest. 
For illustrative purposes, suppose we choose to spike in a complex of five genes. 




given set of 15 individuals (in fact, the probability is only 0.83). We do not force all five to 
be spiked in, as there would be no such guarantee in practice with real patients’ data. 
Therefore, one of the metrics we look at in each test is the number of nodes actually spiked 
in. 
The key result is the number of spiked nodes recovered, which is the number of 
genes from the complex of interest that are returned in the output of BioGranat-IG. This can 
exceed the number actually spiked in. For example, if only four of a complex of five nodes 
are actually spiked in, it is possible that the fifth “true” node could be found as a “jump”. 
In addition, we consider the number of false nodes returned. These are nodes that do 
not form part of the complex of interest, but are nevertheless returned in the output of 
BioGranat-IG. This can occur when, by chance, nodes neighbouring the complex are marked 
with individuals in such a way that an alternative smallest subnetwork can be formed by 
excluding one of the “true” genes in the complex, and including the non-causal neighbour. 
Because BioGranat-IG has no prior knowledge of the “true” disease-linked genes, all genes 
found are returned. 
All numbers referred to in the results section are the average values found in 1,000 
simulations. 
4.3 Results 
In this section, we firstly demonstrate that the principle underlying BioGranat-IG is 
sound and that the program produces valid results, using two diseases known to be 
genetically heterogeneous. We show that BioGranat-IG can recover the genes responsible 
for acne inversa (AI; OMIM #142690) and pseudohypoaldosteronism type I (PHA-I; OMIM 
#264350) using simulated whole exome sequencing output. We then examine the 
performance of BioGranat-IG under various conditions, including the nature of the 
underlying disease complex and the amount and quality of input data. 
4.3.1 BioGranat-IG Recovers Acne Inversa Genes 
AI, an inflammatory skin disease, has been shown to result from a mutation in the 
γ-secretase complex comprising the genes APH1A, NCSTN, PSEN1 and PSENEN , with 
mutations in three of these genes having been directly linked to AI (Wang et al. 2010a). 
Using BioGranat-IG on this complex, we were able to recover all four genes in 957 
of the 1,000 simulations, but a more detailed examination of the results gives more insight 




Of the 1,000 simulations, 43 had three or fewer of the four AI genes: on average the 
number of nodes actually spiked in was 3.957. Of these 43 simulations, none resulted in the 
recovery of all four AI genes. However, for every simulation, every gene that was actually 
spiked in was recovered, so the number of spiked nodes recovered was also 3.957. Whether 
any unspiked “true” nodes are recovered depends on the topology of the network around the 
spiked nodes. In the case of AI, the four genes form a clique in HuPPI2, and consequently, 
any three of the four form a connected subnetwork (see Figure 4.6a). So if only three of the 
genes are marked with individuals, there is no need for the fourth to be incorporated into the 
optimal subnetwork as a jump. 
The average number of false nodes found was 0.021 (one false node in 21 of the 
1,000 simulations). For AI, then, BioGranat-IG would be highly likely to direct the user 
towards the true causal complex, with minimal erroneous results. 
4.3.2 BioGranat-IG Recovers PHA-I Genes, plus Jumps 
The second disease used as a positive control is PHA-I, a disorder of electrolyte 
metabolism which develops in infancy. Clinical symptoms of the systemic salt loss caused 
by PHA-I include dehydration, respiratory problems and a high risk of life-threatening salt-
losing crises (Riepe 2009). Studies have shown that the severe autosomal recessive form of 
PHA-I can be caused by homozygous or compound heterozygous mutations in any of the 
epithelial sodium channel genes SCNN1A, SCNN1B and SCNN1G (Riepe 2009). 
In HuPPI2, these genes are not directly connected; although there is evidence for 
direct protein interactions (Canessa et al. 1994; Firsov et al. 1996), the databases underlying 
HuPPI2 do not list two publications to support this fact and hence the interactions do not 
 
Figure 4.6 – AI and PHA-I genes in HuPPI2 
The subnetworks in HuPPI2 that contain the genes responsible for the two positive control diseases. 
(a) AI has four underlying genes that form a clique; (b) PHA-I has three underlying genes (thick lines) 




meet the quality criteria for inclusion in HuPPI2. However, all three genes are connected to 
NEDD4 and to STX1A (see Figure 4.6b). 
The average number of nodes actually spiked in was 2.990: all three genes were 
spiked in for 990 of the 1,000 simulations. In 989 of these, all three were correctly recovered 
by BioGranat-IG. 
In one case, all three PHA-I genes were spiked in but only two were recovered. This 
occurred because 2 of the 15 individuals were spiked with gene SCNN1G, but for both of 
these individuals, STX1A happened to be one of the 35 randomly-generated non-causal 
variants. As they are not directly connected, any subnetwork including all three PHA-I genes 
requires at least four nodes, but in this case, a smaller subnetwork can be formed from 
SCNN1A, SCNN1B and STX1A, so this smaller subnetwork is returned. Owing to this one 
simulation run, the average number of spiked nodes recovered was lower than the average 
number of nodes actually spiked, at 2.989. 
Because an additional node is always needed to connect the PHA-I genes, and there 
are two alternative ways to do this, both NEDD4 and STX1A are always returned with the 
PHA-I genes found (other than the anomalous case described). Therefore, the average 
number of false nodes found is relatively high at 2.009 (this includes 10 simulations where 
an additional false gene was returned). However, this is a positive result. It shows that 
BioGranat-IG can work successfully even when the network used does not contain the true 
causal genes as a connected complex. Note that returning a small number of false genes 
and/or jumps is not hugely problematic, as BioGranat-IG is intended to be used to highlight 
genes for further experimental investigation. 
4.3.3 The Effectiveness of BioGranat-IG Depends on a Number of Conditions 
Having used “real” diseases to show that BioGranat-IG can find sources of genetic 
heterogeneity, we now examine the performance of BioGranat-IG under various conditions 
using artificial data. 
4.3.3.1 Smaller, Less Connected Complexes Give Better Results 
The ability of BioGranat-IG to find a spiked-in complex and the number of false 
genes it is likely to return depend on both the size of the complex and the local network 
topology. 
To measure this, we identified three complexes of seven nodes each in HuPPI2. 
Complex L-7 has low connectivity (it forms a Y-shaped “branch” with a single neighbour in 
the rest of the network); complex A-7 has average connectivity (each node has degree 3 or 4) 




Table 4.1 – Performance testing for BioGranat-IG 
All numbers shown represent average of 1,000 simulations. “Complex size” = size of complex chosen 
to be spiked in (number of nodes). “Actually spiked” = number of nodes in the complex picked for a 
given simulation (for each individual, one node in the complex is picked randomly with replacement). 
“Recovered” = number of nodes in the complex returned in the program output. “False 
positives” = number of nodes outside the complex returned in the program output. “Total 
nodes” = total number of nodes returned in the program output (= recovered + false positives). Table 
continues onto following pages. 
(a) Test performance on complexes of varying size in low-connectivity region (15 individuals, 35 false 












Complex L-2 2 2.000 2.000 0.000 2.000 
Complex L-3 3 2.994 2.996 0.000 2.996 
Complex L-4 4 3.953 3.981 0.000 3.981 
Complex L-5 5 4.830 4.888 0.021 4.909 
Complex L-6 6 5.590 5.741 0.081 5.822 
Complex L-7 7 6.315 6.574 0.746 7.320 














    Complex A-2 2 2.000 2.000 0.000 2.000 
    Complex A-3 3 2.996 2.998 0.000 2.998 
    Complex A-4 4 3.948 3.961 0.015 3.976 
    Complex A-5 5 4.826 4.881 0.025 4.906 
    Complex A-6 6 5.604 5.789 0.111 5.900 
    Complex A-7 7 6.277 6.568 0.761 7.329 
30 individuals 
    Complex A-6 6 5.973 5.988 0.003 5.991 




Table 4.1 (continued) 














    Complex H-2 2 2.000 2.000 0.000 2.000 
    Complex H-3 3 2.991 2.993 0.043 3.036 
    Complex H-4 4 3.950 3.962 0.395 4.357 
    Complex H-5 5 4.823 4.847 1.264 6.111 
    Complex H-6 6 5.588 5.660 4.665 10.325 
    Complex H-7 7 6.322 6.297 4.657 10.954 
30 individuals 
    Complex H-6 6 5.977 5.984 0.401 6.385 
    Complex H-7 7 6.938 6.938 0.943 7.881 












5  individuals 5 3.388 3.611 1.682 5.293 
10 individuals 5 4.466 4.669 0.163 4.832 
15 individuals 5 4.842 4.900 0.028 4.928 
20 individuals 5 4.931 4.961 0.007 4.968 
25 individuals 5 4.985 4.991 0.006 4.997 
30 individuals 5 4.994 4.995 0.000 4.995 
(e) Test performance with varying stringency of filtering (number of false nodes per individual) (complex 












15 false nodes 7 6.307 6.332 2.068 8.400 
25 false nodes 7 6.332 6.325 3.359 9.684 
35 false nodes 7 6.300 6.274 4.644 10.918 
45 false nodes 7 6.328 6.287 6.395 12.682 




Table 4.1 (continued) 
(f) Test performance when each individual is not guaranteed a mutation in the complex, but has one with a 












No limit on subnetwork size 
    Probability 0.5 5 3.977 2.241 27.565 29.806 
    Probability 0.6 5 4.257 3.227 22.211 25.438 
    Probability 0.7 5 4.474 3.953 18.241 22.194 
    Probability 0.8 5 4.614 4.392 13.618 18.010 
    Probability 0.9 5 4.742 4.718 7.352 12.070 
    Probability 1.0 5 4.806 4.878 0.033 4.911 
Subnetworks limited to size 10 
    Probability 0.5 5 3.944 1.931 13.946 15.877 
    Probability 0.6 5 4.251 2.951 12.890 15.841 
    Probability 0.7 5 4.463 3.769 10.731 14.500 
    Probability 0.8 5 4.622 4.421 9.248 13.669 
    Probability 0.9 5 4.747 4.723 5.896 10.619 






Figure 4.7 – Performance of BioGranat-IG on simulated data in various scenarios 
For each graph, the vertical axis gives the value of each metric against the size of the complex being spiked in, and metrics represent the average value observed in 1,000 
simulations. For example, if the spiked-in complex has four nodes and BioGranat-IG recovered 3.75 of these on average over 1,000 simulations, this would be displayed at 
-0.25 on the vertical axis. Each graph shows a baseline at 0. Note that graphs have different scales. (a) shows the ability to recover a spiked complex that falls in an area of 
low connectivity in the underlying network, for various complex sizes; 15 individuals, 35 false nodes per individual; (b) shows the same in an area of average 
connectivity, for 15 individuals and 35 false nodes per individual. Also shown is the improved performance for larger complexes achieved by increasing the number of 
individuals to 30; (c) shows the same in an area of high connectivity; (d) shows the effect of using a different number of individuals. Complex is size 5, average 
connectivity, with 35 false nodes per individual; (e) shows the effect of using a different filtering stringency (i.e. number of false nodes per individual). Complex is size 7, 
high connectivity, with 15 individuals; (f) shows the effect of changing the probability that each individual has a variant in the complex. Complex is size 5, average 




using subcomplexes of between two and seven nodes from each of these complexes (for 
example, A-5 being the subcomplex of A-7 that has five nodes). 
Results for the low-connectivity complexes were excellent, with frequent recovery 
of additional nodes from the complex not actually spiked in, and few false nodes returned 
(see Table 4.1a and Figure 4.7a). For L-7, on average, only 6.315 nodes from the complex 
are actually spiked in, but 6.574 are recovered. In addition, only 0.746 false nodes are 
returned. The performance improves as the size of the complex gets smaller. This is 
probably owing to the reduced chance of alternative smallest subnetworks forming 
elsewhere by chance and reduced chance of a “true” node not actually being spiked in. 
For the average-connectivity complexes, the performance suffers a little because 
having more nodes neighbouring the complex gives more opportunities for false variants to 
occur by chance in close proximity to the “true” disease nodes, thus offering alternative 
ways to form small subnetworks. However, the number of nodes recovered for the A 
complexes is broadly in line with the L complexes, while the numbers of false nodes 
returned are only slightly higher and still tolerable in practice (see Table 4.1b and Figure 
4.7b). 
The results for the high-connectivity complexes show a more substantial impact due 
to the presence of so many more neighbours, all of which can potentially be included as false 
variants (see Table 4.1c and Figure 4.7c). The power to recover genes in the H complexes is 
slightly reduced relative to the A complexes (for H-7, 6.322 nodes are actually spiked in but 
only 6.297 recovered). This reflects the increased “noise” around the complex making the 
true signal harder to detect. However, the bigger impact is to the number of false nodes 
returned, which is, for example, 4.665 for H-6 and 4.657 for H-7 (intuitively this would 
increase with the size of the complex – it most likely does not owing to the particular 
topologies of H-6 and H-7). 
In summary, when the underlying complex happens to be in a highly connected part 
of the network, the total number of nodes found is generally higher. Because the goal is to 
find an unknown complex, its connectivity is not something that will be known to the 
experimenter a priori, but fortunately sequencing more individuals can help combat this 
problem. We tested H-6 and H-7 again, this time using 30 individuals, and the results were 
much improved (less than one false node found on average in each case). 
4.3.3.2 Sequencing More Individuals Can Improve Results 
To fully characterise the relationship between performance and number of 
individuals, we ran simulations with varying number of individuals on complex A-5 (to 




higher number of individuals leads to increased power to detect the spiked complex and 
fewer false nodes being returned. There are two reasons for this: the increased chance of 
having all nodes in the complex actually spiked in, and the reduced chance of sufficient false 
nodes occurring in the nodes neighbouring the region to offer alternative small subnetworks. 
Clearly, the conclusion that can be drawn here is that increasing the sample size 
increases the power to detect a true disease-linked signal. This suggests a strategy that could 
be followed when BioGranat-IG is used in practice: if the number of genes returned is large, 
sequencing further individuals will help to narrow this list down if there is a true underlying 
cause of locus heterogeneity. 
4.3.3.3 Stringency of Variant Filtering Affects Performance 
As previously described, it is common practice when searching for genetic causes of 
rare diseases using whole exome sequencing data to filter out variants found in patients 
based on a number of criteria (e.g. genes that are well understood or in which variants are 
seen frequently). More stringent filtering should reduce the number of false input nodes per 
individual, which in turn affects the performance of BioGranat-IG. 
We tested this by running simulations on complex A-5 with varying number of false 
nodes per individual, but for this complex, we found a marginal effect (results not shown). 
The effect can be seen more clearly in the equivalent simulations run on complex 
H-7 (see Table 4.1e, Figure 4.7e). As expected, for 35 false variants, the results are close to 
what we saw for the same complex in section 4.3.3.1. With a change in the number of false 
input nodes per individual, there is again a marginal effect on the number of spiked nodes 
recovered, ranging from 6.332 with 15 false variants per individual down to 6.183 with 55 
false variants. But the change in the number of false nodes returned is more dramatic: at 15 
false variants per individual, only 2.068 are returned on average; this rises to 7.761 at 55 
false variants per individual. 
This confirms the intuitive notion that if there is a true disease-linked complex, 
filtering out more false nodes from the input gene lists will result in fewer false positive 
results in the BioGranat-IG output. Of course, the user should also be aware of the risk of 
erroneously filtering out variants that form part of the true complex. 
4.3.3.4 There is Less Chance of Finding the “True” Complex if Some Individuals 
Lack a Variant 
It is of course possible that the whole exome sequencing data will not contain a 
variant for every affected individual in what is nevertheless a true mechanism of locus 




the network, data problems (such as incorrect base calling or incomplete exome sequencing) 
or some individuals being phenocopies (exhibiting a similar phenotype due to environmental 
effects). We simulated this on complex A-5: along with 35 false nodes, each individual 
received a random node from complex A-5, with probability p. We tested a range of p from 
0.5 to 1.0. 
Note that this also provides a good model for the situation where a true disease-
linked complex is only partially represented in the underlying network. This could be the 
case because a true gene is not present in the network or equally because true genes are 
disconnected in different network components or different regions of the same component 
(these are problems common to many network-based analysis methods). 
Initially, subnetworks of any size were allowed (see Table 4.1f). We found that as p 
decreases, it is more difficult for BioGranat-IG to pick out the true underlying complex, 
leading to relatively poor recovery of spiked nodes for low p. Worse still, the number of 
false nodes found grows quickly (e.g. to over 27 at p = 0.5). 
However, better results are obtained by limiting the maximum subnetwork size (see 
Table 4.1f and Figure 4.7f). Without this limit, BioGranat-IG finds subnetworks containing 
all 15 individuals, no matter how big they may be. But it would be unreasonable in practice 
to expect that a large subnetwork identified using just 15 patients would be a true 
mechanism of genetic heterogeneity. 
4.4 Discussion 
We have presented BioGranat-IG, a software tool for the analysis of whole exome 
sequencing data with the aim of identifying groups of genes in interaction networks 
collectively responsible for causing a disease through locus heterogeneity. 
The tool addresses the problem where several patients affected by a rare monogenic 
disease are exome sequenced, but no single gene is found to harbour a sequence variant for 
all patients. It would be possible to solve the minimal set covering problem, without using a 
gene network, to find the smallest number of genes across which all patients have at least 
one variant. However, there are two advantages to using BioGranat-IG to instead perform 
this search within a network. Firstly, the resulting subnetwork will be made up of genes that 
have already been shown to interact, so is more likely to be biologically meaningful. 
Secondly, the number of patients needed for results to be significant is lower in the network 
context, where significance is measured as the likelihood of finding an equivalently small 




Using simulated datasets for two diseases, we have shown that BioGranat-IG is 
capable of identifying the genes known to be responsible for disease phenotype. In addition, 
we have shown that under a range of conditions, BioGranat-IG is generally capable of 
picking out a relatively small subnetwork for which further experimental investigation is 
likely to prove insightful. Depending on the particular disease mechanisms, it is possible to 
use different types of networks for the analysis. For example, to identify causal genes for 
metabolic diseases, a metabolic network might be more informative than a PIN. 
Owing to the highly interconnected nature of interaction networks, we have seen 
that false positive genes can be suggested by BioGranat-IG, particularly when a causal gene 
complex is not fully contained in the network or when there might be alternative disease 
pathways. However, the number of genes returned will be relatively small compared with 
the number of variants identified by the initial exome sequencing, and can typically be 
inspected manually. In addition, BioGranat-IG provides a tool to estimate the significance of 
Table 4.2 – Individuals needed for significance 
Fewer individuals are needed to classify a subnetwork as significantly small using BioGranat-IG in 
the HuPPI2 network than by using a set cover approach (no network). For each region size, the table 
gives the number of individuals at which finding a region of that size in which all individuals have a 
variant represents a significant result; 1% and 5% significance levels are shown. Results are estimated 
using 10,000 random simulations for each number of individuals. For the BioGranat-IG tests in 
HuPPI2, each individual is randomly generated with 35 genes, and the network covers 3,666 genes. 
Set cover tests were performed at two levels: 3,666 total genes with each individual having 35 genes 
chosen at random, and 20,000 total genes with each individual having 200 genes chosen at random. 
This last case represents the full exome, where 200 filtered variants are typically seen. The set cover 
tests implemented a randomised greedy search (genes were chosen to maximise the number of 
individuals not yet covered, with ties broken at random, and 100 iterations used per instance). As an 
example, for region size 4 and using BioGranat-IG in HuPPI2, 6 individuals are needed for 
significance at the 1% level. This means that in the set of 10,000 simulations on 6 individuals, all 
individuals could be covered by 4 genes or fewer less than 1% of the time, but in the set of 10,000 




Individuals needed for significance 
Set cover 
@ (20,000, 200) 
Set cover 
@ (3,666, 35) 
BioGranat-IG 
in HuPPI2 
5% level 1% level 5% level 1% level 5% level 1% level 
1 3 4 3 3 3 3 
2 6 6 5 5 3 4 
3 9 9 7 8 4 5 
4 12 12 10 10 5 6 
5 15 16 12 13 6 7 
6 19 19 15 16 7 8 




the results and configurable parameters to allow flexibility of the subnetworks returned, and 
the visualisation tools in BioGranat can be used to explore the results further. 
If there is a true underlying complex, sequencing more individuals should reduce the 
number of false positive genes returned. It is important to note that many diseases cannot be 
linked to only a small number of genes, in which case BioGranat-IG may not be an 
appropriate tool to identify causative genes. In this case, sequencing more individuals should 
only increase the number of genes returned, rather than focusing in on a particular region. It 
is possible, however, that BioGranat-IG could prove useful for complex diseases in certain 
cases, for example, to study high-severity/early-onset cases or patients having a particular 
subphenotype – in which cases single pathogenic variants could contribute a majority of 
disease risk. (It is important to be able to distinguish these cases from the more common 
multifactorial cases because appropriate treatment options may differ.) Chapter 8 will 
examine this possibility further by describing an application of BioGranat-IG to Crohn’s 
disease. 
In its current form, BioGranat-IG represents only a first step towards solving this 
problem. In particular, the methods used are likely to find the smallest connected 
subnetwork in which all sequenced patients have a variant, but they do not guarantee it – one 
avenue for further work could be to improve the algorithms to minimise the possibility of 
missing an optimal subnetwork. In addition, further work could be done to ascertain whether 
a BioGranat-IG-like approach could perform better for complexes found in highly connected 
regions of a network, and for diseases where there is a reasonable chance of affected 
individuals not having a mutation in a true underlying complex. 
The next chapter will describe HetRank, a tool which takes an alternative approach 
to identifying disease genes in the presence of genetic heterogeneity, and which aims to 





5 Development of HetRank Analysis Tool 
5.1 Introduction 
Intersection filtering has been shown to be a successful strategy for monogenic 
disease gene identification, applicable to both rare inherited and sporadic disorders and 
requiring no prior knowledge of the disease process or a set of candidate genes (Gilissen et 
al. 2011; Ku et al. 2011; Rabbani et al. 2012). While the search is exome-wide, intersection 
filtering is attractive because the number of genes in which several unrelated individuals 
carry post-filtering variants will generally be small. Conversely the effectiveness of the 
approach can be limited by missing data, non-exonic causal variants, and as we have seen, 
genetic heterogeneity (Robinson et al. 2011; Boycott et al. 2013). This thesis is concerned in 
particular with locus heterogeneity, whereby mutations occurring in different genes can 
cause the same phenotypic outcome in different patients – the genes would therefore not be 
revealed by simple intersection filtering (Oti and Brunner 2007; McClellan and King 2010). 
The BioGranat-IG tool presented in the previous chapter tries to overcome this problem by 
effectively widening the frame of intersection from the single gene to connected sets of 
genes in an interaction network. 
In this chapter we present an alternative approach. HetRank is a flexible analysis 
tool which addresses the problem of genetic heterogeneity in exome sequencing studies by 
incorporating information from interaction networks into a gene prioritisation framework. 
Networks are ideally suited to this purpose for the same reasons that they are used by 
BioGranat-IG: because they group together functionally-related genes without restriction to 
existing curated biological pathways (Lehne and Schlitt 2012), and because it has previously 
been observed that genes causing the same monogenic disease are more likely to physically 
interact than non-disease genes (Goh et al. 2007; Feldman et al. 2008). As before it is also 
intuitively reasonable at a molecular level because sequence variants which affect protein 
conformation or the binding affinity of a protein domain can change the way or extent to 
which gene products interact; in theory each of the interaction partners could be vulnerable 
to mutation and a disease phenotype could result from the disruption to their cooperative 
function (Barabasi et al. 2011; Vidal et al. 2011). 
HetRank has several advantages over BioGranat-IG. By incorporating network 
information into a gene-ranking framework, HetRank retains the ability to prioritise genes 




caused by hub genes in the network; in practice hub genes can occur frequently in the 
optimal subnetworks found by BioGranat-IG due to their connectivity rather than true 
disease involvement (hub genes containing no post-filtering variants themselves are often 
returned in optimal subnetwork as “jumps”).* The flexible ranking framework allows 
incorporation of diverse sources of information for variant prioritisation, and removes the 
need to identify appropriate thresholds for filtering of variants. Finally, HetRank can 
incorporate healthy control exomes to address a problem common to many exome 
sequencing studies: that of large and variant-tolerating genes being overrepresented among 
prioritised variants (Fuentes Fajardo et al. 2012; Petrovski et al. 2013); this can cause false 
positive findings using intersection filtering, and hence also using BioGranat-IG. 
There exist several variant prioritisation tools appropriate for the study of rare 
monogenic diseases that integrate various sources of evidence for causality (Li et al. 2012; 
Sifrim et al. 2012; Carter et al. 2013; Frousios et al. 2013; Robinson et al. 2013; Sifrim et al. 
2013). However, where interaction data are used it is generally either to prioritise genes 
based on their proximity to known disease genes in the interaction network, or to allow the 
user to explore genes which interact with those prioritised. To our knowledge HetRank is the 
first approach to incorporate interaction network information directly into the gene-ranking 




We test our new approach using a set of test data comprising 20,000 randomised 
exome sequences and will show in this chapter that network information can help to rank 
disease-causing genes highly even under conditions of high residual unknown heterogeneity. 
This work has been prepared and submitted for publication. Co-author contributions 
are as follows: Dr Mike Weale contributed to the method development by suggesting the 
mechanism by which initial gene rankings are adjusted with respect to healthy control 
exomes; Dr Reiner Schulz, Prof. Rebecca Oakey, Dr Michael Simpson and Dr Thomas 
Schlitt provided general supervision and recommendations regarding the analysis and 
                                                     
*
 Results not presented here, but note for example that in the BioGranat-IG tests depicted in Figure 
4.7f in the previous chapter (using complex A-5, 15 individuals and 35 false nodes per individual), 
when the probability that each individual has a variant in the complex is 0.5 the gene with highest 
degree in HuPPI2 (YWHAG, degree 108) occurs in the optimal subnetwork in 19.7% of tests (and this 
figure rises to 31.4% when BioGranat-IG searches are not limited to subnetworks of 10 genes or 
fewer). In chapters 7 and 8 when BioGranat-IG is used with real whole exome sequencing studies, 
hub-free versions of the networks are used. 
†
 But note that since HetRank was developed, the SPRING tool for prioritising disease-causing 
variants in a single exome was published (Wu et al. 2014). One of the evidence types used by 
SPRING is proximity to other causal genes in a protein interaction network, thereby implicitly 
allowing for genetic heterogeneity. If no known disease-causing genes exist, a set of seed genes can 




presentation of results; Dr Simpson also oversaw and contributed data for test data 
generation, and advised on experimental design; Dr Schlitt also initiated and obtained 
funding for network method development projects (including my PhD studentship). The 
algorithm design (other than that credited to Dr Weale above) and implementation, test data 
generation, analysis, and interpretation of results presented in this chapter were performed 
by Nick Dand. 
5.2 Methods 
All data analysis is performed in the R programming language (R Development 
Core Team 2013), using the igraph library for network analysis (Csardi and Nepusz 2006). 
An implementation of HetRank in R is available online (http://sourceforge.net/p/hetrank). 
5.2.1 Protein Interaction Networks and Disease Subnetworks 
Results in this chapter are based on performing HetRank analysis using the 
PINAmin2 network described in chapter 2. Test data will make use of the OMIM disease 
subnetworks identified in the PINA and PINAmin2 networks in chapter 3. 
5.2.2 Simulation of Whole Exome Sequencing Studies 
To measure the performance of the new approach, we simulate 1,000 exome 
sequencing studies for rare monogenic disease. As with BioGranat-IG performance testing 
in chapter 4, each study is “spiked” with disease-causing variants chosen to model locus 
heterogeneity, and we test HetRank’s ability to recover the spiked genes. However, while 
BioGranat-IG could be tested by generating random gene lists, HetRank requires annotated 
whole exome sequence data and a more sophisticated test dataset is therefore needed. 
Chromosome-wise random selection (without replacement) of sequence data from 
388 exomes obtained through the King’s College London (KCL) rare disease programme (a 
subset of the exomes covered by the in-house exome database) was used to generate 200 test 
exomes. These were partitioned into sets of 20 exomes so that when each set is used to 
simulate an exome sequencing study the other 180 exomes can represent healthy controls. 
This was repeated 100 times to give 1,000 simulated exome sequencing studies (20,000 
random exomes in total). The 388 original exomes come from unrelated individuals and 
include some small groups of patients sharing a rare disease phenotype, although the 





As described in chapter 2, exome variants were annotated using ANNOVAR (Wang 
et al. 2010c), which provided the following criteria which can be used by HetRank to rank 
variants: variant effect (e.g. “nonsynonymous SNV”, “stopgain SNV”), Exome Variant 
Server (EVS) alternative allele frequency, 1000 Genomes Project alternative allele 
frequency. Additional annotation gave the following variant-ranking criteria, resulting in six 
criteria in total: zygosity, number of observations in homozygous form in the in-house 
exome database, number of observations in heterozygous form in the in-house exome 
database. In all tests: homozygous variants were ranked ahead of heterozygous variants; 
“synonymous SNV” was ranked behind all other types of variant effect which were equally 
ranked. 
To simulate exome sequencing studies, one disease-causing variant was added to 
each of the 20 exomes in a set. These were randomly selected from 13,413 pathogenic 
variants in dbSNP (Sherry et al. 2001) (build 138, downloaded 19th July 2013) that 
corresponded to monogenic diseases in OMIM’s Morbid Map (downloaded 20th March 
2013) (Amberger et al. 2009) and were annotated using the same pipeline as the KCL exome 
data. Since dbSNP variants did not include zygosity this was randomly set to homozygous 
with probability 0.9 and heterozygous with probability 0.1. Gene names for the disease-
causing variants were replaced in order to model locus heterogeneity. 
For this purpose OMIM disease subnetworks were randomly selected from those 
identified in PINA and PINAmin2 in chapter 3. PINA contains 305 unique disease 
subnetworks of two genes (including gene pairs drawn from larger disease subnetworks), 
248 of three genes and 280 of four genes; PINAmin2 contains 150 of two genes, 108 of 
three genes and 111 of four genes. Gene names for the disease-causing variants were 
replaced with gene names from the disease subnetwork with probability 1-u (captured 
heterogeneity) or a gene name selected uniformly at random from the whole exome with 
probability u (uncaptured heterogeneity). We model uncaptured heterogeneity because in 
practice we might expect some proportion of disease cases to be explained by reasons other 
than a mutation in the disease subnetwork. To simulate balanced captured heterogeneity 
gene names from the disease subnetwork are randomly selected with equal probability. To 
simulate unbalanced captured heterogeneity gene names from the disease subnetwork are 
used with probabilities p1 = 3(1-u)/4, p2 = (1-u)/4 for two-gene disease subnetworks; 
p1 = (1-u)/2, p2 = p3 = (1-u)/4 for three-gene disease subnetworks, and p1 = (1-u)/2, 




5.2.3 HetRank Gene Prioritisation Approach 
Having established in chapter 3 that interacting genes cause the same monogenic 
diseases, we developed a method to prioritise genes for follow-up analysis in exome 
sequencing studies of monogenic disease, using an interaction network to overcome genetic 
heterogeneity (illustrated in Figure 5.1). The key concept behind the approach is to 
independently rank the sequence variants identified in the exomes of a number of unrelated 
affected individuals (according to evidence supporting each variant’s disease involvement), 
from which a final prioritisation of genes is produced by combining rankings across the 
study. The final gene ranking takes into account variants found in neighbouring genes in the 
interaction network. This allows a gene which is not initially highly ranked in a given 
 
Figure 5.1 – The HetRank analysis framework 
Phase 1: Variants are ranked in each affected individual’s exome sequence according to a set of user-
specified criteria and converted into gene ranks. Healthy control exomes can also be used to more 
accurately rank large and variant-tolerating genes. Phase 2: An interaction network is used to share 
ranking information between neighbouring genes. Neighbouring genes which rank highly in different 
affected individuals improve the evidence for each other’s involvement in the disease process. 




individual to have its ranking improved based on evidence for disease involvement from a 
neighbouring gene; this acts to preferentially improve the rankings of disease genes because 
the sharing of evidence between any pair of interaction partners is more likely to occur 
consistently across unrelated individuals as a result of true locus heterogeneity than due to 
chance. The three key phases are as follows. 
Phase 1: for each of N affected individuals in the study, obtain a ranking of genes 
according to evidence for disease involvement. First, exome sequence variants are ranked 
according to m ranking criteria with average rank being used to resolve ties. Assuming that 
one variant is sufficient to cause the disease in each affected individual, ranking criteria 
would typically include the alternative allele frequency (effectively set to zero for novel 
sequence variants), zygosity and variant effect (such as synonymous, missense or nonsense 
mutation). However, since ranking criteria are specified by the user they could also include 
functional prediction scores or quantification of disease-specific knowledge. Categorical 
criteria are ranked using values from user-supplied reference tables. Ranks are then 




 variant-ranking criterion can be derived from a set of healthy 
control exomes in order to penalise large and variant-tolerating genes that might otherwise 
receive an artificially high ranking. In this case the m
th
 criterion for variant v in gene g is the 
number of healthy control exomes in which gene g harbours a variant with a lower variant 
score (taken across the first m-1 ranking criteria) than variant v. Finally genes are ranked by 
the minimum variant score of any variant they contain (since a single sequence variant is 
sufficient to cause a monogenic disease); gene ranks are normalised by dividing by the total 
number of genes in which the exome carries a mutation. Genes without variants are assigned 
a normalised rank of 1, corresponding to no evidence for disease involvement for that 
affected individual. 
Phase 2: network-adjusted gene rankings are obtained for each of the N individuals. 
The key assumption of our approach is that when there is locus heterogeneity, evidence for a 
gene’s involvement in the disease process (as part of a functional pathway encoded by 
network interactions) can arise from a plausible sequence variant in the gene itself, or in a 
gene with which it interacts. For a gene g, the network d-neighbourhood, Nd(g), is the set of 
genes which can be reached from g via d interactions or fewer (and always includes g itself). 
For individual i and neighbourhood parameter d, an adjusted ranking for each gene is 





elsewhere in the gene’s d-neighbourhood. The adjusted ranking for gene g is: 
                                   
        
        
where Ri(g) is the normalised rank of gene g from phase 1. The conservation factor       is 
designed to limit the sharing of information based on a gene’s connectedness, so that hub 
genes do not always receive a high adjusted ranking. It is defined as: 
       
       
        
 
where MNS(d) is the maximum d-neighbourhood size among all genes in the network. Thus 
a gene whose d-neighbourhood size is close to the biggest in the network has a high value of 
   and its adjusted ranking stays close to its normalised rank from phase 1. On the other 
hand a gene with a very small d-neighbourhood has a low    and its adjusted ranking will 
be close to the normalised rank from phase 1 of its best-ranked neighbour. 
Since disease subnetworks are generally expected to be small (as seen in chapter 3), 
and for reasons of computational feasibility, the final network-adjusted gene ranking looks 
for better-ranked neighbours in d-neighbourhoods up to d = 2: 
                                     
Phase 3: network-adjusted gene rankings are combined across the N individuals in 
the study to give a final prioritised ranking. Although they are not p-values, the network-
adjusted rankings S(i, g) lie in the range (0,1] and a value closer to 0 indicates better 
evidence that gene g is part of a disease-causing process. Fisher’s method for combining p-
values π1, ..., πK from K independent hypothesis tests has test statistic            
 
    
(Fisher 1932). We adapt this statistic, weighting each term to reflect the fact that only some 
of the individuals in the study are likely to provide sequence variants that implicate a given 
causal gene (due to genetic heterogeneity). For each gene g, let i1, ..., iN denote the 
individuals i = 1, ..., N in the study, ordered such that S(i1, g) ≥ ... ≥ S(iN, g) (that is, 
individual i1 provides the least evidence, after network adjustment, for gene g’s involvement 
in the disease, and iN the most). Gene rankings are combined across individuals in the study 
according to                     
 
    (note that we do not use this value to draw 
conclusions about the statistical significance of our results). 
Figure 5.2 illustrates how this weighted form of Fisher’s sum acts when combining 
rankings from two exomes. Relative to Fisher’s sum in its unweighted form, and weighted or 




in only one of the exomes ahead of genes with moderately high rank in both. When there are 
more than two exomes this will mean that very high ranks in a small proportion of the 
exomes should be enough to rank a gene highly, which is intended to ensure that disease 
genes can be identified even when there is no single consistent functional mechanism 
underlying the disease for all cases. Results using simulated test data and the weight 
parameters derived in the next section confirmed that this was the most effective approach 
(results not shown). 
Finally, all genes are ranked according to the score S(g) to produce the final 
prioritised ranking returned by HetRank. 
5.2.4 HetRank Parameters for Testing 
To select appropriate weights for the tests we ran a heuristic optimisation procedure 
to assign weights between 1 and 8 to each ranking factor. The role of the weights is to cause 
the true disease-causing gene in any individual to be ranked as high as possible before the 
gene scores are adjusted using network information. To estimate suitable weights w1, ..., w7, 
1,000 exome sequencing studies were simulated with a single OMIM monogenic disease 
gene specified (instead of sampling from an OMIM disease subnetwork), and with 
uncaptured heterogeneity u = 0.5. We sought a combination of weights that resulted in the 
best average rank of the disease gene across the 1,000 exome studies when HetRank was 
used without incorporating network information (that is, omitting phase 2). 
A heuristic method was used with several steps t = 0, 1, 2, ... such that at each step 
integer weights in the range 1, ..., 2t could be chosen. The optimal set of weights 
w1(t), ..., w7(t) at step t were “fine-tuned” by testing all 2
7
 = 128 combinations of weights 
 
Figure 5.2 – Methods to combine rankings 
Plots compare different methods to combine two normalised rankings (x-axis and y-axis values; better 
ranks closer to 0 at left/bottom respectively) into a final combined ranking. Two (x, y) pairs having 
the same colour indicate equal final rank. (A) sum: pairs (x, y) are ranked according to x + y; (B) 
weighted sum: ranking is according to 2 × min(x, y) + max(x, y); (C) Fisher sum: ranking is according 
to log(x) + log(y); (D) weighted Fisher sum: ranking is according to 2 × log(min(x, y)) 





that could be derived at step t+1 by setting wk(t+1) to be either 2wk(t)-1 or 2wk(t). Initial 
weights were w1(0) = ... = w7(0) = 1 and at each step t the calculation of the 7
th
 ranking 
criterion (which counts how many control exomes have a smaller variant score across the 
first six ranking criteria in a given gene) was performed using the optimal weights from the 
previous step t-1. This was repeated three times, giving final weights w1 = w1(3), ..., 
w7 = w7(3) in the range 1, ..., 8. 
All ranking criteria were assigned weight 1 except for “number of observations in 
homozygous form in the in-house exome database” (assigned weight 8) and the 7th ranking 
factor which down-ranks genes ranked highly in healthy control exomes (assigned weight 8). 
Given their limited ability to discriminate variants the low weights for zygosity and variant 
effect are expected. The optimal weights also imply that the homozygous count in the in-
house exome database is the most informative of the four variant frequency criteria available 
and strongly support the use of healthy control exomes to limit the confounding effect of 
large and variant-tolerant genes in the HetRank methodology. 
All testing was performed using PINAmin2 as the input network for HetRank. 
5.2.5 Ranking Based on Intersection Filtering 
HetRank results are compared against those achieved by intersection filtering, 
obtained as follows. For each simulated exome sequencing study, gene lists for intersection 
filtering were generated for each individual by excluding synonymous variants, variants with 
EVS or 1000 Genomes alternative allele frequency > 0.1%, and variants in the in-house 
exome database (except for homozygous variants previously observed in heterozygous 
form). An additional gene-wise filtering step could be performed by either: excluding all 
genes identified by Fuentes Fajardo et al. as frequently enriched for false positive sequence 
variants in exome sequencing studies (Fuentes Fajardo et al. 2012); or: excluding genes 
which contain post-filtering sequence variants for ten or more of 180 healthy control 
exomes. Either of these additional steps represents a measure that a researcher might take to 
improve their intersection filtering results. 
To obtain a ranking for potential disease involvement based on intersection filtering, 
genes were ranked according to the number of filtered gene lists in which they appear, with 
average rank being used to resolve ties. Gene-wise filtering using control exomes was 
preferred to filtering using the Fuentes Fajardo list, and to not filtering at the gene level, due 
to superior performance. 
(This was ascertained by looking at how well intersection filtering could identify 
genes from three-gene disease subnetworks drawn from the PINA network, with balanced 




gene-wise filtering, an average of 0.700 out of three disease-causing genes were ranked in 
the top ten across 1,000 simulated studies. This increased to 0.817 by excluding the Fuentes 
Fajardo genes, but using control exomes instead substantially improved this figure to 1.269.) 
Genes that are excluded or contain no post-filtering variants in a study are assigned a 
default rank of 10,000. 
5.2.6 BioGranat-IG Results for Comparison 
Finally we tested whether HetRank improves upon BioGranat-IG, described in the 
previous chapter and to our knowledge the only previously existing tool that uses interaction 
networks to address genetic heterogeneity. BioGranat-IG analysis was performed using gene 
lists filtered as for intersection filtering, described above (except that gene-level filtering 
used a threshold of five, rather than ten, observations in control exomes). BioGranat-IG 
triplet search and heuristic (minimum/multi-minimum distance) searches were run separately 
using default settings (results flexibility parameters set to zero; heuristic searches limited to 
ten genes, 1,000 iterations per network gene and 2,000,000 iterations total). The input 
networks used were PINAmin2 and, considering the steps a user might take to reduce the 
number of highly-connected hub genes found, the hub-free version PINAmin2_d50 
(constructed by removing hub genes having 50 or more interaction partners, as described in 
chapter 2). 
5.3 Results 
5.3.1 Network Information Can Improve Ranking of Disease Genes 
Initially, HetRank was tested using 1,000 simulated exome sequencing studies, each 
“spiked” with a disease-causing variant in a gene from an OMIM disease-specific 
subnetwork of three genes (selected at random from those identified in Table 3.1 in chapter 
3) to model locus heterogeneity. In a given study spiked with genes g1, g2 and g3, each of the 
20 case exomes would be assigned gene gi with probability pi, or a uniformly selected gene 
from outside the disease subnetwork with probability u that represents uncaptured 
heterogeneity (such that p1 + p2 + p3 + u = 1). For each study there are 180 exomes available 
to act as healthy controls, with which no sequence data are shared. 
Table 5.1 shows the results of testing our approach with u = 0.5 and the 
heterogeneity captured by the subnetwork split equally between the three genes 
(p1 = p2 = p3). All testing was performed using the high-confidence PINAmin2 interaction 




assign high ranks to the three disease subnetwork genes. This is compared against the 
performance achieved using a simple intersection filtering approach, with variant- and gene-
level filtering as described in section 5.2.5. 
Table 5.1a shows the results obtained when disease-causing variants were assigned 
to OMIM disease subnetworks identified in PINAmin2, corresponding to high network 
coverage (interactions used to model locus heterogeneity are always included in the network 
we use for ranking). Comparing the final gene ranking that is achieved by HetRank after 
network information is incorporated against the ranking achieved using simple intersection 
filtering shows a consistent improvement. Of the 1,000 tests, the number in which a disease 
gene ranks in top position increases from 375 to 853, while the number of tests in which all 
three disease genes rank in positions 1-3 increases more than sixty-fold from 3 to 187. In 
subsequent results sections we will consider ranking in the top ten genes as a successful test 
since we consider ten prioritised genes to be a reasonable number for a researcher to study 
further in practice. The number of tests in which all three disease genes are ranked in the top 
ten increases from 45 to 702 when our network-informed approach is used. 
Table 5.1b shows the results obtained when disease-causing variants were assigned 
to OMIM disease subnetworks with lower network coverage, this time identified in PINA 
(in this case, interactions used to model locus heterogeneity may not be covered by the 
network we use for ranking). Although the performance is slightly reduced, our approach 
still improves the number of tests in which disease genes rank in top position (from 356 to 
636) or positions 1-3 (from 1 to 88) compared to intersection filtering. We now see that the 
number of tests in which any disease gene ranks in the top ten falls slightly, from 844 to 840. 
However, the number in which all three disease genes rank in the top ten still shows 
substantial improvement, from 35 to 349. The conclusion here is that although the power to 
recover the top-ranked disease gene (which should in any case be the easiest to recover 
without the use of network information), may be slightly reduced, our approach can clearly 
boost the power to recover multiple genes involved in the disease process. 
5.3.2 Network Information is More Beneficial with Increased Heterogeneity 
Having demonstrated that our new approach can be a valuable additional analysis 
tool in exome sequencing studies we examined its performance in the presence of different 
levels of genetic heterogeneity. In each scenario we simulated 1,000 exome sequencing 
studies using randomly selected OMIM disease subnetworks of a fixed size (two, three or 
four genes) to simulate captured heterogeneity, and a fixed level of uncaptured 
heterogeneity, u (20%, 40%, 60% or 80%). Further, the captured heterogeneity could be 




each exome) or unbalanced (one gene in the disease subnetwork being more likely to be 
disease-causing than the others) giving a total of 24 scenarios. 
All tests were performed using the high-confidence PINAmin2 interaction network 
to inform gene rankings, using low-coverage disease subnetworks (those identified in the 
PINA network meaning that some interactions may not be covered by PINAmin2). We 
measure the performance of our network-informed HetRank approach by its improved 
ability to assign a rank of ten or less to disease subnetwork genes relative to a ranking based 
on simple intersection filtering. 
Table 5.1 – Ability to recover disease subnetworks comprising three genes 
For all tests: uncaptured heterogeneity u = 0.5; captured heterogeneity split equally between the three 
genes (p1 = p2 = p3). “Intersection filtering” = results obtained using ranking based on intersection 
filtering; “HetRank” = results obtained using HetRank approach using interaction data from 
PINAmin2 network; Gene 1 = highest-ranked of three disease genes in results; Gene 2 = second-
highest ranked; Gene 3 = lowest ranked. 
(a) Results using high-coverage disease subnetworks (identified in PINAmin2 network) 
 
Number of 1000 simulations achieving given 
ranking using high-coverage disease subnetworks 
Intersection filtering HetRank 
Gene in pathway Gene 1 Gene 2 Gene 3 Gene 1 Gene 2 Gene 3 
Ranked #1 375   853   
Ranked #1-2 66  538  
Ranked #1-3 3 187 
Ranked ≤ 10 855 369 45 987 940 702 
Ranked ≤ 100 979 741 246 995 993 900 
       
Median rank 2 39.5 303.5 1 2 6 
 
(b) Results using low-coverage disease subnetworks (identified in PINA network) 
 
Number of 1000 simulations achieving given 
ranking using low-coverage disease subnetworks 
Intersection filtering HetRank 
Gene in pathway Gene 1 Gene 2 Gene 3 Gene 1 Gene 2 Gene 3 
Ranked #1 356   636   
Ranked #1-2 54  352  
Ranked #1-3 1 88 
Ranked ≤ 10 844 356 35 840 665 349 
Ranked ≤ 100 961 700 221 913 786 542 
       




Figure 5.3 presents the results of these tests for the 12 scenarios with balanced 
captured heterogeneity, and the 12 scenarios with unbalanced captured heterogeneity (which 
give materially similar results) are presented in Figure 5.4. Indicators of performance for all 
scenarios are summarised in Table 5.2. 
When the captured genetic heterogeneity is ascribed to only two disease genes 
network-informed ranking has a modest impact compared to ranking by intersection 
filtering. When captured heterogeneity is balanced, and uncaptured heterogeneity is low 
(40% or less), we observe a slight drop in the average number of genes which rank in the top 
ten, and a fall in the number of tests ranking both genes in the top ten. This occurs because 
the limited genetic heterogeneity in these scenarios makes the disease genes easier to 
identify by filtering based on variant properties alone, and the network generally adds 
confounding information (see Figure 5.3). However, we consistently see an improvement in 
performance in all other scenarios. Network-informed ranking has the biggest impact for 
mid-range values of uncaptured heterogeneity (u = 0.4 or 0.6) when captured heterogeneity 
is unbalanced (with in each case >200 additional tests ranking both disease genes in the top 
ten; see Table 5.2). This observation leads us to conclude that our network-informed 
approach is increasingly beneficial over simple intersection filtering as the role of genetic 
heterogeneity becomes more complex, although both methods’ power to prioritise disease 
genes suffers in extreme cases. 
As we consider larger disease subnetworks, the increased levels of genetic 
heterogeneity more clearly demonstrate the value of incorporating network information. For 
example, in the four-gene case the network-informed approach considerably improves the 
average number of disease genes ranked in the top ten (by more than one in some scenarios), 
as well as the number of tests in which all four disease genes rank in the top ten (see Table 
5.2). This is true at all levels of uncaptured heterogeneity and whether captured 
heterogeneity is balanced or unbalanced. Of particular note is the case of 20% uncaptured 
heterogeneity. Here, network information causes an average increase in the number of 
disease genes ranked in the top ten of 0.93 when the captured heterogeneity is balanced, but 
1.31 when captured heterogeneity is unbalanced. This difference reflects the fact that an 
unbalanced split of locus heterogeneity makes it harder to correctly identify the disease 
genes based on variant properties alone, whereas network-informed ranking is relatively 
robust to the allocation of disease involvement between connected genes. 
For three- and four-gene disease subnetworks with 80% uncaptured heterogeneity, 
none of the exome studies ranked all disease genes in the top ten based on intersection 
filtering. The relatively modest results for these scenarios in Table 5.2 reflect the difficulty 





Figure 5.3 – Performance of HetRank at varying levels of genetic heterogeneity when network-captured heterogeneity is balanced 
For each scenario the results of 1,000 simulated exome sequencing studies are displayed, ordered by the number of disease genes ranked in the top ten using the HetRank 
(network-informed) approach (black line). Blue shading indicates the number of disease genes ranked in the top ten based on a simple intersection filtering approach. 
Interpretation: blue shading above the black line equates to drop in performance using HetRank; white space beneath the black line equates to improvement in 





Figure 5.4 – Performance of HetRank at varying levels of genetic heterogeneity when network-captured heterogeneity is unbalanced 





Figure 5.5 gives an alternative presentation of the summary results, which also 
shows the performance that is achieved by HetRank without including the network-
adjustment step (i.e. skipping phase 2 of the process; see section 5.2.3) and the performance 
of simple intersection filtering without performing the gene-level filtering against control 
exomes (described in section 5.2.5) 
Again, a number of inferences can be made from these graphs, which show the 
average number of disease genes identified in 1,000 simulated exome sequencing studies for 
varying levels of genetic heterogeneity. Every line slopes downwards, due to the increased 
difficulty of identifying disease genes at higher levels of uncaptured heterogeneity. As 
expected, intersection filtering is more effective at all levels of genetic heterogeneity when 
gene-level filtering is performed using control exomes (dark blue line) than when no gene-
level filtering is performed (light blue line). Using HetRank without performing the 
network-based rank adjustment (orange line) further improves performance at all levels of 
genetic heterogeneity, suggesting that the HetRank framework makes more effective use of 
sequencing data than intersection filtering. Lastly, the final network-adjusted HetRank 
results (green line) show that network information is more beneficial as heterogeneity 
increases. When captured heterogeneity is modelled by a balanced split between two genes 
(top-left graph in Figure 5.5), the performance is actually less good than using HetRank 
without the network adjustment – suggesting that network information is more confounding 
than informative in this scenario. However, the performance gap decreases as the level of 
uncaptured heterogeneity increases and, further, when the captured heterogeneity is
Table 5.2 – Improved ability to recover disease subnetworks under varying levels of genetic heterogeneity 
using network-informed HetRank approach relative to simple intersection filtering 
All results are based on 1,000 tests. 
 
Average increase: # disease 
genes ranked in top ten 
Increase: # tests in which 
all disease genes rank in 
top ten 
Uncaptured heterogeneity Uncaptured heterogeneity 
20% 40% 60% 80% 20% 40% 60% 80% 
Balanced captured heterogeneity: 
  2-gene disease subnetworks -0.08 -0.11 0.03 0.15 -92 -55 146 105 
  3-gene disease subnetworks 0.15 0.49 0.75 0.48 189 341 262 59 
  4-gene disease subnetworks 0.93 1.36 1.36 0.76 367 297 144 25 
Unbalanced captured heterogeneity: 
  2-gene disease subnetworks 0.11 0.24 0.20 0.09 86 227 275 113 
  3-gene disease subnetworks 0.36 0.57 0.73 0.42 289 344 257 53 





Figure 5.5 – Summary performance of HetRank at varying levels of genetic heterogeneity 




Figure 5.5 – Summary performance of HetRank at varying levels of genetic heterogeneity (previous page) 
Graphs show average number of disease genes ranked in the top ten by each method across 1,000 
simulated exome sequencing studies. “Simple IF” = intersection filtering based on variant properties 
alone; “IF_gene10” = intersection filtering with gene-level filtering against control exomes as 
described in section 5.2.5; “HetRank (ex. network)” = results from HetRank if network-adjustment is 
not included (i.e. skipping phase 2 as described in section 5.2.3); “HetRank” = final HetRank results. 
“IF_gene10” and “HetRank” refer to the tests depicted in Figure 5.3 and Figure 5.4. 
unbalanced (top-right graph) HetRank’s performance with and without network information 
is similar. When captured heterogeneity is modelled by three-gene disease subnetworks 
(middle row of graphs), network information is beneficial at higher levels of uncaptured 
heterogeneity, while for four-gene disease subnetworks it improves performance 
considerably in all scenarios (bottom row of graphs). 
5.3.3 HetRank Improves on BioGranat-IG Results 
BioGranat-IG requires a list of genes that harbour sequence variants (after filtering 
for variant frequency and effect) for each affected individual in the study, and an input 
network. Each post-filtering gene is treated as equally likely to be causal and the tool outputs 
one or more candidate disease subnetworks. We expected the HetRank approach to 
outperform BioGranat-IG due to the fact that it ranks all variants for evidence of disease 
involvement (thus not requiring a fixed threshold) and because it incorporates network 
information into a prioritisation (thus meaning that even genes not featuring in the 
interaction network can be prioritised). HetRank also has the advantage of directly 
addressing problems caused by large and variant-tolerant genes, and genes which are highly-
connected in the network (hubs). 
Figure 5.6 compares the results of the two approaches. Since BioGranat-IG will 
return all the optimal subnetworks that it finds the user cannot specify the number of genes 
that will be returned. Therefore performance of the HetRank approach was assessed by 
considering the number of disease-causing genes to which it assigns a rank better than or 
equal to the number of genes returned by BioGranat-IG for each simulated exome-
sequencing study. 
Figure 5.6a shows that, for exome studies simulated to have 50% uncaptured 
heterogeneity and (balanced) captured heterogeneity modelled by a three-gene disease 
subnetwork, HetRank performed at least as well as BioGranat-IG’s heuristic network search 
in 96.5% of simulations, and better in 72.1% of simulations. BioGranat-IG’s exact triplet 
search failed to produce results for comparison due to the complexity of the PINAmin2 
network. 
Considering the steps a BioGranat-IG user might take to improve their results, we 




Figure 5.6 – HetRank performance compared against BioGranat-IG 
Increase in number of disease genes identified by using HetRank instead of BioGranat-IG (considering same number of result genes) for 1,000 simulated exome studies. 
(A) three-gene disease subnetwork, balanced captured heterogeneity, 50% uncaptured heterogeneity; (B) four-gene disease subnetwork, balanced captured heterogeneity, 
80% uncaptured heterogeneity. Columns represent different conditions for BioGranat-IG runs: M = heuristic (min/multi-min distance) search; T = triplet search; Pm2 = 
using PINAmin2 network; Pm2_H = using hub-free PINAmin2_d50 network; Pm2_H_S = using PINAmin2_d50 with additional gene list filtering against a single list; 
Pm2_H_G = using PINAmin2_d50 with additional gene list filtering against genes overrepresented in control exomes. Interpretation: green shading indicates HetRank 




the overrepresentation of highly-mutated genes we also tried using input gene lists which 
excluded either a fixed set of dubious genes (Fuentes Fajardo et al. 2012) or a set of genes 
overrepresented after variant-filtering in each study’s corresponding set of healthy control 
exomes (as with intersection filtering, defined as containing a post-filtering variant in ten or 
more of 180 controls). We found that even with these modifications to the BioGranat-IG 
methodology, its heuristic network search was outperformed by HetRank. However, 
BioGranat-IG’s exact triplet search (which limits itself to finding small subnetworks of 
interest) performed reasonably well following both network hub removal and additional 
gene filtering against healthy control exomes. Even in this case, HetRank performed as well 
or better in 68.4% of simulations. 
An increased level of genetic heterogeneity results in a more marked improvement 
in results using HetRank compared to BioGranat-IG. Figure 5.6b shows the results of 
simulations where disease-causing genes were selected using a four-gene disease 
subnetwork and uncaptured heterogeneity of 80%. In this case, regardless of the search 
method used in BioGranat-IG or the further steps taken to improve its results, HetRank 
found as many or more disease genes in at least 91.9% of simulations. As we will discuss 
below it is likely that this scenario represents a truer picture for many monogenic diseases 
than the lower-heterogeneity scenario. With this in mind the results here show that our new 
approach is better equipped to deal with this genetic heterogeneity than currently available 
methods. 
5.4 Discussion 
Locus heterogeneity reduces the power of exome-sequencing studies to identify the 
molecular basis of a monogenic disease because it limits the expected overlap of genes 
harbouring deleterious mutations in unrelated affected individuals. This heterogeneity 
presents a challenging problem but we have shown that we can improve the prioritisation of 
disease genes by incorporating information from an interaction network in a hypothesis-free 
manner; that is, without specifying a set of candidate or “seed” genes. 
Such an approach is particularly valuable when there is a high level of 
heterogeneity. There are currently many known sets of two to three interacting and disease-
causing genes (see chapter 3), but we expect to see larger connected sets in future as new 
disease-causing genes are identified and as more comprehensive interaction networks are 
developed (Yu et al. 2011). Gilissen et al. suggest that there is a scale of genetic 
heterogeneity broadly corresponding to disease prevalence (Gilissen et al. 2011), and our 




could include studies of groups of patients with the same or very similar clinical phenotypes 
having unknown and potentially diverse molecular causes. A recent study of autosomal 
recessive hereditary spastic paraplegias, for example, proposed eighteen novel candidate 
genes where a single variant in each was thought to be disease-causing in different families 
(Novarino et al. 2014). 
Our approach performs well in the presence of heterogeneity not captured by an 
interaction network (which we tested using the parameter u). This might include missing 
interaction data, disease variants that are not protein-coding (intronic or intergenic variants), 
as well as potential non-genetic disease causes such as epigenetic or environmental causes. 
As might be expected, though, Table 5.2 shows that better network coverage of interactions 
between disease-causing genes improves HetRank results. Our approach does not 
specifically require a protein interaction network be used and as such it may be beneficial to 
seek increased coverage of the interactome by using networks which integrate different types 
of gene relationships (Lee et al. 2011; Vidal et al. 2011; Khurana et al. 2013). 
Careful inspection of Figure 5.3 and Figure 5.4 shows that network information does 
not improve the performance of all studies equally. Even at higher levels of genetic 
heterogeneity there are examples where more disease genes are ranked in the top ten using 
the simple intersection filtering method. This demonstrates what we already know: it is 
important that a researcher also considers the evidence for a gene’s involvement in a disease 
independently of the genes with which it interacts. One way to do this could be to consider 
HetRank gene prioritisations alongside those obtained by intersection filtering when 
analysing exome sequencing results. 
On a similar note, users of HetRank should understand the limitations of the tool. At 
higher levels of genetic heterogeneity in particular, we saw many simulated studies in which 
no disease genes could be ranked in the top ten. Furthermore, for any given monogenic 
disease, the model underlying HetRank (that locus heterogeneity can be at least partially 
explained by interacting genes) may be inappropriate; the tool itself cannot determine if this 
is the case. Even for an exome sequencing study in which disease-causing genes are ranked 
in the top ten by HetRank (our measure of success in performance tests), those ten will also 
include non-causal genes. A thorough examination of the top-ranked genes is likely to be 
needed to discern the genes of interest. However, what HetRank can do is provide the user 
with a starting point; by studying the high-ranking genes and the variants that they and their 
interaction partners contain, and combining this with existing functional annotation or 
disease-specific knowledge, hypotheses can emerge concerning putative disease mechanisms 




An important point to note is that the use of the HetRank framework does not 
preclude the use of other tools designed for gene or variant prioritisation, but can be 
considered complementary to existing approaches. Variant effect prediction tools such as 
SIFT (Kumar et al. 2009) and PolyPhen (Adzhubei et al. 2010) can be incorporated into 
HetRank by including their prediction scores as variant-ranking criteria, and nothing 
prevents the same approach being taken for existing tools such as Endeavour (Aerts et al. 
2006), Exomiser (Robinson et al. 2013) or CADD (Kircher et al. 2014), which themselves 
integrate diverse sources of evidence for deleteriousness or disease involvement. Even if a 
user relies entirely on an existing tool to integrate evidence sources, HetRank can still make 
a valuable contribution to addressing genetic heterogeneity by adjusting this evidence with 
reference to an interaction network. 
An interesting future exercise might be to compare HetRank performance against 
that of SPRING, a recently developed tool which prioritises non-synonymous variants 
according to the likelihood that they cause a specified disease (Wu et al. 2014). Alongside 
direct variant effect prediction scores, SPRING uses indirect evidence for disease-causality 
(implicitly recognising the potential for locus heterogeneity) by looking for “association” 
with seed genes that cause the same or similar diseases; such association includes similarity 
of Gene Ontology annotation, protein sequence, protein domain annotation and curated 
pathway annotations, as well as proximity in a protein interaction network (Wu et al. 2014). 
SPRING differs from HetRank by taking a different algorithmic approach. Most notably 
from a user’s perspective, HetRank provides complete flexibility to use customised ranking 
criteria and accrues evidence from the exomes of multiple affected individuals to prioritise 
relevant genes. Unfortunately the simulated exome sequencing studies generated in section 
5.2.2 would not be suitable to assess the performance of SPRING because the real disease-
causing variants on which each study’s spiked variants are based are not specific to any 
single phenotype. 
In the HetRank framework, user-specified weights are used to integrate evidence 
sources, and there are several considerations to bear in mind when choosing appropriate 
weights. The weights are applied linearly to combine rankings and can therefore be 
interpreted as quantifying the user’s beliefs about the relative informativeness of each 
evidence source. That is, the ranking criteria reflect aspects of the genetic model assumed to 
underlie the disease and the weights reflect the user’s confidence in the validity of each 
aspect of this model and how well these aspects are represented by the variant annotation. 
In all of our simulated exome sequencing studies we used a previously determined 
set of weights: we chose to use integer weights between 1 and 8, and optimised these using 




a high weight to a measure of variant frequency since mutations that cause rare monogenic 
diseases are expected to be rare and in many cases private (found in a single family), and 
because frequency is a highly discriminative property of sequence variants. A more 
moderate weight is appropriate for ranking criteria that are less specific in their ability to 
distinguish pathogenic mutations from benign variation, such as categorical criteria with few 
distinct categories (like zygosity or variant effect). Care should also be taken when choosing 
weights for criteria that are likely to be correlated, such as different measures of variant 
frequency. 
It is also highly recommended to give a high weight to the additional ranking factor 
that is automatically generated based on healthy control exomes (depending on the number 
of control exomes used). This ranking factor is important because it is designed to de-
prioritise genes which might otherwise rank highly because they have a propensity to 
contain, and tolerate, sequence variants with characteristics typical of disease-causing 
mutations (such as low frequency and non-synonymous effect on the gene’s protein 
product). 
This chapter has presented HetRank, a flexible analysis method which uses variant-
ranking in unrelated exomes to combine several sources of evidence for involvement in a 
monogenic disease. In an interaction network, neighbouring genes which rank highly in 
different affected individuals improve the evidence for each other’s involvement in the 
disease process. The final prioritisation is obtained by combining adjusted gene ranks across 
all exomes in the study, and we have demonstrated using simulated data that this can 
effectively deal with a considerable degree of genetic heterogeneity. 
An application of HetRank to a real whole exome sequencing study will form one of 




6 Supporting Methods for Application to Real 
Disease Data 
This chapter will describe two supporting methods that will be used in the 
subsequent chapters, where the tools developed in chapters 4 and 5 are applied to real exome 
sequencing studies. Section 6.1 describes a method to prioritise BioGranat-IG optimal 
subnetworks for further study. Section 6.2 presents an update to an existing method, Region 
Growing Analysis (RGA; Lehne 2011), which takes a ranked gene list and identifies regions 
in an interaction network that are significantly enriched for highly-ranked genes. RGA will 
be used in chapter 7 for the interpretation of HetRank results, and in chapter 8 as a direct 
analysis tool. 
6.1 Prioritisation of BioGranat-IG results 
As described in chapter 4, the BioGranat-IG tool includes a permutation test that can 
be used to estimate the probability that for an observed optimal subnetwork, a subnetwork 
harbouring post-filtering variants in more exomes or a subnetwork of equal or smaller size 
harbouring post-filtering variants in the same number of exomes could be observed by 
chance. This permutation test makes the simplifying assumption that genes in the network 
are equally likely to contain a post-filtering variant by chance, which is untrue in practice 
(Fuentes Fajardo et al. 2012; Petrovski et al. 2013). 
Further, BioGranat-IG can return several equivalent “optimal” subnetworks. For 
example, a triplet search might return several different triplets harbouring variants in five 
exomes, but none with variants in more than five. BioGranat-IG’s significance test cannot 
discriminate between these results. 
If any of these triplets overlap (have genes in common) then it may be instructive to 
merge them and consider the bigger subnetwork they generate. If not, they must be 
considered separately. The quadruplet search and heuristic searches will likely generate 
different subnetworks too. In addition, BioGranat-IG will be employed using different 
networks and different filtering levels, potentially generating a wide range of results. To 
address this, an alternative method to provide an independent measure of a subnetwork’s 
viability (as a pathway causing a rare monogenic disease through a mechanism of locus 
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heterogeneity) was developed as one means of prioritising subnetworks for efficient follow-
up. 
The method assumes that if all variants v can be assigned an independent score f(v) 
quantifying their likelihood of being involved in the disease, then the most promising 
BioGranat-IG subnetworks should be those which are enriched for high-ranking variants. In 
theory, the score could apply at the variant level (such as a variant effect prediction score) or 
at the gene level to the gene in which v is located (such as the Residual Variation Intolerance 
Score [RVIS]
*
). The score could be specific to the disease in question (such as a measure of 
gene expression in relevant tissues) or could reflect general evidence for disease 
involvement (such as variant effect prediction scores or RVIS). 
In addition to the score f, a summary statistic F(f(v1), ..., f(vn)) is required to 
appropriately combine the scores across variants v1, ..., vn that are observed in the same 
subnetwork. For monogenic diseases where a single variant is expected to be causal for each 
individual, if an exome has two or more variants in the subnetwork F might incorporate only 
the highest scoring of those variants. 
Enrichment of a subnetwork for high-ranking variants is estimated using a 
permutation-based approach. Given a subnetwork that contains a variant for a subset I of the 
case exomes, the summary statistic is calculated as follows. For each individual i in I, having 
ni ≥ 1 variants in the subnetwork, the set Vi of all variants which map anywhere in the 
network is identified. In each permutation, ni variants are randomly selected from Vi for all i 
in I (without reference to the network), and the summary statistic is calculated. 100,000 
permutations are performed and the significance of the observed subnetwork’s test statistic 
is calculated as the proportion of permutations in which a greater or equal summary statistic 
is generated. This test therefore examines how enriched the observed subnetwork is for high-




In the following chapters the variant scores f were obtained from the variant effect 
prediction tool KGGSeq. KGGSeq implements a logistic regression which combines scores 
from SIFT, PolyPhen-2, MutationTaster, PhyloP and a likelihood ratio test based on 
sequence conservation (Li et al. 2012). This results in an estimate for each variant of the 
                                                     
*
 RVIS is a measure that estimates each gene’s tolerance of functional variation based on the observed 
functional and non-functional variation in a sample of ~6,500 whole exome sequences (Petrovski et 
al. 2013). 
†
 Note the test assumes that each individual has a reasonable number of variants remaining after 
filtering. If filtering is so effective that it leaves very few variants per individual then this 
prioritisation test would not be required (because BioGranat-IG would be unlikely to find many 
subnetworks by chance). 
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probability that it causes a monogenic disease. In each study KGGSeq was applied to each 
case exome. For variants which received no score, an estimated score based on variant 
consequence (e.g. “nonsynonymous SNV”, “stopgain SNV”, “frameshift deletion”) was 
used, where this was calculated as the mean value of all (scored) variants across all exomes 
(after filtering on variant frequency only). 
The summary statistic used to combine these probabilities across a subnetwork G’ 
containing variants v1, ..., vn approximates the probability that at least one of the variants in 
the subnetwork causes a monogenic disease (assuming that all variants have independent 
probabilities of being disease-causing). It is calculated as: 
                           
   
  
   
  
where the product is taken over all N’ individuals having a variant in a gene in G’ and   
  is 
the variant with highest probability of causing a monogenic disease among the ni variants 
carried by individual i. (Note that    
  
     .) 
For convenience, this prioritisation method as applied to BioGranat-IG results will 
for the remainder of this thesis be referred to as KGGSeq-prioritisation. 
6.2 Region Growing Analysis 
RGA was originally designed to be used with genome-wide association study 
(GWAS) data, with the aim of identifying regions in an interaction network that are enriched 
for association signal (Lehne 2011). However, since the input data required are simply an 
interaction network and a ranked list of genes (originally the ranked list was derived using 
GWAS p-values), it can be appropriate to apply RGA in other contexts; for example in 
chapter 7 we make use of RGA to help interpret the prioritised list of genes produced by 
HetRank. 
RGA is a bundle in BioGranat (see chapter 2). The original version of RGA was 
implemented by Dr Benjamin Lehne, Nikolaos Barkas and Christopher Tebbe. As part of the 
present work a new algorithm for RGA was devised and implemented, allowing analyses to 
be performed considerably faster. 
Given a ranked gene list, RGA requires two threshold parameters, α and β (≥ α). 
Any gene in the network whose rank is below (i.e. better than) the threshold α is considered 
a seed node. In the original implementation, network regions are “grown” around each seed 
node by incorporating neighbouring genes that have rank <β (termed member nodes). 
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Optionally, “jumps” over one node with rank >β may be permitted, with jumped nodes also 
being added to the region. After each iteration any regions which overlap are merged (see 
Figure 6.1). This process is repeated for a fixed number of iterations. In practice using 
GWAS data, this analysis generally found one large region and a number of much smaller 
regions (Lehne 2011). To test whether a region is larger than expected by chance (contains 
significantly many seed or member nodes), network permutations can be used to generate 
random regions allowing an empirical p-value to be estimated. Permutations use a degree-
constrained label-shuffling approach. Typically this will be repeated for a range of α and β 
thresholds to explore how the regions found vary. 
It is very difficult to estimate accurately the time-complexity of the original RGA 
algorithm due to the number of conditions that can vary between scenarios, but crudely 
(when jumps are allowed) the running time grows as: 
 
                                 
  
      
          
 
  
    ( ) 
 
Here, nperm is the number of network permutations used to estimate significance. nαβ 
is the number of combinations of α and β tested, and nV and nE are the number of nodes and 
edges in the network respectively. The term                 is included because a 
permuted network is generated for each (α, β) pair, requiring network nodes to be sorted by 
degree (with complexity            (Oracle 2011)) and all edges to be processed; the 
term also accounts for locating seeds in the network, with cost O(nV). To this is added a sum 
across all (α, β) pairs. The terms inside the sum are due to the fact that neighbours of each 
node in a region, plus nodes within one jump of a region, are explored at each iteration; niter 
is the number of iterations specified by the user, Vα,β is the set of all nodes in any region for 
thresholds α and β, and   
  
 is the number of such nodes; N1(W) is the 1-neighbourhood of a 
set of nodes W (all nodes in W plus direct neighbours), and d(v) is the degree of node v (it is 
assumed that most nodes in the region are found within the first few iterations so that most 
iterations search over fully- or near-fully grown regions). In this case merging of regions 
should also be covered by the   
  
 term. 
The nature of the network used, parameters chosen and distribution of gene ranks in 
the network all affect which of the terms in the expression will dominate in a given scenario. 
Several innovations were implemented to make the new version of the algorithm 
considerably faster. Firstly, instead of testing each (α, β) pair separately (identifying the 
regions in the original network and assessing the largest region against nperm permuted





Figure 6.1 – Region Growing Analysis 
Nodes in pink are seed nodes because they correspond to genes with a rank below the threshold α. In 
step 1, separate regions are initiated at the two seed nodes (indicated by red and green borders 
respectively). In steps 2 and 3 the regions are expanded to include neighbouring member nodes (with 
rank <β); in the case illustrated here jumps over at most one non-member node are permitted. After 
each iteration, regions which collide (e.g. step 3) are fused to form a single region (step 4). The 
process terminates at step 4 because no further member nodes can be incorporated. Figure adapted 
from fig. 5.1 in (Lehne 2011). 
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networks), all (α, β) pairs are tested together in the same set of permuted networks. This has 
two advantages: we need only generate nperm permuted networks compared with npermnαβ in 
the original algorithm, and comparison between empirical p-values generated for different 
(α, β) pairs is more robust when the same permuted networks underlie the calculations. 
Secondly, a nested approach is used to identify regions at different (α, β) pairs. If 
α ≤ β1 < β2 then all regions found at (α, β1) will lie inside regions at (β2, β2). Therefore when 
performing RGA for (α, β1) it is more efficient to search only within the regions identified 
for (β2, β2) than to search within the whole network. Likewise for α1 < α2 ≤ β all regions 
found at (α1, β) lie inside regions at (α2, β). We therefore work through the full set of (α, β) 
pairs ordered firstly by descending β and then by descending α. 
Thirdly, a pre-processing step is performed at each (α, β) level. This removes from 
the network all edges that join two nodes of rank >β (since at most one such node can be 
jumped in order to grow a region), and subsequently all nodes that have rank >β and 
degree ≤1. This can be done in O (nV + nE) operations when pre-processing the whole 
network and     
  
   
  
  operations when pre-processing within the regions found for 
with thresholds α and β (because of the nested approach to testing (α, β) combinations). 
Finally, for the region identification itself the improved version of RGA identifies 
regions sequentially using breadth-first search (Sedgewick 2003), which after pre-processing 
will have a running time of     
  
   
  
 , instead of iterating over region expansion and 
merging steps to grow all regions simultaneously (as in the original implementation). This 
eliminates the need for multiple iterations. 
The time-complexity of the revised algorithm is therefore approximately: 
                       
  




    
Since the time-complexity ( ) of the original implementation can be rewritten as: 
                                 
  
   
  
     
  
    
where mα,β is a term representing the cost of exploring the genes that neighbour the regions 
found using thresholds α and β, we can see that the revised version should be considerably 
faster due to the nαβ-fold drop in the number of permuted networks generated, the 
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elimination of the niter factor, and the fact that most region-neighbouring genes are removed 
by pre-processing so do not need to be searched. 
This performance improvement was tested by repeating an analysis from (Lehne 
2011), in which regions were identified using each α in {50, 100, 150, 200, 300, 500, 1,000} 
(with β = α) for a ranked gene list derived from the first large-scale type 1 diabetes GWAS 
(Wellcome Trust Case Control Consortium 2007), and compared against 10,000 network 
permutations. In the HuPPI2 network (described in chapter 2) this took 147 s (2.4 mins) on a 
standard PC using the new implementation, compared to 51,978 s (14.4 hours) using the 
original version with the default of 500 iterations (times are average across three 
executions). In theory the maximum number of iterations that could be needed is equal to the 
diameter of the network (the biggest minimum distance amongst all pairs of same-
component genes). HuPPI2 has diameter 23, and when 23 iterations are used the original 
implementation takes 8,546 s (2.4 hours). The revised algorithm therefore represents a 58.1-
fold improvement on this performance. In the HuPPI2_d25 network, the new 
implementation takes 124 s (2.1 mins) compared to 7,728 s (2.1 hours) using the original 
version (with 23 iterations because HuPPI2_d25 also has diameter 23). This represents a 
62.4-fold improvement. As expected, the regions found by the original and new 
implementations match, for both networks. 
The improvement in efficiency of the tool is highly advantageous because it allows 
analyses to cover a much wider or more granular range of α and β thresholds or to run RGA 




7 Analysis of Adams-Oliver Syndrome Exome 
Sequence Data using Network Methods 
7.1 Introduction 
7.1.1 Background 
Adams-Oliver syndrome (AOS; OMIM #100300) is a developmental disorder with 
an incidence of approximately 1 in 225,000 (Stittrich et al. 2014). It is characterised by the 
congenital absence of skin (aplasia cutis congenita; ACC), typically affecting the scalp, and 
serious limb reduction malformations (terminal transverse limb defects; TTLD) (Adams and 
Oliver 1945) (see Figure 7.1). However, AOS displays substantial phenotypic variability: the 
severity of ACC and TTLD can vary between cases to the extent that one or other may be 
entirely absent (in such cases a family history of the disorder indicates a positive diagnosis); 
additional phenotypic effects include congenital heart defects in approximately 20% of 
patients and a rare vascular abnormality, denoted cutis marmorata telangiectasia congenita, 
affecting a similar proportion of cases (Snape et al. 2009). 
AOS is presumed to be a monogenic disorder. It usually occurs sporadically but can 
also segregate in families, where there has been evidence for both autosomal dominant (AD) 
and autosomal recessive (AR) modes of inheritance (Snape et al. 2009). The molecular basis 
of AOS is not fully characterised. Several genes have been identified as causal for AOS; 
however, the identification of further pathogenic variants is challenging due to both genetic 
heterogeneity and incomplete penetrance of disease alleles in AD kindreds (Küster et al. 
1988). 
Southgate et al. showed that two heterozygous truncating mutations (one nonsense 
SNV and one frameshift deletion) in the Rho GTPase-activating protein 31 gene, 
ARHGAP31, cause AOS in unrelated patients (Southgate et al. 2011). GTPases are a class of 
proteins that can switch between two conformational forms (active GTP-bound and inactive 
GDP-bound states), acting as “molecular switches” to regulate a number of cellular 
processes. ARHGAP31 specifically regulates Cdc42 and Rac1, which play a role in cell 
proliferation and migration – key aspects of organ development. Of relevance to AOS, both 
proteins have been shown to function during skin morphogenesis and limb development 
(Southgate et al. 2011). While the wild-type ARHGAP31 inactivates Cdc42 and Rac1, 
mutated versions of the protein were demonstrated to lead to sustained inactivation and 
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hence a deficiency of active Cdc42 and Rac1, indicating a gain-of-function disease 
mechanism for AOS (Southgate et al. 2011). 
Consistent with these results, homozygous mutations in DOCK6 have been shown to 
cause an AR form of AOS (Shaheen et al. 2011). While ARHGAP31 is a GTPase-activating 
protein, which serves to inactivate Cdc42 and Rac1 by stimulating their intrinsic GTPase 
activity, DOCK6 is a guanine nucleotide exchange factor which acts in the opposite 
direction, promoting the transition of Cdc42 and Rac1 from inactive to active states. As 
might be expected, loss-of-function DOCK6 mutations, which lead to reduced levels of 
active GTPase, result in a similar phenotypic effect to gain-of-function ARHGAP31 
mutations (Shaheen et al. 2011). 
However, in 2012 Hassed et al. demonstrated that an AD form of AOS could also be 
caused by mutations in the RBPJ gene, which is not known to be related to the Rho 
signalling family (Hassed et al. 2012). RBPJ is a transcription factor that plays a key role in 
the notch signalling pathway, an intercellular signalling system that is involved in a wide 
range of processes which include cell proliferation and differentiation during embryonic 
development. The heterozygous missense mutations that were shown to cause AOS impair 
the ability of RBPJ to bind to DNA, likely resulting in dysregulation of Notch target gene 
expression (Hassed et al. 2012). Notch signalling is further implicated in the aetiology of 
AOS by the recent discovery of causal variants in NOTCH1 (Stittrich et al. 2014). 
 
Figure 7.1 – Characteristic phenotype of AOS 
Characteristic phenotype of AOS showing severe ACC (left panels) and a range of TTLD defects of 
the hands (middle panels) and feet (right panels), including partial absence of the fingers and toes and 
short distal phalanxes of the fingers and toes. Reprinted from (Southgate et al. 2011), with permission 
from Elsevier. 
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Finally, homozygous mutations in EOGT have been shown to cause an AR form of 
AOS (Shaheen et al. 2013; Cohen et al. 2014). The EOGT enzyme functions as a post-
translational modifier of several extracellular proteins. The mechanism by which EOGT 
mutations cause AOS is not clear, but the authors suggest they could have an effect on cell-
cell or cell-matrix interactions, offering a putative link to ARHGAP31 or DOCK6 forms of 
the disorder. On the other hand, EOGT has been shown to glycosylate NOTCH1 in 
mammals, although it is yet to be established whether a functional effect on notch signalling 
is seen in human cells (Shaheen et al. 2013). 
The recent progress in elucidating the molecular basis of AOS has been due in large 
part to the availability of NGS techniques. Despite this, many cases are not explained by 
mutations in ARHGAP31, DOCK6, RBPJ, NOTCH1 or EOGT (it is thought that fewer than 
half of AOS cases are caused by variants in one of these genes (Stittrich et al. 2014)). AOS 
displays a high level of genetic heterogeneity, and while there are close functional 
relationships between some of the implicated genes it does not appear to be a disorder of a 
single known functional pathway. This makes AOS an ideal candidate for network-based 
exome sequence analysis. 
7.1.2 Analysis Strategy 
Whole-exome sequencing had previously been performed for 20 individuals with 
AOS as part of the King’s College London (KCL) rare disease programme. Of these, one 
resulted in the identification of ARHGAP31 as a causal gene for AOS (Southgate et al. 2011) 
and two more (independently of the first published report) in the identification of NOTCH1 
(Southgate et al., unpublished results). Three further exomes harbour variants which are 
presumed to explain the occurrence of the disease for these individuals: two exomes carry 
compound heterozygous mutations in DOCK6 and one a heterozygous missense mutation in 
RBPJ. However, progress using a simple intersection filtering approach has been limited and 
for the remaining 14 exomes the disease-causing variants have not been identified up to this 
point. These exomes will subsequently be referred to as the unsolved cases. 
Since locus heterogeneity is an established feature of AOS, a network-based 
approach to identifying further causal genes in this cohort is justified. The aim of such 
methods, to find connected sets of genes that represent functional pathways underlying AOS 
(thereby helping to illuminate the disease mechanism), is reasonable: among the known 
AOS genes, ARHGAP31 and DOCK6 are functionally related, as are RBPJ and NOTCH1. 
To date, however, no network-based analyses of AOS have been reported. 
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(A) Simple neighbourhood search: for this candidate-gene approach the neighbourhoods of known 
AOS genes (green nodes) are examined for overrepresentation of post-filtering variants in the sample 
exomes (orange nodes). (B) BioGranat-IG: red, blue and yellow nodes signify post-filtering variants 
in different sample exomes. The tool seeks a small connected set of genes in which all or most sample 
exomes are mutated. (C) HetRank: red, blue and yellow nodes as before. Genes are ranked according 
to the likelihood that they cause AOS based on characteristics of the variants they contain and variants 
in neighbouring genes in complementary sample exomes. 
Three independent network methods were applied to the exome data to propose new 
AOS genes. Firstly a candidate-gene approach was taken, with the network neighbourhoods 
of known AOS genes being examined for overrepresentation of post-filtering (that is, rare 
and non-synonymous) sequence variants. The other approaches were hypothesis-free (they 
did not rely on the known AOS genes). The BioGranat-IG tool developed in chapter 4 was 
used to search for subnetworks in which all or most exomes carry a post-filtering variant. 
Finally, the HetRank tool developed in chapter 5 was used to generate a list of genes 
prioritised with respect to evidence for disease causality. The different approaches are 
illustrated in Figure 7.2. 
Several interaction networks were used to perform the analyses, including three 
protein interaction networks (PINs), a co-expression network and an integrated network of 
several interaction types. Use of different networks allows different types of functional 
pathways to be examined as potentially underlying AOS. Additionally the BioGranat-IG and 
HetRank analyses were performed separately for the full set of sample exomes and for the 
subset of unsolved cases. In the former case this allows us to observe whether the methods 
prioritise the known AOS genes, while in the latter case any confounding information from 
the non-causal variants in the solved cases is removed. (For BioGranat-IG an implicit 
candidate-gene approach could also be explored by using the full set of exomes but filtering 
out all but the causal variants in the solved cases.) 
KGGSeq-prioritisation and Region Growing Analysis (RGA), described fully in the 
previous chapter, were used for the interpretation of BioGranat-IG and HetRank results, 
respectively. 
 
Figure 7.2 – Network-based methods used to analyse AOS exome data 




7.2.1 Exome Data 
Whole exome sequencing was performed on 20 individuals with AOS and 336 
unaffected controls according to the procedure described in chapter 2, section 2.3. 
Table 7.1 lists the properties of the 20 sequenced AOS exomes. All affected 
individuals have a primary diagnosis of AOS but there is some variation in clinical 
phenotypes. 
At 20× coverage, exome capture ranged from 71.0% to 92.6%; while 80-90% is 
considered to be a normal range of coverage, 90% or higher is desirable to maximise the 
power to accurately detect sequence variants (Mertes et al. 2011). For six of the affected 
individuals causal mutations were previously identified. For one of these (exome S0334) one 
of the two variants in DOCK6 that make up the causal compound heterozygous mutation fell 
outside the captured region and had been subsequently identified by Sanger sequencing. 
Therefore the exome data used for this analysis does not include this variant. 
By considering the family histories of the affected individuals, 15 of the 20 were 
assumed to have an AD form of AOS, three an AR form, one either AD or AR, and one 
either AD or X-linked. 
Two of the affected individuals (S0039 and S0301) were related. Since AOS is an 
inherited disorder it is expected that the same mutation causes AOS in both family members. 
Therefore for all analyses these two exomes (having 18,915 and 23,964 called variants 
respectively) were replaced by a single file comprising only the 10,831 called variants 
shared by both individuals, effectively reducing the dataset to 19 AOS exomes (of which 13 
are unsolved cases). All other affected individuals were unrelated. 
The 336 unaffected controls (a subset of the exomes covered by the in-house exome 
database which will be referred to subsequently as non-AOS control exomes) represent 
unrelated individuals of European ancestry sequenced as part of the KCL rare disease 
programme. As such they may include causal variants for a range of diseases other than 
AOS. Since these diseases are clinically diverse the data are considered suitable for use as 
controls for both variant filtering (see section 7.2.2) and for use by the HetRank tool (section 
7.2.6). 
7.2.2 Variant Filtering 
To perform the simple neighbourhood search and BioGranat-IG analyses, variants in 
the exomes of affected individuals were filtered to exclude from consideration those less 
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likely to cause a rare monogenic disease. Five levels of filtering were applied, as illustrated 
in Figure 7.3. For notational convenience these are termed filtering levels 1-5. 
At level 1, all 19 exomes underwent the same filtering steps (no special treatment 
for the six solved cases with known causal variants). Synonymous variants were excluded. 
No assumptions were made about the mode of inheritance of AOS for each exome, so that 
three mutation types were included: heterozygous (AD inheritance), homozygous (AR) and 
compound heterozygous (AR). Since AOS is a very rare disorder, only novel and very rare 
variants were retained. Heterozygous variants were required to have alternative allele 
frequencies of <0.1% according to both 1000 Genomes Project and Exome Variant Server 
Table 7.1 – Properties of AOS exomes 
Blue shading indicates that causal variant has already been identified. Yellow shading denotes exomes 
S0039 and S0301 derived from related AOS patients. CHD = congenital heart defect. * = one of the 
two variants in DOCK6 that make up the causal compound heterozygous mutation for exome S0334 













S0038 AD AOS 71.4% ARHGAP31 - 
S0039 AD AOS 71.2% - 
Related to 
S0301 
S0040 AD AOS 71.0% - - 
S0069 AD AOS 80.9% - - 
S0301 AD AOS 84.5% - 
Related to 
S0039 
S0302 AD AOS 76.6% - - 
S0304 AD AOS 83.2% - - 





S0306 AD AOS 86.1% - - 
S0307 AD AOS 84.8% - - 
S0308 AD or AR AOS 92.6% - - 
S0311 AD AOS 82.5% NOTCH1 - 
S0332 AR 
AOS / Orstavik 
syndrome 
85.1% DOCK6 - 
S0333 AD AOS 83.2% - - 
S0334 AR 
AOS / Orstavik 
syndrome 
85.9% DOCK6* - 
S0335 AD AOS 79.2% NOTCH1 - 
S0336 AD Probable AOS 80.0% - - 




AOS / Dandy-Walker 
syndrome / CHD 
86.3% - - 
S0339 AD 
AOS / Sorsby 
syndrome 
90.2% - - 
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(EVS) annotation, and to have been observed once or fewer in heterozygous form (and never 
in homozygous form) in the in-house exome database (approximately 850 exomes in total). 
Homozygous variants were required to have alternative allele frequencies of <      and 
one or fewer previous observations in homozygous form in the in-house exome database. 
Compound heterozygous variants were included if two or more heterozygous variants in the 
same gene had alternative allele frequencies of <      and one or fewer previous 
observations in homozygous form in the in-house exome database. Finally, variants were 
filtered at the gene level against the 336 non-AOS control exomes in order to address the 
problem that large and highly-polymorphic genes are more likely to be falsely implicated by 
variant-filtering approaches (as discussed in section 1.3.5). Variants were excluded in any 
gene in which 20 or more non-AOS control exomes, after being subject to the same filtering 
steps, carried a post-filtering variant. 
At level 2, variants were additionally filtered to include only those matching the 
expected mode of inheritance for each AOS exome. The individuals S0332 and S0334 were 
assumed to have an AR form of AOS; only homozygous and compound heterozygous 
variants were included for these exomes. Exome S0305 was obtained from an individual 
whose parents are first cousins; for this exome only homozygous variants were included. 
 
Figure 7.3 – Variant filtering levels for AOS exomes 
Filtering levels differ according to: treatment of solved cases (treat same as unsolved cases, include 
only the true causal variant(s) or remove from analysis entirely); frequency threshold (allow novel 
variants only, or also include known variants with sufficiently low minor allele frequency as 
described in main text); and mode of inheritance (make no assumption, or assume variant will be 
consistent with expected mode of inheritance). 
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Individual S0338 (male) was assumed to have either an AD or X-linked form of AOS; a 
conservative approach was taken by including heterozygous variants from all chromosomes 
as well as homozygous and compound heterozygous X chromosome variants. The mode of 
inheritance for exome S0308 had not been determined and therefore no additional filtering 
on variant zygosity was performed. All other cases were assumed to have an AD inheritance 
pattern hence only heterozygous variants were included. Filtering thresholds were otherwise 
identical to level 1. Gene-wise filtering against non-AOS control exomes was performed 
separately for each mode of inheritance using the appropriate filtering for controls. 
Level 3 provided an implicit candidate-gene approach. At level 3, filtering criteria 
were identical to level 2 for the 13 exomes representing unsolved cases but for the six solved 
cases only the true causal variants were included. In the case of exome S0334, for which 
AOS is caused by a compound heterozygous mutation in DOCK6, one of the true causal 
variants was not captured by the whole exome sequencing process. This meant DOCK6 
variants for this exome had been excluded at filtering level 2; the missing variant was 
artificially added at level 3 to ensure that each solved case was represented by variant(s) in 
the appropriate gene. Likewise, for exomes S0311 and S0335, variants in NOTCH1 had been 
excluded at filtering level 2 because 20 of the non-AOS control exomes carried a variant in 
that gene, therefore at filtering level 3 these variants were manually added back. For all other 
solved cases no manual re-instatement of variants was necessary. 
At level 4, the exomes from solved cases were removed from the analysis entirely, 
permitting an analysis of the unsolved cases that was unbiased by the previously-solved 
cases. All filtering criteria for the 13 unsolved cases were as at level 3. 
Finally, filtering at level 5 was identical to level 4 except that previously-observed 
variants were excluded to leave only novel variants. In practice, any variant annotated with 
an alternative allele frequency (of any value) from EVS or 1000 Genomes Project data, or 
contained in the in-house exome database in homozygous or heterozygous form, was 
excluded. As with the other filtering levels, gene-wise filtering against controls used 
matching criteria: variants in any gene in which 20 or more of the 336 non-AOS control 
exomes carried a novel (non-synonymous) variant were excluded. 
Table 7.2 lists the number of called variants for each exome at each level of 
filtering. 
7.2.3 Interaction Networks 
Analyses were performed using several of the networks described in detail in 
chapter 2. These comprised three PINs (PINA and the two smaller but higher-confidence 
7. Adams-Oliver Syndrome 
128 
  
networks PINAmin2 and CPDBconf95), a co-expression network (COXPRES30) and a 
network integrating several types of interaction data (Multinet). 
Since hub genes can be overrepresented in BioGranat-IG results, the hub-free 
networks PINA_d50, PINAmin2_d50, CPDBconf95_d50, COEXPRES30_d50 and 
Multinet_d50 (described in section 2.1.2) were used for BioGranat-IG analyses. All other 
analyses use the full interaction networks. 
To ensure consistency between network node labels and exome gene symbols, a list 
of gene symbol synonyms was obtained from the HUGO Gene Nomenclature Committee 
(Gray et al. 2013). An R programme was implemented to replace the node label with a 
synonymous symbol for any network node whose label did not map to any gene in the 
exome data, but for which an unambiguous mapping existed for one of the synonyms. 
However, in practice no changes were necessary for any of the networks. 
Table 7.2 – Called variants in AOS exomes at each level of filtering 
* = for exome S0334 one of the true causal variants in gene DOCK6 was not captured by the whole 
exome sequencing process; 
†
 = for exomes S0311 and S0335 variants in NOTCH1 would ordinarily 
be filtered out because more than 20 non-AOS controls carry a post-filtering variant in this gene. At 
filtering level 3 appropriate variants were artificially added for these exomes to ensure that each 
solved case was represented by a variant in its causal gene. 
Exome ID 












S0038 19,277 233 180 1 0 0 
S0039_S0301 10,831 85 65 65 65 31 
S0040 18,721 243 195 195 195 119 
S0069 21,363 223 165 165 165 94 
S0302 22,877 256 195 195 195 113 
S0304 23,575 258 220 220 220 146 
S0305 24,606 475 69 69 69 4 
S0306 23,762 201 162 162 162 84 
S0307 23,797 200 164 164 164 86 
S0308 24,839 236 236 236 236 115 
S0311 23,326 224 171 1
†
 0 0 
S0332 23,911 250 112 2 0 0 
S0333 23,613 238 185 185 185 107 
S0334 23,685 221 100 2* 0 0 
S0335 23,772 286 243 1
†
 0 0 
S0336 22,965 196 159 159 159 91 
S0337 22,930 212 166 1 0 0 
S0338 25,638 451 281 281 281 168 
S0339 24,459 225 178 178 178 96 
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7.2.4 Simple Neighbourhood Search 
Since several AOS genes are known, a logical first step in seeking causal variants 
for the 13 unsolved cases was to examine variants in genes which directly or indirectly 
interact with known AOS genes. The following procedure was employed for this purpose. 
Given a set of genes X, two test statistics can be defined to assess the likelihood of 
genes in X being involved in AOS: 
 S1(X), being the number of the 13 unsolved cases in which a post-filtering 
sequence variant is observed in any gene in X, and 
 S2(X), being the number of genes in X which contain a post-filtering sequence 
variant for two or more of the 13 unsolved cases. 
For an undirected network G and seed gene g in G, let Nd(g) denote the neighbourhood 
comprising the set of all genes in G reachable from g via d interactions or fewer. Evidence 
that variants in genes in Nd(g) may cause AOS in the unsolved cases can be quantified by 
comparing S1(Nd(g)) and S2(Nd(g)) against S1(Xk) and S2(Xk), k = 1, ..., 10,000, where each Xk 
is a set of genes of size |Nd(g)| selected uniformly randomly from all genes in G. 
This process was carried out for all five networks. For each network the process was 
repeated using each known AOS gene as the seed gene (provided it was present in the 
network – see results section 7.3.1 below), and additionally using all known AOS genes as 
seed genes simultaneously. Neighbourhood parameters d = 1 and 2 were both tested. Since 
the gene UBC (one of the genes which produces ubiquitin) is exceptionally highly connected 
in several of the networks, and is the node of highest degree in PINA, PINAmin2, 
CPDBconf95 and Multinet, additional tests were performed in these networks using the 
modified neighbourhoods N2*(g), comprising all genes in G reachable from seed gene g via 
two interactions or fewer but excluding paths via the node representing UBC (and UBC 
itself). The process was carried out separately for variants subject to level 4 filtering and to 
level 5 filtering. 
Neighbourhood identification was performed using UNIX commands and 
permutation testing was performed in R. 
7.2.5 BioGranat-IG Analysis 
BioGranat-IG analysis, as detailed in chapter 4, was performed for all five (hub-free) 
networks with variants filtered at each of levels 1-4. 
For each network and filtering level, several BioGranat-IG analyses were performed 
to allow a thorough interrogation of the exome data. Firstly, (exact) triplet and quadruplet 
searches were performed to examine how many AOS cases could potentially be explained 
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by three or four interacting genes. These were repeated for “optimal” (size flexibility = 0; 
number flexibility = 0) and “near-optimal” (size flexibility = 1; number flexibility = 1) 
parameter sets. Secondly combined (heuristic) minimum distance and multi-minimum 
distance searches were performed to examine how few genes could potentially be sufficient 
to explain all (or most) AOS cases. These were repeated with the searches limited to 
subnetworks of size ten or smaller, and with the searches not limited by subnetwork size. 
Only optimal results were considered for these runs. 
To facilitate interpretation of subnetworks found by BioGranat-IG, KGGSeq-
prioritisation (as described in chapter 6) was used to prioritise results. 
7.2.6 HetRank Analysis 
HetRank analysis, as detailed in chapter 5, was performed for all five networks. For 
each network, separate analyses were performed on the set of all 19 exomes and the set 
comprising only the 13 unsolved cases. 
Ranking factors consisted of zygosity, variant consequence (e.g. “nonsynonymous 
SNV”, “stopgain SNV”, “frameshift deletion”), EVS and 1000 Genomes Project alternative 
allele frequencies (two factors) and number of observations of the variant in the in-house 
exome database in homozygous and heterozygous form (two factors). Since the majority of 
AOS cases in this study are assumed to have AD inheritance, the zygosity ranking places 
heterozygous variants ahead of homozygous variants. Since AOS represents a severe 
phenotypic consequence for a single mutation, the variant consequence ranking places 
nonsense (“stopgain”) SNVs and frameshift indels/substitutions ahead of all other non-
synonymous variants, which in turn rank ahead of synonymous SNVs. The other factors are 
ranked numerically in increasing order. 
In all analyses the full set of 336 non-AOS control exomes were used to generate a 
final ranking factor to down-weight genes which rank highly in unaffected controls. 
Unless otherwise stated, the weight parameters used were those determined in 
chapter 5, section 5.2.4, to give an optimal prioritisation based on test data. Thus weights of 
1 were used for all ranking factors except for the number of observations of the variant in the 
in-house exome database in homozygous form, and the factor derived from non-AOS control 
exomes, both of which were given a weight of 8. 
Finally, RGA (described fully in chapter 6, section 6.2) is used to analyse the 
prioritised gene lists returned by HetRank, in the same network that HetRank has used for 
ranking. In each case all thresholds in the range 1 ≤ α ≤ 250 are tested, with β = α. “Jumps” 
are not permitted (because HetRank itself can incorporate information from indirectly-
connected genes to produce its rankings). 10,000 degree-constrained permuted networks are 
7. Adams-Oliver Syndrome 
131 
  
used to estimate significance, with RGA’s default standard deviation of 5.0 nodes used for 
label-shuffling. 
7.2.7 Tools Used for Analysis of Results 
Network diagrams are generated using Cytoscape (Smoot et al. 2011). 
Existing functional annotation for subnetworks or gene lists of interest is explored 
using Gene Ontology (GO) term enrichment analysis. GO terms provide a controlled 
vocabulary describing biological function (Ashburner et al. 2000). GO terms form a directed 
acyclic graph, which means that a term t (e.g. “endocardium development”) can have parent 
terms (describing more general functions of which t is a type, e.g. “heart development”) and 
child terms (more specific functions that are examples of t, e.g. “endocardium 
morphogenesis”). All genes annotated with function t are necessarily annotated with all 
parent terms of t. Enrichment testing examines whether any terms are overrepresented 
among a specific set of genes, relative to a background gene-set from which these genes 
were selected. 
Enrichment testing is performed with the Web-based Gene Set Analysis Toolkit 
(WebGestalt) (Wang et al. 2013a), using default parameters. For subnetworks of interest the 
background gene set comprises all genes in the network from which the subnetwork was 
extracted; for gene lists of interest generated by HetRank the background gene set comprises 
all genes assigned a final rank (that is, all network genes plus any other gene containing a 
variant in any case exome). Unless otherwise stated, only GO biological process terms are 
tested. Enrichment p-values after adjustment for multiple testing (using Benjamini and 
Hochberg’s method which controls the false discovery rate (Benjamini and Hochberg 1995)) 
are presented using the notation adjP. 
Unless otherwise referenced, summaries of individual gene function are obtained 
from GeneCards (www.genecards.org, Stelzer et al. 2011). 
7.3 Results and Discussion 
7.3.1 Simple Neighbourhood Search 
For each network Table 7.3 lists the number of direct (exactly one interaction 
distant) and indirect (exactly two interactions distant) neighbours for each known AOS gene. 
Gene EOGT is not present in any of the networks and therefore was not analysed. DOCK6 is 
not present in the network CPDBconf95 and is only connected to the extreme hub gene UBC 
in PINAmin2. Otherwise all AOS genes were analysed in all networks. 
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Table 7.3 – Properties of known AOS genes in interaction networks 
“Direct neighbours” are distance 1 from known AOS gene; “Indirect neighbours” are distance 2; “Indirect neighbours (excluding UBC)” excludes UBC and genes reached 
exclusively via UBC. In the COXPRES30 network UBC is not an extreme hub gene so no entries are given in column “Indirect neighbours (excluding UBC)”. Table 
















ARHGAP31  5 560 559  
DOCK6  2 7,819 102 NOTCH1 is an indirect neighbour via UBC 
EOGT  - - -  
NOTCH1  65 8,613 2,596 
RBPJ is a direct neighbour 
DOCK6 is an indirect neighbour via UBC 
RBPJ  17 827 826 NOTCH1 is a direct neighbour 
PINAmin2 
ARHGAP31  2 42 41  
DOCK6  1 4,777 0 NOTCH1 is an indirect neighbour via UBC 
EOGT  - - -  
NOTCH1  13 4,829 204 
RBPJ is a direct neighbour 
DOCK6 is an indirect neighbour via UBC 
RBPJ  2 51 50 NOTCH1 is a direct neighbour 
CPDBconf95 
ARHGAP31  2 43 43  
DOCK6  - - -  
EOGT  - - -  
NOTCH1  14 951 196 RBPJ is a direct neighbour 
RBPJ  16 586 585 NOTCH1 is a direct neighbour 
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ARHGAP31  7 72 -  
DOCK6  4 54 -  
EOGT  - - -  
NOTCH1  3 54 -  
RBPJ  5 190 -  
Multinet 
ARHGAP31  1 91 90  
DOCK6  1 104 104  
EOGT  - - -  
NOTCH1  36 3,305 2,320 RBPJ is a direct neighbour 





Table 7.4 – AOS Simple neighbourhood search: permutation tests with significant results 
Neighbourhood: plus2 = genes within distance 2 of starting gene (d = 2); plus2_noUBC = genes within distance 2 of starting gene excluding UBC and genes reached via 
UBC. Variant type: novel_rare = subject to level 4 variant filtering; novel = subject to level 5 variant filtering. Empirical p-values: proportion of 10,000 random tests in 
which a greater of equal test statistic was observed; nominally significant (<0.05) p-values are highlighted in green. 















ARHGAP31 PINA plus2 novel 566 13 0.0310 2 0.5665 
ARHGAP31 PINA plus2_noUBC novel 565 13 0.0278 2 0.5731 
ARHGAP31 PINAmin2 plus2 novel_rare 45 9 0.0073 1 0.3335 
ARHGAP31 PINAmin2 plus2_noUBC novel_rare 44 9 0.0057 1 0.3330 
ARHGAP31 Multinet plus2 novel 93 8 0.0328 1 0.2158 
ARHGAP31 Multinet plus2 novel_rare 93 12 0.0019 3 0.0446 
ARHGAP31 Multinet plus2_noUBC novel 92 8 0.0333 1 0.2086 
ARHGAP31 Multinet plus2_noUBC novel_rare 92 12 0.0018 3 0.0443 
RBPJ COXPRES30 plus2 novel 196 11 0.0188 2 0.1204 
All AOS 
genes 
COXPRES30 plus2 novel_rare 383 12 0.6978 7 0.0483 
 
 




104 different combinations of interaction network, AOS gene (where present in a 
network), neighbourhood type (d = 1, d = 2 or d = 2 excluding UBC) and variant filtering 
level (4 = very rare and novel variants; 5 = novel variants only) were tested using both test 
statistics, S1 (number of the 13 unsolved AOS cases with a variant in the neighbourhood) and 
S2 (number of genes in the neighbourhood with variants in two or more unsolved AOS 
cases). 
In addition 28 different combinations of interaction network, neighbourhood type 
and variant filtering level were tested using all known AOS genes simultaneously as seed 
genes. 
In the 104 tests using individual AOS genes, the value of test statistic S1 ranged from 
0 to all 13 unsolved cases having a variant in the neighbourhood and the value of test 
statistic S2 ranged from 0 to 90 genes in the neighbourhood containing variants for multiple 
AOS cases. However, since the neighbourhoods tested vary widely in size from 1 to 8,613 
genes the test statistic values should be interpreted using the permutation test, which 
considers how the gene neighbourhoods compare to 10,000 randomly selected gene sets of 
the same size. 
Table 7.4 presents the nine tests in which at least one of the test statistics S1 and S2 
had a nominally significant empirical p-value at the 5% level. None of the tests considering 
direct neighbourhoods (d = 1) were significant. 
Eight tests considering the AOS gene ARHGAP31 were significant. These reduce to 
four scenarios since ARHGAP31 is not directly connected to UBC in any of the networks 
and hence the indirect (d = 2) and “indirect excluding UBC” neighbourhoods provide 
equivalent results for the purposes of this analysis (and only the indirect neighbourhoods 
will be examined here). Empirical distributions based on the 10,000 random tests are shown 
in Figure 7.4 for these four scenarios. 
The smallest p-value was observed for the S1 statistic based on novel and rare 
variants in the Multinet network (p = 0.0019), and this was the only scenario which also had 
a significant p-value for the S2 test (p = 0.0446). In a neighbourhood of 93 genes, 12 of the 
13 unsolved AOS cases carried a very rare or novel variant in at least one of these genes, and 
three of these genes harboured a variant for two or more of the AOS exomes. The p-values 
suggest that these observations are higher than would typically be expected for a randomly-
selected set of 93 genes, implying an enrichment of rare or novel variation. It is therefore 
reasonable to examine the variants which fall in the neighbourhood; while a certain 
proportion of these could be due to chance alone (as illustrated by Figure 7.4a) the 
significant enrichment suggests that at least some of the variation could be linked to AOS.   





Figure 7.4 – Empirical distributions for ARHGAP31 neighbourhoods with significant test statistics 
In each panel, top graph shows empirical distribution of statistic S1 (unsolved AOS cases carrying a 
variant) and bottom graph shows distribution of statistic S2 (genes containing a variant in two or more 
unsolved cases) in 10,000 random tests based on neighbourhood size. (a) network = Multinet, 
neighbourhood distance d = 2, variant type = novel and rare, S1 and S2 are both significant; 
(b) network = Multinet, d = 2, variant type = novel only, S1 is significant; (c) network = PINAmin2, 
d = 2, variant type = novel and rare, S1 is significant; (d) network = PINA, d = 2, variant type = novel 
only, S1 is significant.  




The three genes in which two AOS exomes harbour a variant are MAGI1, MAP3K11 
and SYNJ2. (Note that exome S0040 carries a variant in both MAGI1 and SYNJ2, which 
could imply that one of these is not causal for AOS since only one causal variant is expected 
per exome – this assumes that the variants do not act additively through a digenic disease 
mechanism.) In total 14 other genes contain variants. These are CIT, CNTNAP1, DOCK1, 
DOCK2, IL1RAP, KALRN, LATS1, MAP3K4, MCF2L, MCM3AP, MYH9, PARK2, SH3RF1 
and TIAM1. The logic behind the simple neighbourhood search is to start at a known AOS 
gene and search for directly or indirectly interacting genes that may have a disease role. 
Therefore further consideration of this gene list should take into account known gene 
function: would a variant in any of these genes impact the regulation of Rho GTPases, as 
AOS-causing variants in the seed gene ARHGAP31 do? Gene function will be considered 
further below. 
A significant p-value was also observed in the same network (Multinet) for the S1 
statistic based on novel variants only (p = 0.0328; see Figure 7.4b). In this case 8 of 13 AOS 
exomes had a novel variant in the 93 genes in the neighbourhood. Genes with novel variants 
are CIT, CNTNAP1, DOCK2, IL1RAP, KALRN, MAP3K11 (in two exomes, although the S2 
p-value was not significant in this test), MAP3K4, MCF2L, MYH9, PARK2 and SYNJ2. If 
one of the original assumptions of intersection filtering (discussed in section 1.3.4 of the 
thesis introduction), that a highly-penetrant disease-causing variant is unlikely to have been 
listed in a database of sequence variation without linking it to the disease phenotype, is used, 
it could be argued that this subset of genes should be prioritised for follow-up study. 
In the PINAmin2 network, nine AOS cases carry novel or rare variants in a 
neighbourhood of 45 genes (S1 p-value 0.0073; Figure 7.4c). Genes that contain variants are 
CLTC, DNM1, DOCK1, DOCK2, ITSN1, MCF2L, SH3RF1, SOS1, SYNJ2 (variants in two 
exomes but S2 p-value not significant) and TIAM1. In the PINA network all 13 AOS cases 
carry novel variants in a neighbourhood of 566 genes (S1 p-value 0.0310; Figure 7.4d). 
While we see a significant empirical p-value the fact that we observe 35 variants across 33 
of the 566 genes makes these results less informative than those observed in Multinet and 
PINAmin2 so will not be discussed further. 
In total this approach has highlighted 21 genes (17 from Multinet and 10 from 
PINAmin2, with 6 common to both networks) having post-filtering variants in genes that 
interact with ARHGAP31, either directly or indirectly. Follow-up study would be needed to 
confirm that any of these variants cause AOS, which could include laboratory-based 
experiments such as screening for variants in a larger cohort of AOS patients or performing 
functional studies in cell lines or animal models to demonstrate that the AOS phenotype can 
feasibly result from these variants. Due to the expensive and time-consuming nature of such 




experiments a more compelling argument for these variants’ involvement is required. To this 
end we might look particularly at genes with variants in multiple AOS cases, novel variants, 
variants predicted to have a more severe effect on the protein product, and genes where there 
is some existing functional knowledge suggesting a plausible disease mechanism consistent 
with that of ARHGAP31. 
Four of the genes feature (along with ARHGAP31) in the Reactome curated gene set 
“Signalling by Rho GTPases” (downloaded from the Molecular Signatures Database 
[MSigDB] on 30
th
 April 2014 (Subramanian et al. 2005)). Novel missense SNVs were found 
in ITSN1 (exome S0336) and KALRN (exome S0308), and very rare missense SNVs were 
found in SOS1 (exome S0305) and TIAM1 (exome S0308). It should be noted, however, that 
one of the reasons for using interaction networks for this type of analysis is to exploit 
experimentally-obtained evidence for functional relationships that have not yet been fully 
understood and added into curated pathways (Lehne and Schlitt 2012). Therefore genes 
outside of this curated pathway are also of interest. Notably MAP3K11 harbours a novel 
nonsense SNV in exome S0069, as well as a novel missense SNV in S0304. MAP3K11 is a 
kinase in the MAPK signalling pathway, known to have a number of roles including 
involvement “in the transcription activity of NF-kappaB mediated by Rho family GTPases 
and CDC42” (www.genecards.org, Stelzer et al. 2011). In addition, novel splice-site 
mutations were found in CLTC, IL1RAP, MCF2L and PARK2 while a novel (non-
frameshift) insertion was found in MAP3K4, and these genes may also be worth 
investigating further. 
Besides ARHGAP31, RBPJ was the only other known AOS gene for which a 
significant p-value was observed. In the COXPRES30 network, 11 of the unsolved AOS 
cases carried a novel variant in the d = 2 neighbourhood of 196 genes around RBPJ (S1 p-
value = 0.0188, see Figure 7.5). Variants were found in the 15 genes BMP2K, DCP1A, 
DENND4C, EP400, JMJD1C, KIAA1109, NKTR, NR1D2, PUM1, RIF1, ROCK1, SMC5, 
UBR1, VPS13B and YTHDC1. Interpretation of this gene set is more difficult than for the 
results discussed in the previous paragraphs. One reason for this is that the precise nature of 
the interactions in the COXPRES30 network, where genes are connected if their expression 
profiles across a range of microarray samples are sufficiently similar, is less clear than the 
physical interactions represented in the PINAmin2 and Multinet networks. Since mutations 
in RBPJ are thought to cause AOS by disrupting the notch signalling process we can check 
this gene list for genes relevant to this process. However, none are present in the KEGG 
“Notch signalling pathway” obtained via MSigDB (Subramanian et al. 2005). In order to 
explore any shared function among the 15 genes found, a GO term enrichment analysis was 
performed; however, no significant enrichment for any GO biological process term was 




observed (data not shown). A handful of the genes stand out due to the type of variants 
present. In particular, BMP2K contains a novel splice-site variant for the shared 
S0039/S0301 exome and a novel (non-frameshift) insertion for exome S0306, while EP400 
has both a novel (non-frameshift) deletion and a novel missense SNV in exome S0307 (as 
well as a novel missense SNV in exome S0339). Novel splice-site variants were also 
observed in KIAA1109 and NKTR. However, since the genes found in PINAmin2 and 
Multinet’s ARHGAP31 neighbourhoods have better characterised functional links, it would 
be imprudent to recommend follow-up analysis of any of the genes found in COXPRES30’s 
RBPJ neighbourhood ahead of those. 
Finally it is worth noting that of the 28 tests that used all five AOS genes 
simultaneously as seed genes, only one produced a significant result. In the COXPRES30 
network, more genes than would be expected by chance harbour novel or very rare variants 
in two or more AOS exomes, and are within distance d = 2 of a known AOS gene (S2 = 7, 
p = 0.0483; see Figure 7.6). These genes are BMP2K, JMJD1C, KIAA1109 and RANBP2 
which interact indirectly with RBPJ; COL4A2 (indirect interaction with DOCK6); PCDH12 
(indirect interaction with ARHGAP31), and SBF1 (indirect interaction with NOTCH1). (Note 
that we previously saw novel variants in two exomes in the gene EP400, an indirect 
 
Figure 7.5 – Empirical distributions for novel variants in d = 2 neighbourhood of RBPJ in COXPRES30 
Top graph shows empirical distribution of statistic S1 (unsolved AOS cases carrying a variant) and 
bottom graph shows distribution of statistic S2 (genes containing a variant in two or more unsolved 
cases) in 10,000 random tests based on neighbourhood size. S1 is significant. 




neighbour of RBPJ. However, while this gene survives filtering at level 5, the same is not 
true at level 4 because very rare or novel variants are observed too frequently in the non-
AOS control exomes.) These genes could be investigated further, but again due to the 
ambiguous functional relevance of neighbours (especially indirect neighbours) in the co-
expression network this would not be prioritised ahead of following up the PINAmin2 and 
Multinet results described earlier. 
On a technical note, it should be pointed out that the permutation tests include a 
slight bias. This is because each neighbourhood is tested against 10,000 randomly selected 
gene sets of the same size. However, we know that the seed gene in the original 
neighbourhood, and possibly one or more neighbours (other known AOS genes; see Table 
7.3), cannot contain a variant in an unsolved AOS exome. This bias could be corrected by 
factoring in the number of known AOS genes when calculating the size of the random gene 
sets to sample. However, since the bias acts conservatively (the expected p-values would be 
lower for the corrected test) the results presented here are valid.  
This analysis has demonstrated that a network-based candidate-gene approach, such 
as a simple neighbourhood search around known disease-causing genes, can identify 
 
Figure 7.6 – Empirical distributions for novel and very rare variants in combined d = 2 neighbourhoods of 
all known AOS genes in COXPRES30 
Top graph shows empirical distribution of statistic S1 (unsolved AOS cases carrying a variant) and 
bottom graph shows distribution of statistic S2 (genes containing a variant in two or more unsolved 
cases) in 10,000 random tests based on neighbourhood size. S2 is significant. 




promising genes for follow-up study. In particular, we identified several interesting genes 
due to their network proximity to ARHGAP31. The missense variants identified in the Rho 
GTPase signalling genes ITSN1, KALRN, SOS1 and TIAM1, along with the novel variants in 
MAP3K11 (one of which being a nonsense variant), are good candidates to be studied 
further. 
7.3.2 Post-Filtering Variants in Single Genes 
The subsequent results sections (7.3.3 to 7.3.6) will present the results of 
BioGranat-IG analyses, which take a hypothesis-free approach to overcoming genetic 
heterogeneity. In these analyses the aim is to find small connected subnetworks that harbour 
post-filtering variants for as many AOS exomes as possible, with no preference given to any 
genes in the network based on prior knowledge. It is important to view any subnetworks 
found with a preliminary awareness of why these genes might appear in the results. 
Therefore it is sensible to look here at the individual genes that harbour post-filtering 
variants in the highest number of AOS cases. Note that we are essentially performing simple 
intersection filtering; it may be informative in its own right but is presented here to help 
understand the BioGranat-IG results that will follow. 
For each of filtering levels 1-4, Table 7.5 lists the genes in which the most AOS 
exomes carry a post-filtering sequence variant. It is not practical to look at every gene in this 
table individually, but it may be instructive to consider the top few genes. 
CNTNAP3B has post-filtering variants in seven exomes at filtering level 1. This 
number falls to four at filtering level 2, implying that the variants in the other three cases did 
not match the expected mode of inheritance. Since there are also variants in four exomes at 
levels 3 and 4, all four of these exomes must be unsolved cases. In fact, CNTNAP3B 
contains heterozygous missense SNVs in exomes S0069 and S0307, two missense SNVs in 
S0308 that might be compound heterozygous and a novel heterozygous splice-site variant in 
S0338. The role of CNTNAP3B is relatively poorly understood; it is a paralog of CNTNAP1 
which encodes the contactin-associated protein CNTP1 and is associated with several 
diseases of the nervous system (www.genecards.org, Stelzer et al. 2011). Of the 336 non-
AOS control exomes, 19 carry a variant in CNTNAP3B (using the criteria for filtering level 
1). This is just below the exclusion threshold of 20, suggesting that CNTNAP3B may be 
relatively tolerant to functional variation. These observations suggest that CNTNAP3B may 
not be a good candidate for further study. In terms of its effect on BioGranat-IG results, the 
only one of the five hub-free networks that contains CNTNAP3B is COXPRES30_d50. 
CEL has variants in six exomes at filtering level 1, dropping to five at filtering 
level 2 (implying the variant in the other exome did not match the expected mode of 




inheritance). Between filtering levels 2 and 3 the number of exomes carrying a variant falls 
from five to two (not shown in table). This means that only two of the exomes are unsolved 
cases, the other three having known AOS-causing variants in other genes. Since we assume 
AOS is monogenic, we do not expect any additional variants in the solved cases to be linked 
to AOS and CEL will not be considered further. Note that CEL is present in PINA_d50 and 
Multinet_d50 so may influence BioGranat-IG results in these networks. 
NINL has variants in five exomes at filtering level 1, dropping to four at level 2 
(implying one exome did not have a variant that matched the expected mode of inheritance). 
Since there are also variants in four exomes at filtering levels 3 and 4 these must all be 
unsolved cases. In fact NINL contains (the same) novel heterozygous splice-site variant in 
exomes S0307 and S0338, and novel heterozygous missense SNVs in S0308 and S0339. 
NINL encodes ninein-like protein, which is involved in microtubule organisation in 
interphase cells. Of the 336 non-AOS control exomes, eight carry a variant in NINL (using 
Table 7.5 – Genes with variants in the highest number of AOS exomes, by filtering level 
* = note that filtering level 3 excludes all but the true causal variants for the 6 solved AOS cases. 
 
Filtering level 1 
(from 19 exomes) 
Filtering level 2 
(from 19 exomes) 
Filtering level 3 
(from 13+6 
exomes*) 
Filtering level 4 
(from 13 exomes) 
7 exomes CNTNAP3B    





CEL   
4 exomes 
ABCA7, 
ARHGAP4,  ATN1, 
CCDC40,  CDT1, 
CPVL,  ITPR3, 
LPA,  PCDH12, 
PHKB,  PPM1E, 
PRRC2B,  RTL1, 





COL6A3,  ITPR3, 
LPA,  NINL, 
RGPD3 






BHLHE22,   BMP5,  
CILP,  COL6A3,  
GPR124,  GPR125,  
LPA,  LRP2,  
NHSL1,  PHKB,  




BHLHE22,   BMP5,  
CILP,  COL6A3,  
GPR124,  GPR125,  
LPA,  LRP2,  
NHSL1,  PHKB,  








the criteria for filtering level 1). This is slightly higher than average (across all 16,282 genes 
with a post-filtering variant in at least one control the mean is 5.80), but not exceptionally 
high: 2,382 genes harbour post-filtering variants in a higher number of non-AOS control 
exomes. Note that NINL is present in all hub-free networks except PINAmin2_d50 and so 
could influence BioGranat-IG results. 
Other genes will be examined as they occur in BioGranat-IG results. 
7.3.3 BioGranat-IG Results: Summary 
In total, 80 different BioGranat-IG searches were performed using each combination 
of five different networks (PINA_d50, PINAmin2_d50, CPDBconf95_d50, 
COXPRES30_d50 and Multinet_d50), four different search methods (exact triplet and 
quadruplet searches, heuristic search limited to ten genes, unlimited heuristic search) and 
four different variant filtering levels (1-4). Table 7.6 summarises the findings for each 
search, giving the number of genes in an optimal subnetwork and the number of AOS 
exomes in which an optimal subnetwork harbours a variant. Note that optimal subnetworks 
are not necessarily unique because several equivalently good subnetworks might be found in 
a given search (optimality implies that no subnetworks were found to harbour variants in a 
greater number of AOS exomes and no smaller subnetworks were found to harbour variants 
in the same number of AOS exomes). For the triplet and quadruplet searches, near-optimal 
subnetworks are also considered. 
Since it is not practical to examine in detail every subnetwork found, the following 
sections will take a logical approach in order to highlight subnetworks of greatest potential 
interest. Most attention is given to the searches in the PINA_d50 network since this is the 
network of physical interactions with widest genomic coverage (10,375 genes; 
COXPRES30_d50 includes a greater number of genes but interactions in this network are 
less easily interpretable). Subsequently, findings will be compared to the PINAmin2_d50 
and CPDBconf95_d50 networks, which are both smaller PINs than PINA_d50 but whose 
interactions are of higher confidence on average. Finally KGGSeq-prioritisation, as 
described in chapter 6, will be used to identify any additional subnetworks from the 
remaining networks that warrant further attention. 
7.3.4 BioGranat-IG Results: PINA_d50 Network 
7.3.4.1 Filtering Level 4 
Filtering level 4 includes novel and very rare non-synonymous variants that match 
the expected mode of inheritance in the 13 unsolved AOS cases. It is interesting to start with 
the results of this analysis, which does not make use of the exome data from solved AOS 




cases, because BioGranat-IG has the capacity to suggest novel disease mechanisms. It is 
already established that variants in different functional pathways can cause AOS (for 
example, ARHGAP31 and DOCK6 cause AOS through a consistent molecular mechanism 
(Shaheen et al. 2011) with NOTCH1 and RBPJ through another (Stittrich et al. 2014)); while 
the simple neighbourhood search has the potential to find new genes causing AOS through 
an existing mechanism, BioGranat-IG can propose causal mechanisms that are not 
necessarily related to the known AOS pathways. 
At filtering level 4, the optimal triplet found by BioGranat-IG in PINA_d50 contains 
a variant in seven AOS exomes (depicted in Figure 7.7). LPA contains a variant in exomes 
S0308, S0333, and S0338; LRP2 also contains a variant in exome S0333, along with S0306 
and S0336, and MAGI1 contains a variant in S0040 and S0305. The subnetwork has a 
Table 7.6 – Summary of optimal subnetworks for AOS found by BioGranat-IG 
Results take the form: number of AOS cases covered (number of genes). Note this table gives the 
properties of optimal subnetworks found by each search but optimal subnetworks are not necessarily 
unique. 







Filtering level 1  (from 19 exomes) 
PINA_d50 8 (3) 10 (4) 17 (10) 19 (12) 
PINAmin2_d50 6 (3) 7 (4) 12 (9) 19 (18) 
CPDBcon95_d50 7 (3) 9 (4) 15 (10) 19 (16) 
COXPRES30_d50 9 (3) 10 (4) 18 (10) 19 (12) 
Multinet_d50 10 (3) 11 (4) 17 (10) 19 (13) 
Filtering level 2  (from 19 exomes) 
PINA_d50 9 (3) 10 (4) 17 (10) 19 (12) 
PINAmin2_d50 5 (3) 7 (4) 14 (10) 19 (15) 
CPDBcon95_d50 7 (3) 9 (4) 14 (10) 19 (17) 
COXPRES30_d50 7 (3) 9 (4) 15 (10) 19 (15) 
Multinet_d50 9 (3) 10 (4) 17 (10) 19 (13) 
Filtering level 3  (from 19 exomes) 
PINA_d50 7 (3) 8 (4) 13 (9) 14 (12) 
PINAmin2_d50 5 (3) 6 (4) 11 (10) 17 (20) 
CPDBcon95_d50 5 (3) 6 (4) 11 (10) 17 (19) 
COXPRES30_d50 6 (3) 7 (4) 11 (10) 19 (26) 
Multinet_d50 7 (3) 7 (3) 12 (10) 16 (14) 
Filtering level 4  (from 13 exomes) 
PINA_d50 7 (3) 8 (4) 13 (9) 13 (9) 
PINAmin2_d50 5 (3) 6 (4) 11 (10) 13 (13) 
CPDBcon95_d50 5 (3) 6 (4) 11 (10) 13 (12) 
COXPRES30_d50 6 (3) 7 (4) 12 (9) 13 (11) 
Multinet_d50 7 (3) 7 (3) 13 (10) 13 (10) 




significant KGGSeq-prioritisation score when compared against 100,000 sets of randomly 
selected post-filtering variants in the same exomes (probability of containing a disease-
causing variant = 0.8361, p = 0.0221). This score is driven by the high probability (0.6950) 
of causing some monogenic disease assigned by KGGSeq to a novel missense SNV found in 
LRP2 in exome S0333. 
However, there is also evidence suggesting that this triplet might not represent a 
subnetwork involved in AOS. Firstly, exome S0333 has a variant in both of the genes LPA 
and LRP2. Our analysis assumes that AOS is monogenic and therefore we would not expect 
our subnetwork to contain variants in different genes in the same exome. (Note this does not 
 
Figure 7.7 – Summary of BioGranat-IG results for PINA_d50 at AOS filtering level 4 
Dark blue: optimal triplet; adding any one light blue gives optimal quadruplet; bold border: optimal 
heuristic (TG and IGSF5 not included because MAP3K11 already has a variant in the same exomes; 
KIF17 and RPS6KA2 are alternative choices in the optimal heuristic subnetwork because both cover 
exome S0302). The number(s) next to each node refer to the exomes in which they contain variants; 
coloured numbers indicate exomes with multiple variants in the subnetwork. 




definitively rule out this subnetwork: if these genes form a functional pathway underlying 
AOS then two less severe mutations in different genes could feasibly result in a similar 
phenotypic outcome to one more severe mutation in a single gene; alternatively, one of the 
two variants in S0333 could have no functional effect and be present by chance.) Secondly, 
the gene LRP2 appears relatively tolerant to functional variation in the 336 non-AOS control 
exomes. While only 17 of the 336 exomes carry post-filtering heterozygous variants 
(therefore not meeting the exclusion threshold of 20 for these exomes at filtering levels 2-4), 
this number rises to 49 when homozygous or compound heterozygous variants are also 
included (and hence LRP2 is actually excluded at filtering level 1). 
There are four alternative optimal quadruplets. Each can be formed by extending the 
optimal triplet by one gene to find a variant in one additional exome (see Figure 7.7). The 
genes are IGSF5 (variant in S0069), RPS6KA2 (variant in S0302), TG (variant in S0304) and 
TFAP2A (variant in S0339, as well as in S0333 which was already covered by the optimal 
triplet). Individually, each optimal quadruplet has a significant KGGSeq-prioritisation score, 
but the subnetwork found by merging all four quadruplets does not (p = 0.0990). 
The heuristic searches find two overlapping optimal subnetworks of nine genes in 
which all 13 unsolved AOS exomes have a variant. Since the optimal subnetwork has fewer 
than ten genes the unlimited heuristic search gives the same results as the heuristic search 
limited at size ten. Merging the two subnetworks gives a network region of ten genes, which 
include the three genes from the optimal triplet and two of the additional optimal quadruplet 
genes (see Figure 7.7). The KGGSeq-prioritisation score for the merged region is significant 
(probability of containing a disease-causing variant = 0.9857, p = 0.0050). 
The triplet, quadruplet and heuristic searches have identified a network region of 12 
genes in total because there is a concentration of post-filtering variants carried by the 
unsolved AOS exomes in this part of the network. It is therefore natural to examine whether 
these genes are known to play a role in some common functional process. Three significant 
GO biological process annotations were identified. Four genes (MAP3K11, MAPK8IP1, 
RPS6KA2 and SH3RF1) are involved in the “stress-activated MAPK cascade” (p-value after 
adjustment for multiple testing: adjP = 0.0026). This is of potential interest given the critical 
importance of spatially- and temporally-precise cell signalling to normal development 
(Southgate et al. 2011): the known AOS genes ARHGAP31 and DOCK6 regulate the Cdc42 
and Rac1 signalling processes (Shaheen et al. 2011; Southgate et al. 2011) while NOTCH1 
and RBPJ are involved in notch-mediated signalling (Hassed et al. 2012; Stittrich et al. 
2014). In particular, cross-talk between MAPK and notch signalling pathways have been 
demonstrated, although the relationship is not fully understood (Kondoh et al. 2007; 
Yamashita et al. 2013). Four genes (MAP3K11, RPS6KA2, SH3RF1 and TFAP2A) are 




involved in the related process “positive regulation of apoptotic process” (adjP = 0.0105). 
Six genes (EPN1, KIF17, LPA, LRP2, MAPK8IP1 and TG) are involved in “vesicle-
mediated transport” (adjP = 0.0105). 
The 12 genes identified almost certainly do not represent a previously unknown full 
explanatory functional pathway underlying AOS. The main argument for this is network 
coverage: of the 1,983 genes in which post-filtering variants were identified across all 13 
unsolved AOS exomes only 1,087 (54.8%) map to genes in PINA_d50. Network coverage is 
limited both by having removed hub genes and by the fact that current knowledge of the 
interactome is far from complete (Yu et al. 2011). In addition, we should consider the 
secondary problem of whole exome sequencing coverage: Table 7.1 lists exome capture 
scores as low as 71.0% at 20× coverage, meaning that for some of the exomes the true AOS-
causing variant may not even have been sequenced to a sufficient depth to have been 
correctly identified (we know for example that this was the case for one of the DOCK6 
mutations that cause AOS in exome S0334). However, BioGranat-IG is designed to carry 
out a specific search and is unaware of these wider considerations; its unlimited heuristic 
search in particular will continue to add additional genes to promising subnetworks until it 
has found variants for all of the exomes, meaning that sequencing coverage is more 
problematic for BioGranat-IG than it might be for simple intersection filtering. (This leaves 
aside the possibility that since the minimum distance and multi-minimum distance searches 
are not exact they could fail to identify a smaller subnetwork in which all exomes carry a 
variant.) 
There are also features specific to this set of 12 genes that should be noted. Four of 
the 13 unsolved AOS cases carry more than one variant in the subnetwork, and as described 
previously only one per exome would be expected to be causal. 
One gene (MAPK8IP1) contains no post-filtering variant in any of the exomes. On 
one hand this means there is no direct evidence that would link this gene to AOS, but on the 
other hand this could be explained by sampling effects (variants in this gene can cause AOS 
but not for any of the affected individuals we have sequenced) or because the gene is too 
critical to the pathway to tolerate mutations of severe effect (or not critical enough to cause 
the AOS phenotype, for example due to the existence of paralogous genes). 
The 12 genes are connected in the network by 11 edges, the minimum number 
required to connect 12 nodes. There is some evidence to suggest that densely-connected 
network regions are more likely to be involved in disease (Garcia-Alonso et al. 2012). 
None of the 12 genes in this network region interact directly or indirectly with a 
known AOS gene in PINA_d50. (However, in section 7.3.1 we saw that MAGI1, MAP3K11 




and SH3RF1 were part of the neighbourhood of ARHGAP31 in the Multinet network that 
was significantly enriched for post-filtering variants in the simple neighbourhood search.) 
Although the full network region is unlikely to be an AOS disease pathway, it is still 
possible that some part of it plays a role in AOS. Notwithstanding the potentially interesting 
finding of genes involved in MAPK signalling at the periphery of the region, the most 
promising genes are perhaps the optimal triplet genes (and to a lesser extent the optimal 
quadruplet genes) that form the core of the region, due to the concentration of variants 
across the AOS exomes. 
To investigate other small regions containing a high concentration of post-filtering 
variants the triplet and quadruplet searches were repeated to search for near-optimal results. 
Since the optimal triplet contained a variant for seven AOS cases, near-optimal triplets must 
cover six AOS cases and near-optimal quadruplets must cover seven. The near-optimal 
triplet search identified triplets in two distinct regions. Firstly, eight triplets, each containing 
at least two of LPA, LRP2 and MAGI1 give a region of nine genes when merged, covering 
11 AOS cases. These genes largely overlap with the network region already discussed and 
will not be discussed further. Secondly, seven triplets covering six AOS cases each can be 
merged to give a region of ten genes covering ten AOS cases. However, these results are 
driven by the gene NINL which contains a variant in four AOS cases (as discussed in section 
7.3.2 above). Therefore whether this region could plausibly be an AOS disease pathway 
rests mainly on the question of whether NINL is an AOS gene. 
The near-optimal quadruplet search identified 57 quadruplets which form a merged 
region of 47 genes (including LPA, LRP2 and MAGI1, as well as NINL) covering all 13 AOS 
cases. It is difficult to draw conclusions about the AOS disease process by studying a 
network region of this size. 
7.3.4.2 Filtering Level 3 
Filtering level 3 is the same as filtering level 4 except that the six solved AOS cases 
are also included, but with only the true causal variants being included for each. 
The optimal triplets and optimal quadruplets found in PINA_d50 at filtering level 3 
were identical to those found at level 4. This implies that there are not sufficient post-
filtering variants in the vicinity of any of the known AOS genes to form highly-mutated 
triplets or quadruplets. Even though we have implicitly weighted the search towards the 
known AOS genes, the small region around LPA, LRP2 and MAGI1 still has the strongest 
evidence for AOS involvement, in terms of variants in AOS exomes. 
This is true to the extent that even the near-optimal triplets and quadruplets found at 
filtering level 3 are the same as those found at level 4. 




For the minimum distance and multi-minimum distance searches, when these were 
limited at size ten the same two sets of nine genes were found as for filtering level 4. 
However, when no limit was placed on subnetwork size BioGranat-IG identified an optimal 
subnetwork of 12 genes in which 14 of the 19 AOS exomes carried a variant (depicted in 
Figure 7.8). This region contains variants for all 13 unsolved cases, as well as the true causal 
variant for exome S0337 in the gene RBPJ. There is substantial overlap (eight genes) 
between this network region and the one previously identified at filtering level 4 and 
presented in Figure 7.7. Both regions contain the core triplet of LPA, LRP2 and MAGI1, plus 
a path of interactions connecting LRP2 up to SH3RF1 via MAP3K11 and one leading out to 
EPN1 from MAGI1. However, at filtering level 3 a path of length four is added from the 
gene TFAP2A to incorporate RBPJ. This path includes two connecting genes (FHL1 and 
WWP1) which do not harbour a post-filtering variant in any of the AOS exomes. Based on 
the fact that so few variants are observed in this path it seems unlikely that there is a genuine 
AOS-relevant functional link between RBPJ and the previously identified genes. Rather, this 
 
Figure 7.8 – Optimal subnetwork found in PINA_d50 at AOS filtering level 3 using unlimited heuristic 
searches 
Dark blue: overlap with optimal triplet; light blue: also in one of the optimal quadruplets. The 
number(s) next to each node refer to the exomes in which they contain variants; coloured numbers 
indicate exomes with multiple variants in the subnetwork. 




path has been identified because BioGranat-IG’s objective is simply to connect together 
variants in as many AOS exomes as it can. 
However, existing functional annotation suggests that RBPJ may be more closely 
linked to the previously identified genes than inspection of this network region might 
suggest. An enrichment test based on the optimal subnetwork genes found by the unlimited 
heuristic search (the genes in Figure 7.8) identified two significant GO biological process 
annotations. Three of the four genes found earlier to play a role in the “stress-activated 
MAPK cascade” remain in this region (MAP3K11, MAPK8IP1 and SH3RF1; 
adjP = 0.0194). In addition three genes are involved in “regulation of ERBB signalling 
pathway”: EPN1, RBPJ and TFAP2A (adjP = 0.0066). 
Also of note is the fact that the KGGSeq-prioritisation score is significant for this 
region (probability of containing a disease-causing variant = 0.9848, p = 0.0047). Of course 
we know this region does contain a disease-causing variant in RBPJ for exome S0337. 
KGGSeq ascribes this variant a probability of 0.1723 of causing a monogenic disease, which 
is relatively high (92.44% of the variants across all exomes at filtering level 3 have a lower 
probability). However, the significant score is driven by a probability of 0.8604 assigned to a 
novel missesnse SNV found in MAP3K11 in exome S0304 and a probability of 0.6950 
assigned to a novel missense SNV found in LRP2 in exome S0333. 
Finally, it is worth noting why BioGranat-IG did not find a region which included 
the genes ARHGAP31, DOCK6 and NOTCH1, since these genes contain post-filtering 
variants in the five additional exomes not covered by the region depicted in Figure 7.8. This 
is because, although all three of these genes are present in the full PINA network, none 
remain in PINA_d50 after hub removal. NOTCH1 is removed because it is itself a hub gene 
(65 interaction partners in PINA), while ARHGAP31 and DOCK6 are only connected to the 
rest of the network via hub genes so are lost when these hubs are removed. Table 7.7 
summarises the presence of the known AOS genes in each of the five hub-free networks. 
7.3.4.3 Filtering Level 2 
At filtering level 2, all 19 AOS exomes are subject to the same filtering steps, giving 
all novel and very rare non-synonymous variants that match the expected mode of 
inheritance for each AOS case. The only difference to filtering level 3 is that the solved 
cases are now represented by a full list of filtered variants and not just the variants we know 
to cause AOS. This allows us to simulate a scenario in which the true causal AOS variants 
have not yet been identified for the six solved cases, and to ask whether BioGranat-IG can 
pick out these true causal variants. We can also examine how the “noise” introduced by the 
non-causal variants in the solved cases affects the subnetworks that BioGranat-IG finds. 




Of course, there are two reasons we know in advance that BioGranat-IG will not be 
able to pick out all of the known AOS genes. Firstly, since one of the true causal mutations 
in DOCK6 for exome S0334 was not captured by the whole exome sequencing process this 
gene is not represented in the gene lists at filtering level 2. Secondly, PINA_d50 does not 
cover the genes ARHGAP31, DOCK6 or NOTCH1. 
The optimal triplet found by BioGranat-IG in PINA_d50 is the same as that found 
for filtering levels 3 and 4. It consists of the genes LPA, LRP2 and MAGI1. However, when 
variants are filtered at level 2 this triplet now covers two additional AOS exomes (nine in 
total). Exome S0038 has a variant in LPA, although we know in reality that a mutation in 
ARHGAP31 causes AOS for this individual; likewise exome S0335 carries a variant in 
MAGI1 but in this case AOS is caused by NOTCH1. 








ARHGAP31  Only connected to hub genes in full network 
DOCK6  Only connected to hub genes in full network 
EOGT  Not in full network 
NOTCH1  Hub gene in full network 
RBPJ   
PINAmin2_d50 
ARHGAP31   
DOCK6  Only connected to hub genes in full network 
EOGT  Not in full network 
NOTCH1  RBPJ is a direct neighbour 
RBPJ  NOTCH1 is a direct neighbour 
CPDBconf95_d50 
ARHGAP31   
DOCK6  Not in full network 
EOGT  Not in full network 
NOTCH1  RBPJ is a direct neighbour 
RBPJ  NOTCH1 is a direct neighbour 
COXPRES30_d50 
ARHGAP31   
DOCK6   
EOGT  Not in full network 
NOTCH1   
RBPJ   
Multinet_d50 
ARHGAP31  Only connected to hub genes in full network 
DOCK6  Only connected to hub genes in full network 
EOGT  Not in full network 
NOTCH1  RBPJ is a direct neighbour 
RBPJ  NOTCH1 is a direct neighbour 




Similarly, the results of the optimal quadruplet search at filtering level 2 are broadly 
comparable with those found at levels 3 and 4. It is now possible to cover ten of the 19 AOS 
exomes using a four-gene subnetwork, and eight such optimal quadruplets were identified. 
However, in the region of 11 genes formed by merging those quadruplets, seven are the 
same genes identified by quadruplet search at filtering levels 3 and 4, while the other four 
are only present due to variants in the six solved cases that we know do not cause AOS. In 
fact, two of the new genes (DAB1 and PIP5K1C) are identified because they harbour a 
variant in exome S0337, for which the true AOS-causing variant can be found in RBPJ 
elsewhere in the network. This clearly demonstrates a limitation of BioGranat-IG in dealing 
with “noisy” exome sequencing data: these genes are picked up instead of RBPJ because 
they are closer (in network terms) to the concentration of variants in the other exomes 
around the genes LPA, LRP2 and MAGI1. 
When the heuristic searches were performed with no size limit they were are able to 
find a subnetwork of 12 genes in which all 19 of the AOS exomes contain a variant at 
filtering level 2. The subnetwork does not add any new insight: it is based around LPA, 
LRP2 and MAGI1; it does not have a significant KGGSeq-prioritisation score (p = 0.1269); 
it is not densely connected, having the minimum number of edges (11) required to be 
connected, and all six of the solved AOS cases are represented by variants that we know are 
not causal (including S0337, the only one where the true causal gene is in PINA_d50 but 
which is covered in this subnetwork by DAB1). 
Likewise, the heuristic searches limited to subnetworks of size ten add little. Three 
optimal subnetworks of ten genes were found, each covering 17 of the 19 AOS exomes. 
Common to all three are DAB1, LRP2, MAGI1 and MYO6, and two of the subnetworks also 
cover NINL (which contains a variant for four of the unsolved exomes as discussed in 
section 7.3.2). The known AOS gene RBPJ is not covered. As before, the differences 
between these results and the heuristic search results at filtering levels 3 and 4 are due to 
variants in the solved cases which we know are not actually causal (under the assumption 
that only one variant per exome causes AOS). 
7.3.4.4 Filtering Level 1 
By examining the BioGranat-IG results at filtering level 1 we can see the effects of 
relaxing the filtering criterion that requires variants to match the expected mode of 
inheritance in each AOS case. One initial observation is that variants in LRP2 are excluded 
at filtering level 1 (as discussed when the filtering level 4 results were presented in section 
7.3.4.1 above, LRP2 contains post-filtering variants in more than 20 of the 336 non-AOS 
control exomes when mode of inheritance is disregarded). This means the results are not 




expected to match closely what we saw at filtering levels 2-4, where LRP2 was central to 
most of the optimal subnetworks. 
Optimal triplets in PINA_d50 harbour variants in eight AOS cases at filtering level 
1. There are 13 such optimal triplets, which form two distinct merged regions in the network 
(see Figure 7.9). Ten include the gene NINL, which has been previously discussed and 
contains variants in five AOS exomes at filtering level 1 (one of which is the solved case 
S0332). In the merged region, 13 genes cover 15 of the AOS cases in total. There are six 
surplus variants (that is, the region contains 21 variants in total for these 15 cases) and the 
region is not densely connected (it has the minimum number of edges required for 
connectivity), each of which arguably points away from a disease role. Neither the merged 
region nor any of the individual triplets has a significant KGGSeq-prioritisation score. This 
region is almost certainly not of relevance to AOS unless the individual gene NINL is. The 
second merged region is formed by the remaining three triplets, all of which include the 
genes CEL and LTF. As described in section 7.3.2, CEL contains variants in six exomes at 
filtering level 1, and again whether this merged region is of relevance to AOS is highly 
dependent on this gene. 
The optimal quadruplet search results are consistent with the optimal triplets. Again, 
the five optimal quadruplets (which cover 10 AOS cases each) form two distinct merged 
regions in the network, one based around NINL and one based around CEL (see Figure 7.9), 
and do not warrant further discussion. 
Interestingly, the optimal subnetworks identified by the heuristic searches (both 
when limited to subnetworks of size ten and when executed with no limit) contain the genes 
LPA, LRP2 and MAGI1, despite the fact that LRP2 variants are excluded at filtering level 1. 
Further, there is no overlap between the optimal triplets and quadruplets and the results from 
the heuristic searches (see Figure 7.10). However, other than the three genes LPA, LRP2 and 
MAGI1, there are no other genes in common with any of the regions found at filtering 
level 4 (that is, with any of the genes in Figure 7.7). The presence of LPA, LRP2 and MAGI1 
is most likely explained by the fact that LRP2, with 41 interaction partners, is relatively 
highly connected in the PINA_d50 network (with degree 49 in the full PINA network, LRP2 
is just short of the threshold for removal as a hub gene). Nodes of high degree are more 
likely than lower-degree nodes to be identified in BioGranat-IG results as connecting genes 
because of the higher probability that two or more of the neighbouring genes will contain 
post-filtering variants. LPA contains post-filtering variants in four AOS cases, and MAGI1 in 
three, although for each gene one is a solved case, having a causal variant in a known AOS 
gene. There is little other evidence that the regions identified by the heuristic searches are 




Figure 7.9 – Optimal subnetworks found in PINA_d50 at AOS filtering level 1 using triplet and quadruplet searches 
Merged regions shown. Optimal triplets shown in blue; quadruplets in yellow; overlap in green. The number(s) next to each node refer to the exomes in which they 
contain variants; bold italic indicates a solved AOS case with causal mutations found elsewhere; coloured numbers indicate exomes with multiple variants in the same 
merged region. 




All genes: merged region found by unlimited heuristic searches; bold border: optimal subnetwork 
when searches limited to subnetworks of ten genes or fewer. The number(s) next to each node refer to 
the exomes in which they contain variants; bold italic indicates a solved AOS case with causal 
mutations found elsewhere; coloured numbers indicate exomes with multiple variants in the region. 
limited and unlimited network regions, and the 14 genes that make up the regions are 
connected by the minimum number of edges possible to ensure connectivity (13). 
Looking beyond optimal subnetworks, the near-optimal triplet search results give an 
indication of which regions of the network are enriched for closely connected variants after 
filtering at level 1. A near-optimal triplet harbours a variant in seven AOS cases, and such 
triplets were found in six distinct network regions. One is based around the gene NINL, one 
around CEL, and one around the LPA-LRP2-MAGI1 triplet; these genes have been 
previously discussed. The remaining three network regions, shown in Figure 7.11, are each 
of interest for different reasons. 
The triplet of genes formed of AHCTF1, NUP62 and NUP98 is fully connected, 
suggesting a close functional relationship. An enrichment test found significant GO 
biological process terms “mRNA transport genes” (all three genes; adjP = 2.38×10-5) and 
 
Figure 7.10 – Optimal subnetworks found in PINA_d50 at AOS filtering level 1 using heuristic searches 




“nuclear pore organisation” (AHCTF1 and NUP98; adjP = 2.38×10-5). Two of the genes, 
AHCTF1 and NUP62, were previously seen as part of the optimal subnetworks found by the 
heuristic searches (see Figure 7.10). 
Four triplets form a region of six genes, based around PTPRJ and PTPRG. This 
region contains three additional edges above the minimum required for connectivity. Note 
that in PINA_d50, PTPRJ has degree 23 and PTPRG has degree 15; there are 11 genes 
connected to both of them (the region identified here contains four of these, each containing 
one post-filtering variant). The GO enrichment test revealed several functional roles for the 
genes involved: ALK, GRIN2B and PTPRJ are involved in “regulation of MAPK cascade” 
(adjP = 0.0204); PTPRG and PTPRJ in “peptidyl-tyrosine dephosphorylation” 
(adjP = 0.0144); TIE1 and NSF in “plasma membrane fusion” (adjP = 0.0015), and TIE1 
and PTPRJ in “negative regulation of cell motility” (adjP = 0.0204). Note that all of the 
 
Figure 7.11 – Three regions of near-optimal triplets found in PINA_d50 at AOS filtering level 1 
The number(s) next to each node refer to the exomes in which they contain variants; bold italic 
indicates a solved AOS case with causal mutations found elsewhere; coloured numbers indicate 
exomes with multiple variants in the same region. Not shown: three network regions based around the 
gene NINL, the gene CEL and the triplet LPA-LRP2-MAGI1 respectively. 




variants observed in PTPRJ come from the exomes of solved AOS cases, and are therefore 
not expected to be disease-relevant. 
Finally, six near-optimal triplets form a network region centred on the gene USP32, 
which contains five post-filtering variants (although three come from solved AOS cases). 
This region is of interest because it has the most significant KGGSeq-prioritisation score 
(probability of containing a disease-causing variant = 1.0000, p < 10
-5
). This is driven by the 
three variants found in the gene ABCD1: two (in exomes S0040 and S0311) are annotated 
with disease-causing probabilities of >0.99 and the other (in exome S0333) has a probability 
of 0.7938. However, ABCD1 is found on the X chromosome, and none of these AOS cases 
are expected to have X-linked mode of inheritance. 
7.3.5 BioGranat-IG Results: Higher-Confidence PINs 
Having studied in detail the BioGranat-IG results in the network PINA_d50, we now 
examine whether these are supported by the results found in PINAmin2_d50 and 
CPDBconf95_d50. These PINs cover a lower proportion of the genome than PINA_d50 but 
only include higher-confidence interactions. Regions identified by BioGranat-IG in these 
networks are less likely to contain false positive protein-protein interactions (PPIs) and 
therefore more likely to represent genuine functional relationships. 
7.3.5.1 Filtering Level 4 
The region of 12 genes identified in PINA_d50 by the optimal searches at filtering 
level 4 (as depicted in Figure 7.7) is not found intact in either of the higher-confidence PINs 
PINAmin2_d50 or CPDBconf95_d50 (see Figure 7.12). This means that BioGranat-IG will 
not pick out precisely the set of genes seen previously. 
In the PINAmin2_d50 network optimal triplets at filtering level 4 contain variants in 
five of the unsolved AOS cases. One optimal triplet comprises LRP2, MAP3K11 and 
MAPK8IP1, which formed part of the network found in PINA_d50. This subnetwork has a 
highly significant KGGSeq-prioritisation score (probability of containing a disease-causing 
variant = 0.9712, p = 2.0×10
-5
). There are three other optimal triplets which overlap, forming 
a merged region comprising MAPK1, NRIP1, RPS6KA2, RXRA and THRA (see Figure 7.13). 
The quadruplet search in PINAmin2_d50 found three optimal subnetworks covering six 
AOS cases each, and these all included MAPK1 and RXRA. Together, the triplets and 
quadruplets including MAPK1 and RXRA form a merged region of nine genes. None of the 
triplets or quadruplets has a significant KGGSeq-prioritisation score, but the network region 
is reasonably densely connected, having three edges more than strictly necessary for 




Figure 7.12 – PINA_d50 optimal AOS filtering level 4 regions retained in higher-confidence PINs 
The 12 genes are those found by optimal searches in PINA_d50 network (as depicted in Figure 7.7). Bold line: node or edge retained in higher-confidence PIN; dotted 
line: node or edge not retained in higher-confidence PIN. (A) PINAmin2_d50; (B) CPDBconf95_d50. 




Merged regions shown. Genes found in optimal triplets are in blue; quadruplets in yellow; overlap in 
green. The number(s) next to each node refer to the exomes in which they contain variants; coloured 
numbers indicate exomes with multiple variants in the same merged region. 
annotated with “positive regulation of gene expression” (adjP = 6.03×10-6), although this is 
a relatively high-level term. 
The optimal heuristic search results (both size-limited and unlimited searches) in 
PINAmin2_d50 also form merged regions based around MAPK1 and RXRA. However, in 
both cases the regions contain numerous surplus variants (that is, multiple post-filtering 
variants for the same exome), include several connecting genes which do not contain 
variants, and have non-significant KGGSeq-prioritisation scores. The nine-gene region of 
optimal triplets and quadruplets around MAPK1 and RXRA, shown in Figure 7.13, would 
therefore be a better candidate for follow-up study. Note there is no overlap between any of 
the genes identified by the heuristic searches and the region of 12 genes identified in 
PINA_d50 by the optimal searches at filtering level 4 (as depicted in Figure 7.7). 
In the CPDBconf95_d50 network, optimal triplets again contain variants in five of 
the unsolved AOS cases at filtering level 4. Eight optimal triplets were found which include 
the gene NINL. Since this gene itself contains variants in four AOS cases these results are 
not of further interest (note that we did not find optimal triplets containing NINL in 
PINAmin2_d50 because the gene is absent from that network). The only other optimal 
triplet identified comprises the genes AHCTF1, NUP62 and RANBP2 (depicted in Figure 
7.14), the first two of which were identified by the optimal heuristic searches and near-
optimal triplet search at filtering level 1 in PINA_d50 (see section 7.3.4.4, Figure 7.10 and 
 
Figure 7.13 – Optimal subnetworks found in PINAmin2_d50 at AOS filtering level 4 using triplet and 
quadruplet searches 




Figure 7.11). However, none of the optimal triplets overlap with the optimal subnetworks 
found at filtering level 4 in PINA_d50 (Figure 7.7). 
Optimal quadruplets in CPDBconf95_d50 harbour variants in six unsolved AOS 
cases. 12 such subnetworks contain NINL and are not discussed further. There are three 
optimal quadruplets that include AHCTF1 and NUP62, and in a distinct network region 
another which includes LRP2 (which was central to many of the optimal subnetworks found 
in PINA_d50). These findings are presented in Figure 7.14. The quadruplet which includes 
LRP2 has a significant KGGSeq-prioritisation score (probability of containing a disease-
causing variant = 0.8345, p = 0.0484). 
The heuristic searches limited to subnetworks of ten genes or fewer can cover 11 of 
the 13 unsolved AOS exomes in CPDBconf95_d50. However, BioGranat-IG finds 35 ways 
to do this, resulting in a merged region of 53 genes. This region is too big to provide any 
specific insights into mechanisms of AOS (and it contains many surplus mutations and 
connecting genes containing no variants). However, it contains a number of genes we have 
previously seen: NINL; all six of the genes in the region of optimal quadruplets around 
AHCTF1 and NUP62 in Figure 7.14, and three genes (KIF17, LRP2 and MAP3K11) that 
 
Figure 7.14 – Two regions of optimal triplets and quadruplets found in CPDBconf95_d50 at AOS filtering 
level 4 
Optimal quadruplets shown in yellow; overlap with optimal triplets in green. The number(s) next to 
each node refer to the exomes in which they contain variants. Not shown: network region based 
around the gene NINL. 




feature in the optimal region in PINA_d50 (as depicted in Figure 7.7). We conclude that in 
this case the heuristic search acts so as to connect together previously-identified regions in 
which a concentration of post-filtering variants are found. The unlimited heuristic searches 
give materially similar findings so will not be described in further detail. 
The heuristic searches in the higher-confidence subnetworks provide little support 
for the results seen in PINA_d50. This highlights a potential weakness of the minimum 
distance and multi-minimum distance search methods in BioGranat-IG: subnetworks will 
continue to be extended until all exomes are covered (i.e. carry a variant in the subnetwork); 
since the input data are noisy (each exome has many variants in the network) and the 
average path length in a network is small, it will usually be possible to find network-
dependent paths between a few key genes that contain enough variants to be found by 
BioGranat-IG as a viable optimal subnetwork. This leads to large and difficult-to-interpret 
regions harbouring several post-filtering variants for many of the exomes and including 
several connecting genes without variants. Therefore, it is perhaps more fruitful to focus on 
the optimal triplets and quadruplets found by BioGranat-IG, since these tend to identify 
small regions more densely enriched for post-filtering variants. 
7.3.5.2 Filtering levels 1-3 
A full discussion of all results found at filtering levels 1-3 in the higher-confidence 
PINs would be too lengthy for inclusion here, but we can make several observations 
concerning the known AOS genes and the extent to which the PINA_d50 results are 
supported. 
Firstly, at filtering level 3 (which is the same as level 4, except that the solved AOS 
cases are included with only the true causal variants) the optimal triplets and quadruplets 
identified in both PINAmin2_d50 and CPDBconf95_d50 are the same as those found at 
filtering level 4. This suggests that there are not sufficient post-filtering variants in the 
vicinity of any of the known AOS genes to form highly-mutated triplets or quadruplets. This 
is despite the fact that both higher-confidence PINs contain ARHGAP31, NOTCH1 and 
RBPJ (unlike PINA_d50 in which the only known AOS gene present is RBPJ). 
However, in PINAmin2_d50 one of the seven distinct regions formed by near-
optimal triplets contains NOTCH1 (22 genes in total, including MAPK1 and RXRA). One of 
the three distinct regions formed by near-optimal quadruplets contains both NOTCH1 and 
RBPJ (63 genes in total, including MAPK1 and RXRA as well as several genes from the 
optimal heuristic subnetwork in PINA_d50 at filtering level 3: LRP2, MAP3K11, 
MAPK8IP1 and RPS6KA2). In CPDBconf95_d50, one of the three distinct regions formed 
by near-optimal quadruplets also contains both NOTCH1 and RBPJ (58 genes in total, 




including AHCTF1 and NUP62, as well as MAP3K11 from the optimal heuristic subnetwork 
in PINA_d50). 
The heuristic searches limited to ten genes in PINAmin2_d50 find NOTCH1 and 
RBPJ. There is no overlap (other than RBPJ) with any optimal subnetwork genes found in 
PINA_d50 at filtering level 3. The unlimited heuristic searches find ARHGAP31, NOTCH1 
and RBPJ in a network region of 31 genes in total, which includes EPN1 and TFAP2A from 
the PINA_d50 results. Similarly, the size-limited heuristic searches in CPDBconf95_d50 
find NOTCH1 and RBPJ and there is no other overlap with optimal subnetwork genes found 
in PINA_d50, while the unlimited searches find ARHGAP31, NOTCH1 and RBPJ in a 
merged region of 27 genes, with MAP3K11 the only gene overlapping with PINA_d50 
results. As with filtering level 4, the heuristic searches in the higher-confidence PINs at 
filtering level 3 provide little support for the results in PINA_d50, again suggesting that the 
most relevant BioGranat-IG results will come from the triplet and quadruplet searches. 
Secondly, at filtering level 2 (which is the same as level 3, except that exomes for 
the solved cases now include all variants matching the expected mode of inheritance, and not 
just the true causal variants) there are five distinct network regions formed by optimal 
triplets in PINAmin2_d50. One includes four genes (LRP2, MAP3K11, MAPK8IP1 and 
MYO6) that were found in the PINA_d50 filtering level 2 optimal subnetworks (although the 
latter three were only found in the heuristic search results) and another includes the gene 
RPS6KA2, which was in an optimal quadruplet in PINA_d50. Of the three regions formed 
by optimal quadruplets, one includes DAB1, LRP2 and RELN, all of which were found in 
optimal quadruplets in PINA_d50. Notably, with the extra (non-causal) variants that are 
introduced at filtering level 2 for the solved cases, none of the known AOS genes are present 
in any of the optimal subnetworks in PINAmin2_d50. 
In CPDBconf95_d50 none of the optimal triplets overlap with any of the PINA_d50 
optimal subnetworks, although the unique optimal quadruplet found contains LRP2. Again 
none of the known AOS genes are present in any of the CPDBconf95_d50 optimal triplets. 
Finally, at filtering level 1 (which is the same as level 2, except that variants are not 
filtered based on mode of inheritance) none of the optimal subnetworks found in 
PINAmin2_d50 (by any search method) overlap with those found in PINA_d50, and none of 
the known AOS genes are identified. However, in CPDBconf95_d50 there are three distinct 
regions of optimal triplets, one of which includes NINL (there were regions of optimal 
triplets and optimal quadruplets around this gene in PINA_d50) and one of which includes 
AHCTF1 and NUP62 (which were found by the heuristic searches in PINA_d50). The one 
merged region formed by optimal quadruplets also contains the latter two genes. Again, 




however, none of the known AOS genes were identified in any of the optimal subnetworks 
in CPDBconf95_d50. 
7.3.6 BioGranat-IG Results: Top Prioritised Results in all Networks 
Having considered BioGranat-IG results from the PINs in detail, we can look at the 
KGGSeq-prioritisation p-values across all networks to establish whether there were 
subnetworks of interest found in the other networks. 
Table 7.8 lists the prioritisation scores that achieve nominal significance (p ≤ 0.05) 
for each distinct subnetwork (triplet and quadruplet searches) or merged region (all search 
methods) for all networks and variant-filtering levels. Of the 19 distinct subnetworks listed, 
18 include the gene LRP2, while LPA (13 subnetworks), MAGI1 (13), MAP3K11 (six) and 
MAPK8IP1 (five) are also well-represented. 
LRP2 features prominently due to variants with KGGSeq probabilities of being 
disease-causing of 0.69495 in exome S0333, plus 0.21881 in exome S0306 and 0.09828 in 
exome S0336. The first two of these in particular represent high KGGSeq probabilities, as 
can be seen in the cumulative frequency plot given in Figure 7.15. LPA has variants with 
disease-causing probabilities between 0.05 and 0.1 in four exomes (S0308, S0338, S0038 
and S0333). MAGI1 has one between 0.05 and 0.1, and two between 0.025 and 0.05. 
MAP3K11 has a variant with disease probability 0.86036 in exome S0304 (the fifth-highest 
probability among all post-filtering variants at level 4) and 0.03938 in exome S0069. 
MAPK8IP1 does not harbour post-filtering variants itself, but connects LRP2 and MAP3K11 
in PINA_d50 and PINAmin2_d50. 
We also see from the table that 17 of the 19 subnetworks were identified in 
PINA_d50, PINAmin2_d50 or CPDBconf95_d50, and have been previously discussed. The 
optimal subnetwork with the most significant KGGSeq-prioritisation score is the LRP2-
MAP3K11-MAPK8IP1 triplet found in PINAmin2_d50 at filtering levels 4 (discussed in 
7.3.5.1), 3 and 2. 
In row 11 of Table 7.8 is an optimal triplet identified in Multinet_d50 at filtering 
levels 3 and 4 (and since no set of four genes was found containing variants in more AOS 
cases, the three genes also represent the best subnetwork found using the quadruplet search). 
However, this is the same LPA-LRP2-MAGI1 triplet found in PINA_d50 at filtering levels 3 
and 4 (row 4 in the table), and it has the same connecting edges in Multinet_d50. The same 
KGGSeq-prioritisation score is assigned because the same variants are observed in the same 
exomes (probability of containing a disease-causing variant = 0.8361), but a slightly 
different p-value is estimated in Multinet_d50 (p = 0.0380, compared to 0.0221 in 
PINA_d50) because permutation occurs over all variants that map into the network. 
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Table 7.8 – Top BioGranat-IG optimal subnetworks by KGGSeq-prioritisation score for AOS 
Includes any optimal subnetwork (for any network, variant-filtering level and search method) with nominally significant KGGSeq-prioritisation score. Ordered by 











1 2/3/4 PINAmin2_d50 Triplet 3 5 0.971175 0.00002 LRP2, MAP3K11, MAPK8IP1 
2 3 PINA_d50 
Heuristic – 
unlimited 
12 14 0.984823 0.00473 
EPN1, FHL1, HIVEP3, LPA, LRP2, MAGI1, MAP3K11, 
MAPK8IP1, RBPJ, SH3RF1, TFAP2A, WWP1 
3 3/4 PINA_d50 
Heuristic –  
limit 10 (3, 4), 
unlimited (4) 
10 13 0.985712 0.00497 
EPN1, KIF17, LPA, LRP2, MAGI1, MAP3K11, 
MAPK8IP1, RPS6KA2, SH3RF1, TFAP2A 
4 3/4 PINA_d50 Triplet 3 7 0.836116 0.02208 LPA, LRP2, MAGI1 
5 2 PINA_d50 
Heuristic – 
 limit 10 
17 18 0.994622 0.02274 
COL6A3, DAB1, DGKD, DYSF, FLNC, KIF17, LPA, 
LRP2, MAGI1, MAP3K11, MAP3K12, MAPK8IP1, 
MBIP, MYO6, NINL, RPS6KA2, SH3RF1 
6 3/4 PINA_d50 Quadruplet 4 8 0.842374 0.02799 IGSF5, LPA, LRP2, MAGI1 
7 2 PINAmin2_d50 Triplet 5 7 0.982985 0.02864 GIPC1, LRP2, MAP3K11, MAPK8IP1, MYO6 
8 2 PINAmin2_d50 Triplet 3 5 0.873156 0.02909 GIPC1, LRP2, MYO6 
9 3/4 PINA_d50 Quadruplet 4 8 0.843510 0.02935 LPA, LRP2, MAGI1, TFAP2A 
10 2 PINAmin2_d50 Quadruplet 4/5 7 0.827065 0.03428 DAB1, LRP2, RELN, with LRP8 or VLDLR 
11 3/4 Multinet_d50 
Triplet/ 
Quadruplet 
3 7 0.836116 0.03795 LPA, LRP2, MAGI1 















13 1 COXPRES30_d50 Quadruplet 4 10 0.936203 0.04250 ABCA7, ARHGAP4, MAP3K11, SIPA1 
14 2 PINA_d50 Quadruplet 4 10 0.860602 0.04487 DAB1, LPA, LRP2, MAGI1 
15 3/4 PINA_d50 Quadruplet 4 8 0.841958 0.04495 LPA, LRP2, MAGI1, TG 
16 2 PINA_d50 Quadruplet 4 10 0.859761 0.04550 LPA, LRP2, MAGI1, PIP5K1C 
17 2 PINA_d50 Quadruplet 4 10 0.858163 0.04628 IGSF5, LPA, LRP2, MAGI1 
18 3/4 PINA_d50 Quadruplet 4 8 0.837872 0.04817 LPA, LRP2, MAGI1, RPS6KA2 
19 3/4 CPDBconf95_d50 Quadruplet 4 6 0.834526 0.04839 APOB, HSP90B1, ITPR3, LRP2 





The only subnetwork in COXPRES30_d50 that has a significant KGGSeq-
prioritisation score is an optimal quadruplet identified at filtering level 1 (row 13 in Table 
7.8; probability of containing a disease-causing variant = 0.9362, p = 0.0425). It comprises 
the genes ABCA7, ARHGAP4, MAP3K11 and SIPA1 and contains variants for 10 of the 19 
AOS exomes (see Figure 7.16). The gene ARHGAP4 stands out because it encodes a Rho 
GTPase-activating protein (as does the AOS-causing gene ARHGAP31), and contains a 
variant in four of the 19 AOS exomes (which is also true of its neighbour, ABCA7; both 
genes are listed in Table 7.5 due to the high burden of post-filtering variants they contain at 
level 1). However, two of the variants that ARHGAP4 contains are in solved AOS cases: 
S0311 is known to be caused by NOTCH1 and S0337 by RBPJ. Further, the variant that 
ARHGAP4 harbours in exome S0302 is homozygous, but the expected mode of inheritance 
for this case is AD. Considering these observations, the fact that two of the exomes in which 
ABCA7 contains a variant are also solved cases for which other genes cause AOS, and the 
fact that the subnetwork is not densely connected, contains one surplus variant and one 
connecting gene with no post-filtering variant, there is no strong argument for further 
investigation of these genes. 
 
Figure 7.15 – Cumulative frequency plots of probabilities for causing disease that KGGSeq assigns to post-
filtering variants in AOS exomes 
Cumulative frequencies taken across all post-filtering variants at filtering level 1 (across all 19 AOS 
exomes) and filtering level 4 (13 unsolved exomes only) are highly similar. 




7.3.7 HetRank Results: PINA Network 
While BioGranat-IG outputs specific variant-harbouring subnetworks, HetRank 
ranks all genes according to the evidence that they contain an AOS-causing variant (with 
network neighbours playing an important role in the ranking). Therefore a different approach 
is needed to interpret HetRank results and identify plausible functional pathways that are 
enriched for highly-ranked genes (and thus could underlie AOS). In this section, results from 
the full PINA network will be discussed; subsequent sections will compare these results to 
those found in the other networks and examine how the results change as a result of minor 
changes to the input data and parameters (that are intended to better discriminate causal 
variants). 
HetRank does not require pre-filtering of variants, and is therefore not performed 
using different levels of filtering criteria. However, in considering the PINA results, we will 
first look at the results of employing HetRank analysis using only the 13 unsolved exomes 
(as with BioGranat-IG this allows the possibility of identifying novel AOS pathways without 
 
Figure 7.16 – KGGSeq-significant optimal quadruplet found in COXPRES30_d50 at AOS filtering level 1 
The numbers next to each node refer to the exomes in which they contain variants; bold italic 
indicates a solved AOS case with causal mutations found elsewhere; coloured numbers indicate the 
exome has multiple variants in the region. 




a close functional relationship to known AOS genes), and then compare this to the results 
based on all 19 AOS exomes (which also allows us to judge how well HetRank picks out the 
known AOS genes). 
7.3.7.1 HetRank Analysis Using the 13 Unsolved AOS Exomes 
The HetRank tool works by first ranking genes in each exome according to the 
evidence that they contain a disease-causing variant, before adjusting the rankings based on 
neighbouring genes in the network and producing a final rank by combining across exomes. 
Therefore a logical first step is to consider the results obtained without performing the 
network-based adjustment, which should indicate the genes that carry most evidence 
independently of their network neighbours. 
Table 7.9 gives the genes ranked 1-20 without network-adjusted rankings, also 
indicating whether each gene is present in the PINA network. These final positions combine 
separate rankings across all 13 unsolved exomes; to understand where the evidence 
supporting these genes comes from we can examine the individual exomes in which each 
gene receives a high ranking. When variants were filtered (see Table 7.2 in the Methods 
section of this chapter) we saw that the number of plausible disease-causing variants in a 
typical exome was of the order of 200. This gives a convenient threshold with which to 
address the rankings in each individual exome. 
ABCA10 is ranked first overall. Four of the 13 unsolved AOS exomes have ABCA10 
ranked among the top 200 genes likely to contain the disease-causing variant. In S0040 there 
are two heterozygous frameshift deletions that are not present in 1000 Genomes or EVS data 
(although each has been seen 24 times in heterozygous form in the in-house exome 
Table 7.9 – Top 20 genes ranked by HetRank without network-based rank adjustment, based on 13 








1 ABCA10   11 CCDC144NL  
2 ZDHHC13   12 AGAP6  
3 EXO5   13 NBPF11,NBPF24  
4 NINL   14 GNRH2  
5 PRAMEF1   15 NBPF15,NBPF16  
6 SLC9B1   16 LAPTM4B  
7 COTL1   17 ADAMTS7  
8 VCX   18 FAM86B2  
9 GJB2   19 CNTNAP3B  
10 RGPD3   20 NBPF6  




database); S0302 and S0336 also contain these same two frameshift deletions, and S0338 
contains a different heterozygous frameshift deletion that is not present in 1000 Genomes or 
EVS data but has been seen 15 times in the in-house exome database. These variants result 
in a high rank for ABCA10 in four of the exomes because a low weight is assigned to the 
ranking factor “number of observations in heterozygous form in the in-house exome 
database”. However, in practice the previous observations (in non-AOS exomes) rule out the 
possibility that these variants cause AOS. While one of the aims of the HetRank tool is to 
dispense with the need for fixed filtering thresholds for exome data, this is an example of a 
case where a simple filter would have removed these variants from further consideration. 
Without resorting to fixed filtering thresholds, one option available is to increase the weight 
assigned to this ranking factor. This will be explored further in section 7.3.9.2. 
ZDHHC13 is ranked second overall, also having four exomes in which it ranks 
among the top 200 genes. In S0305 it contains a novel heterozygous frameshift insertion; in 
S0308 it contains a heterozygous missense SNV that is not present in 1000 Genomes or EVS 
data but has been seen once in heterozygous form in the in-house exome database; in S0333 
there is a novel heterozygous missense SNV, and in S0339 there is a heterozygous missense 
SNV which is not present in 1000 Genomes or EVS data and is not in the in-house exome 
database (but is not strictly novel as it has a dbSNP reference number – note that presence or 
absence of a dbSNP identifier is not used as a ranking factor in HetRank). Inspection of 
these variants would suggest that ZDHHC13 is a better candidate than ABCA10 to be 
involved in an AOS disease mechanism. (Note that the four variants described were all 
present after filtering at level 1, the only one filtered out at levels 2-4 being the insertion in 
S0305, since this individual is expected to have an AR form of AOS caused by a 
homozygous mutation. This is reflected in Table 7.5.) ZDHHC13 encodes a 
palmitoyltransferase (which is not inconsistent with a signalling role) and has been 
associated with a wide range of phenotypes in mouse models (www.genecards.org, Stelzer et 
al. 2011). 
EXO5 is ranked third overall, with four exomes in which it ranks among the top 200 
genes. It contains a low-frequency heterozygous missense SNV in the shared S0039/S0301 
exome and identical low-frequency heterozygous frameshift insertions in S0306, S0308 and 
S0339 (albeit a variant that has been seen 21 times in the in-house exome database in 
heterozygous form). As with ABCA10 the previous observations of the frameshift insertion 
mean we have little evidence to support an AOS role for EXO5. 
It is of course possible to consider every gene in this list individually. However, we 
will just note that the other genes ranked in the top 20 all have three or fewer top-200 
rankings in individual exomes, and that there are some genes here that we have seen 




previously. In particular, NINL (ranked 4
th
) and CNTNAP3B (19
th
) were picked out in Table 





) and, as previously mentioned, ZDHHC13 (2
nd
) also 
featured in Table 7.5 due to their burden of post-filtering variants; this is reassuring because 
ranking and filtering provide different approaches to the same problem, and hence some 
overlap is expected. 
By considering the results of performing HetRank analysis using the PINA network, 
we can see how these rankings change when evidence that a gene is involved in AOS is 
supported by its network neighbours; if AOS is caused by several functionally-related genes 
in these 13 cases we would hope that PINA reflects this relationship and hence the ranking 
of these genes is improved. Table 7.10 gives the results of performing HetRank analysis on 
the 13 unsolved AOS cases using the PINA network. 
The top-ranked gene is POLN. This gene already had a relatively high ranking of 25 
(out of 18,838 genes in total) in the non-network-adjusted rankings due in part to top-200 
rankings in three of the exomes. In S0302 POLN harbours a low-frequency heterozygous 
frameshift deletion (seen twice in the in-house exome database) but its pre-network ranking 
of 20 in this exome falls to 71 after the network adjustment as a result of other genes having 
their rankings improved elsewhere in the network. Interestingly, the other two exomes in 
which POLN has a pre-network ranking in the top 200 still have a ranking in the top 200 
after network adjustment, but due in part to better-ranked variants in network neighbours. 
In the shared S0039/S0301 exome POLN has a pre-network rank of 170 thanks to a 
low-frequency missense SNV. However, POLN is a direct neighbour in PINA of the gene 
ATR, which was ranked joint-top in the pre-network ranking for this exome due to a novel 
frameshift deletion. HetRank works on the premise that this connection in the network could 
signify a shared functional relationship; POLN’s rank is therefore adjusted to reflect this and 
it is consequently ranked third in this exome. (The ranking adjustment takes neighbourhood 
size into account, but since the direct neighbourhood of POLN contains only nine genes, 
compared to a network maximum of 7,805 genes, the adjusted ranking is almost fully 
weighted toward ATR’s value. Reassuringly, since there are no genes in the network with a 
better rank, ATR’s rank is not adjusted and it remains joint-top in the final rankings for this 
exome.) 
Likewise in exome S0307 POLN has a pre-network rank of 104 due to a novel 
heterozygous missense SNV. However, POLN is an indirect neighbour in PINA of the gene 
ANTXR2, which has a pre-network rank of 28 in this exome (also due to a novel 
heterozygous missense SNV; the difference in ranking must reflect the fact that the ranking 
factor derived from non-AOS control exomes rates this occurrence as more unusual in 




ANTXR2). The final ranking of POLN in S0307 is thus adjusted based on ANTXR2’s score 
(although adjustments to other genes mean POLN’s final ranking in this exome actually falls 
to 117). 
This illustrates an unexpected consequence of HetRank’s network-based rank 
adjustment. In only one of the 13 unsolved AOS exomes (S0302) is POLN’s rank not 
adjusted because of a better-ranked neighbour. This is not exceptional: of the top 20 genes in 
Table 7.10, 14 have their pre-network rankings adjusted due to a better-ranked neighbour in 
all 13 exomes. The gene whose ranking is least-frequently adjusted is ABCA10 (which was 
ranked top overall in the non-network-adjusted rankings), and even this remains unadjusted 
in only three of the 13 exomes. 
This feature of the rank adjustment (that very few ranks remain unadjusted) is 
explained by the typical neighbourhood sizes of genes in the network: only one member of a 
gene’s neighbourhood is required to have a better rank for an adjustment to be made, and 
Table 7.10 – Top 20 genes ranked by HetRank using PINA network, based on 13 unsolved AOS exomes 
“Rank” = overall ranking combined across all 13 exomes after network-based adjustment; “# top 200 
ranks” = number of the 13 exomes in which gene is ranked ≤200; “Pre-network rank” = overall 
ranking combined across all 13 exomes before network-based adjustment (the top 20 such genes were 
shown in Table 7.9); Nd = gene’s d-neighbourhood size (number of genes within distance d). 
Rank Gene 









1 POLN 3 25 3 9 353 
2 FCGR3A 3 224 0 14 412 
3 KIF17 3 319 1 8 256 
4 SH2D1B 3 846 1 7 165 
5 ABCA10 4 1 4 3 770 
6 HGFAC 2 1,510 0 7 111 
7 LPA 4 98 1 13 524 
8 DBH 2 779 0 3 98 
9 GLYCTK 2 7,420 0 4 69 
10 FRZB 2 728 0 6 153 
11 IL12RB2 3 385 1 7 161 
12 FXYD3 3 1,067 2 6 306 
13 CINP 2 1,663 1 4 90 
14 BCR 2 75 2 71 9,129 
15 ADCY2 2 6,026 0 5 104 
16 SLC26A8 1 4,983 0 4 144 
17 MST1 1 22 1 6 88 
18 SFTPC 1 1,460 1 5 293 
19 MUC4 3 2,963 0 3 131 
20 SOX7 2 72 2 3 95 




most neighbourhoods contain many genes (most of the 2-neighbourhoods in Table 7.10, for 
example, contain hundreds of genes). If AOS has a basis of locus heterogeneity which can 
be understood in terms of a functional relationship in PINA (and if the 13 unsolved AOS 
cases reflect this underlying relationship), we would probably expect to see the genes ranked 
highest by HetRank having high ranks (around the top 200) in several exomes due to 
variants they themselves contain, and high ranks in several other exomes due to variants in a 
handful of neighbours. The fact that we are not seeing this (our top 20 genes are being 
adjusted in all or nearly all exomes, and no gene has a top-200 ranking in more than four 
exomes after adjustment) could indicate a flaw in the design of HetRank, or alternatively 
that there is no underlying functional pathway in PINA that causes AOS for these cases. 
The gene ranked second overall is FCGR3A, which had a non-network-adjusted rank 
of 224. In all 13 exomes FCGR3A’s rank is adjusted due to a better-ranked neighbour; in 
three exomes this results in a top-200 ranking: in S0302 its rank is adjusted due to a novel 
heterozygous nonsense SNV in the indirect neighbour PIK3C2B (ranked joint-top pre-
adjustment in that exome); in S0308 its rank is adjusted due to a novel heterozygous 
nonsense SNV in the indirect neighbour LAT (ranked joint-top pre-adjustment), and in 
S0333 its rank is adjusted due to a novel heterozygous nonsense SNV in the indirect 
neighbour GRAP2 (ranked joint-top pre-adjustment). FCGR3A has 398 indirect neighbours, 
and the fact that three of these contain severe variants in AOS exomes is insufficient grounds 
to conclude that this gene plays a role in AOS. 
KIF17 is ranked third overall, compared to a non-network-adjusted ranking of 319. 
This is an interesting gene because we have previously seen it in the optimal subnetworks 
identified by BioGranat-IG at filtering level 4 in the PINA_d50 network (see Figure 7.7). 
There, KIF17 had a post-filtering variant in S0302 while its direct neighbour MAP3K11 
contained variants in S0069 and S0304, and its indirect neighbour SH3RF1 contained a 
variant in the shared S0039/S0301 exome. 
What happens to KIF17’s ranking in these exomes in HetRank? The novel 
heterozygous missense SNV that KIF17 contains in S0302 gives it a rank of 91 before 
adjustment; however KIF17 is an indirect neighbour of NUP62 (another gene we recognise 
from the PINA_d50 BioGranat-IG results – see Figure 7.10 and Figure 7.11), which is 
ranked 36.5 before adjustment due to its own novel heterozygous missense SNV. KIF17’s 
rank is therefore adjusted to take into account NUP62’s score, giving a final rank of 184 in 
exome S0302 (which is lower than either gene’s pre-adjustment rank due to other genes 
having their rankings improved elsewhere in the network). In S0069, the novel heterozygous 
nonsense SNV in MAP3K11 does indeed boost KIF17’s ranking from 2,756 to 10 and in 
S0304 the novel heterozygous missense SNV in MAP3K11 boosts KIF17’s ranking from 




411 to 222. Finally, in the shared S0039/S0301 exome KIF17’s rank is adjusted, but not by 
SH3RF1 which we saw in the BioGranat-IG results. While SH3RF1 harbours a low-
frequency heterozygous missense SNV which gives it a rank of 104 in this exome before 
adjustment, another indirect neighbour, XRCC1, has a pre-adjustment rank of 91 due to a 
rarer missense SNV. However, this is only enough to boost KIF17’s rank from 4,537 to 
2,826 in this exome. There is one other exome in which KIF17 has a top-200 rank after 
adjustment. In exome S0339 KIF17 has a pre-adjustment rank of 271, but its indirect 
neighbour KALRN has a rank of 10 due to a low-frequency heterozygous nonsense SNV. 
This results in an adjusted rank of 56 for KIF17. 
Some of these examples of how KIF17’s ranks are adjusted in individual exomes 
hint at another subtlety of HetRank’s network-based rank-adjustment process. When a 
network neighbour has a better rank in a given exome, HetRank adjusts the score by which a 
gene will be ranked. The new score is a weighted average of the gene’s original score and its 
neighbour’s original score; the weight is based on neighbourhood size and reflects the extent 
to which a better-ranking neighbour is assumed to be relevant (genes with very large 
neighbourhoods receive only small adjustments to their scores because it is more likely they 
will have a high-ranking neighbour by chance). While this formulation reflects a level of 
belief about the value of the information obtained by looking at network neighbours, in 
practice the consequence is that a gene’s adjusted rank depends on both it and its 
neighbour’s original scores (when under the assumption that only one variant in each exome 
can cause AOS, one of these should have no disease role). However, the relationship is 
complicated by the weight derived from the neighbourhood size. Figure 7.17 shows that 
genes with high original rank tend to have a relatively high rank after adjustment (that is, 
higher than genes with lower original rank that have a neighbourhood of similar size). 
We see several different types of adjustment for KIF17: for example, its rank is 
boosted from 2,756 to 10 in S0069 (relatively low original rank but the direct neighbour 
MAP3K11 has a particularly high rank and the direct neighbourhood, at eight genes, is 
small); in the shared S0039/S0301 exome its rank is only boosted from 4,537 to 2,826 (low 
original rank, the indirect neighbour XRCC1 has a relatively good rank of 91 but the indirect 
neighbourhood has 256 genes), and in S0339 its rank is boosted from 271 to 56 (relatively 
high original rank, the indirect neighbour KALRN has a high original rank and the 
neighbourhood has 256 genes). 
There are a few other genes of note in Table 7.10. As previously noted, ABCA10 
(the top-ranked gene before the network-based adjustment) is ranked fifth. 
Ranked seventh is LPA, which was a key gene in the optimal subnetworks identified 




Figure 7.17 – Relationship between original rank, adjusted rank and neighbourhood size, by exome 
See next page for full figure legend. 




Figure 7.17 – Relationship between original rank, adjusted rank and neighbourhood size, by exome 
(previous page) 
(A) Original vs. adjusted rankings in exome S0040, for genes whose ranks are adjusted due to a 
neighbour with original rank of 20 or less. Ranks are normalised to range (0,1] and best-ranked genes 
are at top/right of plot. Each point represents a gene; colour represents the size of the gene’s 2-
neighbourhood (ranges chosen to give approximately equal number of genes in the network of each 
colour). The vertical line at 0.719 represents genes not containing a variant, which are all ranked joint 
last before network adjustment. Some stratification by neighbourhood size is evident (genes with 
smaller neighbourhoods [e.g. purple to blue] tend to have their ranks improved more than genes with 
bigger neighbourhoods [e.g. green to red]; this is expected because HetRank assumes high-ranking 
neighbours are more relevant when the neighbourhood is small). Also evident is that adjusted rank is 
not independent of original rank: genes with high original rank tend to have a relatively high adjusted 
rank (more so than lower-ranked genes with similar network size, i.e. of the same colour). The curve 
of mainly red, orange and yellow points represents genes with a large neighbourhood size; although 
they do have a neighbour with original rank of 20 or less, their adjusted rank is low because little 
weight is given to this neighbour’s rank. The shape of this curve demonstrates how the adjusted rank 
falls as a result of other genes in the network having their ranks boosted. (B) and (C) demonstrate that 
the red/orange/yellow curve is entirely explained by genes of large neighbourhood size: PINA has one 
gene of exceptionally high degree (UBC); genes which are direct neighbours of UBC necessarily have 
a very large 2-neighbourhood. (B) and (C) show the same information as (A) but for the subset of 
genes that are not/are direct neighbours of UBC, respectively. (D) Plots for the other 12 unsolved 
AOS exomes show that the relationships in S0040 are typical. 
had a post-filtering variant in three exomes (S0308, S0333 and S0338). In HetRank, LPA’s 
rank is adjusted in all three of these exomes: in S0308 it is originally ranked 166 but has an 
indirect neighbour (PIGK) ranked 32.5; in S0333 it is originally ranked 283 but has an 
indirect neighbour (BCR) ranked 20, and in S0338 it is originally ranked 667.5 but has an 
indirect neighbour (TAC1) ranked 25.5. In the BioGranat-IG results LPA’s direct neighbour 
LRP2 also had a post-filtering variant in three exomes (S0306, S0333 again and S0336) and 
its indirect neighbours TG (S0304) and MAGI1 (S0040 and S0305) also contained post-
filtering variants. In all of these exomes LPA’s rank is adjusted not because of these genes 
but because of other better-ranked neighbours. A key difference between HetRank and 
BioGranat-IG is that while BioGranat-IG searches for optimal subnetworks with respect to 
the post-filtering variants in all exomes together, HetRank is free to adjust a gene’s rank in 
any exome by examining all of its direct and indirect neighbours – independently of the 
variants in other exomes. 
Ranked ninth is GLYCTK, of note due to its pre-adjustment rank of 7,420. This 
change comes about because GLYCTK is a direct neighbour of the gene ranked second in 
S0338 and an indirect neighbour of the genes ranked 4.5 in the shared S0039/S0301 exome, 
4.5 in S0306 and 12 in S0339 (so that it ranks in the top 500 for four exomes post-
adjustment, two being top-200 rankings). Furthermore, GLYCTK has relatively small direct 
(4 genes) and indirect (69 genes) neighbourhoods, which means that the weighting used in 
the adjustment favours the neighbours’ scores. This serves to illustrate how volatile the 
adjustment to gene rankings can be. 




Looking at individual genes that are highly ranked by HetRank has allowed us to 
study the evidence supporting a role in AOS for each gene, but it is difficult to draw any 
clear conclusions about an underlying disease mechanism in this way. The RGA tool (Lehne 
2011) offers a convenient way to systematically pick out network regions that are enriched 
for genes ranked highly by HetRank, thereby proposing candidate functional pathways 
linked to AOS. 
RGA was employed to test all alpha thresholds in the range 1 ≤ α ≤ 250, excluding 
outlier genes (so that for each value of alpha RGA identifies the largest connected network 
region comprising genes with rank less than or equal to alpha), and with empirical p-values 
determined with reference to 10,000 degree-constrained permuted networks (the significance 
of an identified region in the original network is estimated by the proportion of permuted 
networks in which a region of equal or greater size is found). Region sizes and p-values are 
presented in Figure 7.18a. There are three ranges of alpha values at which we see a 
nominally significant region size: α = 21 (region size 2), 24 ≤ α ≤ 65 (region size 3, 
increasing to 4 at α = 61) and 148 ≤ α ≤ 151 (region size 7). The lowest p-value is seen at 
α = 24 (p = 0.0015). The regions identified are presented in Figure 7.18b. Note that three 
distinct network regions are found at different alpha levels; note also that none of the regions 
support any of the main subnetworks found by BioGranat-IG in the PINA_d50 network 
(discussed in section 7.3.4). 
At α = 21 there is a region of two genes (p = 0.0485), LY9 and SH2D1B, which 
increases to three genes with the addition of CD244 at α = 24 (p = 0.0015). These genes’ 
rankings reflect a novel frameshift deletion in LY9 in exome S0305 and a novel 
heterozygous missense SNV in SH2D1B in exome S0339, both of which are the highest 
ranked genes in the neighbourhoods of all three genes in the respective exomes. In terms of 
common function, a GO enrichment test finds LY9 and SH2D1B to be annotated with 
“lymphocyte mediated immunity” (adjP = 0.0044), while all three genes are involved in 
“immune system process” (adjP = 0.0102). 
At α = 61 there is a region of four genes (p = 0.0027): ATN1, SLIT1, SSPO and 
ZNF862. In exome S0333 SSPO contains a heterozygous frameshift deletion that was only 
seen once in the in-house exome database, making it the best-ranked gene in the 
neighbourhoods of all four genes in this exome. In exome S0336 ATN1 contains a novel 
heterozygous non-frameshift insertion, making it the best-ranked gene in the 
neighbourhoods of SLIT1 and ZNF862 for this exome (although ATN1 itself has its rank 
adjusted due to a better-ranked neighbour, GNAS, which contains a novel heterozygous 
frameshift deletion). An enrichment test on these four genes finds no GO terms to be 




significantly overrepresented; the most enriched annotation is “regulation of neuron 
differentiation” (ATN1 and SLIT1; adjP = 0.1716). 
At α = 148 there is a region of seven genes (p = 0.0387): BCR, CLCN3, GAB2, 
PDZK1 and three solute carrier genes SLC15A2, SLC17A1 and SLC22A12. In exome S0302 
BCR harbours a low-frequency heterozygous missense SNV and is the best-ranked gene in 
the neighbourhoods of the three solute carrier genes; in S0306 BCR contains a heterozygous 
 
Figure 7.18 – RGA output based on PINA HetRank rankings for 13 unsolved AOS exomes 
(A) For each alpha value, size of network region and empirical p-value are plotted. The nominal 
significance threshold is plotted at 0.05. This output is characteristic of RGA results: the region size is 
an increasing step function; at each alpha value where there is an increase in region size, the empirical 
p-value falls; between such alpha values the empirical p-value steadily increases. (B) Nominally 
significant regions found at alpha levels 24 (three genes, of which SH2DB1 and LY9 form the 
significant region of two genes at α = 21), 61 and 148. Final ranks are indicated in red. 




frameshift insertion seen 28 times in the in-house exome database and is the best-ranked 
gene in the neighbourhood of GAB2 (although the six other genes are all at least indirect 
neighbours of CFTR which contains a novel heterozygous frameshift deletion); the same 
frameshift insertion is found in S0333, making BCR the best-ranked gene in the 
neighbourhoods of CLCN3, PDZK1 and the three solute carrier genes. Notably in both of the 
exomes S0304 and S0308, five of the genes in the region have their ranks adjusted due to 
variants in SLC22A11, which is not part of the region (it has an overall rank of 280 in the 
HetRank results). In terms of a shared function, all seven genes are annotated with the high-
level GO term “transport” (adjP = 0.0014); we also see two genes involved in the “urate 
metabolic process” (SLC17A1 and SLC22A12; adjP = 0.0013) and two more in “regulation 
of myeloid leukocyte mediated immunity” (BCR and GAB2; adjP = 0.0014). 
These results demonstrate that from the HetRank results RGA can pick out network 
regions in which different genes boost each other’s rankings because they contain variants in 
different exomes. However, it is also the case that genes just outside of a found region can 
be direct or indirect neighbours of most or all region genes. Therefore a severe variant in 
such a gene for one exome can boost the rankings of most or all region genes, without this 
neighbour being picked up by RGA. Arguably, then, RGA is only partially effective as a 
means of making sense of HetRank results. 
Besides RGA, another approach to systematically analyse the genes ranked highest 
by HetRank is to look for shared functional annotation. However, a GO enrichment test of 
the top 20 genes (those in Table 7.10) found no significantly enriched GO biological process 
terms, the lowest adjusted p-value found being for “chloride transport” (genes FXYD3, 
ranked 12
th
, and SLC26A8, ranked 16
th
; adjP = 0.1386). If the test is instead performed using 
all genes ranked in the top 250 (consistent with the range of alpha values used for RGA), we 
find several significant terms. 15 genes are annotated with “regulation of membrane 
potential” (adjP = 0.0069), the highest-ranked such gene being CAV3 (ranked 23rd). Three 
genes are annotated with “maintenance of cell polarity” (ANK1, ranked 82nd; ATN1, ranked 
61
st
 and which was picked up by RGA, and DST, ranked 167
th
; adjP = 0.0145). 31 genes are 
annotated with “cell adhesion” (adjP = 0.0145), the highest-ranked being MUC4 (ranked 
19
th
) but also including LY9 and SSPO which were picked up (albeit in different regions) by 
RGA. Finally, four genes were annotated with “retinal ganglion cell axon guidance” 
(adjP = 0.0221), the highest-ranked being SLIT1 which was also picked up by RGA. It is not 
immediately clear whether any of these biological process terms are relevant to AOS 
aetiology; whether or not the genes involved should be investigated further could be 
ascertained by a more detailed examination of the variants they harbour in the AOS exomes. 




A final note on the HetRank results using PINA and the 13 unsolved AOS exomes 
regards the ranking of genes that are not in the network. The gene EXO5 was ranked third 
overall by HetRank without any network-based rank adjustment (see Table 7.9). However, 
in the final network-adjusted results it is assigned a rank of 6,036. As would be expected, it 
has the highest rank among non-network genes. What this indicates is that network genes 
tend to receive a substantial boost to their ranks. Genes have a great advantage in HetRank 
by simply being part of the network, because the relatively large neighbourhood sizes give a 
high likelihood that a better-ranked neighbour will exist and a gene’s rank will be adjusted 
upwards. In particular, this is compounded when the final rankings are calculated by 
combining adjusted ranks across all exomes. EXO5 had pre-adjustment ranks of 17 in exome 
S0306, 19 in S0308, 18 in S0339 and 144 in the shared S0039/S0301 exome. After 
adjustment these drop to 77, 62, 75 and 2,151 respectively due to the effect of adjustments to 
network genes. While the first three of these ranks are still relatively high, there are nine 
other exomes in which EXO5 did not start with such a high rank and where a network 
neighbourhood of several hundred genes would have offered a very good chance of an 
adjustment. Although the rank-adjustment process in HetRank does limit the advantage 
bestowed on genes with large neighbourhoods, the allowance is clearly not sufficient to 
allow non-network genes to be assigned a reasonable final rank. On the other hand it is not 
clear how this could be rectified in an unbiased way; after all, if variants in neighbouring 
genes in the network do constitute evidence for a shared role in AOS (as HetRank assumes), 
then genes in the network are indeed predisposed to have more evidence of this type. It is 
worth pointing out that if a non-network gene were ranked first in each exome before the 
ranks are adjusted (or indeed simply ranked ahead of the highest-ranked network gene in 
each exome), then it will still rank ahead of all network genes after the adjustment and hence 
in the final combined rankings. The paradox is that this situation would most likely arise for 
a disease where only a single gene is causal, so that there is no locus heterogeneity. In this 
case the gene would likely be identified using simple intersection filtering, and HetRank 
would not be required at all. 
7.3.7.2 HetRank Analysis Using all 19 AOS Exomes 
To judge how well HetRank picks out the known AOS genes, and to see how the 
results change from the previous section when additional exomes are added, we can examine 
the results of performing HetRank analysis on all 19 AOS exomes using the PINA network. 
As before, it is instructive to start with the rankings obtained without any network-
based adjustment. The top 20 genes ranked in this way are shown in Table 7.11, which also 




lists the ranks they were assigned by the same procedure using the 13 unsolved AOS exomes 
only (cf. Table 7.9). 
There is substantial overlap between this top 20 and the top 20 genes based on the 
13 unsolved cases (12 genes are common to both), as would be expected given the overlap in 
the underlying exome data. Of the top 20, 19 were previously ranked 134 or better, 
suggesting that the procedure used by HetRank to combine rankings across exomes is 
reasonably robust to the addition of new exomes. 
As an example of the effect of this additional exome data, consider the top-ranked 
gene SLC9B1. This gene was ranked sixth when HetRank analysis was performed without a 
network adjustment for the 13 unsolved AOS exomes, due in large part to a heterozygous 
stopgain SNV that is found in exomes S0302 and S0333 (albeit observed 17 times in the in-
house exome database). However, in the additional exomes SLC9B1 has high ranks in S0311 
(for which AOS is known to be caused by NOTCH1) and S0337 (AOS caused by RBPJ) due 
to the same variant. Leaving aside the fact that this specific variant would be ruled out by the 
previous observations in the in-house database, the assumption that only one variant per 
exome causes AOS already implies that SLC9B1 cannot have an AOS role in the solved 
cases. So these rankings are impacted by non-causal variants in the solved cases. 
The gene in the top 20 with the biggest jump in rank due to the addition of the six 
solved cases is NOTCH1, ranked 16
th
 (and previously ranked 1,843). Encouragingly, this is 
caused primarily by the novel heterozygous frameshift insertion in exome S0311 and the 
novel heterozygous frameshift deletion in exome S0335 that do cause AOS (and which both 
cause NOTCH1 to be ranked joint-top in their respective exomes). 
Table 7.11 – Top 20 genes ranked by HetRank without network-based rank adjustment, based on all 19 
AOS exomes 
“Prev. rank” = previous rank assigned to the gene based on 13 unsolved AOS exomes only (i.e. by 












1 SLC9B1  6  11 AQR  27 
2 AGAP6  12  12 PRAMEF1  5 
3 ADAMTS7  17  13 NINL  4 
4 VCX  8  14 ATN1  33 
5 ABCA10  1  15 RGPD3  10 
6 EXO5  3  16 NOTCH1  1,843 
7 FAM86B2  18  17 ZDHHC13  2 
8 PUSL1  42  18 ITPR3  126 
9 COTL1  7  19 NBPF14  73 
10 ARHGEF5  21  20 SGK223  134 




The other known AOS genes do not rank in the top 20. ARHGAP31 is assigned a 
rank of 839, which is considerably higher than its previous rank of 8,916 due to the novel 
heterozygous nonsense mutation that causes AOS in exome S0038 (ARHGAP31 is ranked 
joint-top in this exome). DOCK6 is ranked 520, which compares to 3,502 previously. This is 
due to a novel heterozygous missense SNV ranked 164 in exome S0332 (one of the two 
variants which together form a compound heterozygous mutation that causes AOS in this 
individual), and a novel heterozygous splice-site variant ranked 162 in exome S0334 (one of 
two variants causing AOS; note the other was not captured by whole exome sequencing). 
RBPJ is assigned a rank of only 4,138, which compares to 10,041 previously; the variant 
which causes AOS in S0337 is a novel heterozygous missense SNV which gives RBPJ a 
rank of 37 in this exome. Finally EOGT, which does not cause AOS in any of the six solved 
cases, has a rank of 10,575 due to various low-ranking variants in eight of the exomes 
(compared to a previous rank of 11,484 due to low-ranking variants in five of the unsolved 
cases). 
Table 7.12 shows the results of performing HetRank analysis on all 19 AOS exomes 
using the PINA network. The “pre-network rank” column shows that the network-based 
adjustment causes considerable changes in the rankings, with many genes in the top 20 
having had their rank adjusted by several thousand places (we previously saw the same thing 
in Table 7.10 based on only the 13 unsolved exomes). 
The “previous rank” column allows comparison with the final rank (after network-
based adjustment) that was assigned to each gene by HetRank using the 13 unsolved cases 
only (discussed at length in section 7.3.7.1 above). Six of the previous top 20 genes are still 
in the top 20 here (for example, POLN, which was the top-ranked gene based on the 13 
unsolved exomes and is ranked sixth here based on all 19 AOS exomes). On the other hand, 
there are several genes now in the top 20 which had a rank above 1,000 previously. Again 
the gene with the biggest improvement in position is NOTCH1, ranked seventh (compared to 
2,166 previously). This is primarily due to the AOS-causing variants that it contains in 
S0311 and S0335; it is also helped by an adjusted rank of 266 in exome S0038 due to a 
better-ranked neighbour (NOTCH3), and notably due to a relatively good adjusted rank of 
342 in exome S0337 – which is due to the AOS-causing variant in its direct neighbour 
RBPJ. 
This is a situation where HetRank works exactly as it is designed to do: the 
underlying functional relationship between NOTCH1 and RBPJ is captured by an edge in 
PINA; consequently NOTCH1’s final rank, which is already high pre-adjustment because of 
the AOS-causing variants in S0311 and S0335, is boosted due to the AOS-causing variant 
that RBPJ harbours in S0337. This can be considered a proof-of-principle for HetRank: had 




we not already known any of the causal genes for AOS, an inspection of the top ten genes 
identified by HetRank would have put forward NOTCH1 as a candidate. 
To explore why other genes undergo such an improvement in rank compared to the 
ranks based on the 13 unsolved exomes, consider the next-best improvement. LFNG was 
ranked 2,098 previously, and only ranked 6,006 based on all 19 exomes before the network 
adjustment, yet has a final adjusted rank of 10. As might be expected, this is because LFNG 
is a direct neighbour of NOTCH1 and its rank is boosted due to this association (in fact it 
only has two direct neighbours, so the adjustment weights it heavily toward NOTCH1’s 
scores in the relevant exomes). But since LFNG does not have a variant that confers it a high 
rank in any of the unsolved cases, it can be considered a false positive finding here. 
Table 7.12 – Top 20 genes ranked by HetRank using PINA network, based on all 19 AOS exomes 
“Rank” = overall ranking combined across all 19 exomes after network-based adjustment; “# top 200 
ranks” = number of the 19 exomes in which gene is ranked ≤200; “Prev. rank” = previous rank 
assigned to the gene based on 13 unsolved AOS exomes only (i.e. by HetRank using PINA network; 
the top 20 genes were summarised in Table 7.10); “Pre-network rank” = overall ranking combined 
across all 19 exomes before network-based adjustment (the top 20 such genes were shown in Table 
7.11). 
Rank Gene 







# top 200 
ranks 
(pre-) 
1 CAPN11 4 54 22 4 
2 MAML2 2 668 364 1 
3 COL23A1 2 684 3,276 0 
4 DBH 3 8 853 0 
5 FCGR3A 3 2 284 0 
6 PPP1R26 3 560 727 1 
7 NOTCH1 2 2,166 16 2 
8 POLN 3 1 150 3 
9 MMP12 1 90 908 0 
10 LFNG 2 2,098 6,006 0 
11 MAML3 2 1,151 3,117 1 
12 ABCA10 5 5 5 5 
13 HGFAC 2 6 1,672 0 
14 SH2D1B 3 4 1,534 1 
15 GOLGA8A 2 103 59 4 
16 ABCB5 3 188 80 2 
17 GIF 4 555 2,352 1 
18 HPCAL4 2 323 5,109 0 
19 JAG2 2 1,010 4,949 0 
20 MFNG 2 1,490 2,959 2 




We saw that NOTCH1’s rank was boosted due to the true causal variant in RBPJ. 
The converse also holds: RBPJ’s rank is boosted from 4,138 to 897 by the network-based 
adjustment, mainly due to the causal variants that NOTCH1 contains in S0311 and S0335. 
However, the true causal variants in the three exomes for which AOS is caused by RBPJ and 
NOTCH1 do not provide sufficient signal for HetRank to rank RBPJ anywhere near the top 
20 genes, since the rankings are also based on 16 other exomes for which these are not the 
genes responsible for AOS. This means that if we did not already know that RBPJ was a 
causal gene for AOS, this analysis would not identify it. 
(If HetRank analysis is performed using only the three exomes for which AOS is 
caused by NOTCH1 or RBPJ, NOTCH1 is ranked top and RBPJ is ranked 20
th
 [full results 
not shown]. This suggests that RBPJ would be much more likely to be found by HetRank 
were the locus heterogeneity of AOS limited to these two genes.) 
ARHGAP31 is assigned a rank of 272, up from 839 before the network adjustment: 
as well as the true causal variant it harbours in S0038, its indirect neighbour ITSN2 is ranked 
joint-top for exome S0332 (actually known to have AOS due to a compound heterozygous 
mutation in DOCK6) and its direct neighbour ITSN1 is ranked 30
th
 for S0336 (an unsolved 
exome). 
DOCK6 is ranked 10,216, despite a rank of 520 before the network adjustment. This 
comes about because DOCK6 does not have any network neighbours that substantially boost 
its rank in any of the 19 exomes (in particular, while DOCK6 is an indirect neighbour of 
NOTCH1, this link is via the exceptionally high-degree node UBC which implies that 
DOCK6 has a very large indirect neighbourhood and hence the extent of any adjustment in 
the exomes for which NOTCH1 causes AOS is very small). For exomes S0332 and S0334, 
in which DOCK6 does contain AOS-causing variants, its ranks fall from 164 and 162 to 
1,034 and 1,148 respectively, as a result of improvements to other genes’ ranks elsewhere in 
the network. 
Considering some of the very top-ranked genes, CAPN11 is ranked first due to a 
heterozygous frameshift insertion it contains in the unsolved cases S0308 and S0336, and 
variants in its neighbours QRSL1 and NOTCH1 in the solved cases S0334 and S0335 
respectively (with the latter being a true causal variant). This would make CAPN11 a good 
candidate for follow-up study, except that the frameshift insertion has previously been seen 
in 20 other non-AOS exomes in the in-house exome database; this demonstrates that this 
variant does not cause AOS and thereby removes any direct evidence for CAPN11’s 
involvement in the disease process. MAML2 is ranked second, mainly because it is a direct 
neighbour of NOTCH1 and has a high adjusted rank in the two solved cases for which 
NOTCH1 is causal (although MAML2 itself contains a novel heterozygous non-frameshift 




deletion in the unsolved case S0306). COL23A1 is ranked third, due primarily to a variant in 
its indirect neighbour ITSN2 in the solved exome S0332 (where DOCK6 is causal) and the 
true causal variant in its indirect neighbour NOTCH1 in exome S0335. To a lesser extent, 
variants in indirect neighbours in four other exomes also contribute to its high rank – 
although one of these variants is in a non-causal gene in the solved case S0337. Since 
COL23A1’s pre-network rank was not especially high there is little direct evidence that it 
plays a role in AOS. 
We can again look for an underlying disease mechanism by employing RGA or by 
testing whether relevant functional annotation exists for highly-ranked genes. 
RGA was carried out using all alpha thresholds in the range 1 ≤ α ≤ 250, and every 
threshold from 11 (region of four genes) up to 250 (region of 24 genes) gave highly 
significant results (p < 0.0001). Unlike what we saw based on the 13 unsolved exomes only 
(Figure 7.18 in the previous section), the significant regions found at increasing alpha 
thresholds form a nested series (see Figure 7.19). At lower alpha thresholds the regions form 
around NOTCH1 (such as the four-gene region at α = 11 comprising LFNG, MAML2, 
MAML3 and NOTCH1), but as the alpha threshold increases the regions grow to incorporate 
a set of four genes previously identified by RGA based on HetRank in the 13 unsolved 
exomes (ATN1, SLIT1, SSPO and ZNF862; Figure 7.18b, α = 61) and subsequently an 
extension which includes LPA (ranked 39
th
), which was highly ranked by HetRank using the 
13 unsolved exomes (Table 7.10) and was previously a key gene in several of the optimal 
BioGranat-IG subnetworks (for example, see Figure 7.7). 
To investigate whether this region is functionally relevant to AOS, a GO enrichment 
test was performed on all 24 genes. Unsurprisingly, “notch signalling pathway” is the most 
enriched term, covering nine genes in the region (NOTCH1, NOTCH2 and direct interactors; 
adjP = 6.91×10
-10), with four of them also involved in “notch receptor processing” 
(adjP = 1.30×10
-5
). The other significantly enriched terms are also related to notch-
signalling, including “cardiac atrium morphogenesis” (DLL4, NOTCH1 and NOTCH2; 
adjP = 0.0007) and “morphogenesis of an epithelial sheet” (DLL4, MMP12, NOTCH1 and 
NOTCH2; adjP = 4.76×10
-5
), both of which are consistent with the cardiac defects seen in 
some cases of AOS (Snape et al. 2009). Other than this last term, which covers MMP12, the 
only significantly enriched biological process annotation was for NOTCH1, NOTCH2 and 
direct neighbours, which does not suggest a close functional link with any of the more 
peripheral genes in the region. It is important to note the possibility that several of the genes 
in the region (particularly those connected to NOTCH1) have little direct evidence that they 
are involved in AOS and HetRank only ranks them highly due to variants in their neighbours 




Figure 7.19 – RGA output based on PINA HetRank rankings for all 19 AOS exomes 
(A) Blue nodes: highly significant region of four genes at α = 11; at subsequent alpha thresholds this region is extended and remains highly significant right through to the 
maximum alpha value tested (α = 250; all 24 genes). Final ranks are indicated in red. (B) Plot of region size (red) and empirical p-value (blue) by alpha value (same 
format as plot shown in Figure 7.18a) clearly shows that region size is nominally significant over almost the entire range. 




demonstrated role that notch signalling genes play in AOS (Hassed et al. 2012; Stittrich et al. 
2014) the genes in this region could benefit from further investigation. 
Aside from RGA, the other way we can interpret HetRank results is to perform an 
enrichment test directly on the top-ranked genes. Based on the top 20 genes, “notch 
signalling pathway” (JAG2, LFNG, MAML2, MAML3, MFNG and NOTCH1; 
adjP = 4.02×10
-6) and “morphogenesis of an epithelial sheet” (MMP12 and NOTCH1; 
adjP = 0.0452) are the significantly enriched GO biological process terms, which is 
consistent with the RGA results. If we look at the top 250 genes, “notch signalling pathway” 
is still significantly enriched (11 genes; adjP = 0.0029), but so is “cell adhesion” (50 genes; 
adjP = 1.32×10
-11) and its child term “homophilic cell adhesion” (13 genes; 
adjP = 9.51×10
-5), “endocytosis” (19 genes; adjP = 0.0014), “cell morphogenesis involved 
in neuron differentiation” (24 genes; adjP = 0.0032), and “extracellular structure 
organisation” (13 genes; adjP = 0.0041). Depending on the plausibility that deficiencies in 
any of these functions could result in the phenotypes associated with AOS, these gene-sets 
could represent several different avenues for follow-up work. 
7.3.8 HetRank Results: Other Networks 
We now consider the results of carrying out HetRank analysis on the 13 unsolved 
AOS exomes, using the other four networks to adjust ranks. Table 7.13 gives the top 20 
ranked genes for the higher confidence PINs, PINAmin2 and CPDBconf95, and for the 
COXPRES30 and Multinet networks, and compares the results to those obtained using 
PINA. 
It is immediately clear that there is little overlap between the top-ranked genes using 
the different networks: no genes are ranked in the top 20 by both PINA and PINAmin2, with 
only two, two and three of the top 20 PINA-ranked genes being ranked in the top 20 using 
CPDBconf95, COXPRES30 and Multinet, respectively. This is illustrated further by Figure 
7.20 which depicts the final ranks based on each alternative network of the 200 genes which 
were ranked highest using PINA. For all four of the alternative networks, many of the top 
200 PINA-ranked genes are assigned ranks of 2,000 or more. We previously saw in section 
7.3.7.1 that the network-based adjustment (using PINA in that case) had a volatile effect on 
the unadjusted rankings. The same is true for the other four networks (Table 7.13), but 
Figure 7.20 also tells us that the post-adjustment rankings for different networks are highly 
variable relative to each other. One trend that can be picked out from the figure is that genes 
which rank relatively highly across several of the networks (these are easier to pick out for 
the top 20 genes; e.g. POLN, ABCA10, LPA, BCR and MST1) tend to be those which were 
ranked relatively highly without any network adjustment (final column). This implies that 
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Table 7.13 – Top 20 genes ranked by HetRank using remaining four networks, based on 13 unsolved AOS exomes 
“Pre-net.” = overall ranking combined across all 13 exomes before network-based adjustment (top 20 such genes given in Table 7.9); “PINA rank” = corresponding rank 
when adjustment uses PINA network (top 20 such genes given in Table 7.10). 
Rank 





















1 DNM1 943 1,740 NINL 4 88 NINL 4 88 ABCA10 1 5 
2 GRAP2 4,760 2,407 MAP3K11 46 248 SP140L 186 7,511 NINL 4 88 
3 LRP2 81 222 LRP2 81 222 ZDHHC13 2 2,514 POLN 25 1 
4 CTTN 2,419 4,574 XRCC1 533 3,790 MST1 22 17 COTL1 7 3,332 
5 ARHGAP32 676 1,880 DST 457 167 GJB2 9 431 GRIK1 107 7,711 
6 ALK 1,419 155 CROCC 859 6,050 RTTN 3,823 12,548 PER2 3,904 5,821 
7 SHB 7,636 698 APPL2 430 286 GOLGA8A 43 103 ARHGEF5 21 2,154 
8 WASL 2,403 1,732 TEP1 97 5,314 WDR67 88 7,385 ZNF679 616 40 
9 ITGB4 166 714 KRT83 544 12,737 AS3MT 776 10,154 GRIK2 1,106 396 
10 PIK3AP1 1,509 6,694 FCGR3A 224 2 COTL1 7 3,332 SGK223 134 6,648 
11 PTPN12 304 1,145 LAT2 684 7,046 LAPTM4B 16 147 CYP2F1 700 13,048 
12 MAP4K3 5,108 5,473 KIDINS220 645 5,861 ANGPT2 89 787 HSPBP1 93 1,338 
13 EPB41L2 375 1,585 CD3G 756 102 LPA 98 7 TEP1 97 5,314 
14 SYNJ1 1,772 866 MUTYH 2,814 9,562 LRP2 81 222 DTX2 79 4,598 
15 FANCD2 1,756 2,015 ALS2 4,572 12,431 PTPRG 49 1,072 TBXA2R 1,345 3,731 
16 MLLT4 3,467 2,999 PKD1 451 7,317 GNRH2 14 8,329 ZNF358 124 8,656 
17 CD22 2,826 3,571 BCR 75 14 PNLIPRP3 28 9,324 MST1 22 17 
18 GAB2 3,859 134 AQR 27 4,834 ZNF358 124 8,656 CHST15 140 5,453 
19 SORBS1 5,358 6,022 ECH1 2,416 8,871 ARHGEF5 21 2,154 ADAM22 753 471 
20 MAPK8IP1 5,421 292 GJB1 15,863 1,445 PUSL1 42 6,451 ITGA1 238 39 





Figure 7.20 – Heatmap depicting rank using other networks of top 200 PINA-ranked genes, based on 13 
unsolved AOS exomes 
Y-axis = genes which are ranked 1-200 by HetRank using PINA for network-based adjustment; the 
top 20 genes (as in Table 7.10) are labelled individually; x-axis = other networks; colours represent 
rank of gene if other networks used for HetRank adjustment. The last column gives the corresponding 
rank if no network adjustment is performed. 




such genes are consistently ranked highly due to the direct evidence for causality conferred 
by the variants they contain, and not due to indirect evidence inferred from network 
neighbours. 
It is perhaps most surprising that the PINA results are not more consistent with those 
from PINAmin2, which is a higher-confidence subnetwork of PINA. This can be understood 
by looking more closely at the relative rankings. In Figure 7.21a the rank assigned to each 
gene when adjustments are based on PINAmin2 is compared to the rank assigned using 
PINA-based adjustments. As the discussion in section 7.3.7.1 would suggest, genes that are 
not in the PINAmin2 network tend to be assigned a low rank when HetRank uses 
PINAmin2, and so these genes (plotted in grey) generally undergo a fall relative to their 
PINA-based rank. Genes which are direct neighbours of the exceptionally high-degree node 
UBC in both networks (plotted in red) will have very large indirect neighbourhoods, and 
because the network-based adjustment takes neighbourhood size into account it will tend to 
have limited effect in both networks. On average, these genes experience an improvement in 
rank largely because of the number of genes that are not in PINAmin2 (and whose rank 
falls). Genes which are direct neighbours of UBC in PINA but not in PINAmin2 (plotted in 
green) tend to undergo a substantial improvement in their rank when PINAmin2 is used for 
adjustment, because their neighbourhood sizes are much smaller and therefore more weight 
can be given to neighbours which rank highly. Finally, for genes which are in both networks 
but not direct neighbours of UBC in either (plotted in blue), the changes to their network 
neighbourhoods may be smaller but they still have complex effects that cause dramatic 
changes in rank. This can be seen in Figure 7.21b: for each of the top 20 PINA-ranked and 
PINAmin2-ranked genes, this figure shows the number of individual exomes for which the 
same neighbour is used to adjust the rank (i.e. has the best unadjusted rank) in both 
networks. In a large majority of cases genes have their ranks adjusted due to different 
neighbours in the two networks. 
To establish whether the HetRank results based on the other networks suggest any 
plausible new AOS genes, we can look at genes which are ranked highly using multiple 
networks, and we can look at RGA and functional enrichment test results for each network. 
Three genes are ranked in the top 20 using three different networks. LRP2 
(PINAmin2, CPDBconf95 and COXPRES30) has been previously identified as a key gene 
in the BioGranat-IG results in PINA_d50 (see section 7.3.4) and NINL (CPDBconf95, 
COXPRES30 and Multinet) was singled out in section 7.3.2 due to the high number of 
variants it contains after filtering. MST1 (PINA, COXPRES30 and Multinet) has not 
previously been discussed; it has a relatively high rank of 22 without any network 




Figure 7.21 – Comparison of HetRank results based on PINA and PINAmin2, for 13 unsolved AOS exomes 
See next page for full figure legend. 




Figure 7.21 – Comparison of HetRank results based on PINA and PINAmin2, for 13 unsolved AOS 
exomes (previous page) 
(A) For each gene in PINA, the final rank assigned by HetRank using PINAmin2 is plotted against 
the final rank using PINA. Ranks are normalised to range (0,1] and best-ranked genes are at top/right 
of plot. UBC has exceptionally high degree in both networks so to aid interpretation points are 
coloured according to whether they are direct neighbours of this node in both networks, in PINA only 
or in neither network. The red horizontal line at 0.5412 represents 550 genes that do not contain any 
variants themselves but are direct neighbours of UBC in PINAmin2 with no other direct neighbours 
(thus all receive an equal rank). The grey horizontal line at 1.0 represents 1,925 genes (13.4% of 
genes in PINA) that do not contain any variants and are not in PINAmin2 (thus not assigned a rank by 
HetRank using PINAmin2). (B) Agreement between PINA and PINAmin2 of neighbours used for 
adjustment, by individual exome. For each gene and exome, the colour indicates whether the gene’s 
final rank in that exome was adjusted with respect to the rank of the same neighbouring gene in PINA 
and in PINAmin2. 
exome is adjusted due to different neighbours for each exome (therefore does not point 
towards a consistent disease mechanism underlying AOS). 
Nine genes are ranked in the top 20 using two different networks. For ABCA10, 
BCR, FCGR3A, LPA and POLN, one of these networks was PINA and these will not be 
discussed further. ARHGEF5 (COXPRES30 and Multinet) stands out because it encodes a 
protein that regulates Rho GTPases (as does the AOS-causing gene ARHGAP31). It has a 
relatively high rank of 21 without any network adjustment, due to a heterozygous nonsense 
SNV in exome S0304 (seen 28 times in the in-house exome database) and a heterozygous 
frameshift insertion in exome S0333 (seen twice in the in-house exome database) – these 
previous observations would suggest these variants do not cause AOS. The other genes with 
top 20 rankings in two networks are COTL1 (COXPRES30 and Multinet; pre-network rank 
of 7 and adjusted using different neighbours in every exome), TEP1 (CPDBconf95 and 
Multinet; pre-network rank of 97 and adjusted using the same neighbour in five of the 13 
exomes) and ZNF358 (COXPRES30 and Multinet; pre-network rank of 124 and adjusted 
using the same neighbour in one of the 13 exomes). 
Considering the results from each network in turn, the top 20 genes using 
PINAmin2 contain two that we previously saw in the optimal BioGranat-IG results for 
PINA_d50 and PINAmin2_d50 (see e.g. Figure 7.13): LRP2 and MAPK8IP1. Both of these 
genes are highly ranked due to a number of network adjustments, particularly due to variants 
in MAP3K11 (another gene identified by BioGranat-IG but ranked 981 by HetRank) for 
exomes S0069 and S0304 and in MAPK9 for exome S0333, and due to the novel 
heterozygous splice-site variant that LRP2 harbours in exome S0336. We also previously 
saw the top-ranked gene DNM1 picked out by the simple neighbourhood search around the 
known AOS gene ARHGAP31 in PINAmin2 (it is an indirect neighbour). 
A GO enrichment test based on the genes ranked in the top 20 using PINAmin2 
identifies one significant functional annotation: “receptor-mediated endocytosis” (DNM1, 




SYNJ1, WASL and LRP2; adjP = 0.0056). When the top 250 genes are tested for functional 
enrichment, the biological process terms identified are highly significant, including “cellular 
response to stimulus” (162 genes; adjP = 2.68×10-22), “cellular communication” (150 genes; 
adjP = 5.99×10
-19) and a child term of both, “signal transduction” (138 genes; adjP = 
1.05×10
-18
). The fact that these terms are highly enriched could indicate that the network 
contains a region enriched for genes involved in signalling, and that plausible AOS-causing 
variants in some of these genes cause many of them to be highly ranked by HetRank. 
Performing RGA using the HetRank results enables this notion to be explored further. 
Testing all alpha in the range 1 ≤ α ≤ 250, RGA finds several highly significant 
regions (p < 0.0001); since we seek a compact functional pathway underlying AOS we 
consider the smallest of these, which contains 14 genes and is presented in Figure 7.22. The 
gene that particularly stands out in this region is ARHGAP32 because it encodes a GTPase-
activating protein which acts on Cdc42 and Rac1, among other Rho GTPases (as does the 
AOS-causing gene ARHGAP31). However, ARHGAP32 does not contain variants in any 
exomes that offer strong direct evidence for AOS causality; its high rank is due to variants in 
neighbouring genes, in particular its indirect neighbours MAP3K11 (in exome S0069) and 
BCR (in S0306). An enrichment test based on the 14 genes in the region finds several 
equally significant GO biological process terms: “regulation of response to stimulus” (ten 
genes), “positive regulation of cellular component organisation” (six genes) and its child 
term “positive regulation of cell projection organisation” (ABL2, MET, RET and WASL) all 
have a multiple-test-adjusted p-value of 0.0036. Notably six of the genes are significantly 
annotated as “transmembrane receptor protein tyrosine kinase signalling pathway” (CRK, 
EPS15, GAB1, GAB2, LCP2 and RET; adjP = 0.0044). 
(If we consider the largest region found, of 71 genes at α = 247 [p = 0.0001], a GO 
test shows these genes to be enriched for “signal transduction” [55 genes; adjP = 
2.39×10
-12
], specifically its child term “transmembrane receptor protein tyrosine kinase 
signalling pathway” [29 genes; adjP = 1.85×10-14], as well as “phosphorylation” [36 genes; 
adjP = 1.69×10
-12
]. This supports the idea raised above that PINAmin2 contains a region 
enriched for functionally related genes with mutually supportive evidence for a role in AOS. 
It could therefore be beneficial to study these genes further.) 
Among the top 20 genes using CPDBconf95, several have been previously 
identified by means other than HetRank: NINL (ranked top) contains a high number of post-
filtering variants (see section 7.3.2); MAP3K11 (ranked second) was identified by the simple 
neighbourhood search as a neighbour of ARHGAP31 in Multinet (section 7.3.1), and 
subsequently found in BioGranat-IG results in PINA and PINAmin2 (sections 7.3.4 and 




Figure 7.22 – RGA output based on HetRank rankings for 13 unsolved AOS exomes using other networks 
For each network: top = plot of region size (red) and empirical p-value (blue) by alpha value, with same format as plot shown in Figure 7.18a; bottom = most significant 
network region found. Where multiple alpha thresholds result in equally significant regions (i.e. having the same empirical p-value), the smaller threshold is used (since 
we seek a compact network region). Final ranks are indicated in red. 




A GO enrichment test using the top 20 genes finds no significantly enriched 
biological process annotation (data not shown). Based on the top 250 genes we find several 
equally significant terms with a multiple-test-adjusted p-value of 1.14×10
-13: “cell junction 
organisation” (27 genes), “cell adhesion” (57 genes) and “cellular component movement” 
(64 genes). 
Testing all alpha in the range 1 ≤ α ≤ 250, RGA finds several highly significant 
regions (p < 0.0001). The smallest, a region of eight genes, occurs at α = 92 (see Figure 
7.22). Interestingly, two of the genes were also in the smallest RGA region based on the 
PINAmin2 results. As discussed above, ARHGAP32 shows little direct evidence for AOS 
involvement; the other gene is MET, which is also assigned its relatively high rank of 92 
based on variants in a number of neighbouring genes. A GO enrichment test of all eight 
genes finds that five of them (CDH2, DST, ITGA6, ITGB4 and PTPRJ) are involved in “cell 
junction assembly” (adjP = 3.03×10-5), six of them (these five plus MET) are involved in 
“cell motility” (adjP = 0.0007), and three (DST, ITGA6 and ITGB4) are part of the “integrin-
mediated signalling pathway”. 
Again using COXPRES30, some of the genes in the top 20 have previously been 
identified by means other than HetRank. NINL is again ranked first; ZDHHC13 (ranked 
third) was in Table 7.5 due to the high number of post-filtering variants it contains; LPA 
(13th) and LRP2 (14th) were key genes in the optimal subnetworks identified by BioGranat-
IG in PINA_d50 (section 7.3.4), and PTPRG (15th) was picked out in a region of near-
optimal triplets that BioGranat-IG identified in PINA (Figure 7.11). 
A GO enrichment test using the top 20 genes finds no significantly enriched 
biological process annotation (data not shown). Based on the top 250 genes we find one 
significantly enriched term: “homophilic cell adhesion” (11 genes; adjP = 0.0095). 
When RGA is employed to test thresholds 1 ≤ α ≤ 250, the most significant region is 
found at α = 9 (p = 0.0053). It comprises two genes, NINL and AS3MT (see Figure 7.22). 
The key drivers of AS3MT’s high rank appear not to be variants in NINL but variants in 
various other neighbours, although AS3MT itself harbours a novel splice-site variant in 
exome S0336. AS3MT encodes an arsenic methyltransferase, and it is not clear how this 
function could relate to that of NINL, which is involved in microtubule organisation in 
interphase cells. This illustrates a key problem with the COXPRES30 network: the edges are 
difficult to interpret. By querying the COXPRESdb database for NINL and AS3MT we see 
that they have a mutual rank of 7.3, making AS3MT the top co-expressed gene of NINL and 
NINL the third-most similarly expressed gene of AS3MT. This occurs because NINL and 
AS3MT have correlated expression across a range of gene expression samples. However, this 




cannot tell us directly whether the genes encode proteins involved in some common process. 
Based on a GO enrichment test, both genes are involved in “cellular process” (adjP = 1.0). 
Among the top 20 genes using Multinet, the only gene that has previously been 
picked out by other methods is NINL (ranked second). 
In a GO enrichment test for the genes ranked in the top 20, GRIK1 and GRIK2 are 
both annotated with “regulation of short-term neuronal synaptic plasticity” and “negative 
regulation of synaptic transmission, glutamatergic” (adjP = 0.0055). Using the top 250 
genes, the most significantly enriched terms are “regulation of excitatory postsynaptic 
membrane potential” (seven genes, including GRIK1 and GRIK2; adjP = 0.0014), plus “cell 
adhesion” (34 genes) and its child term “homophilic cell adhesion” (12 genes; both with 
adjP = 0.0014). 
Testing all alpha in the range 1 ≤ α ≤ 250, RGA finds several highly significant 
regions (p < 0.0001). The smallest, a region of four genes, occurs at α = 38 (see Figure 7.22). 
The four genes are CYP2F1, LCMT2, METTL2B and UGT1A7, none of which we have 
previously identified by other methods. A GO enrichment test on the four genes suggests 
that CYP2F1 and UGT1A7 are involved in the “xenobiotic metabolic process” 
(adjP = 0.0018). The direct evidence linking these four genes to AOS is a novel 
heterozygous frameshift deletion that LCMT2 harbours in exome S0069 and a novel 
heterozygous frameshift deletion that UGT1A7 contains in exome S0305 (both of which are 
ranked joint-top in their respective exomes before the network-based adjustment). However, 
the functional annotation suggested by the enrichment test is not strongly supportive of a 
role in AOS. 
As we have seen, the HetRank results from different networks support each other – 
and the results previously identified by BioGranat-IG – in a few instances, but often many 
new candidate genes are suggested. This emphasises the importance of a careful 
consideration of the evidence for a gene’s involvement in the disease, which includes both 
the direct evidence (the nature of the variants identified by whole exome sequencing) and the 
indirect evidence from the network (the nature of the connections between genes and the 
relevance of any shared function that they undertake). 
7.3.9 HetRank Results: Alternative Input Data and Parameters 
The final results section looks at how the HetRank results change when either the 
input data or HetRank parameters (i.e. the weights assigned to different ranking factors) are 
modified. All results are obtained by performing HetRank analysis for the 13 unsolved AOS 
using the PINA network, and will be compared to the main results reported in section 
7.3.7.1. 




7.3.9.1 Alternative Input Data 
AOS is almost certainly not caused by common genetic variants, due to its low 
prevalence, severe clinical phenotype and the monogenic causal mechanism previously 
identified in the known AOS genes. Therefore, it could be suggested that applying a weak 
filter to the whole exome sequencing data before it is analysed with HetRank might lead to 
more valid results by reducing the level of “noise” in the network-based rank adjustment 
step (meaning that genes will not have their ranks adjusted due to common variants in 
neighbours). In order for the HetRank tool design to remain valid, the input data must retain 
sufficient numbers of variants in case and control exomes (particularly in controls due to the 
nature of the control-derived ranking factor) to give a meaningful ranking of genes. 
Table 7.14 – Top 20 genes ranked by HetRank before and after network adjustment using PINA, based on 
13 unsolved AOS exomes with common variants removed 
“All var. rank” = corresponding rank assigned to gene when HetRank analysis used the full exome 
data (top 20 ranked genes without network adjustment are in Table 7.9; top 20 genes after network 
adjustment are in Table 7.10); “Pre-net.” = rank assigned to gene without network adjustment. 









1 VCX 8  1 HGFAC 864 6 
2 RGPD3 10  2 CD244 5,326 24 
3 NINL 4  3 FXYD3 1,413 12 
4 GJB2 9  4 POLN 117 1 
5 ZDHHC13 2  5 GALNT7 7,896 475 
6 MAPK6 148  6 ZNF440 5,709 661 
7 TWISTNB 64  7 ZNF600 3,910 141 
8 MST1 22  8 LIG4 2,436 46 
9 GOLGA8A 43  9.5 KDSR 13,558.5 453 
10 CNTNAP3B 19  9.5 FBXL16 13,558.5 388 
11 MAP3K11 46  11 CDH13 13,558.5 251 
12 BMP5 56  12 SIM1 2,261 214 
13 MTX1 165  13 CA1 13,558.5 922 
14 NBPF6 20  14 LHB 6,487 53 
15 NBPF15,NBPF16 15  15.5 DLK2 13,558.5 1,039 
16 GNRH2 14  15.5 EGFL9 13,558.5 1,319 
17 SOX7 72  17 AFTPH 9,735 372 
18 COTL1 7  18 ADCY2 9,692 15 
19 ARHGEF5 21  19 FCGR1A 4,167 1,318 
20 CCDC144NL 11  20 FCGR3A 466 2 




To this end, HetRank analysis was repeated with all common variants (defined as 
having either 1000 Genomes Project or EVS alternative allele frequency of ≥ 0.05) removed 
from the 13 unsolved AOS exomes and from all 336 non-AOS control exomes. The genes 
ranked in the top 20, both with and without the network-based rank adjustment, are 
presented in Table 7.14. 
The top 20 genes before adjustment show a substantial overlap of 11 genes with the 
corresponding top 20 obtained when common variants were included (Table 7.9). This 
should be expected since high-ranking genes under both sets of input data (with and without 
common variants) should be those in which several different exomes contain novel or 
relatively rare nonsense, frameshift or missense variants – which would be present in both 
sets of data. 
The top ranked gene is VCX, which was ranked eighth when the input data contained 
common variants. It contains variants in eight exomes (compared to all 13 including 
common variants) and its rank improves in seven of them, resulting in top-200 rankings in 
five exomes (compared to three previously). To understand why its rankings change we can 
consider one of the exomes in detail; in S0069 VCX is ranked 35.5 (compared to 78.5 
previously). Since VCX’s rank improves, other genes’ ranks must get worse – the biggest 
drop being for MAN2A2 (from 10 based on all variants to 383 when common variants are 
excluded). VCX contains a heterozygous missense SNV annotated only with one previous 
observation in the in-house exome database, while MAN2A2 contains a heterozygous 
nonsense SNV which is not in the in-house exome database but which has alternative allele 
frequencies of 0.0016 according to 1000 Genomes Project annotation and 0.0019 according 
to EVS. Since neither of these variants would class as common, they are present in both sets 
of data. The main reason that MAN2A2’s rank falls appears to be the ranking factor derived 
from control exomes: based on all variants, there are no non-AOS control exomes with a 
better (lower) ranking-score than MAN2A2 has in exome S0069 but when common variants 
are excluded there are 11 non-AOS control exomes with a lower ranking-score (and given 
the high weight attached to the control-derived ranking factor, this causes MAN2A2’s rank to 
worsen). For VCX there are no such non-AOS control exomes for either set of data. This 
serves to illustrate the complex way in which variants in the non-AOS control exomes 
contribute to the final HetRank rankings. 
Note that it would be a mistake to assume that common variants always result in a 
very poor ranking. For example, in exome S0336 the gene OR4D10 has a relatively high 
non-network-adjusted rank of 111 when all variant types are included (due to a heterozygous 
nonsense SNV that has an EVS alternative allele frequency of 0.0763) but is unranked when 
common variants are excluded. 




Considering now the final rankings after the network-based adjustment, a number of 
immediate observations can be made based on the top 20 genes in Table 7.14. Firstly, six of 
the genes have a non-network-adjusted rank of 13,558.5. These are all genes which contain 
no variants in any of the 13 unsolved AOS exomes when common variants are excluded 
(and HetRank therefore assigns them a “joint-last” pre-adjustment rank with the other 7,242 
genes in PINA which do not harbour a variant). Their high final ranks are therefore entirely 
due to indirect evidence for AOS causality contributed by network neighbours. Secondly, for 
the first time among HetRank analyses we see genes in the top 20 having equal rank: for 
example, KDSR and FBXL16 are both ranked 9.5. Neither of these genes contains a variant 
in any of the case exomes, and both have their ranks adjusted due to the same network 
neighbours in each exome. Further, they are both only connected to MAPK6 in PINA which 
means they have identical direct and indirect neighbourhood sizes (meaning that their ranks 
are adjusted using the same weighting in each exome). The genes ranked 11th and 13th 
(CDH13 and CA1) also have their ranks adjusted with reference to the same neighbours as 
these genes in every exome, but their final ranks are slightly lower due to having slightly 
larger neighbourhoods. We are seeing genes with equal final rank because, compared to 
when common variants were included, a greater number of genes have their ranks assigned 
based solely on indirect evidence from network neighbours, and therefore HetRank is less 
able to discriminate between genes. (Across the 13 unsolved AOS exomes there are on 
average 9,212.4 genes per exome that contain variants when common variants are included, 
but only 2,117.1 per exome when they are excluded.) 
There are only five genes in common between the top 20 in Table 7.14 and the 
corresponding top 20 obtained when common variants were included (Table 7.10). This 
variability reflects the changes in the pre-adjustment ranks of individual genes as well as 
their network neighbours. The most notable change in rank is EGFL9, which had a final 
PINA-adjusted rank of 1,319 based on all variant types but has a rank of 15.5 when common 
variants are excluded. EGFL9 itself contains no variants in any of the exomes and its high 
final rank is mainly due to relatively good adjusted ranks (between 160.5 and 292.5) in four 
of the exomes. When common variants are excluded, EGFL9 undoubtedly benefits from the 
reduction in the number of genes containing variants, based on the following logic. If 
EGFL9 contains no variants it will be ranked joint-last (pre-adjustment) in every exome. In 
any given exome more genes will contain no variants and hence be ranked joint-last when 
common variants are excluded, and because tied genes are given an average rank this means 
EGFL9’s joint-last rank is relatively better when they are excluded than when they are kept. 
Since a gene’s adjusted rank in each exome is based not only on the unadjusted rank of its 
best-ranked neighbour but on its own unadjusted rank, this should make EGFL9’s network-




adjusted rank better in each exome and hence in the final combined prioritisation. This is 
arguably a sensible outcome, since there is little reason to believe that a gene containing a 
very common variant is more relevant to AOS than one containing no variant. (Note also 
that differences in the pre-adjustment ranks of neighbourhood genes resulting from inclusion 
or exclusion of common variants will also have an effect.) 
To establish whether the final rankings suggest a different mechanism for AOS than 
has previously been suggested, we can look for enriched functional annotation in high-
ranking genes, and employ RGA. 
A GO enrichment test based on the top 20 genes finds no significantly enriched 
biological process terms (data not shown). Using the top 250 genes, the most significantly 
enriched terms include “regulation of membrane potential” (18 genes; adjP = 7.79×10-6), 
“regulation of synaptic transmission” (14 genes; adjP = 0.0002) and “glutamate receptor 
signalling pathway” (seven genes; adjP = 0.0007). 
Testing all alpha in the range 1 ≤ α ≤ 250, RGA finds several highly significant 
regions (p < 0.0001). The smallest is at α = 36 and comprises ten genes (see Figure 7.23). 
The region is based around MAPK6, which was ranked sixth before the network-based 
adjustment, mainly due to a heterozygous missense variant in exome S0069 that has not 
been previously seen in the in-house exome database or in 1000 Genomes Project or EVS 
data (although not technically novel because it has a dbSNP identifier), a novel heterozygous 
 
Figure 7.23 – RGA output based on PINA HetRank rankings for 13 unsolved AOS exomes with common 
variants removed 
(A) RGA region found at α = 36. Final ranks are indicated in red. (B) Plot of region size (red) and 
empirical p-value (blue) by alpha value (same format as plot shown in Figure 7.18a) clearly shows 
that region size is nominally significant over almost the entire range. 




splice-site variant in S0338 and a novel heterozygous SNV in S0339 which is synonymous 
but nevertheless relatively highly ranked (MAPK6 has a pre-adjustment rank of 106 in that 
exome). These variants have a large influence on the high final ranks of the other nine genes 
in the region after adjustment. However, a GO enrichment test on these ten genes does not 
find any significant common functional annotation (data not shown) 
7.3.9.2 Alternative Parameters 
In section 7.3.7.1 we found that ABCA10 was ranked first without the network-based 
adjustment, and fifth after adjustment, despite the fact that the heterozygous frameshift 
deletions it contains in four exomes had been seen 15-24 times in the in-house exome 
database. This suggests that the weight parameter used for the ranking factor “number of 
observations in heterozygous form in the in-house exome database” could be too low (a 
weight of 1 has been used, compared to a weight of 8 for the corresponding homozygous 
observation count). Therefore HetRank analysis was repeated with this weight increased to 
4, and all other weights kept the same. (The homozygous in-house observation count still 
has a higher weight because if a variant can cause AOS in heterozygous form we would 
certainly not expect it to have been previously observed in homozygous form.) 
The top 20 genes, both with and without the network-based adjustment, are shown 
in Table 7.15. Considering the top 20 before the network-based adjustment, we see 
substantial overlap of eight genes with the corresponding top 20 using the original HetRank 
weight parameters (given in Table 7.9). Only one of the genes had a pre-adjustment rank of 
over 100 using the original parameters. This is encouraging because we expect a relatively 
small change in the input parameters to cause only a relatively small change in the rankings. 
ABCA10, which was ranked first using the original parameters, experiences a fall in pre-
adjustment rank to 270 – suggesting that the parameter change is appropriately down-
ranking genes whose variants would be good candidates for disease causality were it not for 
previous observations in the in-house exome database. We saw a similar drop in rank, from 
3 to 98, for EXO5 – which we also noted in section 7.3.7.1 contained a variant in three 
exomes that almost certainly does not cause AOS because of previous observations in the in-
house exome database. 
The top 20 genes after adjustment are also fairly consistent with the corresponding 
top 20 using the original parameters (given in Table 7.10): there is an overlap of 12 genes, 
including the same top-ranked gene, POLN. No gene in the top 20 had been ranked below 51 
using the original parameters. Again, this suggests a reasonable degree of robustness in the 
results to small changes in the input parameters. ABCA10’s post-adjustment rank is now 377, 




having been ranked fifth using the original parameters, suggesting that the parameter change 
is effective. 
Again we can consider common functional annotation or RGA results to establish 
whether the new results suggest an underlying disease mechanism for AOS. 
A GO enrichment test on the top 20 genes finds no significant biological process 
annotation (data not shown). However, using the top 250 genes we find: “regulation of 
membrane potential” (16 genes; adjP = 0.0004) and its child term “regulation of excitatory 
postsynaptic membrane potential” (seven genes; adjP = 0.0004); “nervous system 
development” (51 genes; adjP = 0.0004), and “cell adhesion” (34 genes; adjP = 0.0005). 
Encouragingly, these are highly consistent with the enriched function that was found in the 
top 250 genes using the original parameters (section 7.3.7.1), as well as overlapping with the 
Table 7.15 – Top 20 genes ranked by HetRank, with alternative input parameters, before and after 
network adjustment using PINA, based on 13 unsolved AOS exomes 
“Prev. weights rank” = corresponding rank assigned to gene when HetRank analysis was performed 
using the original parameters (top 20 ranked genes without network adjustment are in Table 7.9; top 
20 genes after network adjustment are in Table 7.10); “Pre-net.” = rank assigned to gene without 
network adjustment. 











1 NINL 4  1 POLN 26 1 
2 ZDHHC13 2  2 SH2D1B 824 4 
3 RGPD3 10  3 KIF17 191 3 
4 CNTNAP3B 19  4 HGFAC 1,061 6 
5 PRB1 39  5 MUC4 1,112 19 
6 ANKRD36 31  6 LY9 129 21 
7 CCDC144NL 11  7 DBH 1,052 8 
8 AQR 27  8 LPA 50 7 
9 AGAP6 12  9 ZNF516 869 48 
10 KRTAP10-3 23  10 SOX7 43 20 
11 GJB2 9  11 CINP 1,833 13 
12 VCX 8  12 SCN4A 1,310 47 
13 ZFHX3 83  13 ADCY2 6,868 15 
14 SIPA1L3 132  14 ZNRF4 114 29 
15 ABCC1 24  15 RNF152 4,101 36 
16 ZNF782 30  16 CAV3 2,849 23 
17 ATN1 33  17 FCGR3A 501 2 
18 BMP2K 76  18 CD244 8,265 24 
19 CCDC40 70  19 AGAP1 190 51 
20 AHCTF1 35  20 MST1 31 17 




enriched function identified in CPDBconf95 and Multinet results (section 7.3.8) and PINA 
results when common variants were removed (section 7.3.9.1). 
When RGA is performed using alpha in the range 1 ≤ α ≤ 250, the most significant 
region is found at α = 18 and comprises the three genes CD244, LY9 and SH2D1B (p < 
0.0001; see Figure 7.24). This same region was previously also found by RGA based on the 
HetRank results with the original parameters (see Figure 7.18b, α = 24). The next-most 
significant region occurs at α = 205 and comprises 15 genes (p = 0.0002; see Figure 7.24). 
Interestingly, this region contains the four genes that were found in the significant region at 
α = 61 using the original parameters (Figure 7.18b) but also has substantial overlap with the 
optimal subnetworks identified by BioGranat-IG in PINA_d50 (KIF17, LPA, LRP2, 
MAPK8IP1 and MAP3K11 form a key part of the region in Figure 7.7, for example). While 
these results therefore appear promising, they do not point towards a known shared function 
that could explain AOS. An enrichment test on these 15 genes finds no significant GO 
biological process annotation. The most significantly enriched terms – including “JNK 
cascade” (MAPK8IP1 and MAP3K11), “negative regulation of response to stimulus” (four 
genes), “anatomical structure morphogenesis” (six genes) and “nervous system 
development” (six genes) – all have a multiple-test-adjusted p-value of 0.2387. However, 
given that these terms relate to the broadly AOS-relevant signalling and developmental 
processes, and the fact that these results to some extent support what we found using 
BioGranat-IG, these genes may be worth studying further. 
7.4 Conclusions 
7.4.1 Findings from Network Analysis Regarding the AOS Disease Mechanism 
AOS is a rare genetic disorder for which substantial locus heterogeneity makes it 
difficult to identify causal genes. We have used several network-based methods to study 
AOS whole exome sequencing data in light of this heterogeneity, including both candidate-
gene and hypothesis-free (exome-wide) approaches. 
Our results highlight sequence variants in several genes and subnetworks that could 
make good candidates for further study. For example: 
 In section 7.3.1 the simple neighbourhood search around the known AOS gene 
ARHGAP31 in the Multinet and PINAmin2 networks identified several genes of 
potentially relevant function (such as ITSN1, KALRN, MAP3K11, SOS1 and 
TIAM1) carrying rare functional variants. 





Figure 7.24 – RGA output based on PINA HetRank rankings, using alternative input parameters, for 13 
unsolved AOS exomes 
(A) RGA regions found at α = 98 and α = 205. Blue nodes indicate genes which were previously 
identified by BioGranat-IG in PINA_d50 (see Figure 7.7); yellow nodes indicate genes which were 
previously found in the RGA regions based on HetRank results using the original parameters (see 
Figure 7.18b). Final ranks are indicated in red. (B) Plot of region size (red) and empirical p-value 
(blue) by alpha value (same format as plot shown in Figure 7.18a) shows that region size is nominally 
significant for several ranges of alpha thresholds. 




 BioGranat-IG analysis in PINA_d50 identified a small network region which 
comprised genes containing post-filtering variants for all of the unsolved AOS 
cases, was annotated by KGGSeq as significantly likely to contain a disease-
causing variant, and was implicated in biological functions of potential relevance 
(see Figure 7.7). Genes in this region, notably LRP2 and MAP3K11 were 
subsequently found by BioGranat-IG in other networks including the high-
confidence PINAmin2_d50 (see section 7.3.5.1). 
 HetRank results were more difficult to interpret but results from the PINAmin2-
adjusted rankings (in section 7.3.8) were of potential functional relevance, and in 
particular results from the PINA-adjusted rankings using the revised weighting 
parameters (in section 7.3.9.2) supported some of the results found by the other 
analyses. 
It should be noted that while the existence of relevant functional annotation (such as 
enrichment for GO biological process terms) has been used to evaluate the results of the 
analyses presented here, our knowledge of gene and protein function across the genome is 
incomplete and constantly evolving. Therefore some of the other genes and network regions 
highlighted by our analyses could prove to harbour AOS-causing variants, perhaps leading 
to new functional insights. 
Selection of genes and variants to be investigated further will be guided by 
geneticists with expertise in the study of AOS. The initial task will be to confirm the validity 
of the variants identified in these AOS-affected individuals by Sanger sequencing. 
Subsequently genes of interest can be examined in additional AOS cases that do not contain 
variants in known AOS genes, by Sanger sequencing or targeted resequencing depending on 
the number of samples and genes considered. A cohort of ~45 independent AOS-affected 
families and >50 sporadic cases is available at KCL for this purpose. Finally, genes for 
which multiple variants are found in the screening cohort could be selected for functional 
experiments. This could include study of expression levels in mutagenised versus wild-type 
cell lines, or gene-specific experiments in cell lines grown from AOS patient biopsies. 
Of course if it were felt that the assumptions used in these analyses did not 
accurately reflect the current understanding of AOS genetics, the analyses could be repeated 
using different parameters. 
It is important to recognise several limitations of the analyses performed. As alluded 
to earlier in the discussion of BioGranat-IG results (section 7.3.4), the incomplete nature of 
existing interaction networks could limit the discovery of new functional pathways 
underlying AOS. In addition, even for genes that are represented in the networks used, 




limited whole exome sequencing coverage for some of the exomes (see Table 7.1) could 
result in insufficient power to detect AOS-causing sequence variants. This is especially 
relevant for the pair of related AOS cases (S0039 and S0301) in which only shared sequence 
variants were considered. In order to reduce the risk of missing a causal variant due to 
incomplete sequencing coverage in one of these individuals, an alternative approach could 
be to perform the analyses using the union (rather than the intersection) of variants identified 
in these cases (albeit with the disadvantage that this would introduce many confounding 
variants of no relevance to AOS). 
Filtering levels 2-5 require that variants’ zygosities match the expected mode of 
inheritance for each AOS case. Incorrect judgements about the mode of inheritance for each 
AOS case could therefore render these assumptions inappropriate, and a further source of 
error could be incorrect zygosity-calling for sequenced variants (zygosity being assigned by 
likelihood based on the observed reads). Note also that although no filtering was undertaken 
for the HetRank analyses presented here, zygosity was used as a ranking criterion. 
AOS is a rare disease with severe phenotype, and as such is expected to be caused 
by a rare highly-penetrant variant. As with any whole exome sequencing study for such a 
disease, the number of variants per exome remaining after filtering could be reduced by 
increasing the number of unaffected exomes used for comparison. This would be of 
particular benefit for the simple neighbourhood search and BioGranat-IG analyses. 
Therefore, it may be informative to repeat the analyses at a future time when a larger in-
house exome database is available for filtering. 
Finally, AOS is known to have substantial clinical variability (Snape et al. 2009), 
and phenotypic differences were observed in the cases studied here (see Table 7.1). While 
the analyses presented here are consistent with a hypothesis that genetic heterogeneity could 
to some extent explain this phenotypic heterogeneity (indeed, they test previous assertions 
that interaction networks could be used to elucidate this relationship (Oti and Brunner 
2007)), we have not made use of any specific phenotype information. Future analyses might 
therefore make use of tools that perform phenotype-aware prioritisation of whole exome 
sequencing variants, such as PHIVE (PHenotypic Interpretation of Variants in Exomes; 
Robinson et al. 2013). 
7.4.2 Relative Merits of the Network-Based Methods 
We have employed several network-based methods to address the problem of 
genetic heterogeneity in a rare monogenic disease. Due to its rarity and established locus 
heterogeneity, AOS is a good match to the genetic model assumed by BioGranat-IG and 




HetRank; the fact that there are several known causal genes as well as many unsolved cases 
makes it an ideal disease for the application and comparison of these methods. 
The existence of known causal AOS genes makes the simple neighbourhood search 
around these genes a natural starting point. It is effectively a candidate-gene approach; for 
any promising variants found by this search it should (in theory) be relatively easy to 
establish a functional link to an existing AOS disease mechanism due to network proximity. 
For the same reason it is encouraging when the subsequent hypothesis-free approaches 
identify some of the same genes (e.g. as we saw with MAP3K11 here; see section 7.3.4.1). 
In general, however, overlap between the results obtained using different analysis 
methods should not be unquestioningly taken as confirmation that we have an interesting 
finding. This is because all of the methods will be predisposed to highlight genes containing 
rare non-synonymous variants in multiple AOS cases, such as those listed in Table 7.5. In 
addition, a degree of overlap between the results obtained using different networks might 
also be anticipated, since there is some degree of overlap between the networks themselves 
(indeed, four of the five networks used are partially or entirely based on PPIs from common 
underlying databases) (see chapter 2 and Table 2.3 in particular). In one sense, then, it is 
reassuring that genes such as LRP2 and NINL occur in numerous optimal and near-optimal 
BioGranat-IG subnetworks and are highly ranked by HetRank across multiple networks; 
however, these methods can only prioritise genes for further study and a true role in the AOS 
disease mechanism can only be established by additional investigations that are independent 
of the interaction networks. 
As discussed in section 7.3.5.1, limited network coverage coupled with the 
abundance of sequence variants identified by whole exome sequencing tends to cause 
BioGranat-IG’s heuristic (minimum distance and multi-minimum distance) searches to 
report optimal subnetworks containing many false positive findings. This is due to these 
searches’ mandate to continue growing subnetworks until variants have been found for all 
exomes (or as many exomes as possible). Perhaps the most useful results from BioGranat-IG 
are therefore generated by the exact triplet and quadruplet searches, which can identify 
relatively small subnetworks with a concentration of post-filtering variants in different 
exomes. 
It is disappointing that in none of the networks were the true causal genes found in 
optimal BioGranat-IG triplets and quadruplets at filtering levels 1 and 2 (where variants in 
the six solved AOS exomes were filtered no differently from the unsolved cases), and 
particularly so at level 3 (where the input gene lists for the six solved cases were fully 




filtered to include only the causal genes).
*
 In networks where the known AOS genes are 
present, we do not find them in the optimal triplets and quadruplets because more 
concentrated enrichment of post-filtering variants occurs in other parts of the networks. An 
alternative way to look at this is that because the genetic heterogeneity is so great (at least in 
the AOS cases studied here), and the known AOS genes are insufficiently proximal in the 
networks, BioGranat-IG is underpowered to recover these genes. 
BioGranat-IG analyses were performed using hub-free versions of the networks 
because BioGranat-IG results tend to be biased by the presence of hub genes. Hub-removal 
resulted in the loss of known AOS genes from several networks (as listed in Table 7.7). This 
meant firstly that BioGranat-IG was unable to recover these genes for the solved AOS cases 
at filtering levels 1-3, but secondly that the searches at filtering level 3 in particular were 
unable to be implicitly weighted towards these genes by the variants in solved cases, in order 
to propose potential extensions of known AOS disease pathways. 
Further, network hub removal as used here removes highly-connected genes using 
an arbitrary degree threshold. This can have a considerable impact on the optimal 
subnetworks found by BioGranat-IG. For example, LRP2 was identified as a key gene in 
several subnetworks in PINA_d50 (see for example Figure 7.7) but has a degree of 49 in the 
full PINA network. If the threshold for hub removal had been any lower than 50 as used 
here, this gene would have been removed. A more sophisticated strategy for hub removal is 
suggested in the Concluding Discussion (section 9.2.3). 
HetRank analysis achieved mixed success. It was able to rank NOTCH1 seventh 
when solved AOS cases were included (using PINA for the network-based rank adjustment; 
see Table 7.12); this largely resulted from true AOS-causing variants, in the gene itself for 
two of the solved cases and in its direct neighbour RBPJ for a third. We also found some 
promising results using the unsolved AOS cases only, as described in the previous section. 
In section 7.3.9.2 we saw that by careful consideration of initial HetRank results, the 
weighting parameters could be adjusted to more accurately reflect expectations about the 
properties of AOS-causing variants, resulting in a more plausible final ranking. 
On the other hand, however, while HetRank was able to prioritise NOTCH1 it did 
not find its neighbour RBPJ, confirming (as we found using simulated exome data in chapter 
5) that its performance is limited at high levels of genetic heterogeneity. HetRank results 
were often difficult to interpret and a comparison of results across multiple networks 
                                                     
*
 Note however that at filtering level 3: NOTCH1 was found in a near-optimal triplet in 
PINAmin2_d50; NOTCH1 and RBPJ were found in near-optimal quadruplets in PINAmin2_d50 and 
CPDBconf95_d50; and DOCK6 and RBPJ were found in near-optimal quadruplets in 
COXPRES30_d50. 




suggests that the method relies too heavily on indirect evidence (via interaction data) and 
insufficiently on direct evidence (via the variants contained in the genes themselves) for 
highly-ranked genes (see section 7.3.8). HetRank’s design takes into account node 
connectivity when adjusting gene ranks, but as illustrated by Figure 7.17 the approach needs 
to be refined in order to adequately deal with the problem caused by hub genes. Likewise as 
discussed in section 7.3.7.1 subsequent iterations of the tool should address the fact that 
genes not represented in the network are at a considerable disadvantage in the final rankings. 
The fact that the results in section 7.3.9.1 differ markedly from those found earlier in the 
chapter (see Table 7.14) also suggest that the many variants unlikely to be of relevance to 
the disease in question (in the case of AOS, common variants) are too influential over the 
final rankings. For ranking, rather than filtering, of variants to be a viable analysis method 
this problem will also need to be addressed. 
Given some of these difficulties with the application of HetRank, in particular the 
somewhat volatile effect of the network-based rank adjustment, there are immediate 
alternative approaches that could be considered to make use of the HetRank framework in a 
more tractable manner. For example, HetRank could be used without a network-based 
adjustment to produce a final gene ranking that reflects only the direct evidence for disease-
causality across all exomes in the study; RGA could then be used to address locus 
heterogeneity by identifying small network regions enriched for highly-ranked genes. 
Alternatively, HetRank could be used only for the purpose of ranking genes within 
individual exomes; BioGranat-IG analysis could then be performed using the genes 
exceeding some fixed threshold as the candidate genes for each exome. 
The network-based analyses presented in this chapter have proposed several novel 
disease pathways that can be investigated further. However, it is clear that none of these 
methods can fully replace the knowledge and experience of a skilled geneticist who has 
studied the disease closely. The tools are thus limited to prioritising variants and genes for a 
genetic researcher, and cannot directly demonstrate disease involvement. However, given 





8 Analysis of Familial Crohn’s Disease Exome 
Sequence Data using Network Methods 
8.1 Introduction 
8.1.1 Background 
Crohn’s disease (CD) is one of the two main types of inflammatory bowel disease 
(IBD), the other being ulcerative colitis (UC). IBD is a group of disorders characterised by 
relapsing chronic inflammation of the gastrointestinal tract and which can result in 
diarrhoea, bleeding, weight loss, abdominal pain and fatigue (Mathew 2008; Matricon et al. 
2010). CD is distinguished from UC by the location and nature of inflammation. While CD 
inflammation usually occurs in the ileum and colon, it can affect any part of the 
gastrointestinal tract (unlike UC, where it is confined to the colon and rectum); it is also 
transmural (whereas UC is limited to the intestinal lining) (Mathew 2008; Matricon et al. 
2010). CD is a relatively common disorder; prevalence estimates range from 26 to 375 cases 
per 100,000 people in populations of European ancestry (Loftus 2004; Mathew 2008). 
CD is a complex disease for which genetic, environmental and lifestyle factors all 
contribute to disease risk. The microbial environment within the gut is thought to play a 
major role in CD pathogenesis, while smoking is an example of a lifestyle factor that can 
increase disease susceptibility and severity (Matricon et al. 2010; Khor et al. 2011). 
However, among complex diseases CD appears to have a relatively strong genetic 
component (Mathew 2008; Khor et al. 2011; Liu and Anderson 2014; Zhang and Li 2014). 
This is implied by an estimated concordance rate of around 30.3% in monozygotic twins 
(Brant 2011) and a sibling relative risk ratio in the range 15-42 (Halme et al. 2006). 
Much progress has been made in understanding the genetic basis of CD, with the 
first susceptibility gene, NOD2, being identified by linkage-informed candidate-gene 
approaches in 2001 (Hugot et al. 2001; Ogura et al. 2001). Since then, the advent of 
genome-wide association studies (GWAS) has heralded a rapid increase in the number of 
genomic loci associated with CD risk, with a 2010 meta-analysis bringing this number to 71 
(Franke et al. 2010). In 2012, Jostins et al. reported a GWAS meta-analysis that combined 
CD and UC cases and brought the total number of loci implicated in IBD to 163. A 
combined IBD association test was performed, along with separate tests for CD and UC; in 
total 30 CD-specific associated loci were found, and 76 IBD-associated loci also achieved 




genome-wide significance (p < 5×10
-8
) in the CD test (Jostins et al. 2012). The associated 
loci are estimated to explain 13.6% of disease variance in CD, with the biggest contribution 
coming from variants in NOD2, followed by IL23R (Jostins et al. 2012). 
Despite the number of associated loci, the molecular mechanisms underlying CD are 
still not fully understood, although several functional pathways are thought to play a role in 
pathogenesis. Firstly, NOD2 encodes a protein which plays an important role in the innate 
immune system by recognising bacterial molecules and activating NF-κB, a rapid-acting 
primary transcription factor that stimulates the immune response. One model for CD 
suggests that loss-of-function mutations in NOD2 can impair this immune response leading 
to increased bacterial survival (Mathew 2008). (Although some CD-associated variants in 
NOD2 appear not to affect NF-κB activation, implying that impairment of other functions of 
the NOD2 protein can also influence CD susceptibility (Rivas et al. 2011)). Secondly, the 
IL23 pathway is thought to be a key process influencing CD through its role in mucosal 
inflammation. Variants in the receptor gene IL23R have been found to be protective against 
CD, while others appear to elevate risk (Duerr et al. 2006; Rivas et al. 2011). The IL23 
cytokine activates proinflammatory Th17 cells, and several proteins involved in the 
downstream signalling pathway are also encoded by genes associated with CD (Brand 
2009). Thirdly, associated variants in autophagy-related genes (ATG16L1 (Hampe et al. 
2007) and IRGM (Parkes et al. 2007)) suggest a role for this process, possibly by impairing 
its ability to remove intracellular microbes (and note also that autophagy can be activated by 
NOD2, raising the potential of interactions with another CD pathway) (Khor et al. 2011). 
Many of the associated loci reported in the recent GWAS meta-analysis supported 
these disease models, while others suggested that there are additional mechanisms of CD 
biology yet to be elucidated (Jostins et al. 2012). Interestingly, several network-based 
methods were employed in this study to explore potential IBD pathways: GRAIL and 
DAPPLE were used to prioritise genes around associated loci (using text-mined interactions 
and protein-protein interactions respectively; see introduction section 1.4.6), while weighted 
gene co-expression network analysis was used to highlight associated modules (see section 
1.4.4). This is encouraging because it suggests that in the case of IBD (and CD in particular) 
interaction networks can help to bridge the gap between hypothesis-free genetic observations 
and a full understanding of the molecular processes that result in the clinical phenotype. 
As a complex disease, most cases of CD are expected to be caused by a combination 
of genetic, environmental and lifestyle factors, and most genetic risk factors have small 
effect size (Jostins et al. 2012). This multifactorial nature of CD means that despite the 
relatively increased disease risk carried by relatives of CD patients, strong patterns of 
recurrence within families are atypical. For families where such patterns occur it is therefore 




reasonable to consider alternative models for the genetic basis of CD; one possibility is that 
for some such families one or a small number of inherited rare and highly-penetrant variants 
could be responsible for most of the disease risk, making these cases effectively monogenic 
or oligogenic forms of CD. There is precedent for this model of disease because several 
other complex traits, such as diabetes and hypertension, are known to have rare monogenic 
forms (Peltonen et al. 2006). Interestingly, there are also several monogenic forms of very 
early-onset IBD (Uhlig et al. 2014). Although these disorders generally present in infancy 
and the clinical features are not identical to adult-onset CD, it nonetheless seems feasible 
that monogenic forms of adult-onset CD could exist and give rise to familial recurrence. 
Using whole exome sequence data from 25 pedigrees exhibiting recurrent CD, this 
chapter will test the hypothesis that families with multiple affected members are more likely 
to carry one, or very few, highly-penetrant risk variants. As will be seen, no single gene is 
clearly implicated in these familial cases of CD and so network methods will be employed to 
examine the possibility that familial CD has a monogenic or oligogenic basis with genetic 
heterogeneity. 
8.1.2 Analysis Strategy 
Twenty-four pedigrees in which three or more individuals have CD, and one 
pedigree in which two individuals have CD, were recruited for study at King’s College 
London (KCL) or at the Institute of Clinical Molecular Biology (ICMB) at the University of 
Kiel, Germany. For each pedigree between two and four affected individuals were whole 
exome sequenced (67 individuals in total). Under the assumption that instances of CD within 
each family are caused by the same variant(s), we sought candidate disease-causing variants 
shared by all sequenced exomes in a pedigree. Subsequently, these shared variants will be 
referred to as variants carried by a pedigree. 
Three independent network methods were applied to the exome data to propose 
familial CD genes. All three methods are hypothesis-free in the sense that they use no prior 
knowledge of CD aetiology. Firstly the BioGranat-IG tool developed in chapter 4 was used 
to search for subnetworks in which all or most pedigrees carry a shared post-filtering variant, 
testing the possibility that these CD cases are monogenic but subject to locus heterogeneity 
(see Figure 8.1a). 
To test whether an oligogenic basis for CD could be established in any of the 
pedigrees by identifying multiple post-filtering variants in functionally-related genes, a 
constrained version of Region Growing Analysis (RGA; described fully in chapter 6, section 
6.2) was employed separately for each pedigree (see Figure 8.1b). This method will be 
referred to as within-pedigree RGA. The relevance of any regions found was examined by 




testing for statistically significant clustering of regions within the network (making the broad 
assumption that there will be an overlap between a topological module in the network and a 
so-called CD disease module (Barabasi et al. 2011)). 
For the third method, no assumptions are made about the number of causal variants 
that we expect to identify for each pedigree. Instead we use RGA to test for network regions 
that are enriched for post-filtering variants in any pedigree (see Figure 8.1c). This will be 
referred to as across-pedigree RGA and is a more typical use of the RGA tool, whereby any 
 
Figure 8.1 – Network-based methods used to analyse CD exome data 
(a) BioGranat-IG: different-coloured tokens signify post-filtering variants in different pedigrees. The 
tool seeks a small connected set of genes in which all or most pedigrees carry a variant. (b) Within-
pedigree RGA: connected sets of genes containing post-filtering variants in the same pedigree (tokens 
of the same colour) are sought. This method hypothesises that the variants in such genes could 
underlie an oligogenic form of familial CD. (c) Across-pedigree RGA: no assumptions are made 
about the number of variants expected to be observed in each pedigree; RGA is performed on a list of 
genes ranked by the number of pedigrees in which they carry a post-filtering variant. 




significantly large enriched network regions can be examined as candidate disease pathways 
(Lehne 2011). 
8.2 Methods 
8.2.1 Exome Data 
Whole exome sequencing was performed on 22 individuals with CD from 9 
pedigrees recruited at KCL, and 45 individuals with CD from 16 pedigrees recruited at 
ICMB, according to the procedure described in chapter 2, section 2.3. Pedigree structures, 
affection statuses and sequenced individuals are illustrated in Figure 8.2. 
In two of the pedigrees, one individual was affected with UC. In a small number of 
the pedigrees individuals affected or unaffected with CD displayed other inflammatory or 
immune-mediated phenotypes, such as asthma and psoriasis (data not shown). This 
additional phenotype data was not considered further in this study. 
Table 8.1 summarises the sequenced exomes for the 25 pedigrees. At 20× coverage, 
exome capture ranged from 63.8% to 92.6%, with only three of the 67 exomes falling below 
80%. This is generally considered to be a reasonable level of coverage for variant calling, 
although 90% or higher is desirable to maximise the power to accurately detect sequence 
variants (Mertes et al. 2011). 
338 unaffected control exomes (a subset of the exomes covered by the in-house 
exome database which will be referred to subsequently as non-CD control exomes) were also 
used in the analysis. These represent unrelated individuals of European ancestry sequenced 
as part of the KCL rare disease programme. As such they may include causal variants for a 
range of diseases other than CD. Since these diseases are clinically diverse the data are 
considered suitable for use as controls for variant filtering. These exomes will also contain 
known or as-yet-unidentified risk variants having small effects on susceptibility for the 
common complex form of CD. This is acceptable because we are specifically interested in 
high-penetrance variants with large effect in this study. 
8.2.2 Variant Filtering 
Since we are testing a mono/oligogenic disease model, all three analyses require a 
set of candidate causal variants for each pedigree. Firstly, it was assumed that within each 
pedigree one or a small number of identical-by-descent variants cause CD in all affected 
individuals. Therefore for each pedigree the set of variants shared by all sequenced CD cases 
was obtained. The number of variants for each pedigree is given in Table 8.1. Due to the





Figure 8.2 – Familial CD pedigree diagrams 
Affection status for CD and UC are indicated. 




varying number and relatedness of sequenced cases between pedigrees, there is a wide 
variation in the number of shared variants per pedigree, from 5,729 to 16,223. 
Subsequently, variants carried by each pedigree were filtered to exclude from 
consideration those less likely to cause a rare monogenic disease. Synonymous variants were 
excluded. No assumptions were made about the expected zygosity for causal variants. Since 
we expect causal variants to be rare and highly-penetrant, heterozygous variants were 
required to have alternative allele frequencies of <1% according to both 1000 Genomes 
Table 8.1 – Summary of sequencing for CD pedigrees 
“Min-” and “Max coverage (to 20×)” refer to minimum and maximum coverage across all sequenced 






















(in # genes) 
KCL pedigrees: 
13 2 90.8% 91.2% 11,122 53 (53) 191 (175) 
23 2 81.0% 81.2% 14,983 115 (107) 410 (373) 
31 3 80.2% 83.0% 8,932 34 (34) 99 (95) 
32 4 63.8% 83.9% 5,729 7 (7) 23 (22) 
41 2 80.4% 83.9% 11,173 47 (47) 152 (142) 
48 2 81.5% 83.0% 10,715 35 (34) 126 (116) 
64 2 80.4% 81.6% 11,833 54 (54) 205 (188) 
90 3 81.9% 83.0% 8,754 36 (36) 118 (110) 
107 2 81.2% 82.3% 10,748 30 (30) 118 (108) 
ICMB pedigrees: 
263 3 79.5% 92.0% 10,921 53 (53) 197 (175) 
265 2 90.3% 91.3% 15,208 138 (131) 360 (326) 
286 2 87.9% 91.2% 11,950 49 (49) 168 (156) 
312 3 90.2% 92.3% 8,767 36 (35) 123 (115) 
867 3 82.3% 91.7% 9,899 60 (60) 165 (160) 
879 3 92.5% 92.6% 12,836 102 (101) 290 (265) 
888 3 90.7% 91.9% 12,701 106 (98) 309 (272) 
903 3 89.9% 91.6% 10,498 70 (68) 201 (176) 
1066 3 85.5% 92.0% 15,439 139 (129) 428 (382) 
1068 3 66.6% 90.6% 10,260 59 (59) 214 (201) 
1699 3 86.9% 92.5% 12,576 84 (84) 259 (227) 
1709 3 89.4% 92.5% 12,380 105 (104) 273 (248) 
12320 2 89.6% 90.1% 16,223 173 (170) 470 (428) 
12420 2 90.5% 91.9% 15,520 126 (120) 406 (366) 
12679 3 82.5% 86.3% 10,473 64 (64) 200 (182) 
53185 4 84.3% 92.6% 8,256 52 (50) 120 (112) 




Project and Exome Variant Server (EVS) annotation, and to have been observed fewer than 
ten times in heterozygous form (and never in homozygous form) in the in-house exome 
database (approximately 850 exomes in total). Homozygous variants were required to have 
alternative allele frequencies of <10% (corresponding to a genotype frequency <1%), and 
fewer than ten previous observations in homozygous form in the in-house exome database. 
Finally, variants were filtered at the gene level against the 338 non-CD control exomes in 
order to address the problem that large and highly-polymorphic genes are more likely to be 
falsely implicated by variant-filtering approaches (as discussed in section 1.3.5). Variants 
were excluded in any gene in which 20 or more non-CD control exomes, after being subject 
to the same filtering steps, carried a post-filtering variant. The number of variants per 
pedigree after filtering is given in Table 8.1, and ranges from 7 (all in different genes) to 173 
(in 170 unique genes). 
For within-pedigree RGA only, where subnetworks are identified in which the same 
pedigree carries two or more variants, filtering was relaxed to allow for the decreased 
probability that a member of a population carries two variants together. In this case, 
heterozygous variants were required to have alternative allele frequencies of <    (i.e. 
<10%) according to both 1000 Genomes Project and EVS annotation, and to have been 
observed fewer than 100 times in heterozygous form (and never in homozygous form) in the 
in-house exome database. Homozygous variants were required to have alternative allele 
frequencies of <    , and fewer than 100 previous observations in homozygous form in 
the in-house exome database. Variants were excluded in any gene in which 80 or more of the 
non-CD control exomes, after being subject to the same filtering steps, carried a post-
filtering variant (since                 ). Again, Table 8.1 gives the number of 
variants per pedigree after filtering, which ranges from 23 (in 22 unique genes) to 470 (in 
428 unique genes). 
We make the assumption to ignore any potential population structure differences 
between the British (KCL) and German (ICMB) pedigrees. This is because in general we are 
seeking to prioritise single variants that could cause CD, rather than to perform statistical 
association testing; a rare non-synonymous variant in a gene is assumed to be equally likely 
to have a pathogenic effect in both populations. It is possible therefore that since non-CD 
control exomes are predominantly drawn from a British population, gene-level filtering 
against controls could allow through variants in ICMB pedigrees in a small number of genes 
that would potentially have been excluded had the non-CD control exomes been drawn from 
a German population, leading to a few false positive findings in ICMB pedigrees. As will be 
seen in the results section 8.3.1, the use of a different sequencing platform for ICMB 
pedigrees relative to non-CD control exomes appears more likely to cause this problem. 




Finally note that known NOD2 risk variants were identified in several of the 
pedigrees, including two in pedigrees 13 and 12420 that pass the (non-relaxed) frequency-
filtering criteria described above (but were subsequently excluded because NOD2 is 
relatively highly polymorphic, containing post-filtering variants in 35 of the 338 non-CD 
control exomes). Since NOD2 is well-studied in the context of CD, and these variants are 
known to increase risk as part of a multifactorial mechanism (rather than being highly-
penetrant disease-causing variants), these pedigrees were not excluded from the network 
analysis. It is hypothesised that in these strongly familial cases there may be other rare 
highly-penetrant variants that are chiefly responsible for CD. 
Likewise, none of the pedigrees were screened for variants in genes known to cause 
very-early-onset IBD (Uhlig et al. 2014). This is because a different disease mechanism is 
expected to be responsible for adult-onset CD in these pedigrees. However, where relevant 
any very-early-onset IBD genes that are identified by our analyses will be noted. 
8.2.3 Interaction Networks 
Analyses were performed using several of the networks described in detail in 
chapter 2. These comprised three protein interaction networks (PINs; PINA_d50 and the two 
smaller but higher-confidence networks PINAmin2_d50 and CPDBconf95_d50), a co-
expression network (COXPRES30_d50) and a network integrating several types of 
interaction data (Multinet_d50). These are the hub-free versions of the networks because hub 
genes can be overrepresented in optimal BioGranat-IG subnetworks, and can reduce the 
power of RGA (Lehne 2011). 
To ensure consistency between network node labels and exome gene symbols, a list 
of gene symbol synonyms was obtained from the HUGO Gene Nomenclature Committee 
(Gray et al. 2013). An R programme was implemented to replace the node label with a 
synonymous symbol for any network node whose label did not map to any gene in the 
exome data, but for which an unambiguous mapping existed for one of the synonyms. 
However, in practice no changes were necessary for any of the networks. 
8.2.4 BioGranat-IG Analysis 
BioGranat-IG analysis, as detailed in chapter 4, was performed for all five (hub-free) 
networks using gene lists derived from the post-filtering variants carried by each pedigree. 
In chapter 7, discussion of the optimal subnetworks for Adams-Oliver syndrome 
(AOS) highlighted that BioGranat-IG’s heuristic minimum distance and multi-minimum 
distance searches frequently introduce false positive findings into optimal subnetworks, due 
to their tendency to keep extending a subnetwork until it contains variants for as many 




exomes as possible. For CD, then, only the (exact) triplet and quadruplet searches are 
undertaken, which examine how many of the pedigrees could potentially have CD due to 
three or four interacting genes. The searches were repeated for each network using “optimal” 
(size flexibility = 0; number flexibility = 0) and “near-optimal” (size flexibility = 1; number 
flexibility = 1) parameter sets. Where several overlapping optimal triplets or quadruplets are 
identified, they can be considered separately or merged into a region. These searches should 
therefore highlight network regions enriched for post-filtering variants that cover as many 
pedigrees as possible. 
To prioritise alternative optimal subnetworks, KGGSeq-prioritisation is used, as 
described fully in chapter 6, section 6.1. This method tests whether the variants in a given 
subnetwork are more likely to include one which causes a monogenic disease, as quantified 
by the KGGSeq variant effect prediction tool (Li et al. 2012), than a set of variants chosen 
uniformly at random from the same pedigrees without regard to network connections 
between genes. 
8.2.5 Within-Pedigree RGA 
To test each pedigree for multiple variants in connected genes, which might indicate 
an oligogenic disease mechanism, RGA (described fully in chapter 6, section 6.2) was 
performed separately for each pedigree. RGA is designed to identify connected regions of a 
network that are enriched for highly-ranked genes from a ranked gene list provided as input. 
However, RGA can also be used in “binary” form by providing an input gene set (without 
ranks) and having RGA report connected regions of a network made up of genes in this set 
(or optionally regions where genes in the set are connected via “jumps” of up to one node). 
The advantage of this approach is that RGA’s degree-constrained network permutation test 
can be used to estimate how likely it is that the largest identified region could have occurred 
by chance. 
For each pedigree, the gene set used as input comprises all genes containing post-
filtering variants for that pedigree (using the relaxed filtering criteria described in section 
8.2.2 to allow for the decreased probability that a member of a population carries two 
variants together). The binary form of RGA is performed using all five (hub-free) networks. 
Jumps are not permitted. 10,000 degree-constrained permutations of each network are used 
to establish whether a significantly large region is identified for any pedigree, with RGA’s 
default standard deviation of 5.0 nodes used for label-shuffling. 
For each network tested, the regions found are compared across all pedigrees. Of 
particular interest is whether the largest regions found in different pedigrees (whether or not 
they are significantly large) cluster in one or more parts of the network. If so, this could 




suggest that the genes in that part of the network are part of a functional module of relevance 
to CD. 
To quantify the evidence for clustering, only regions found within the large 
component of each network are considered. For the network G, suppose that pedigree i has 
post-filtering variants in ni genes in the large component of G, and that the largest region 
found using RGA contains mi genes. If pedigree i is found to have li > 1 such regions then all 
li × mi genes are included together for pedigree i for the purposes of measuring clustering. 
The observed degree of clustering in network G is measured using two methods (illustrated 
in Figure 8.3). Firstly, the average distance between largest regions is calculated, where the 
average is taken across all pairs of pedigrees for which regions were identified. Here, the 
distance between regions for pedigrees i and j is the length of the shortest path connecting 
any of the li × mi genes in pedigree i’s largest regions in G to any of the lj × mj genes in 
pedigree j’s largest regions in G. The distance is zero for pedigrees with overlapping largest 
regions. Secondly, since this first method uses regions identified in all pedigrees and we are 
also interested in clustering among a subset of pedigrees, the number of pairs of pedigrees 
having overlapping or adjacent regions (i.e. a distance ≤ 1) is counted. 
 
Figure 8.3 – Region clustering measures 
Largest regions are illustrated for three pedigrees G, R and B. Pedigree G has a largest region of four 
genes (mG = 4; green nodes); pedigree R has a largest region of two genes (mR = 3; red nodes); 
pedigree B has a largest region of two genes and there are two such regions (mB = 2, lB = 2; blue 
nodes). For the first clustering measure, the distances between the regions are calculated as: G to R 
has distance 5 (indicated by orange dotted line); G to B has distance 1 (grey dotted line); R to B has 
distance 2 (purple dotted line). The average distance is (5 + 1 + 2)/3 = 2.67. For the second clustering 
measure, of the three pairs of pedigrees (G+R, G+B and R+B) only one has overlapping or adjacent 
regions (G+B; grey dotted line). 




In order to test the null hypothesis that the observed degree of clustering could occur 
by chance due to the number and size of regions compared, the degree of clustering was also 
determined in 10,000 sets of randomly-generated regions (having the same number and size 
as the observed regions for each pedigree). To avoid potential bias due to topological 
properties (such as node degree or cliques) that could predispose certain parts of the network 
to contain regions, these regions were generated using an acceptance-rejection approach that 
emulates RGA as follows. For pedigree i, ni genes were uniformly randomly selected from 
the large component of G. The largest regions formed by these nodes were identified. If 
these regions had size mi, and ≥ li such regions were found, then these were accepted as a 
sampled observation (with li of the regions chosen at random in cases where > li were 
found). Otherwise the regions were rejected. This process was repeated until 10,000 sampled 
observations had been accumulated for each pedigree. A p-value for the test that clustering 
occurs by chance was generated as the fraction of the 10,000 sampled sets of regions that 
exhibited an equal or greater degree of clustering (using the two measures described 
previously). 
Randomly-generated regions were produced using a custom bundle in BioGranat 
(see chapter 2); subsequent analysis was performed in R (R Development Core Team 2013). 
8.2.6 Across-Pedigree RGA 
Finally, across-pedigree RGA was performed to identify network regions enriched 
for post-filtering variants in any pedigree, with no assumptions made about the underlying 
genetic architecture for each pedigree. This is done by ranking genes according to the 
number pedigrees in which they contain post-filtering variants, and using RGA to identify 
regions enriched for highly-ranked genes. 
Ranked gene lists were obtained using two methods. Firstly, genes were ranked 
using a simple count. For each gene the number of pedigrees carrying a post-filtering variant 
was established (filtering is described in section 8.2.2; note that the relaxed criteria for 
variant filtering, as used for within-pedigree RGA, were not used here). Genes were ranked 
according to this count, and any gene in which 20 or more of the 338 non-CD control 
exomes carried a post-filtering variant was excluded from the list (meaning it is unranked 
and will not be a member node for any region; see chapter 6, section 6.2). For reasons that 
will be described in the results section 8.3.1 below, it was also necessary to exclude the four 
top-ranked genes. 




Secondly, since the simple count ranking has limited ability to discriminate between 
genes (all but 16 genes contain post-filtering variants in zero, one or two pedigrees
*
), a more 
granular ranking was obtained using a case-control approach. Filtering was performed as 
described in section 8.2.2, except that all genes were retained (genes in which 20 or more of 
the 338 non-CD control exomes carried a post-filtering variant were not excluded). Genes 
were subsequently ranked according to the degree to which the number of pedigrees carrying 
a post-filtering variant exceeded the number that would be expected assuming that the 
distribution of post-filtering variants among genes in the 338 non-CD control exomes is 
typical. Thus: 
 Genes in which post-filtering variants were found only in the case pedigrees and 
not in the non-CD controls were ranked first, ordered by decreasing number of 
pedigrees carrying a variant. 
 Genes in which both case pedigrees and non-CD control exomes carried a post-
filtering variant were then ranked according to: 
     
   
  
where Og gives the number of pedigrees in which gene g carries a post-filtering 
variant, and: 
      
      
      
 
gives the expected number. Here Ng is the number of the 338 non-CD controls 
carrying a post-filtering variant in gene g and the sums are taken across the set of 
genes H which contain post-filtering variants in both the case pedigrees and non-
CD control exomes (the ratio of sums ensures the correct total number of 
expected observations). 
  The same four genes were excluded for case-control ranking as for the simple 
count ranking. (Note that as discussed in section 8.2.2 above, we are ignoring any potential 
population structure differences between German [ICMB] pedigrees and British [KCL] 
pedigrees and non-CD control exomes. For this analysis specifically, population structure 
and sequencing platform differences could lead to a subtle skewing of the rankings because 
                                                     
*
 This drops to 12 genes after removing the four top-ranked genes. 




the expected number of pedigrees carrying a post-filtering variant is derived from KCL 
exomes only, while the observed numbers are from KCL and ICMB pedigrees.) 
RGA is performed for both ranking methods using all five (hub-free) networks, with 
and without jumps being permitted. For the simple count ranking where genes are assigned 
relatively few distinct ranks, all combinations of α and β thresholds are tested. For the case-
control ranking, all thresholds in the range 1 ≤ α ≤ 1,000 are tested, with β = α. 10,000 
degree-constrained permutations of each network are used to establish whether a 
significantly large region is identified for any pedigree, with RGA’s default standard 
deviation of 5.0 nodes used for label-shuffling. 
8.2.7 Tools Used for Analysis of Results 
As described in full in section 7.2.7 in the previous chapter: network diagrams are 
generated using Cytoscape (Smoot et al. 2011); exploration of existing functional annotation 
for gene sets is performed using Gene Ontology (GO) biological process term enrichment 
analysis using WebGestalt (Wang et al. 2013a); and unless otherwise referenced, summaries 
of individual gene function are obtained from GeneCards (www.genecards.org, Stelzer et al. 
2011). 
In addition, to assess previous evidence for involvement in CD, results are compared 
against the list of 300 prioritised genes identified by the IBD GWAS meta-analysis by 
Jostins et al. (Jostins et al. 2012). It is important to recognise that absence from this list does 
not exclude genes from consideration as causal for familial CD, for several reasons: the 
meta-analysis focused on sporadic (rather than familial) cases of IBD which we are 
assuming result from a different disease mechanism, as discussed in section 8.1.1; the list of 
300 genes may omit the true disease-relevant genes at some IBD-associated loci due to 
assumptions made by the underlying prioritisation methods; and the 163 loci reported by 
Jostins et al. do not comprise a definitive list (efforts are ongoing to identify further IBD-
associated loci). However, we might expect some overlap between the functional pathways 
involved in different forms of CD, and thus the presence on this list of a putative familial 
CD gene could be considered supporting evidence for disease involvement. 
Results will also be compared against relevant curated pathways downloaded from 
the Molecular Signatures Database (MSigDB) on 30
th
 April 2014 (Subramanian et al. 2005). 




8.3 Results and Discussion 
8.3.1 Post-Filtering Variants in Single Genes 
As in the previous chapter, the interpretation of BioGranat-IG results (sets of up to 
four interacting genes found to contain post-filtering variants for as many CD pedigrees as 
possible) is aided by a consideration of the individual genes harbouring variants in the 
highest number of pedigrees; that is, a consideration of what would be revealed by simple 
intersection filtering. 
Table 8.2 lists the genes in which the most CD pedigrees carry a post-filtering 
sequence variant. It is not practical to look at every gene in this table individually, but 
several observations will be made here. 
ZNF610, which encodes a zinc finger protein, harbours a variant in 14 of the 25 
pedigrees. Of the 338 non-CD control exomes, 16 carry a post-filtering variant in this gene, 
which is below the exclusion threshold of 20, but still suggests the gene may be reasonably 
tolerant to functional variation. Further, all 14 pedigrees with a ZNF610 variant are from the 
16 pedigrees sequenced at ICMB (none of the pedigrees sequenced at KCL carry a variant) 
and in all 14 pedigrees the same variant is observed. This allocation between pedigrees is 
highly unlikely to occur by chance: an empirical test for non-random allocation gave a p-
value of p = 0.0007 (obtained by 10
6
 simulations in which 14 pedigrees were sampled 
without replacement from the full set of 25, with probabilities proportional to the number of 
genes in which each pedigree carries a post-filtering variant). This suggests that ZNF610 is 
most likely a sequencing artefact seen due to platform differences between the whole exome 
sequencing performed at ICMB and at KCL. As such, and because all of the non-CD control 
exomes were sequenced at KCL, the variants in ZNF610 are likely to be false positives. It 
would be expected that this gene would be excluded if control exomes from ICMB were 
available to perform gene-level filtering. 
A similar phenomenon is also observed for the next three genes in the list: MYL12B 
has identical variants in 11 of the pedigrees (all of them sequenced at ICMB; empirical 
allocation p-value p = 0.0114), and only 11 of the 338 non-CD controls; MYO19 has variants 
in 10 of the pedigrees (all ICMB, p = 0.0219; four distinct variants in total but on average 
1.8 variants per pedigree) and 10 non-CD controls; and KCNA6 has identical variants in 8 of 
the pedigrees (all ICMB; p = 0.0644) and 5 non-CD controls. Again, these are assumed to be 
false positive findings which pass gene-level filtering due to platform differences between 
whole exome sequencing of cases at ICMB and non-CD controls at KCL. 
For this reason, and because these genes will be predisposed to occur in optimal 
BioGranat-IG subnetworks and RGA regions, the four genes ZNF610, MYL12B, MYO19 and 




KCNA6 were removed from the filtered gene lists before performing BioGranat-IG analysis 
and across-pedigree RGA (see results in sections 8.3.2 and 8.3.4 respectively). 
Subsequently in Table 8.2 there are four genes having variants in four pedigrees. For 
three of the genes all four pedigrees come from the 16 ICMB pedigrees, but this is 
unremarkable (empirical allocation p-value p = 0.3185), while for the other gene (PCDHB3) 
one of the pedigrees was sequenced at KCL. These genes and those with variants in fewer 
pedigrees will be retained for BioGranat-IG analysis and across-pedigree RGA. 
There appears to be no single gene which is a strong candidate to explain the 
occurrence of CD in a majority of the pedigrees. However, it could be that the gene-level 
filtering step, which excludes genes in which 20 or more of the 338 non-CD control exomes 
carry a post-filtering variant, is too restrictive (particularly since the variant-level filtering 
criteria are more relaxed than the variant-level filtering criteria used for the AOS exomes in 
chapter 7
*
). We can see that this is not the case by considering the final column of Table 8.2, 
                                                     
*
 Here 1,675 genes are excluded due to the variants they contain in the non-CD control exomes; at 
filtering level 1 in the previous chapter only 572 genes were excluded due to the variants they contain 
in the non-AOS control exomes. 
Table 8.2 – Genes with rare non-synonymous variants in the highest number of CD pedigrees 
“Count” gives the number of CD pedigrees (of 25 in total) in which each gene contains a variant (after 
filtering based on frequency and variant consequence as described in section 8.2.2). “Genes after 
filtering” includes those genes in which fewer than 20 of the 338 non-CD control exomes carry a rare 
non-synonymous variant; these genes are all taken forward for BioGranat-IG analysis and across-
pedigree RGA apart from those in red, which are thought to be false positive findings (see main text). 
“Genes excluded due to variants in non-CD control exomes” are those genes in which 20 or more of 
the 338 non-CD control exomes carry a rare non-synonymous variant; none of these genes are taken 
forward for BioGranat-IG analysis and across-pedigree RGA. 
Count Genes after filtering 
Genes excluded due to variants in 
non-CD control exomes 
14 pedigrees ZNF610  
11 pedigrees MYL12B  
10 pedigrees MYO19  
9 pedigrees  BCAP31 
8 pedigrees KCNA6  
6 pedigrees  TTN 
5 pedigrees  TYRP1 
4 pedigrees 
CLEC2B,  MYO9A,  NBPF3,  
PCDHB3 
DNAH1,  DNAH5,  FLG,  MRPL36,  
MUC4,  NOD2,  PCNT,  SSPO,  
SYNE1 
3 pedigrees 
AK2,  FANK1,  IK,  KRTAP2-2,  
PCDHB2,  PKIB,  RAD52,  WDFY3 
17 genes 




which indicates the genes that would be listed were it not for the gene-level filtering step. 
The first gene in this column is BCAP31, and only nine of the pedigrees carry a variant in 
this gene. So too do 65 of the 338 non-CD control exomes. TTN harbours a variant in six of 
the pedigrees, but is also the gene displaying the most post-filtering variation in controls 
(248 of 338 non-CD controls carry a variant). These and the other genes in the final column 
of Table 8.2 are excluded because according to our threshold they tolerate post-filtering 
variants in the non-CD controls, but it is not true that this gene-level filtering has excluded 
many otherwise-strong candidates. 
Note that NOD2, the gene currently thought to explain the most variance in CD 
disease risk (Jostins et al. 2012), also appears in this table with variants in four pedigrees. 
This includes two known risk variants, but as discussed earlier we suspect that these 
pedigrees may carry other rare variants of interest. NOD2 contains a post-filtering variant in 
35 of the non-CD control exomes (which may or may not include variants that have a small 
effect on CD susceptibility, as noted in section 8.2.1) and is therefore one of the genes 
excluded by the gene-level filtering step. 
We can conclude, therefore, that no single gene shows strong evidence for causality 
in a majority of pedigrees. Therefore it is reasonable to assume that locus heterogeneity may 
be present, so that studying the CD pedigrees in a network context is justified. 
8.3.2 BioGranat-IG Results 
As in chapter 7, most attention is given to the searches in the PINA_d50 network 
since this is the network of physical interactions with widest genomic coverage (10,375 
genes); subsequently KGGSeq-prioritisation will be used to identify any additional 
subnetworks from the remaining networks that warrant further attention. 
8.3.2.1 Results Summary 
In total, ten different BioGranat-IG searches were performed using each 
combination of five different networks (PINA_d50, PINAmin2_d50, CPDBconf95_d50, 
COXPRES30_d50 and Multinet_d50) and two different search methods (exact triplet and 
quadruplet searches). 
Table 8.3 summarises the findings for each search, giving the number of genes in an 
optimal subnetwork and the number of CD pedigrees in which an optimal subnetwork 
harbours a variant. Note that optimal subnetworks are not necessarily unique because several 
equivalently good subnetworks might be found by a given search (optimality implies that no 
subnetworks were found to harbour variants in a greater number of CD pedigrees and no 
smaller subnetworks were found to harbour variants in the same number of CD pedigrees). 




8.3.2.2 PINA_d50 Network 
Optimal triplets found by BioGranat-IG in PINA_d50 harbour variants in five of the 
CD pedigrees. There are ten such subnetworks, which can be merged to form three distinct 
regions in the network, as depicted in Figure 8.4. 
One region comprises a single triplet consisting of the genes ERCC1, ERCC4 and 
RAD52. ERCC1 and ERCC4 encode proteins forming a heterodimer that functions in the 
nucleotide excision repair pathway, and a GO enrichment test suggests that all three genes 
are involved in “DNA recombination” (adjP = 6.43×10-5) and “double-strand break repair” 
(adjP = 1.45×10
-5
). The KGGSeq-prioritisation score is not significant (probability of 
containing a disease-causing variant = 0.3595, p = 0.3383), and none of the genes are 
included in the list of 300 prioritised genes identified by the CD GWAS meta-analysis by 
Jostins et al. (Jostins et al. 2012). There is therefore little evidence from existing functional 
annotation or previous association studies that the variants in this subnetwork could cause 
CD. 
A second region comprises two triplets which include the genes ANK1, NBPF3, 
SLC4A1 and SLC4A3. In total these genes harbour variants in six of the pedigrees, although 
no variants occur in ANK1, the gene that connects the other three in the network. This region 
is found primarily because of the gene NBPF3, in which the same 6 bp deletion is identified 
in four of the CD pedigrees. Therefore, whether this region is of interest depends mainly on 
whether NBPF3 is likely to have a role in CD. NBPF3 is a member of the neuroblastoma 
breakpoint family, a group of recently-duplicated genes containing many tandem repeats of 
the DUF1220 protein domain (which has unknown function). This raises the possibility that 
the variants observed are the result of sequencing or alignment errors (inspection of the 
sequencing reads against the segmental duplication track (Bailey et al. 2001; Bailey et al. 
2002) of the UCSC Genome Browser (Kent et al. 2002) suggests that the deletion falls in a 
duplicated region); to establish whether these variants are genuine, Sanger sequencing could
Table 8.3 – Summary of optimal subnetworks for familial CD found by BioGranat-IG 
Results take the form: number of CD pedigrees covered (number of genes). There are 25 CD 
pedigrees in total. Note this table gives the properties of optimal subnetworks found by each search 
but optimal subnetworks are not necessarily unique. 
Network Triplet search Quadruplet search 
PINA_d50 5 (3) 6 (4) 
PINAmin2_d50 4 (3) 5 (4) 
CPDBcon95_d50 5 (3) 5 (3) 
COXPRES30_d50 7 (3) 7 (3) 




Figure 8.4 – Optimal subnetworks found in PINA_d50 using triplet and quadruplet searches for CD pedigrees 
Merged regions shown. Genes found in optimal triplets are in blue; quadruplets in yellow; overlap in green. The number(s) next to each node refer to the pedigrees in 
which they contain variants; coloured numbers indicate exomes with multiple variants in the same merged region. 




be employed. In practice this is not recommended because NBPF3 does not appear to be a 
strong candidate CD gene. Copy number variations of the DUF1220 domain have been 
linked with several developmental and neurogenetic diseases, while diseases associated with 
NBPF3 itself include schizophrenia and neuroblastoma (www.genecards.org, Stelzer et al. 
2011). It is not clear, therefore, how this gene might play a role in CD. Additionally, the 
KGGSeq-prioritisation score of this network region is not significant (probability of 
containing a disease-causing variant = 0.3918, p = 0.3213), and none of the genes are 
included in the list of 300 prioritised genes identified by Jostins et al. (Jostins et al. 2012). 
Lastly we find a region of eight genes formed by seven overlapping optimal triplets, 
which in total harbour variants in eight of the pedigrees. Common to all of these triplets is 
MYO9A, in which four of the pedigrees carry a variant; no other gene contains a variant in 
more than one pedigree, and most of the region is connected via two relatively highly-
connected genes, MYZAP (with degree 18) and POLR2M (with degree 16), which contain no 
variants themselves. As with the previous region, whether this region could indicate a 
possible CD disease mechanism or not depends mainly on a single gene, in this case 
MYO9A. This gene encodes a member of the myosin family of motor proteins. Interestingly, 
mutations in another myosin gene, MYO9B, have been associated with IBD and it is 
hypothesised that they influence intestinal permeability (van Bodegraven et al. 2006). 
However MYO9A itself has not been clearly linked to any disease; it is widely expressed and 
is thought to be involved in neuron development – which does not readily suggest a role in 
CD (www.genecards.org, Stelzer et al. 2011). The region as a whole is not enriched for any 
known function, based on a GO enrichment test (data not shown); the KGGSeq-prioritisation 
score for the region is not significant (probability of containing a disease-causing variant = 
0.4803, p = 0.3344); and none of the genes feature in the list of 300 prioritised genes 
identified by Jostins et al. (Jostins et al. 2012) (although MYZAP and POLR2M do interact 
directly with one gene in the list, CEBPG). 
In summary, based on this preliminary examination none of the regions identified by 
the optimal triplet search are strongly suggestive of a functional role relevant to CD, and 
moreover none harbour variants for a majority of the pedigrees. 
In the case of the quadruplet search in PINA_d50, we find that optimal subnetworks 
of four genes harbour variants in six of the CD pedigrees. There are 13 such subnetworks, 
which can be merged to form four distinct regions in the network; these are also depicted in 
Figure 8.4. 
One region comprises the quadruplet ANK1-NBPF3-SLC4A1-SLC4A3, and another 
is based around the gene MYO9A. These were discussed above because they were also 
identified by the triplet search. 




In addition we find a quadruplet comprising the genes CRNKL1, ESYT2, KBTBD10 
and SLC2A4. Of these genes, SLC2A4 does not contain a variant for any of the pedigrees, 
but acts to connect together the three other genes in the network. Since this gene is relatively 
highly connected, with 36 direct neighbours in PINA_d50, this finding is likely to have 
occurred by chance and not be of relevance to CD. This conclusion is supported by the fact 
that a GO enrichment test finds no statistically significant functional annotation and the 
quadruplet does not have a significant KGGSeq-prioritisation score (data not shown). 
Finally we see a quadruplet comprising the genes CENPE, MAP3K4, NCF1 and 
TRAF4. Again one gene (TRAF4) is a connecting gene that contains no variants itself, but 
has a relatively high degree of 25. The quadruplet’s KGGSeq-prioritisation score is far from 
significant (probability of containing a disease-causing variant = 0.1961, p = 0.9827). These 
factors would suggest that the quadruplet is unlikely to represent a candidate disease 
pathway. However, a GO enrichment test suggests that CENPE, MAP3K4 and TRAF4 are 
involved in “positive regulation of kinase activity”/”regulation of protein phosphorylation” 
(adjP = 0.0059 in each case), which are of potential relevance to CD given the role that 
phosphorylation signalling plays in the immune system (Cohen 2014). Further, TRAF4 is a 
direct neighbour in PINA_d50 of TNFRSF4, which encodes a member of the tumour 
necrosis factor receptor superfamily and has an immune signalling role (and is also 
annotated with the GO terms “regulation of kinase activity”/“regulation of protein 
phosphorylation”). TNFRSF4 was highlighted by Jostins et al. as a possible candidate gene 
tagged by the SNP rs12103, which displayed genome-wide significant association in their 
IBD GWAS meta-analysis (which combines CD and UC cases), including in their CD-
specific test (Jostins et al. 2012). Finally, variants in NCF1 have been shown to cause 
chronic granulomatous disease, an early-onset disease which can present with CD-like 
intestinal inflammation (Uhlig et al. 2014). For these reasons, further study of this 
subnetwork may be justified. 
Consideration of near-optimal subnetworks from the triplet and quadruplet searches 
is also worthwhile because these may implicate different network regions that are enriched 
for post-filtering variants in CD pedigrees, but for which any given set of three or four 
connected constituent genes does not quite achieve optimality. Since the BioGranat-IG 
parameters for near-optimal searches specify size flexibility = 1 and number flexibility = 1, 
near-optimal subnetworks can contain variants for one pedigree fewer than optimal 
subnetworks, but can only be up to one gene bigger than the smallest subnetwork that does 
this. For the triplet search, since an optimal subnetwork comprises three genes with variants 
in five CD pedigrees, but the smallest subnetworks having variants in four CD pedigrees are 
in fact single genes (MYO9A and NBPF3 being the only two in PINA_d50), near-optimal 




subnetworks are those of up to two genes that contain variants in four CD pedigrees. For the 
quadruplet search, where optimal subnetworks comprise four genes with variants in six CD 
pedigrees, near-optimal subnetworks are those of four genes with variants in five CD 
pedigrees. 
For the triplet search, near-optimal subnetworks identify the same regions as were 
found by the optimal triplet search. In addition we see a region comprising the two genes 
ABCC6 (variant in one CD pedigree) and AK2 (variant in three CD pedigrees) (see Figure 
8.5). These genes share no statistically significant enrichment for GO biological process 
annotation and do not have a significant KGGSeq-prioritisation score (data not shown), and 
neither features in the list of 300 prioritised genes identified by Jostins et al. (Jostins et al. 
2012). 
However, both genes are part of a region of nine genes found by the near-optimal 
quadruplet search, shown in Figure 8.5. This region harbours variants in seven of the CD 
pedigrees, with two variants for pedigrees 23, 1068 and 12420. In the previous chapter, 
when a region contained multiple variants for the same exome this suggested at least one of 
the variants were not relevant to the disease process; this was because AOS was not 
expected to be caused by more than one sequence variant in an affected individual. For 
familial CD, however, we do not hold this prior belief about the genetic architecture and the 
fact that these pedigrees carry two variants in a putative disease pathway may constitute 
increased evidence of involvement. A GO enrichment test finds only one significantly 
associated biological process term, “extracellular matrix disassembly” (CMA1 and MMP1; 
adjP = 0.0153), and the KGGSeq-prioritisation score is not significant (probability of 
containing a disease-causing variant = 0.6642, p = 0.1575). Note, however, that MST1 was 
highlighted by Jostins et al. as a possible candidate gene tagged by the SNP rs3197999, 
which displayed genome-wide significant association in their IBD GWAS meta-analysis 
(which combines CD and UC cases), including in their CD-specific test (Jostins et al. 2012). 
Additionally the near-optimal quadruplet search identifies a region of 132 genes 
which contain variants for 23 of the 25 CD pedigrees. This region includes the genes from 
the various regions found by the optimal quadruplet search around the genes MYO9A, 
TRAF4 and SLC2A4 (see Figure 8.4), as well as the optimal triplet ERCC1-ERCC4-RAD52. 
Since 132 genes are too many to suggest a closely-related functional pathway underlying 
mono/oligogenic CD, it is more informative to study the smaller regions derived from the 
optimal searches, as has been discussed previously. 




8.3.2.3 Top Prioritised Results in all Networks 
None of the results found in PINA_d50 had a significant KGGSeq-prioritisation 
score, and the same was found to be true of the other four networks. Table 8.4 lists the ten 
optimal subnetworks (and merged regions of optimal subnetworks) that achieved the 
smallest KGGSeq-prioritisation p-values across all tests in all networks. Two of these 
subnetworks (quadruplets containing the gene MYO9A) were found in PINA_d50, discussed 
in the previous section. 
The other eight subnetworks were all found in PINAmin2_d50, one of the high-
confidence PINs. The most significant KGGSeq-prioritisation score is achieved by an 
optimal quadruplet comprising the genes ACTB, CCT4, NCF1 and SMARCE1 and 
harbouring post-filtering variants for five CD pedigrees (probability of containing a disease-
causing variant = 0.6527, p = 0.0668). Slightly less significant is the merged region of nine  
 
Figure 8.5 – Near-optimal subnetworks found in PINA_d50 using triplet and quadruplet searches for CD 
pedigrees 
Merged region shown. Genes found in near-optimal quadruplets are in yellow; overlap with near-
optimal triplets in green. The number(s) next to each node refer to the pedigrees in which they contain 
variants; coloured numbers indicate exomes with multiple variants in the region. Not shown: regions 
based around the genes already identified by the optimal searches (and shown in Figure 8.4). 
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Table 8.4 – Top BioGranat-IG optimal subnetworks by KGGSeq-prioritisation score for CD 
No optimal subnetworks or merged regions had a nominally significant KGGSeq-prioritisation score. In lieu of this, the table shows the top ten optimal subnetworks or 
merged regions by KGGSeq-prioritisation p-value. Also shown are the most significant scoring optimal subnetworks or merged regions found in networks with no optimal 













1 PINAmin2_d50 Quadruplet Subnetwork 4 5 0.652719 0.06679 ACTB,  CCT4,  NCF1,  SMARCE1 
=2 PINA_d50 Quadruplet Subnetwork 4 6 0.537896 0.07695 HK1,  MYO9A,  MYZAP,  SCMH1 
=2 PINA_d50 Quadruplet Subnetwork 4 6 0.537896 0.07695 HK1,  MYO9A,  POLR2M,  SCMH1 
4 PINAmin2_d50 Quadruplet 
Merged 
region 
9 9 0.739091 0.08228 
ACTB,  ACTG1,  CCT4,  CCT8,  NCF1,  NCF4,  
PBRM1,  PRKCB,  SMARCE1 
5 PINAmin2_d50 Quadruplet Subnetwork 4 5 0.502803 0.08527 ITK,  PLCG1,  SH3BP2,  SOS2 
6 PINAmin2_d50 Triplet Subnetwork 3 4 0.447994 0.10201 PLCG1,  SH3BP2,  SOS2 
7 PINAmin2_d50 Triplet Subnetwork 3 4 0.441567 0.10633 ITK,  PLCG1,  SOS2 
8 PINAmin2_d50 Quadruplet Subnetwork 4 5 0.492858 0.13756 KDR,  PLCG1,  SH3BP2,  SOS2 
9 PINAmin2_d50 Quadruplet Subnetwork 4 5 0.488271 0.14046 KDR,  NRP1,  PLCG1,  SOS2 
10 PINAmin2_d50 Quadruplet Subnetwork 4 5 0.486953 0.14174 ITK,  KDR,  PLCG1,  SOS2 
31 Multinet_d50 Triplet Subnetwork 3 5 0.365272 0.28635 GRINL1A,  MYO9A,  SCMH1 
39 CPDBconf95_d50 Triplet Subnetwork 3 5 0.359492 0.31414 ERCC1,  ERCC4,  RAD52 
80 COXPRES30_d50 Triplet Subnetwork 3 7 0.377081 0.56055 PCDHB15,  PCDHB3,  PCDHGA1 
 




genes formed from this and five other optimal quadruplets (probability of containing a 
disease-causing variant = 0.7391, p = 0.0823) (see Figure 8.6). The near-significant 
KGGSeq-prioritisation scores achieved by this subnetwork and merged region are largely 
driven by a novel heterozygous missense SNV that pedigree 12320 carries in CCT4. 
KGGSeq annotates this variant with a probability of 0.5752 of causing a monogenic disease, 
the fourth highest probability among all post-filtering variants in genes found in 
PINAmin2_d50. CCT4 itself encodes a subunit of a molecular chaperone complex involved 
in protein-folding, which does not immediately present a clear link to the CD phenotype. 
This is reflected in a GO enrichment test using all nine genes, where the most significantly 
enriched biological process annotation is for “'de novo' posttranslational protein folding” 
(ACTB, CCT4 and CCT8; adjP = 0.0017). Significant enrichment was also observed for 
“phagosome maturation” (NCF1 and NCF4; adjP = 0.0053), which may be of more direct 
relevance to CD: both of these neutrophil cytosolic factor genes have been shown to cause 
chronic granulomatous disease, which can cause CD-like intestinal inflammation (Uhlig et 
al. 2014). Of the nine genes, PRKCB is highlighted by Jostins et al. as a possible candidate 
gene tagged by rs7404095, which displayed genome-wide significant association in their 
 
Figure 8.6 – Region of optimal CD quadruplets found in PINAmin2_d50 having most significant KGGSeq-
prioritisation scores 
Blue dashed region = optimal quadruplet described in row 1 of Table 8.4; all genes = merged region 
described in row 4. Genes found in quadruplets in PINAmin2_d50 are in yellow; overlap with optimal 
triplets in green (full results not shown). The number(s) next to each node refer to the pedigrees in 
which they contain variants; coloured numbers indicate exomes with multiple variants in the region. 




IBD GWAS meta-analysis (which combines CD and UC cases) although does not quite 
reach genome-wide significance in their CD-specific test (Jostins et al. 2012). This gene 
encodes a kinase involved in many cellular functions; this includes an established immune 
role – it is an element of Reactome’s curated “Activation of NF-κB in B-cells” pathway 
(obtained via MSigDB). 
The remaining six subnetworks having the most significant KGGSeq-prioritisation 
scores are all optimal triplets or quadruplets in PINAmin2_d50 and each contain both 
PLCG1 and SOS2. The near-significant prioritisation scores are primarily driven by a novel 
heterozygous missense SNV that pedigree 1066 carries in SOS2. KGGSeq annotates this 
variant with a probability of 0.3166 of causing a monogenic disease. The six subnetworks 
form a region of six genes when considered together (see Figure 8.7). A GO enrichment test 
based on all six genes suggests significant shared function related to “positive regulation of 
endothelial cell migration” (KDR, NRP1 and PLCG1; adjP = 0.0007) and “activation of 
phospholipase C activity” (ITK and PLCG1; adjP = 0.0102). Inspection of relevant curated 
pathways from MSigDB highlights the presence of ITK and PLCG1 in Reactome’s 
“adaptive immune system” pathway (the latter more specifically involved in “cytokine 
signalling in the immune system”) and KDR in KEGG’s “Cytokine – cytokine receptor 
interaction” pathway. These are of note because one of the key molecular mechanisms 
underlying CD, the IL23 pathway, involves cytokine signalling (Brand 2009). SOS2 itself 
encodes a guanine nucleotide exchange factor and is a member of KEGG’s “JAK/STAT 
 
Figure 8.7 – Additional region of optimal CD triplets and quadruplets found in PINAmin2_d50 and having 
near-significant KGGSeq-prioritisation scores 
Region shown merges optimal subnetworks described in rows 5-10 of Table 8.4. Genes found in 
quadruplets in PINAmin2_d50 are in yellow; overlap with optimal triplets in green (full results not 
shown). The number(s) next to each node refer to the pedigrees in which they contain variants; 
coloured numbers indicate exomes with multiple variants in the region. 




signalling pathway”. None of the six genes are included in the list of 300 prioritised genes 
identified by Jostins et al. (Jostins et al. 2012) (although KDR interacts directly with one 
gene on the list, FYN). Considering these findings together, there is only limited direct 
evidence that this region could be responsible for CD in six of the pedigrees, but the existing 
functional annotation of these genes could justify further investigation. 
For the remaining networks, Table 8.4 lists the optimal subnetwork or merged 
region having the most significant KGGSeq-prioritisation score (although none of these are 
among the ten most significant across all tests). 
In Multinet_d50, the network that combines multiple interaction types, the highest-
placed subnetwork (ranked 31
st
) is a triplet that includes the gene MYO9A (probability of 
containing a disease-causing gene = 0.3627, p = 0.2864). Optimal triplets in this network 
harbour variants for five pedigrees. This triplet was not present in PINA_d50, where optimal 
triplets also contain variants for five pedigrees, but since MYO9A contains a variant in four 
of the CD pedigrees the same logic as presented in section 8.3.2.2 applies (namely that the 
relevance of this subnetwork to CD is primarily dependent on the relevance of MYO9A). 
In CPDBconf95_d50, the high-confidence PIN, the highest-placed subnetwork 
(ranked 39
th
) is the triplet ERCC1-ERCC4-RAD52 (probability of containing a disease-
causing gene = 0.3595, p = 0.3141). This triplet was previously found in PINA_d50 (see 
discussion and Figure 8.4 in section 8.3.2.2). The fact that it is also found in 
CPDBconf95_d50 suggests that we can be fairly confident in the validity of the interactions 
between the products of these genes. 
Finally in COXPRES30_d50, the co-expression network, the highest-placed 
subnetwork (ranked 80
th
) is an optimal triplet comprising the genes PCDHB3, PCDHB15 
and PCDHGA1 and harbouring post-filtering variants in seven CD pedigrees (probability of 
containing a disease-causing gene = 0.3771, p = 0.5606). Two of these genes are members of 
the protocadherin beta subfamily. As will be seen in the subsequent results sections, 
members of this family of genes appear prominently in the results obtained from within-
pedigree RGA and across-pedigree RGA. Discussion will therefore be deferred to the next 
results section. 
8.3.3 Within-Pedigree RGA Results 
For each network, a binary form of RGA was performed separately for each 
pedigree to identify connected sets of genes for which the pedigree carries a post-filtering 
variant (using the relaxed filtering criteria). This was done to suggest possible oligogenic 
disease mechanisms causing familial CD. 




Table 8.5 gives the size of the largest region found for each pedigree in each 
network. Also given are the number of such largest regions identified, and the p-value 
generated by RGA that quantifies the degree to which the region found is larger than would 
be expected under the null hypothesis that regions occur by chance due to the number and 
degree of genes in the network that contain variants. 
In total, 11 significantly large regions were identified. These are summarised in 
Table 8.6. It may be informative to study these regions directly to assess their likelihood of 
being relevant to CD. A preliminary analysis of these regions leads to the following 
observations. 
For pedigree 1068 the largest regions identified in PINA_d50 and Multinet_d50 
were identical, and the same is true for pedigree 12679 in PINAmin2_d50 and Multinet_d50. 
Other than this, the only overlap between significant regions was for pedigrees 265 and 888, 
which both had significantly large regions in COXPRES30_d50 (of nine genes and eight 
genes; p = 0.0054 and 0.0063 respectively; eight genes in common). All of the genes are 
protocadherin beta genes, one of three clustered families of genes on chromosome 5 
encoding cell-adhesion proteins (Chen and Maniatis 2013). This could represent a 
sequencing artefact due to a high degree of homology among the genes in each cluster. This 
was investigated by inspection of the whole exome sequencing reads using the UCSC 
Genome Browser (Kent et al. 2002). For most of the genes in which both pedigrees carried a 
variant, the variant was identical. The majority of reads appeared to have aligned well to the 
reference genome (although notably one exome in particular from pedigree 265 had visibly 
lower quality alignment around several of the called variants). By comparison to the 
browser’s segmental duplication track (Bailey et al. 2001; Bailey et al. 2002), only around 
half of the variants found appeared to lie in duplicated sequence regions. These observations 
suggest that at least some of the variants found in these genes may be genuine; one way to 
confirm this would be to perform Sanger sequencing across the protocadherin beta gene 
cluster. However, it is unlikely in practice that this would be justified given that these genes 
appear to have little relevance to CD, being primarily expressed in the nervous system and 
playing a key role in neurodevelopment (Chen and Maniatis 2013). 
For pedigree 90 a region of three genes (comprising INADL, MAPK12 and RGS3) 
was identified in PINA_d50 (p = 0.0250). This finding is of potential interest because of 
MAPK12’s role in the innate immune system. Of particular note, given that NOD2 is the 
gene currently thought to explain the most variance in CD disease risk (Jostins et al. 2012), 
MAPK12 is a member of Reactome’s curated “NOD1/2 signalling pathway” (obtained via 
MSigDB); the MAPK pathway can be activated as a downstream consequence of NOD1 and 
NOD2 signalling (Windheim et al. 2007). 
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Table 8.5 – Summary of within-pedigree RGA results for CD 
m = size of largest region; p = RGA p-value indicating significance of region size; l = number of largest regions; lLC = number of largest regions in large component of 
network. Green shading indicates a significantly large region was found; “-” = no region found. 
Pedigree ID 
PINA_d50 PINAmin2_d50 CPDBconf95_d50 COXPRES30_d50 Multinet_d50 
m p l lLC m p l lLC m p l lLC m p l lLC m p l lLC 
13 2 0.9492 2 2 2 0.7556 1 1 2 0.8499 2 2 3 0.6662 1 1 2 0.8118 2 2 
23 5 0.0650 1 1 2 0.9087 2 2 2 0.9793 6 6 5 0.2550 1 1 3 0.7758 1 1 
31 2 0.5694 1 1 - - - - - - - - 2 0.7149 1 1 - - - - 
32 - - - - - - - - - - - - - - - - - - - - 
41 2 0.8590 1 1 2 0.5000 1 1 2 0.8549 3 2 2 0.9832 3 2 2 0.5581 1 1 
48 2 0.5583 1 1 - - - - - - - - 2 0.9116 3 3 2 0.3823 1 1 
64 2 0.9486 2 2 - - - - - - - - 2 0.9912 6 6 5 0.0067 1 1 
90 3 0.0250 1 1 - - - - - - - - 3 0.1326 1 1 - - - - 
107 2 0.2925 1 1 - - - - - - - - 3 0.1514 1 1 - - - - 
263 2 0.9658 1 1 - - - - 2 0.8915 1 1 4 0.0855 2 2 2 0.9035 1 1 
265 4 0.1175 1 1 - - - - 2 0.9123 1 1 9 0.0054 1 1 2 0.9973 9 9 
286 2 0.8280 3 3 2 0.3044 2 1 2 0.5341 2 2 3 0.3386 1 1 2 0.8066 3 3 
312 2 0.4956 1 1 - - - - - - - - 2 0.9359 4 4 - - - - 
867 2 0.9056 2 2 - - - - 2 0.6845 1 1 2 0.9964 9 9 2 0.8702 1 1 
879 3 0.5531 1 1 2 0.8806 2 2 2 0.9400 2 2 4 0.2648 2 2 3 0.4014 1 1 
888 2 0.9852 5 5 2 0.9129 3 2 2 0.9543 4 4 8 0.0063 1 1 2 0.9898 4 4 
903 2 0.8543 3 3 2 0.6686 2 1 2 0.8088 3 3 3 0.4562 1 1 3 0.3764 1 1 
1066 3 0.7860 2 2 2 0.9500 2 2 2 0.9898 4 4 11 0.0025 1 1 2 1.0000 7 7 
1068 4 0.0262 1 1 - - - - 2 0.6892 1 1 5 0.0175 1 1 4 0.0057 1 1 
1699 2 0.9648 4 4 - - - - 2 0.8730 2 2 3 0.8182 2 2 2 0.9749 5 5 
1709 3 0.5528 2 2 2 0.9094 2 2 3 0.3198 2 2 4 0.2096 1 1 2 0.9741 4 4 
12320 4 0.3148 1 1 2 0.9858 2 2 2 0.9996 7 7 5 0.5379 1 1 3 0.7101 1 1 
12420 4 0.3062 1 1 2 0.9122 2 2 2 0.9879 3 2 7 0.0239 1 1 3 0.4710 1 1 
12679 3 0.1773 2 2 4 0.0111 1 1 3 0.1614 1 1 4 0.1100 1 1 4 0.0198 1 1 
53185 2 0.3646 1 1 - - - - 2 0.3507 2 2 2 0.9552 1 1 2 0.2808 2 1 
 




The largest region found is for pedigree 1066, where 11 of the 382 genes containing 
post-filtering variants are connected in COXPRES30_d50 (p = 0.0025). This includes the 
gene TYK2, which was highlighted by Jostins et al. as a possible candidate gene tagged by 
the SNP rs11879191, which displayed genome-wide significant association in their IBD 
GWAS meta-analysis (which combines CD and UC cases), including in their CD-specific 
test; the authors also noted that it had been previously implicated in Mendelian susceptibility 
to mycobacterial disease (Jostins et al. 2012). In addition, TYK2 encodes a tyrosine kinase 
which is a member of several curated pathways of potential relevance to CD (obtained via 
MSigDB), including Reactome’s “Cytokine signalling in the immune system” and KEGG’s 
“JAK/STAT signalling pathway”. The region also includes MYO9B, which has previously 
been associated with IBD and is thought to influence intestinal permeability (van 
Bodegraven et al. 2006). As mentioned in the previous chapter, one of the problems with the 
COXPRES30_d50 network is the functional interpretation of edges: connections indicate 
correlated expression across a range of gene expression samples but do not directly indicate 







64 Multinet_d50 5 0.0067 
ALDH1B1;  ASMT;  LIPA;  LPL; 
PTPN4 
90 PINA_d50 3 0.0250 INADL;  MAPK12;  RGS3 
265 COXPRES30_d50 9 0.0054 
PCDHB2;  PCDHB3;  PCDHB4; 
PCDHB7;  PCDHB10;  PCDHB11; 
PCDHB12;  PCDHB14;  PCDHB16 
888 COXPRES30_d50 8 0.0063 
PCDHB2;  PCDHB3;  PCDHB4; 
PCDHB7;  PCDHB10;  PCDHB11; 
PCDHB12;  PCDHB16 
1066 COXPRES30_d50 11 0.0025 
DENND4B;  GON4L;  INF2; 
MAPK8IP1;  MYO9B;  PKD1; 
SHKBP1;  TAF1C;  TYK2;  UBN2; 
WIZ 
1068 
PINA_d50 4 0.0262 
GIPC1;  MMS19;  PDXDC1;  
TYRP1 
COXPRES30_d50 5 0.0175 
CLSTN2;  GFRA1;  TFF1;  TFF2; 
TFF3 
Multinet_d50 4 0.0057 
GIPC1;  MMS19;  PDXDC1;  
TYRP1 
12420 COXPRES30_d50 7 0.0239 
ANKRD11;  GLG1;  JARID2;  
NUP153;  SIK3;  SPG7;  TCF25 
12679 
PINAmin2_d50 4 0.0111 SMG1;  TELO2;  UPF1;  UPF2 
Multinet_d50 4 0.0198 SMG1;  TELO2;  UPF1;  UPF2 




involvement in a common process. A GO enrichment test based on all 11 genes finds no 
significant enrichment for any GO biological process (data not shown). 
For pedigree 12420 a region of seven genes was identified in COXPRES30_d50 
(p = 0.0239), including NUP153. This is of note because of NUP153’s role in the immune 
system, specifically in cytokine signalling (Reactome curated pathway “Cytokine signalling 
in the immune system” via MSigDB). 
In addition to studying the identified regions directly, we also examined all the 
regions identified (whether significantly large or not) for evidence of clustering in one or 
more parts of each network. For each network, Table 8.7 gives the observed value for the 
two measures of clustering used: the average pairwise distance between the largest regions 
found for different pedigrees, and the number of pairs of pedigree for which overlapping or 
adjacent regions were found. Also shown are the p-values derived from 10,000 randomly-
generated sets of regions, quantifying the degree to which the observed degree of clustering 
does not occur by chance. 
The networks PINA_d50, PINAmin2_d50, CPDBconf95_d50 and Multinet_d50 do 
not show evidence for clustering of within-pedigree RGA regions using either measure. For 
the co-expression network COXPRES30_d50, the average distance between largest regions 
(for the 24 pedigrees for which regions were found) is 0.83, and this value is significantly 
small (p = 0.0033). Although the number of pedigrees having overlapping or adjacent largest 
regions was not significant (19 of 276 pairs of pedigrees; p = 0.2071), it is informative to 
consider the pedigrees for which overlapping regions were found, as these will contribute to 
the significantly small average distance. 
Table 8.7 – Clustering of within-pedigree RGA results for CD 
“# peds with regions” = number of the 25 CD pedigrees in which within-pedigree regions were 
identified; “# pairs of peds” = number of ways of choosing two of these pedigrees for comparison; 
“Average distance” = average taken across all pairs of minimum distance between regions in different 
pedigrees (first clustering measure); “# overlapping or adjacent” = number of pairs with minimum 
distance ≤1 (second clustering measure); “Obs.” = observed value; “P-value” = probability of same or 
greater clustering estimated from 10,000 randomly-generated sets of regions. Green shading indicates 








# overlapping or 
adjacent 
Obs. P-value Obs. P-value 
PINA_d50 24 276 1.13 0.0592 16 0.0838 
PINAmin2_d50 12 66 1.67 0.5959 2 0.8682 
CPDBconf95_d50 18 153 1.00 0.2459 19 0.1761 
COXPRES30_d50 24 276 0.83 0.0033 19 0.2071 
Multinet_d50 20 190 1.50 0.9018 10 0.7880 




Overlapping regions were found for five pairs of pedigrees, illustrated in Figure 8.8. 
One of the pairs comprises pedigrees 888 and 1066, whose largest regions are made up of 
protocadherin beta genes and were discussed earlier. Several of the pedigrees illustrated in 
the figure had multiple largest regions of only two genes, and since a region of two genes is 
not significantly large for any pedigree (see Table 8.5) these are unlikely to be of interest in 
general. One possible exception is the two-gene region consisting of SULT1A1 and 
SULT1A2, both of which contain post-filtering variants in pedigrees 41 and 48. These genes 
encode two members of a family of phenol sulphotransferase enzymes, which have a role in 
chemical metabolism (Gamage et al. 2006). Both genes were highlighted by Jostins et al. as 
possible candidate genes tagged by the same SNP (rs26528), which displayed genome-wide 
significant association in their IBD GWAS meta-analysis (which combines CD and UC 
cases), including in their CD-specific test (Jostins et al. 2012). 
There is also a connected set of twelve genes in which four pedigrees carry variants. 
BRD2 contains a post-filtering variant along with BCR and SMARCA4 for pedigree 107, and 
with BPTF, EP300, MLL5 and USP42 for pedigree 12320. In addition, RANBP2 contains a 
variant along with EIF3A for pedigree 31, and with ATXN7, SRSF4 and USP47 for pedigree 
64. Both EP300 and RANBP2 have known immune system roles, with EP300 an element of 
KEGG’s curated “JAK/STAT signalling pathway” and RANBP2 present in Reactome’s 
“cytokine signalling in the immune system” pathway (both obtained via MSigDB). A GO 
enrichment test based on all twelve genes finds the region enriched for genes involved in 
several biological processes: “chromatin modification” (six genes – including five of the 
seven containing variants for pedigrees 107 and 12320; adjP = 0.0003); “protein 
deubiquitination” (three genes; adjP = 0.0019), and “positive regulation by host of viral 
transcription” (two genes; adjP = 0.0023). 
As previously discussed, one of the main limitations of the COXPRES30_d50 
network is the difficulty in determining the existence and nature of functional relationships 
underlying the network edges. However, given that we find some significantly large regions 
and evidence of clustering, together with previous evidence for statistical association with 
IBD and an immune system role, these regions may justify further study. 
8.3.4 Across-Pedigree RGA Results 
Network regions that are enriched for post-filtering variants (allowing any number 
per pedigree) were identified by across-pedigree RGA using two gene-ranking methods: 




Figure 8.8 – Overlapping within-pedigree RGA regions for CD in the large component of COXPRES30_d50 
Dashed boxes indicate largest regions found in each pedigree; there are five overlaps between different pedigrees in total. Note in several pedigrees there were multiple 
disconnected largest regions found (grouped together in the figure). Colours are used only for ease of interpretation and have no additional meaning. 




8.3.4.1 Simple Count Ranking 
With genes ranked according to a simple count, RGA was performed using all 
possible α and β thresholds. These thresholds can be thought of in terms of the number of 
pedigrees carrying a post-filtering variant in each gene. For example, when α and β 
correspond to three and two pedigrees respectively, this means that regions are seeded by 
genes in which three or more pedigrees carry a variant, and are expanded to include member 
genes in which two or more carry a variant. 
A summary of results for all combinations of α and β is given in Table 8.8. As well 
as the sizes of the largest regions found, the table also gives the empirical p-value that 
measures the significance of the observed region size (number of seed or member nodes it 
contains; see chapter 6, section 6.2) against regions found in 10,000 permuted networks. 
Regions of nominally significant size (p < 0.05) were found in only two of the networks. 
In the COXPRES30_d50 network, when RGA was performed without jumps being 
permitted, the most significant region was identified for α corresponding to genes containing 
variants for four pedigrees and β corresponding to two pedigrees (p < 10-4). This region 
comprises seven of the protocadherin beta genes that were previously discussed in section 
8.3.3 above, and will therefore not be discussed further here. 
In the CPDBconf95_d50 high-confidence PIN, when RGA was performed with 
jumps being permitted, the most significant region was identified for α corresponding to 
genes containing variants for three pedigrees and β corresponding to one pedigree. This 
region comprised 827 genes in total, with 354 being seed or member nodes for the region 
(p = 0.0013). The fact that the network is significantly large may be of broad interest, but in 
practice it highlights too many genes to suggest a closely-related functional pathway 
underlying mono/oligogenic CD, and should therefore not be prioritised for further study. 
In two additional networks, regions were found having empirical p-values that were 
close to being nominally significant (p < 0.1), suggesting weak evidence of non-random 
enrichment for post-filtering variants in CD case pedigrees (illustrated in Figure 8.9). 
In the PINA_d50 network, when jumps were permitted the most significant region 
was identified for α = β corresponding to genes containing variants for two pedigrees. The 
region comprised twelve genes in total, with seven being seed nodes for the region (Figure 
8.9a; p = 0.0750). The twelve genes include two sets of four genes that were previously 
identified by BioGranat-IG as optimal quadruplets: CENPE, MAP3K4, NCF1 and TRAF4; 
and CRNKL1, ESYT2, KBTBD10 and SLC2A4 (discussed in section 8.3.2.2; see Figure 8.4). 
Further, all twelve genes feature in near-optimal BioGranat-IG quadruplets. Of the four 
additional genes, only TELO2 is a seed gene (containing variants for two of the pedigrees). 




Table 8.8 – Across-pedigree RGA results for CD using simple count ranking 
See next page for full table legend. 
Network 












1 1 33 0.3667 1586 677 0.1944 
2 1 33 0.3449 1586 677 0.1944 
3 1 4 0.5325 1586 677 0.1944 
4 1 1 1.0000 1586 677 0.1917 
2 2 1 1.0000 12 7 0.0750 
3 2 1 1.0000 3 2 0.7349 
4 2 1 1.0000 1 1 1.0000 
3-4 3-4 1 1.0000 1 1 1.0000 
PINAmin2_d50 
1 1 10 0.3249 372 200 0.2443 
2 1 10 0.2055 372 200 0.2443 
3 1 1 1.0000 372 200 0.2041 
2 2 1 1.0000 6 4 0.0759 
3 2-3 1 1.0000 1 1 1.0000 
4 1-4 0 1.0000 0 0 1.0000 
CPDBconf95_d50 
1 1 19 0.3121 827 354 0.0013 
2 1 19 0.2713 827 354 0.0013 
3 1 3 0.3907 827 354 0.0013 
2 2 1 1.0000 5 3 0.7518 
3 2-3 1 1.0000 1 1 1.0000 
4 1-4 0 1.0000 0 0 1.0000 
COXPRES30_d50 
1 1 48 0.9144 3998 1182 0.2161 
2 1 48 0.9137 3998 1182 0.2161 
3 1 9 0.9470 3998 1182 0.2161 
4 1 9 0.6110 3998 1182 0.2161 
2 2 7 0.0002 47 25 0.2089 
3 2 7 < 0.0001 47 25 0.2055 
4 2 7 < 0.0001 14 7 0.5979 
3 3 2 0.0360 2 2 0.3403 
4 3 2 0.0237 2 2 0.2193 
4 4 1 1.0000 1 1 1.0000 
Multinet_d50 
1 1 26 0.2817 1138 512 0.6617 
2 1 26 0.2614 1138 512 0.6617 
3 1 5 0.2076 1138 512 0.6602 
4 1 1 1.0000 1138 512 0.5663 
2 2 1 1.0000 8 3 0.7807 
3 2 1 1.0000 7 4 0.1129 
4 2 1 1.0000 1 1 1.0000 
3-4 3-4 1 1.0000 1 1 1.0000 
 




Table 8.8 – Across-pedigree RGA results for CD using simple count ranking (previous page) 
“# pedigrees” = definition of the RGA threshold parameters α and β in each test according to the 
number of pedigrees in which genes contain post-filtering variants; “No jumps” = Results of tests in 
which RGA does not permit region expansion to include jumps of up to one non-seed/member node; 
”With jumps” =  Results of tests in which RGA allows such jumps; “Region size” = number of nodes 
in a region; “Seed/member nodes” = number of nodes with rank ≤β (here β corresponds to a number 
of pedigrees in which genes contain post-filtering variants, so seed/member nodes are genes 
containing variants in this many pedigrees or greater); “p-value” = standard p-value produced by 
RGA, calculated as the proportion of 10,000 degree-constrained permuted networks in which regions 
with greater or equal number of seed/member nodes are identified. Green shading indicates nominally 
significant p-value of < 0.05; yellow shading indicates < 0.1. 
None of the twelve genes feature in the list of 300 prioritised genes identified by Jostins et 
al. (Jostins et al. 2012), although TRAF4 and SLC2A4 directly interact with genes from the 
list in PINA_d50. A GO enrichment test based on all twelve genes found no significantly 
enriched biological process annotation (data not shown). As we found in section 8.3.2.2., the 
quadruplet CENPE-MAP3K4-NCF1-TRAF4 alone does show enrichment for a potentially 
relevant process, suggesting that these four genes should be prioritised for further study 
(although conversely, as with many of the regions we find, it could be argued that the 
additional genes in the region could warrant further attention for the purpose of de novo 
pathway discovery). 
In the PINAmin2_d50 high-confidence PIN, when jumps were permitted the most 
significant region was again identified for α = β corresponding to genes containing variants 
for two pedigrees. The region comprised six genes in total, with four being seed nodes for 
the region (Figure 8.9b; p = 0.0759). One gene (NCF1) was also found in the PINA_d50 
region discussed in the previous paragraph, and three of the genes (ACTB, NCF1 and 
SMARCE1) were previously identified by BioGranat-IG as an optimal triplet and as part of 
the optimal quadruplet with the most significant KGGSeq-prioritisation score (see Table 8.4 
and Figure 8.6). Of the three additional genes, two (NCOA2 and PGR) are seed genes, each 
containing post-filtering variants for two of the pedigrees. Pedigree 265 carries a variant in 
three of the six genes. None of the six genes feature in the list of 300 prioritised genes 
identified by Jostins et al. (Jostins et al. 2012), although there are several direct interactions 
in PINAmin2_d50 connecting NCF1, NCOA1 and NCOA2 with genes on the list. To identify 
shared function among the genes in the region a GO enrichment test was performed. The 
most enriched terms, including “intracellular steroid hormone receptor signalling pathway” 
(3 genes; adjP = 0.0086) and “cerebellum development” (2 genes; adjP = 0.0243), were all 
based on the function of the two nuclear receptor coactivator genes NCOA1 and NCOA2 
(only the first of which contains post-filtering variants for any of the CD pedigrees). The 




Figure 8.9 – Near-significant regions for CD identified by across-pedigree RGA using simple count ranking 
In both subnetworks: red nodes correspond to seed genes; numbers next to each node refer to the pedigrees in which they contain variants. (A) Region of 12 genes 
identified in PINA_d50 with α = β corresponding to post-filtering variants in two pedigrees. Green dashed regions were previously found as optimal quadruplets using 
BioGranat-IG (shown in Figure 8.4). (B) Region of six genes identified in PINAmin2_d50 with α = β corresponding to post-filtering variants in two pedigrees. Blue 
dashed region was previously found as an optimal triplet and part of an optimal quadruplet using BioGranat-IG (cf. Figure 8.6). 
 




of transcription and consequently influence a wide range of functional systems (York and 
O'Malley 2010), although there is no established link to IBD. 
8.3.4.2 Case-Control Ranking 
With genes ranked according to the degree to which the number of pedigrees 
carrying a post-filtering variant exceeded the expected number (based on a null distribution 
derived from the 338 non-CD control exomes), RGA was performed using all thresholds in 
the range 1 ≤ α ≤ 1,000, with β = α. 
Figure 8.10 shows the size and significance of the largest regions found at each α 
level for each network, and a summary of the most significant regions identified in each 
network is given in Table 8.9. 
The only network in which region sizes achieved nominal significance (p < 0.05) 
was PINA_d50. When RGA was performed using this network with jumps disallowed, the 
lowest p-value found was 0.0037, and the first threshold for which this value was observed 
was α = 23. The resulting region comprised three genes: PPIB, SURF4 and TMBIM4 (see 
Figure 8.11). All three genes contained a post-filtering variant for one of the 25 pedigrees 
(pedigrees 1066, 879 and 1709 respectively), but no post-filtering variants in any of the 338 
non-CD control exomes. It is worth noting that whole exome sequencing for all three of 
these pedigrees was performed at ICMB, while all non-CD control exomes were sequenced 
at KCL, so it is possible that this finding represents technical differences between 
sequencing platforms (but note that only 27 of the 43 genes for which variants were found in 
case pedigrees but not in non-CD control exomes have variants exclusively in ICMB
Table 8.9 – Most significant CD regions for across-pedigree RGA using case-control ranking 
“No jumps” = results of tests in which RGA does not permit region expansion to include jumps of up 
to one non-seed node (node with rank >α); ”With jumps” =  results of tests in which RGA allows such 
jumps; “Lowest p-value” = lowest empirical RGA p-value observed across tests at each threshold α in  
1 ≤ α ≤ 1,000; “smallest α” = smallest α to have achieved this p-value; “Region size” = number of 
nodes in largest region at this α threshold; “Seed nodes” = number of nodes with rank ≤α in this 
region. Green shading indicates nominally significant p-value of < 0.05; yellow shading indicates < 
0.1. 
Network 















PINA_d50 0.0037 23 3 0.0057 106 31 15 
PINAmin2_d50 0.3940 78 2 0.1017 862 171 88 
CPDBconf95_d50 0.6197 265 3 0.2221 971 419 185 
COXPRES30_d50 0.2139 207 4 0.1024 487 1065 347 




Figure 8.10 – Across-pedigree RGA results for CD using case-control ranking 
Each plot gives results for a different network. For each alpha value, size of network region and empirical p-value are plotted. The nominal significance threshold is 
plotted at 0.05. This output is characteristic of RGA results: the region size is an increasing step function; at each alpha value where there is an increase in region size, the 




Figure 8.11 – Significant regions for CD identified in PINA_d50 by across-pedigree RGA using case-control ranking 
Red nodes correspond to seed genes; numbers next to each node refer to the pedigrees in which they contain variants. Whole region of 31 genes was identified at α = 106 
when jumps were permitted; three genes within green dashed region were also identified at α = 23 when jumps were not permitted. 




pedigrees (62.8%); since 16 of the 25 pedigrees were sequenced at ICMB (64.0%) this does 
not suggest a bias due to platform differences). Since only three pedigrees carry a variant in 
this region, these three genes are best considered as a part of the region to be discussed in the 
following paragraph. 
When RGA was performed using PINA_d50 with jumps permitted, the lowest p-
value found was 0.0057, and the first threshold for which this value was observed was 
α = 106. The resulting region comprised 31 genes, of which 15 are seed nodes (including 
PPIB, SURF4 and TMBIM4 which were found when jumps were not permitted) (see Figure 
8.11). This region is intriguing due to the existing functional annotation for several of the 
genes. It includes a highly-connected module of six proteasome subunit genes, of which 
PSMB1 and PSMB9 are seed nodes (PSMB1 has a rank of 23 with a post-filtering variant in 
one pedigree and none in the 338 non-CD control exomes; PSMB9 has a rank of 77.5 with a 
variant in one CD pedigree and one non-CD control exome). The other subunit genes do not 
contain post-filtering variants in any CD pedigree. The proteasome has an important role in 
the adaptive immune system: it digests cytoplasmic proteins, including antigens which can 
be presented to the immune system by major histocompatibility complex (MHC) class I 
molecules (van Kasteren et al. 2014). Thus the most enriched GO biological process term 
based on all 31 genes in the region is “antigen processing and presentation of peptide antigen 
via MHC class I”, with which all six proteasome genes, plus BCAP31 and NCF1, are 
annotated (adjP = 1.07×10
-8
). The six proteasome genes plus BCL10 are elements of 
Reactome’s curated “activation of NF-κB in B-cells” pathway (obtained via MSigDB). 
ATF1 is also present in Reactome’s “activated TLR4 signalling” pathway, an innate immune 
process that responds to bacterial infection. One of the genes, NCF1, was found in an 
optimal BioGranat-IG quadruplet (see Figure 8.4), and four others were found along with 
NCF1 in a merged region of 132 genes formed from near-optimal quadruplets (discussed in 
section 8.3.2.2). As described earlier, we also know that mutations in NCF1 can result in an 
early-onset CD-like phenotype (Uhlig et al. 2014). None of the genes feature in the list of 
300 prioritised genes identified by Jostins et al. (Jostins et al. 2012), although seven have 
direct interactions in PINA_d50 with genes on this list. 
Inspection of the network diagram in Figure 8.11 leads to two further observations. 
Firstly, note that BCAP31 is included in the region and contains post-filtering variants in 
nine genes (as we saw in Table 8.2; recall that for RGA using case-control ranking we have 
not excluded genes with 20 or more post-filtering variants in the non-CD control exomes). 
Nevertheless, BCAP31 is not a seed gene and has been incorporated into the region as a 
jump. It has a rank of 213 due to the 65 non-CD control exomes in which it contains a 
variant. Likewise RIMS1 is included as a jumped node despite containing a variant in one 




pedigree. Secondly, of the six proteasome subunit genes, four are included as jumps; only 
one pedigree actually carries a variant in each of the other two genes. This could have biased 
the functional enrichment tests described above, and it is perhaps more prudent to examine 
only genes containing variants (as these are the only ones for which we have direct evidence 
that could suggest perturbed function in our pedigrees). Repeating the GO enrichment test 
using only these genes (the 15 seed nodes plus BCAP31 and RIMS1) results in the same 
biological process (“antigen processing and presentation of peptide antigen via MHC class 
I”) being most enriched (BCAP31, NCF1, PSMB1 and PSMB9; adjP = 0.0017), with “G1/S 
transition of mitotic cell cycle” also significantly enriched (CAMK2A, CAMK2G, PSMB1 
and PSMB9; adjP = 0.0063). 
On balance, this region’s significant RGA p-value and prior functional annotation 
make it a potential candidate for further study. Initially this could comprise testing for rare 
sequence variants in these genes in an additional cohort of familial CD samples, but 
subsequent laboratory-based experiments (using appropriate cell lines or animal models) 
would be needed to show that these variants could be linked to the CD phenotype for any of 
the 16 pedigrees in which the region contains a variant. 
The only other network in which a near-significant region (p < 0.1) was identified 
was Multinet_d50. When jumps were not permitted the lowest p-value found was 0.0596, 
corresponding to α = 862 and a region of twelve genes (see Figure 8.12). To give an idea of 
the enrichment implied by this alpha threshold, the lowest-ranked genes in the region (each 
having the same rank of 861.5) were GPD1, LPL and NFX1. These genes contain post-
filtering variants in one CD pedigree each, and in eight of the 338 non-CD control exomes. 
Four of the genes (ALDH1B1, ASMT, LIPA and LPL) were previously found in a 
significantly large region found by within-pedigree RGA (see Table 8.6; all four genes and a 
direct neighbour contain a variant in pedigree 64, but note that relaxed variant-filtering 
criteria were used in that analysis). None of the genes were previously found in optimal 
BioGranat-IG triplets or quadruplets, although nine of the twelve genes were found in near-
optimal subnetworks (results not shown). None of the twelve genes, and no genes with 
which they directly interact, feature in the list of 300 prioritised genes identified by Jostins et 
al. (Jostins et al. 2012). The region appears to be broadly implicated in metabolism, the most 
significantly enriched GO biological process term being “small molecule metabolic process” 
(11 genes; adjP = 5.83×10
-5
) with more specific annotation including “alcohol metabolic 
process” (5 genes; adjP = 0.0005) and “lipid metabolic process” (7 genes; adjP = 0.0005). 
Although this may be of broad interest (although diet has not been shown to affect disease 
risk, there appears to be a complex relationship between nutrition and inflammation in IBD 
(O'Sullivan and O'Morain 2006)), the non-significant region size and lack of statistical 




association in the recent IBD GWAS meta-analysis mean that this region should not be 
prioritised for further study. 
8.4 Conclusions 
Most research into the genetics of CD is concerned with (not necessarily rare) 
variants that increase the carrier’s risk of disease as part of a multifactorial mechanism. In 
this chapter we have used whole exome sequencing and network analysis to investigate 
evidence for an alternative form of CD whose genetic architecture is closer to a monogenic 
or oligogenic disease, such that one or a small number of rare highly-penetrant variants are 
responsible for most of the disease risk. 
For 25 affected pedigrees we filtered the shared variants identified by whole exome 
sequencing so that we were left with rare non-synonymous variants in genes that do not 
frequently contain such variants in non-CD controls. One clear conclusion is that there is no 
single gene, and no small subnetwork in any of the networks tested, in which all or most of 
the pedigrees carry a shared post-filtering variant. This suggests that if these families do 
 
Figure 8.12 – Near-significant region for CD identified in Multinet_d50 by across-pedigree RGA using 
case-control ranking 
Numbers next to each node refer to the pedigrees in which they contain variants. Jumps were not 
permitted therefore all genes in the region are seed nodes. 




have a monogenic or oligogenic form of CD then genetic heterogeneity could present a 
substantial difficulty in identifying the causal variants. 
However, our hypothesis-free (that is, candidate-gene-free) network analyses found 
several subnetworks for which relevant previous functional annotation suggests that further 
study could be beneficial. The most promising subnetworks include: the quadruplet CENPE-
MAP3K4-NCF1-TRAF4 in PINA_d50 (Figure 8.4) and several optimal subnetworks in 
PINAmin2_d50 (Figure 8.6 and Figure 8.7) that were identified by BioGranat-IG (under the 
assumption of a monogenic cause); the significantly clustered regions found in 
COXPRES30_d50 using within-pedigree RGA (under the assumption of an oligogenic 
cause; Figure 8.8); and  the region of 31 genes found in PINA_d50 by across-pedigree RGA 
using case-control gene ranking (Figure 8.11), which includes several proteasome subunit 
genes and is significantly enriched for rare non-synonymous variants in the CD pedigrees. 
There is some overlap between these regions, which is not surprising given that there is 
overlap between the different networks used (see chapter 2) and that, despite the different 
assumptions they make about the possible genetic architecture of CD, the primary goal of all 
of the network methods used is to identify connected sets of genes having a concentration of 
post-filtering sequence variants. 
Follow-up work for these regions could involve several steps. Sanger sequencing of 
the identified variants in these pedigrees would be able to confirm that they had been 
correctly identified by whole exome sequencing (although the fact that each variant used in 
these analyses has been independently called in at least two related individuals gives 
confidence that they are correct). Next, sequencing or genotyping of candidate genes in an 
additional familial CD cohort could be performed in order to replicate these findings. Over 
100 families with multiple CD-affected individuals and a further ~100 individuals with a 
self-reported family history of CD are available to provide DNA for this purpose at KCL. 
Finally, strong candidate genes can be subjected to laboratory-based expression and 
functional testing to establish a biological link to the CD phenotype (such as expression in 
appropriate tissues, altered expression in mutagenised cell lines or a consistent phenotype in 
gene knockdown or knockout animal models). 
Interestingly none of the genes identified by our analyses interact directly (in any of 
the networks used) with NOD2, currently the most explanatory CD gene (Jostins et al. 
2012). NOD2 is thought to be central to CD biology; for example, in the hypothesised 
autophagy pathway for CD, the protein encoded by the key CD risk gene ATG16L1 was 
shown to be recruited to the cell membrane by NOD2 as a bacterial response (Cooney et al. 
2010; Travassos et al. 2010). (Note, however, that this relationship is not represented by an 




interaction in any of the networks studied here.) Interaction with NOD2 would therefore be 
seen as strong supporting evidence of a CD role. 
It should be noted that this study has a number of limitations. A major drawback is 
that network coverage of the genome is still limited. For example, of the 1,602 genes in 
which a post-filtering variant is found for at least one pedigree, only 842 (52.6%) are 
represented in the main interaction network considered here, PINA_d50. Therefore we 
cannot yet definitively conclude that no small set of interacting genes is responsible for CD 
in all or most of these families, and it may be worth repeating these analyses when more 
comprehensive interaction networks become available. 
We might also have missed true causal variants due to incomplete sequencing 
coverage (see Table 8.1). This is of particular relevance in this study where a sequence 
variant needs to be identified independently in multiple related individuals to be included in 
our analyses. A more sophisticated approach that might partially overcome this problem 
could be to perform sequence-based identity-by-descent analysis (Su et al. 2012; Zhuang et 
al. 2012) within pedigrees to find shared chromosomal segments, and to add to the analysis 
variants found in at least one individual in any of these regions. 
Other limitations are common to the usual intersection filtering approach to whole 
exome sequence data analysis. We assume that if there are rare highly-penetrant variants 
underlying familial CD in these pedigrees, these variants will be found in coding regions; in 
practice variants in introns, or within regulatory elements such as promoters, enhancers and 
silencers, can also cause inherited disease (Cooper et al. 2010). We also assume that the 
filtering steps that we take to reduce the number of variants under consideration (excluding 
relatively common variants, synonymous variants, and variants in genes that are tolerant of 
rare non-synonymous variants) are appropriate. This could also be incorrect and it is of 
course possible to repeat all of the analyses using different filtering criteria. 
We have tested the hypothesis that CD in these families is caused by high-impact 
perturbations to specific molecular processes, with the consequence that CD can be 
effectively thought of as a monogenic or oligogenic disease in these cases. This will almost 
certainly be an oversimplification of the true disease mechanism. For example, several of the 
pedigrees may also carry common (known or as-yet-unknown) risk variants for CD; indeed, 
we know that this is the case for several of the known NOD2 risk variants (see section 
8.2.2). If one or a small number of variants is chiefly responsible for CD in these pedigrees, 
it is likely that these common risk variants could also play a role as modifying mutations. As 
described in section 8.2.1, a small number of the CD cases considered were comorbid for 
other inflammatory or immune-mediated phenotypes, and a small number of CD-unaffected 
family members were affected by such phenotypes, including UC. The relevance of these 




other phenotypes to the molecular basis of CD in these cases is undetermined; due to their 
clinical heterogeneity a pedigree-by-pedigree investigation of these cases would be 
warranted to consider possible disease interactions. Finally it should also be acknowledged 
that there could be a risk of ascertainment bias. Since the common complex form of CD has 
a substantial genetic component, relatives of CD-affected individuals are at increased risk of 
developing CD, and the families recruited for this study could represent the unfortunate few 
where this increased risk is borne out in multiple individuals. 
In summary, while the pedigrees studied in this work show strong patterns of 
inheritance for CD, there is no single gene that is responsible for causing familial CD. CD is 
a complex disorder and these familial cases are at best likely to have one or a few primary 
causal variants that sharply increase disease risk alongside smaller effects from many other 
genetic and non-genetic factors. By undertaking network analyses that examine several 
potential genetic architectures we make an important step towards elucidating these 
mechanisms. These analyses have proposed several network regions that could represent key 





9 Concluding Discussion 
9.1 Summary of Findings 
Genetic heterogeneity presents a considerable challenge to next generation 
sequencing studies of rare disease, and there is a need for novel analysis tools to address this 
problem. I showed in chapter 3 that many monogenic diseases can be caused by different 
genes that are connected in interaction networks. This motivated the development of two 
bioinformatic tools, each taking very different approaches to the problem but both making 
the broad assumption that for a given disease the ability to successfully identify true disease-
causing variants among the many identified by whole exome sequencing can be improved by 
considering genes that are proximal in an interaction network. 
BioGranat-IG does this by taking an approach that is very similar to intersection 
filtering, but does not use individual genes as discrete genomic units in which to look for 
intersection. Instead, by solving the minimal connected set cover (MCSC) problem 
BioGranat-IG identifies small connected subnetworks of genes that contain post-filtering 
variants in all or most exomes in a study. In chapter 4 I simulated data for two real diseases 
and verified that this concept could effectively overcome genetic heterogeneity. Using 
synthetic data I also confirmed that BioGranat-IG is most effective when locus heterogeneity 
is modelled by a disease subnetwork that is small, has relatively low network connectivity 
and harbours disease-causing variants in the majority of exomes in the study. 
HetRank represents a more radical departure from the intersection filtering method; 
sequence variants are ranked instead of filtered against expected pathogenicity criteria with 
ranks being adjusted to account for possible locus heterogeneity based on network data. At 
the time HetRank was developed, experience with real whole exome sequencing data 
suggested that the simulated data used in chapter 4 to test BioGranat-IG might have been 
relatively optimistic about the degree of genetic heterogeneity underlying many rare 
monogenic diseases. In chapter 5 I therefore strove to construct a more realistic set of test 
data, simulating 1,000 exome sequencing studies of 20 exomes each based on real sequence 
data and allowing a range of genetic heterogeneity to be modelled. I showed that HetRank 
was able to prioritise disease-causing genes, achieving a substantial improvement over 
intersection filtering and BioGranat-IG at higher levels of heterogeneity. 




How successfully do network-based methods such as BioGranat-IG and HetRank 
overcome the limitations of intersection filtering that are imposed by the assumptions 
discussed in the introduction (section 1.3.4)? These were: 
 That the disease-causing variants occur in exons. This is of course a 
fundamental constraint of any study limited to whole exome sequencing data and 
thus applies to both methods. However, as we gain increased understanding of the 
diverse functional roles of non-coding genomic regions, intersection filtering 
itself may in future be applicable to whole genome sequencing data. If so, there 
will undoubtedly also be a role for methods such as these, making use of 
networks that systematically describe interactions between genomic regions of 
discrete function (e.g. Gerstein et al. 2012). 
 That the exonic variants are identified by whole exome sequencing. For 
performance-testing of both BioGranat-IG and HetRank, simulated data was 
designed to model a range of scenarios in which the true disease-causing variants 
were missing from genes in the interaction network (parameter p in chapter 4; 
“uncaptured heterogeneity” u in chapter 5). This could equally well represent 
imperfect sequencing coverage as imperfect network coverage, with results 
suggesting that network-based methods may be better equipped than intersection 
filtering to deal with a small amount of missing data in the presence of locus 
heterogeneity. Naturally all methods are better powered to prioritise the true 
causal variants if they are present in whole exome sequencing output. 
 That the filters applied are appropriate (e.g. for rare, non-synonymous variants 
or expected mode of inheritance). BioGranat-IG, as a generalisation of 
intersection filtering, is still subject to this assumption. HetRank, however, uses 
variant-ranking to dispense with the need for filtering, which removes the risk of 
excluding true causal variants. (But note that for this method we still must assume 
that our ranking criteria are appropriately chosen and weighted.) 
 That a single gene is responsible for all or most cases of the disease. Network-
based methods explicitly challenge this assumption. They suppose that disease 
phenotypes result from the disruption of a functional pathway of interacting gene 
products and that the information encoded by interaction networks can help to 
identify and understand these pathways (e.g. Oti and Brunner 2007; Barabasi et 
al. 2011). This idea is central to both BioGranat-IG and HetRank. 




The subsequent chapters have been concerned with the application of BioGranat-IG, 
HetRank and other network-based methods to real diseases where an intersection filtering 
approach had previously been unable to identify strong candidate disease genes. All of the 
methods investigated allowed an exploration of possible mechanisms of locus heterogeneity. 
In chapter 7 BioGranat-IG and HetRank were employed to study Adams-Oliver syndrome 
(AOS), an archetypal rare monogenic disease with a heterogeneous genetic basis. Both 
methods, which are hypothesis-free in the sense that they are exome-wide, highlighted genes 
with plausible functional links to the disease phenotype and there was some overlap in 
results. However, arguably the most promising approach was to examine the network 
neighbourhoods of known disease genes. In chapter 8 familial cases of a complex disorder, 
Crohn’s disease (CD), were studied in order to test the hypothesis that these might be rare, 
effectively mono- or oligogenic forms of the disease. BioGranat-IG analysis examined the 
evidence for a monogenic disease mechanism under locus heterogeneity, while two different 
applications of Region Growing Analysis (RGA; an existing tool of which an improved 
version was implemented in chapter 6) went beyond this to explore whether a multifactorial 
genetic architecture, characterised by oligogenicity and genetic heterogeneity, can be 
elucidated using interaction networks. 
Despite suggesting intriguing avenues for further study in each disease, these studies 
fell short of identifying a “smoking gun” in either case. One reason for this could be the 
level of genetic heterogeneity underlying each disease, which could make the true causal 
variants indistinguishable from background variation even when some of these variants 
occur in interacting genes. If this is the case then larger sample sizes would be expected to 
provide better power to identify these disease-causing mechanisms using network-based 
methods (for example, this was demonstrated using simulated data for BioGranat-IG in 
chapter 4). 
Due to the large number of variants identified by whole exome sequencing, one 
objective of the methods developed here was to prioritise a small number for further study. 
The range of networks used and analyses performed, however, resulted in a considerable 
number of subnetworks demanding further attention, albeit ones whose interactions should 
relatively quickly allow their plausibility as disease mechanisms to be assessed by 
researchers specialising in these diseases. (But note that for the preliminary assessments I 
have presented in chapters 7 and 8, existing functional annotation was used as one method of 
evaluating candidate disease subnetworks; it should be noted that the very use of interaction 
networks is to facilitate de novo pathway discovery (Lehne and Schlitt 2012).) 
A desirable property of a gene prioritisation method would be to generate a p-value 
indicating how unlikely the observed results would be under some null hypothesis (as, for 




example, produced by an association test). This would be problematic for the methods 
described here due to the difficulties in specifying an appropriate null distribution in light of 
all the variability involved, which includes network structure, sequencing coverage, the 
propensity of different genes to tolerate functional variation and the necessarily unknown 
degree of genetic heterogeneity of the disease under study. In addition, BioGranat-IG and 
HetRank are designed to be used for rare disease studies with relatively small sample size, 
making them particularly susceptible to confounding statistical noise. The methods should 
therefore be thought of, like intersection filtering itself, as explorative tools to generate 
hypotheses rather than statistical methods that test them. 
Finally, it is important to be aware that the networks used in this thesis provide a 
static (and incomplete) representation of an interactome viewed at the whole-organism level. 
In reality genes are expressed at different levels in different tissues, and these change over 
time (for example, during embryonic development). To fully understand the functional 
pathways underlying a disease would require knowledge of the molecular interactions that 
occur in disease-relevant tissues at appropriate time points. However, until the aetiology of a 
disease is understood, the most relevant tissues and time points may not be known. 
Therefore the networks that we use provide a proxy, albeit most likely a poor one, for the 
“real” interaction network in the body. 
9.2 Future Work 
9.2.1 BioGranat-IG 
In chapter 4 it was suggested (as felt at the time of development) that further work to 
improve the performance of the heuristic minimum- and multi-minimum distance searches 
would be beneficial (improved performance here equating to an increased probability that all 
true optimal MCSC solutions are identified by the algorithms). However, the findings of 
chapter 7, where BioGranat-IG was applied to real disease data, suggested that the results of 
the heuristic searches (which by design continue extending candidate subnetworks until they 
harbour a post-filtering variant for all exomes) may be less informative than the results of 
the exact triplet and quadruplet searches. I would therefore argue that further development 
efforts for BioGranat-IG should focus on improving the efficiency of the exact searches. For 
example, one possible starting point to improve running time might be to work through 
network genes in descending order of the number of exomes in which they contain variants, 
examining the triplets and quadruplets they occur in, and stopping this process when it 
becomes impossible to find a better subnetwork than one already found (a similar short-cut 




is already taken by the heuristic searches). Inefficiencies in memory usage should also be 
addressed, for example due to the accumulation of triplets and quadruplets that are not 
optimal or within the limits allowed by the user-specified flexibility parameters. 
One advantage of improved efficiency would be a better ability to perform searches 
quickly for highly-connected networks. For example, we saw in chapter 5 (for the 
comparison against HetRank) that the current implementation was unable to provide triplet 
search results from 1,000 simulated studies in the full (hub-retained) PINAmin2 network. It 
might also make it more feasible to estimate the significance of the observed results by 
permutation testing. This would itself require development of a more sophisticated 
significance test; the relatively crude test implemented in chapter 4 makes the 
oversimplifying assumption that network genes are equally likely to contain post-filtering 
sequence variants in case exomes. One option would be to estimate each gene’s propensity 
to contain variants using control exomes; another is to use the original data in a permuted 
network (but note this would fix the number of genes containing variants in multiple 
exomes). 
Whether or not improvements to efficiency or algorithm accuracy are made, 
BioGranat-IG in its present form assumes that solving the discrete unweighted MCSC 
problem can usefully highlight possible disease-causing pathways based on the presence or 
absence of variants, and I have tested this concept thoroughly in this thesis. But it would be 
interesting to consider whether we can move beyond the intrinsic limitations of this model. 
For example, a formulation of the problem that builds weights into the measure of “fitness” 
of a candidate subnetwork (currently based on size and number of exomes covered only) 
might be more effective. Node weights might represent the ability of each gene to tolerate 
functional variation (thus avoiding the need to exclude variants in highly polymorphic genes 
as is done in chapters 7 and 8) or a pathogenicity score from a variant effect prediction tool 
(so that for example the variant scores used in KGGSeq-prioritisation, introduced in chapter 
6, are incorporated into the identification of optimal subnetworks and not just the 
retrospective evaluation of them). Edge weights might reflect interaction confidence or the 
degree to which interactions are disrupted by the variants in case exomes (assuming the 
availability of a suitable genome-wide reference database (see e.g. Zhong et al. 2009; Wang 
et al. 2012)). 
9.2.2 HetRank 
Of the two methods developed in this thesis, HetRank requires the most additional 
development to improve its effectiveness at prioritising genes for further study in the 




presence of genetic heterogeneity. Application of HetRank to the AOS exomes in chapter 7 
revealed a number of features that should be addressed in future iterations of the tool. 
A key problem is to redesign the network-based rank adjustment to have a more 
neutral effect on final gene ranks. At present genes are conferred a considerable ranking 
advantage simply by being present in the network; this conflicts with one of the original 
design principles of HetRank: that network-informed ranking would replace subnetwork 
identification so as not to prevent non-network genes from being prioritised. It is also the 
case that most of the genes that HetRank prioritised had had their ranks adjusted by better-
ranked neighbours in the majority of exomes. While this might be expected due to the 
presumably small number of actual causal variants and large network neighbourhoods, many 
of the genes appeared to be highly-ranked on the basis of indirect evidence from network 
neighbours alone. To be able to demonstrate a causal relationship it is necessary that at least 
some of the case exomes in a study have direct evidence in the form of a causal variant, and 
a reformulation of the adjustment mechanism should also try to address this imbalance. 
The user-specified weight parameters that HetRank uses to combine variant ranks 
from various criteria into a final gene rank for each exome should also be considered further. 
As with any exploratory tool it is important that these parameters can be adjusted to allow 
different hypotheses to be considered. For example, when the tool was applied to AOS data 
in chapter 7 we saw that a carefully-reasoned change to the weights – reflecting the belief 
that causal AOS variants should not be present in other exomes in our in-house database – 
resulted in genes with more-feasible pathogenic variants being prioritised (see section 
7.3.9.2). However, a more systematic approach to calibrating these parameters is desirable, 
allowing a user to easily quantify their beliefs about the genetic architecture of the disease 
being studied. This is particularly important when new ranking criteria are introduced, and 
while various considerations were discussed in chapter 5, further application of HetRank to 
real datasets should help to establish this approach. 
Ideally, HetRank could suggest an initial set of weights automatically based on the 
input data. There would be several factors to consider. Since a criterion’s ability to 
discriminate different variants is important, weights might account for the information 
contained in the various criteria (by estimating a measure such as the information entropy of 
each ranking factor from the input data (Shannon 1948)). However, it would also be 
necessary to account for correlation between different ranking criteria, such as different 
measures of allele frequency. A more sophisticated approach again could see the user choose 
from a list of common disease models (e.g. “rare autosomal dominant”) and assign their 
ranking criteria to built in “types” (e.g. “allele frequency”, “zygosity”, “pathogenicity”). 




Again, extensive testing with real datasets would be required to establish the best way to use 
this information. 
Finally, it would be beneficial to develop and test a more formal method of 
interpreting the ranked gene list output by HetRank. In chapter 7 several approaches were 
used to focus on individual genes, including counting the number of exomes in which genes 
are highly ranked, performing RGA and testing for enrichment of existing functional 
annotation. Ideally these and other methods should be compared and evaluated to produce a 
recommended HetRank protocol. One possibility might be to incorporate network 
permutations that allow gene ranks to be compared against those expected under a null 
hypothesis of non-informative interactions. As with BioGranat-IG, however, a more efficient 
implementation of HetRank would be required to make this feasible. 
9.2.3 Interaction Networks 
One of the biggest limitations of all the network-based methods described in this 
thesis is the incomplete nature of currently available interaction networks. Performance 
testing in chapters 4 and 5 clearly demonstrated that BioGranat-IG and HetRank both benefit 
from better network coverage, and we saw in chapter 7 that the ability of both tools to find 
known AOS genes was compromised by the absence of interactions reflecting the 
underlying disease mechanisms in several networks. This problem is one that should be 
gradually resolved by continuing efforts to generate reference interactomes using high-
throughput methodologies (see e.g. CCSB 2014). 
Meanwhile there are several measures that can be taken to make more effective use 
of current interaction networks. Firstly, one problem encountered in chapters 7 and 8 was the 
interpretation of subnetworks identified in the COXPRES30 and COXPRES30_d50 co-
expression networks, due to the fact that interactions represent correlated gene expression 
rather than direct functional relationships. To make these analyses more useful it would be 
necessary to investigate methods to systematically interpret such subnetworks. The 
developers of COXPRESdb suggest that consideration of tissue-specific expression or 
existing functional annotation (such as Gene Ontology or KEGG annotation) could be 
usefully employed for this purpose (Obayashi et al. 2008). However, the automation of 
processes such as these would make a challenging data integration project. 
Where BioGranat-IG and RGA have been utilised in this thesis, highly-connected 
hub genes have been removed from the interaction networks used because they tend to be 
overrepresented in results. However, a pragmatic approach was taken by using an arbitrary 
degree threshold to select hubs for removal. Identification of a more sophisticated strategy 
for hub removal would represent a substantial undertaking in itself. One way this could be 




done would be to use simulated exome data (as generated in chapter 5, for example) to 
systematically test the ability of BioGranat-IG to correctly identify “spiked” disease 
subnetworks over a range of hub-removal thresholds in multiple networks. Optimal hub-
removal thresholds would then need to be characterised in terms of network properties in 
order to make this approach applicable to alternative interaction networks that may become 
available in future. 
9.2.4 Adams-Oliver Syndrome and Familial Crohn’s Disease 
It would of course be beneficial to re-analyse AOS and familial CD whole exome 
sequencing data if the improvements to the methods and interaction networks described 
above are implemented. Meanwhile the putative disease-causing genes highlighted in this 
thesis can be evaluated. This could lead to the analyses being repeated using alternative 
parameters following feedback from geneticists with expertise in the respective diseases, or 
to further laboratory-based experiments to validate or reject candidate genes, as discussed 
more fully in chapters 7 and 8. 
9.3 Conclusions 
It was already known that because they encode relationships between genes and 
gene products, interaction networks can be used to help address a range of problems in 
genetic data analysis. In this thesis we have shown that one viable application is to help 
overcome the problem of locus heterogeneity in whole exome sequencing studies of rare 
monogenic disease, a problem that limits simpler approaches such as intersection filtering. 
We have seen that network-based methods can suggest novel disease mechanisms 
for monogenic diseases and can be used to study suspected mono- or oligogenic forms of 
complex diseases, potentially leading to an improved understanding of the disease biology 
which could also be relevant to the common multifactorial form of the disease. 
Developments in several areas are needed to make these methods more dependable 
and results more tractable. These include wider and more precise coverage of relevant 
interactomes by interaction networks and more comprehensive sources of functional 
annotation data. Additionally, improvements to the design of the tools presented in this 
chapter should aim to make them more efficient and more accurate. As next generation 
sequencing leads to the identification of more causal genes for genetically-heterogeneous 
monogenic diseases, publicly-deposited sequence data will provide valuable benchmark tests 
for this task. 




It is clear that network-based methods cannot substitute for the knowledge and 
expertise of skilled geneticists in the identification of disease-causing genes. However, when 
used appropriately they have the potential to direct researchers towards relevant genes and 
functional pathways, thus hastening improvements in our understanding of disease biology 
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Appendix A: OMIM Disease Subnetworks 
The following table lists all disease subnetworks identified in the PINA and 
PINAmin2 networks. Disease subnetworks are connected sets of genes causing the same 
monogenic disease. See chapter 3 for full description. Note that generalised disease terms 
have had disease “type” or “group” designations removed 
Network Generalised disease term 
Causal genes connected in 
network 
PINA 3-M syndrome  CUL7, OBSL1 
PINAmin2 3-M syndrome  CUL7, OBSL1 
PINA 46XY sex reversal  MAP3K1, SRY 
PINA Acne inversa familial  PSEN1, NCSTN, PSENEN 
PINAmin2 Acne inversa familial  PSEN1, NCSTN, PSENEN 
PINA Afibrinogenemia congenital FGB, FGA 
PINAmin2 Afibrinogenemia congenital FGA, FGB 
PINA Agammaglobulinemia  
CD79A, CD79B, BLNK, 
IGHM 
PINAmin2 Agammaglobulinemia  CD79A, BLNK, CD79B 
PINA Albinism oculocutaneous type  TYR, TYRP1 
PINAmin2 Albinism oculocutaneous type  TYR, TYRP1 
PINA Arrhythmogenic right ventricular dysplasia  
JUP, DSP, DSC2, DSC3, 
DSG2, PKP2 
PINAmin2 Arrhythmogenic right ventricular dysplasia  JUP, DSP 
PINA 




Arthrogryposis renal dysfunction and 
cholestasis  
VPS33B, VIPAS39 
PINA Atrial fibrillation familial  KCNQ1, KCNE2 
PINA Axenfeld-Rieger syndrome type  FOXC1, PITX2 
PINA Baraitser-Winter syndrome  ACTB, ACTG1 
PINAmin2 Baraitser-Winter syndrome  ACTB, ACTG1 
PINA Bardet-Biedl syndrome  
ARL6, BBS1, BBS4, BBS12, 
BBS7, BBS9, BBS10, BBS2, 
MKKS, BBS5, TTC8 
PINAmin2 Bardet-Biedl syndrome  
BBS1, BBS4, BBS7, BBS9, 
BBS12, BBS2, ARL6, MKKS, 
BBS5, TTC8 
PINA Bare lymphocyte syndrome type  TAP1, TAPBP 
PINAmin2 Bare lymphocyte syndrome type  TAPBP, TAP1 
PINA 
Bare lymphocyte syndrome type 
complementation group  
RFX5, RFXAP 
PINA Basal cell carcinoma somatic PTCH1, SMO, PTCH2 
PINA Bernard-Soulier syndrome type  GP9, GP1BB 




Network Generalised disease term 
Causal genes connected in 
network 
PINA Brachydactyly type  
BMPR1B, BMP2, GDF5, 
NOG 
PINAmin2 Brachydactyly type  
BMP2, BMPR1B, GDF5, 
NOG 
PINA Bradyopsia RGS9, RGS9BP 
PINA Breast cancer TP53, ESR1, PPM1D 
PINA 
Bronchiectasis with or without elevated 
sweat chloride  
SCNN1B, SCNN1A, 
SCNN1G 
PINA Brugada syndrome  CACNA1C, CACNB2 
PINA C1q deficiency C1QA, C1QB, C1QC 
PINAmin2 C1q deficiency C1QA, C1QB, C1QC 
PINA C8 deficiency type  C8A, C8B 
PINA Cardiofaciocutaneous syndrome BRAF, MAP2K1, MAP2K2 
PINAmin2 Cardiofaciocutaneous syndrome BRAF, MAP2K2, MAP2K1 
PINA Cardiomyopathy familial hypertrophic  
TNNI3, TPM1, TNNT2, 
TNNC1 
PINA Cardiomyopathy familial hypertrophic  MYBPC3, TTN 
PINAmin2 Cardiomyopathy familial hypertrophic  TNNI3, TNNT2, TNNC1 
PINA Cataract Coppock-like CRYBB2, CRYGC 
PINA Cerebrooculofacioskeletal syndrome  ERCC2, ERCC6, ERCC5 
PINAmin2 Cerebrooculofacioskeletal syndrome  ERCC5, ERCC6 
PINA Charcot-Marie-Tooth disease axonal type  HSPB1, HSPB8 
PINAmin2 Charcot-Marie-Tooth disease axonal type  HSPB1, HSPB8 
PINA Charcot-Marie-Tooth disease type  NEFL, MTMR2 
PINA Charcot-Marie-Tooth disease type  PMP22, MPZ 
PINA Choriodal dystrophy central areolar  PRPH2, PRPH 
PINA Cirrhosis cryptogenic KRT18, KRT8 
PINAmin2 Cirrhosis cryptogenic KRT8, KRT18 
PINA Cockayne syndrome type  ERCC6, ERCC8 
PINAmin2 Cockayne syndrome type  ERCC8, ERCC6 
PINA 
Colorectal cancer hereditary nonpolyposis 
type  
MLH1, MSH2, PMS2, MSH6 
PINAmin2 
Colorectal cancer hereditary nonpolyposis 
type  
MLH1, MSH2, MSH6, PMS2 
PINA Colorectal cancer somatic 
EP300, APC, CTNNB1, 
AKT1, BRAF, BUB1B, 
DLC1, AXIN2 
PINA Colorectal cancer somatic NRAS, PIK3CA 
PINAmin2 Colorectal cancer somatic 
AKT1, APC, CTNNB1, 
EP300, AXIN2 
PINA 
Combined cellular and humoral immune 
defects with granulomas 
RAG1, RAG2 
PINA Cone-rod dystrophy  GUCA1A, GUCY2D 
PINAmin2 Cone-rod dystrophy  GUCA1A, GUCY2D 
PINA Congenital disorder of glycosylation type  DPM1, DPM2, DPM3 
PINA Congenital disorder of glycosylation type  
COG1, COG4, COG7, 
COG5, COG6 
PINAmin2 Congenital disorder of glycosylation type  
COG1, COG4, COG7, 
COG6, COG5 




Network Generalised disease term 
Causal genes connected in 
network 
PINA Cornelia de Lange syndrome  RAD21, SMC3, NIPBL 
PINAmin2 Cornelia de Lange syndrome  RAD21, SMC3 
PINA Cowden syndrome  AKT1, PTEN 
PINA Cutis laxa autosomal recessive type  EFEMP2, FBLN5 
PINA Deafness autosomal dominant  SIX1, EYA4 
PINA Deafness autosomal recessive  
MYO7A, CDH23, DFNB31, 
MYO15A 
PINA Dejerine-Sottas disease PMP22, MPZ 
PINA Dementia Lewy body SNCA, SNCB 
PINA Diabetes mellitus permanent neonatal INS, GCK 
PINA Diabetes mellitus transient neonatal  ABCC8, KCNJ11 
PINA Diamond-Blackfan anemia  RPL5, RPL11 
PINAmin2 Diamond-Blackfan anemia  RPL5, RPL11 
PINA Dysfibrinogenemia type FGB, FGG 
PINAmin2 Dysfibrinogenemia type FGB, FGG 
PINA Ehlers-Danlos syndrome type  COL1A1, COL1A2 
PINA Ehlers-Danlos syndrome type  COL5A2, COL5A1 
PINAmin2 Ehlers-Danlos syndrome type  COL1A1, COL1A2 
PINA Epidermolysis bullosa simplex type KRT5, KRT14 
PINAmin2 Epidermolysis bullosa simplex type KRT14, KRT5 
PINA Epidermolysis bullosa junctional type ITGB4, COL17A1 
PINA Epidermolysis bullosa junctional type LAMB3, LAMA3, LAMC2 
PINAmin2 Epidermolysis bullosa junctional type LAMB3, LAMA3, LAMC2 
PINA Epilepsy nocturnal frontal lobe  CHRNB2, CHRNA4 
PINAmin2 Epilepsy nocturnal frontal lobe  CHRNB2, CHRNA4 
PINA 




Epilepsy progressive myoclonic 2B 
(Lafora) 
EPM2A, NHLRC1 
PINA Epiphyseal dysplasia multiple  COL9A1, COMP, MATN3 
PINA Episodic ataxia type  CACNA1A, CACNB4 
PINA Erythrocytosis familial  VHL, EPAS1, EGLN1 
PINAmin2 Erythrocytosis familial  VHL, EPAS1, EGLN1 
PINA Exostoses multiple type  EXT1, EXT2 
PINA Fanconi anemia complementation group  
FANCA, FANCG, FANCM, 
BRCA2, PALB2, FANCC, 
FANCB, FANCI, FANCD2, 
FANCE, FANCF, BRIP1 
PINAmin2 Fanconi anemia complementation group  
FANCG, BRCA2, FANCA, 
FANCM, FANCC, FANCD2, 
FANCE, PALB2, FANCF, 
FANCB, FANCI 
PINA 
Foveomacular dystrophy adult-onset with 
choroidal neovascularization 
PRPH2, PRPH 
PINA Frontonasal dysplasia  ALX1, ALX4 
PINA Glanzmann thrombasthenia ITGB3, ITGA2B 
PINAmin2 Glanzmann thrombasthenia ITGA2B, ITGB3 
PINA Griscelli syndrome type  RAB27A, MLPH, MYO5A 
PINAmin2 Griscelli syndrome type  MLPH, RAB27A, MYO5A 




Network Generalised disease term 
Causal genes connected in 
network 
PINAmin2 Hemangioma capillary infantile somatic KDR, FLT4 





PINA Hepatocellular carcinoma somatic CTNNB1, AXIN1, CASP8 
PINAmin2 Hepatocellular carcinoma somatic AXIN1, CTNNB1 
PINA Hermansky-Pudlak syndrome  DTNBP1, BLOC1S3 
PINA Hermansky-Pudlak syndrome  HPS1, HPS4 
PINA Hermansky-Pudlak syndrome  HPS6, HPS5 
PINAmin2 Hermansky-Pudlak syndrome  BLOC1S3, DTNBP1 
PINAmin2 Hermansky-Pudlak syndrome  HPS6, HPS5 
PINA Hyperinsulinemic hypoglycemia familial  ABCC8, KCNJ11 
PINA 
















Immune dysfunction with T-cell 
inactivation due to calcium entry defect  
ORAI1, STIM1 
PINAmin2 
Immune dysfunction with T-cell 
inactivation due to calcium entry defect  
ORAI1, STIM1 
PINA Immunodeficiency common variable  CD19, CR2, CD81 
PINAmin2 Immunodeficiency common variable  CD19, CR2, CD81 
PINA Iridogoniodysgenesis type  FOXC1, PITX2 
PINA Kabuki syndrome  KDM6A, MLL2 
PINAmin2 Kabuki syndrome  KDM6A, MLL2 
PINA LADD syndrome FGFR2, FGF10 
PINAmin2 LADD syndrome FGF10, FGFR2 
PINA LEOPARD syndrome  RAF1, BRAF 
PINAmin2 LEOPARD syndrome  RAF1, BRAF 
PINA 
Leigh syndrome due to mitochondrial 
complex I deficiency 
NDUFS3, NDUFA9 
PINAmin2 
Leigh syndrome due to mitochondrial 
complex I deficiency 
NDUFS3, NDUFA9 
PINA Leukemia acute myeloid CEBPA, RUNX1 
PINA Leukemia acute promyelocytic type ZBTB16, PML 
PINA 
Leukoencephalopathy with vanishing white 
matter 
EIF2B1, EIF2B2, EIF2B5, 
EIF2B3 
PINAmin2 
Leukoencephalopathy with vanishing white 
matter 
EIF2B5, EIF2B1 
PINA Li-Fraumeni syndrome CHEK2, TP53 
PINAmin2 Li-Fraumeni syndrome TP53, CHEK2 
PINA Liddle syndrome SCNN1B, SCNN1G 
PINA Lissencephaly  TUBA1A, PAFAH1B1 
PINA Loeys-Dietz syndrome type  





Network Generalised disease term 
Causal genes connected in 
network 
PINAmin2 Loeys-Dietz syndrome type  
TGFBR1, SMAD3, TGFBR2, 
TGFB2 
PINA MODY type  HNF4A, HNF1A 
PINA Macular dystrophy PRPH2, PRPH 
PINA Macular dystrophy patterned PRPH2, PRPH 
PINA Macular dystrophy vitelliform PRPH2, PRPH 
PINA Maple syrup urine disease type  BCKDHA, BCKDHB 
PINAmin2 Maple syrup urine disease type  BCKDHA, BCKDHB 
PINA Meckel syndrome  TMEM67, MKS1 
PINA Meier-Gorlin syndrome  
CDC6, CDT1, ORC4, ORC1, 
ORC6 
PINAmin2 Meier-Gorlin syndrome  
CDC6, ORC1, ORC4, CDT1, 
ORC6 
PINA Mental retardation X-linked  GDI1, FTSJ1 
PINA Mental retardation autosomal dominant  
SMARCA4, ARID1A, 
CTNNB1, GRIN1, GRIN2B, 
ARID1B, SMARCB1, 
CDH15, SYNGAP1, CDH3, 
CACNG2 
PINAmin2 Mental retardation autosomal dominant  
SMARCA4, ARID1A, 
SMARCB1, ARID1B 
PINAmin2 Mental retardation autosomal dominant  CTNNB1, CDH3 
PINAmin2 Mental retardation autosomal dominant  GRIN2B, GRIN1 
PINA Methemoglobinemia type  CYB5A, CYB5R3 
PINA Microcephaly primary autosomal recessive CEP135, CENPJ 
PINA Mismatch repair cancer syndrome MLH1, MSH2, PMS2, MSH6 
PINAmin2 Mismatch repair cancer syndrome MLH1, MSH2, MSH6, PMS2 
PINA Mitochondrial complex I deficiency NDUFS3, NDUFS2 
PINAmin2 Mitochondrial complex I deficiency NDUFS3, NDUFS2 
PINA Muir-Torre syndrome MLH1, MSH2 
PINAmin2 Muir-Torre syndrome MLH1, MSH2 
PINA Multiple pterygium syndrome type CHRND, CHRNA1, CHRNG 
PINAmin2 Multiple pterygium syndrome type CHRNA1, CHRND 
PINA Muscular dystrophy limb-girdle type  
DYSF, TCAP, DNAJB6, 
CAPN3, TTN, CAV3, SGCG, 
SGCA, SGCB, SGCD 
PINAmin2 Muscular dystrophy limb-girdle type  TCAP, CAPN3, TTN 
PINAmin2 Muscular dystrophy limb-girdle type  SGCG, SGCB, SGCA, SGCD 
PINA 
Muscular dystrophy-dystroglycanopathy 









(limb-girdle) type  
POMT2, POMT1 
PINA 
Myasthenic syndrome congenital 
associated with acetylcholine receptor 
deficiency 
CHRNB1, MUSK, RAPSN 
PINA 
Myasthenic syndrome fast-channel 
congenital 




Network Generalised disease term 
Causal genes connected in 
network 
PINAmin2 




Myasthenic syndrome slow-channel 
congenital 
CHRND, CHRNA1, CHRNE 
PINAmin2 








Mycobacterial infection atypical familial 
disseminated 
STAT1, IFNGR1 
PINA Myopathy congenital with fiber-type  ACTA1, TPM3 





PINA Nephrotic syndrome type  NPHS1, NPHS2 
PINA Neuropathy distal hereditary motor type  HSPB1, HSPB8 
PINAmin2 Neuropathy distal hereditary motor type  HSPB1, HSPB8 
PINA 
Neuropathy hereditary sensory and 
autonomic type  
SPTLC1, SPTLC2 
PINA Noonan syndrome  SOS1, PTPN11 
PINA Noonan syndrome  NRAS, KRAS, RAF1, BRAF 
PINAmin2 Noonan syndrome  SOS1, PTPN11 
PINAmin2 Noonan syndrome  RAF1, BRAF, KRAS, NRAS 
PINA Omenn syndrome RAG1, RAG2 
PINA Orofacial cleft  SUMO1, MSX1, TP63 
PINA Osteogenesis imperfecta type  COL1A1, BMP1, COL1A2 
PINAmin2 Osteogenesis imperfecta type  COL1A1, COL1A2 
PINA Osteopetrosis autosomal recessive  TNFSF11, TNFRSF11A 
PINA Osteopetrosis autosomal recessive  CLCN7, OSTM1 
PINA Osteosarcoma somatic CHEK2, RB1 
PINA Ovarian cancer somatic ERBB2, CTNNB1 
PINA Ovarioleukodystrophy EIF2B2, EIF2B5, EIF2B4 
PINA Pachyonychia congenita type KRT17, KRT6A 
PINA Pancreatic cancer TP53, BRCA2 
PINAmin2 Pancreatic cancer TP53, BRCA2 
PINA Paragangliomas  SDHA, SDHB 
PINAmin2 Paragangliomas  SDHB, SDHA 
PINA Parkinson disease  HTRA2, EIF4G1 
PINA Parkinson disease  SNCA, LRRK2 
PINA Persistent Mullerian duct syndrome type  AMH, AMHR2 
PINA Pick disease MAPT, PSEN1 
PINA Pituitary hormone deficiency combined  PROP1, HESX1 
PINA Pontocerebellar hypoplasia type  TSEN2, TSEN54, TSEN34 
PINA Porencephaly  COL4A1, COL4A2 
PINAmin2 Porencephaly  COL4A1, COL4A2 
PINA Propionicacidemia PCCB, PCCA 
PINA Pseudohypoaldosteronism type  
SCNN1B, SCNN1A, 
SCNN1G 




Network Generalised disease term 
Causal genes connected in 
network 
PINA Retinitis pigmentosa  
ABCA4, CNGB1, PRPH2, 
PRPH 
PINA Retinitis pigmentosa digenic PRPH2, PRPH, ROM1 
PINA Retinitis punctata albescens PRPH2, PRPH 
PINA Roussy-Levy syndrome PMP22, MPZ 
PINA 




Severe combined immunodeficiency T cell-
negative B-cell/natural killer-cell positive 
CD3D, CD3E 
PINAmin2 
Severe combined immunodeficiency T cell-
negative B-cell/natural killer-cell positive 
CD3D, CD3E 
PINA Sitosterolemia ABCG8, ABCG5 
PINAmin2 Sitosterolemia ABCG8, ABCG5 
PINA Spastic paraplegia autosomal recessive 
AP4E1, AP4M1, AP4S1, 
AP4B1 
PINAmin2 Spastic paraplegia autosomal recessive AP4E1, AP4B1 
PINA Spherocytosis type  SPTA1, SPTB 
PINA Spherocytosis type  SLC4A1, ANK1 
PINAmin2 Spherocytosis type  SPTA1, SPTB 
PINA Spinocerebellar ataxia  ATXN1, ATXN2 
PINA Stickler syndrome type  COL2A1, COL9A2 
PINA 




Surfactant metabolism dysfunction 
pulmonary  
CSF2RA, CSF2RB 
PINA Telangiectasia hereditary hemorrhagic type  ENG, ACVRL1 
PINA Thrombocythemia  JAK2, MPL, THPO 
PINAmin2 Thrombocythemia  THPO, MPL 
PINA Thrombophilia dysfibrinogenemic FGB, FGG 
PINAmin2 Thrombophilia dysfibrinogenemic FGB, FGG 
PINA Thyroid carcinoma papillary TRIM24, TRIM33 
PINA Treacher Collins syndrome  POLR1C, POLR1D 
PINAmin2 Treacher Collins syndrome  POLR1C, POLR1D 
PINA Trichothiodystrophy ERCC2, ERCC3 
PINAmin2 Trichothiodystrophy ERCC3, ERCC2 
PINA UV-sensitive syndrome  ERCC6, ERCC8 
PINAmin2 UV-sensitive syndrome  ERCC8, ERCC6 
PINA Usher syndrome type  
MYO7A, CDH23, DFNB31, 
USH1C, USH1G 
PINAmin2 Usher syndrome type  CDH23, USH1C 
PINA Ventricular septal defect  GATA4, NKX2-5 
PINAmin2 Ventricular septal defect  GATA4, NKX2-5 
PINA Waardenburg syndrome type  EDNRB, EDN3 
PINA Waardenburg syndrome type  SOX10, PAX3, MITF 
PINAmin2 Waardenburg syndrome type  PAX3, SOX10 
PINA Warburg micro syndrome  RAB3GAP2, RAB3GAP1 
PINA Xeroderma pigmentosum group  
ERCC2, ERCC3, XPA, XPC, 
ERCC5, ERCC4 





Appendix B: Example of a Network in which Both 
of BioGranat-IG’s Heuristic Searches Fail 
 
Figure B.1 – Example of a network in which all of BioGranat-IG’s search algorithms fail to find the 
optimal subnetwork 




Figure B.1 – Example of a network in which all of BioGranat-IG’s search algorithms fail to find the 
optimal subnetwork (previous page) 
(a) An example of a network for which both the minimum distance search and multi-minimum 
distance search would fail to find the smallest subnetwork containing all individuals A-P. Nodes are 
labelled with the individuals attached to them. (b) The true optimal subnetwork comprises 20 nodes in 
the top section of the graph, shown in green. (c) However, nodes from the bottom section will be 
incorporated into any subnetwork found by the minimum distance and multi-minimum distance 
searches, regardless of which node the search starts from. The smallest subnetworks found by 
BioGranat-IG contain 31 nodes. There were 50 alternative such subnetworks, one of which is shown 
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